[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5_9eWvWekgzWc-P9TqMTWV17nQ0HQcj2_SAAwnzdUyE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"Wake Forest University",[6,4],"Wake Forest University Health Sciences",1442,false,260,44,889308,114,963,[15,18,21,24,26,29,32,35],{"name":16,"count":17},"Obesity",41,{"name":19,"count":20},"Breast Cancer",38,{"name":22,"count":23},"Depression",27,{"name":25,"count":23},"Pain",{"name":27,"count":28},"Cancer",23,{"name":30,"count":31},"Anxiety",22,{"name":33,"count":34},"Lung Cancer",21,{"name":36,"count":37},"Head and Neck Cancer",20,[39,44,49,54,59,64,69,74,79,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03246347","A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer","2022-09-01","ADT+Docetaxel+Enzalutamide",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04113018","Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","2023-06-28","Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03141359","Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","2023-07-12","Carboplatin",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03505762","Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment","2024-03-28","Cyclophosphamide",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05582434","Experience With Topical Acne Treatment","2025-06-19","clindamycin phosphate 1.2%\u002Fadapalene 0.15%\u002FBPO 3.1% gel",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06523621","Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel","2026-03-21","Nivolumab",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04096170","Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo","2026-05","IV lidocaine",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05416333","Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)","2026-06","azelaic acid",{"nctId":80,"briefTitle":81,"date":77,"intervention":82},"NCT04026776","Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm","Allopurinol",{"nctId":84,"briefTitle":85,"date":77,"intervention":86},"NCT04858269","First Line Weekly Chemo\u002FImmunotherapy for Metastatic Head\u002FNeck Squamous Cell Carcinoma Patients","Pembrolizumab",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,134,231,291,327,367,408,442,469,487,505,531,555,573,597,615,639,663,681,699,717,735,753,779,797,815,839,862,887,905,932,956,974,992,1041,1063,1098,1125,1143,1169,1193,1214,1238,1256,1274,1299,1317,1342,1360,1430,1498,1547,1739,1859,1934,1996,2046,2096,2118,2151,2173,2253,2377,2441,2539,2577,2607,2639,2665,2696,2718,2740,2762,2791,2817,2842,2864,2888,2906,2924,2944,2962,2987,3011,3036,3058,3082,3100,3118,3136,3161,3179,3198,3216,3243,3267,3293,3319,3341,3366,3392,3414,3432,3450,3474,3498,3519,3543,3561,3599,3644,3667,3685,3708,3731,3778,3831,3865,3912,3951,3991,4029,4060,4097,4132,4165,4202,4229,4253,4275,4298,4323,4341,4365,4383,4401,4430,4448,4466,4484,4502,4528,4553,4571,4589,4607,4631,4659,4677,4695,4718,4736,4759,4783,4801,4819,4844,4862,4887,4905,4932,4950,4973,4991,5015,5033,5057,5075,5097,5120,5142,5166,5187,5211,5238,5256,5274,5292,5314,5338,5356,5379,5401,5419,5437,5460,5485,5508,5530,5555,5579,5597,5621,5648,5671,5694,5712,5734,5760,5785,5803,5829,5854,5880,5898,5921,5939,5962,5980,6003,6021,6043,6068,6086,6112,6130,6154,6180,6204,6226,6249,6271,6297,6320,6376,6412,6459,6482,6506,6524,6542,6560,6585,6609,6636,6654,6672,6698,6716,6742,6760,6778,6803,6826,6851,6869,6892,6916,6934,6952,6970,6988,7006,7032,7050,7075,7093,7119,7142,7166,7189,7329,7405,7473,7531,7586,7643,7690,7730,7762,7804,7830,7865,7895,7934,7964,7986,8015,8037,8076,8107,8132,8163,8185,8207,8244,8262,8289,8311,8335,8360,8384,8408,8430,8454,8484,8505,8523,8541,8559,8577,8599,8617,8635,8653,8671,8689,8707,8725,8747,8773,8797,8815,8838,8861,8883,8906,8929,8953,8971,8995,9013,9035,9057,9175,9198,9223,9245,9273,9291,9309,9332,9350,9371,9389,9407,9425,9443,9461,9479,9503,9526,9550,9568,9586,9604,9622,9640,9658,9681,9699,9723,9745,9763,9787,9810,9833,9860,9878,9901,9919,9937,9955,9973,9991,10009,10033,10051,10074,10098,10116,10139,10161,10185,10203,10221,10252,10276,10294,10316,10340,10358,10382,10408,10426,10450,10468,10491,10513,10534,10558,10582,10605,10623,10645,10663,10688,10713,10731,10749,10774,10798,10825,10849,10871,10893,10914,10937,10955,11007,11025,11049,11072,11096,11120,11144,11169,11192,11213,11236,11258,11276,11298,11323,11350,11368,11393,11411,11429,11447,11465,11483,11508,11536,11560,11582,11617,11646,11664,11682,11707,11725,11754,11772,11797,11822,11846,11868,11894,11924,11945,11975,11993,12011,12035,12053,12077,12095,12117,12140,12161,12184,12210,12237,12259,12277,12295,12319,12337,12393,12427,12467,12505,12537,12563,12610,12641,12663,12696,12723,12750,12772,12794,12816,12841,12865,12887,12908,12926,12949,12972,12996,13014,13032,13054,13077,13099,13122,13147,13171,13194,13215,13233,13251,13269,13290,13308,13329,13350,13372,13396,13419,13437,13464,13487,13510,13528,13553,13571,13589,13607,13629,13647,13679,13697,13715,13741,13759,13783,13801,13824,13842,13864],{"intervention":96,"totalTrials":97,"cells":98},"Duloxetine 30 mg",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":132},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":126},[110,122],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT05851898","Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures","RECRUITING",[92],"2028-12","2024-04-08",100,[119,120],"Depression in Old Age","Fragility Fracture",[96],{"nctId":123,"briefTitle":124,"status":113,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":117,"conditions":128,"interventions":129},"NCT05976347","Identifying and Treating Depression in the Orthopaedic Trauma Population",[92],"2027-05","2025-06-25",[22],[130,131],"Fluoxetine 20 MG","Duloxetine 30 MG",{"trials":133,"activeCount":101},[],{"intervention":135,"totalTrials":136,"cells":137},"Liposomal bupivacaine",7,{"EARLY_PHASE1":138,"PHASE1":153,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":229},{"trials":139,"activeCount":101},[140],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":97,"conditions":147,"interventions":151},"NCT03867188","Liposomal Bupivacaine (Exparel) in Sarcomas","TERMINATED",[88],"2019-06-11","2019-01-14",[148,149,150],"Soft Tissue Sarcoma","Soft Tissue Tumor","Soft Tissue Tumor and\u002For Sarcoma",[152],"Liposomal Bupivacaine",{"trials":154,"activeCount":101},[155],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":166},"NCT05537883","Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients","COMPLETED",[89],"2023-12-07","2022-11-29",72,[164,165],"Morbid Obesity","Bariatric Surgery Candidate",[135,167],"Bupivacaine",{"trials":169,"activeCount":101},[],{"trials":171,"activeCount":101},[],{"trials":173,"activeCount":228,"soonestReadout":191},[174,186,198,209,219],{"nctId":175,"briefTitle":176,"status":177,"phases":178,"primaryCompletion":179,"completion":179,"start":180,"enrollment":101,"conditions":181,"interventions":184},"NCT04232306","Liposomal Bupivacaine + Bupivacaine vs. Bupivacaine Alone on Opioid Use After Elective c\u002FSection","WITHDRAWN",[92],"2025-12","2024-03",[182,183],"Postoperative Pain","Cesarean Section",[135,185],"Bupivacaine HCl",{"nctId":187,"briefTitle":188,"status":189,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT07097493","Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty","NOT_YET_RECRUITING",[92],"2026-12-31","2026-08",90,[195],"Knee Arthroplasty, Total",[152,197],"Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination",{"nctId":199,"briefTitle":200,"status":143,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT03845894","Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants",[92],"2022-06-25","2020-03-03",25,[206],"Shoulder Arthroplasty",[135,208],"Bupivacaine with adjuvants",{"nctId":210,"briefTitle":211,"status":158,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT03722927","The Use Of Liposomal Bupivacaine For Pain Control",[92],"2020-01-29","2018-06-14",3,[217],"Pain, Breast",[167,152],{"nctId":220,"briefTitle":221,"status":158,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":162,"conditions":226,"interventions":227},"NCT03875664","Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy",[92],"2019-03-12","2019-03-31","2018-07-23",[182],[135],1,{"trials":230,"activeCount":101},[],{"intervention":232,"totalTrials":233,"cells":234},"Normal Saline",4,{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":250,"PHASE3":263,"PHASE4":277,"NA":289},{"trials":236,"activeCount":101},[],{"trials":238,"activeCount":101},[239],{"nctId":240,"briefTitle":241,"status":143,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT01193777","L-Carnitine Administration in Early Sepsis",[89],"2012-02","2010-09",31,[247],"Septic Shock",[249,232],"L-Carnitine",{"trials":251,"activeCount":101},[252],{"nctId":253,"briefTitle":254,"status":143,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT02100956","Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain",[90],"2022-10-10","2014-06-19",8,[260],"Neuropathic Pain",[262,232],"oxytocin 100 micrograms",{"trials":264,"activeCount":101},[265],{"nctId":266,"briefTitle":267,"status":158,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":275},"NCT02975999","Use of Vasopressin Following the Fontan Operation",[90,91],"2019-12","2016-12",12,[273,274],"Pleural Effusion","Single-ventricle",[276,232],"Vasopressin",{"trials":278,"activeCount":228,"soonestReadout":283},[279],{"nctId":280,"briefTitle":281,"status":189,"phases":282,"primaryCompletion":283,"completion":283,"start":77,"enrollment":284,"conditions":285,"interventions":287},"NCT07246629","Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage",[92],"2027-01",214,[286],"Subarachnoid Hemorrhage",[232,288],"Nicardipine",{"trials":290,"activeCount":101},[],{"intervention":292,"totalTrials":97,"cells":293},"Angiotensin II",{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":325},{"trials":295,"activeCount":101},[],{"trials":297,"activeCount":101},[],{"trials":299,"activeCount":101},[],{"trials":301,"activeCount":101},[],{"trials":303,"activeCount":228,"soonestReadout":318},[304,314],{"nctId":305,"briefTitle":306,"status":158,"phases":307,"primaryCompletion":308,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":313},"NCT03733145","Angiotensin II in General Anesthesia",[92],"2023-03-21","2019-10-03",32,[312],"Hypertension",[292],{"nctId":315,"briefTitle":316,"status":189,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},"NCT06746753","Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock",[92],"2028-07","2028-08","2026-07",78,[247],[292,324],"Norepinephrine",{"trials":326,"activeCount":101},[],{"intervention":328,"totalTrials":97,"cells":329},"Oxycodone",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":353,"NA":365},{"trials":331,"activeCount":101},[],{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":101},[],{"trials":337,"activeCount":101},[338],{"nctId":339,"briefTitle":340,"status":143,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":349},"NCT05597878","Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy",[90,91],"2026-02-26","2023-04-18",58,[346,347,348],"Pain Management","Opioid Use","Prostate Cancer",[328,350,351,352,350],"Acetaminophen","Ketamine","Ketorolac",{"trials":354,"activeCount":228,"soonestReadout":359},[355],{"nctId":356,"briefTitle":357,"status":189,"phases":358,"primaryCompletion":359,"completion":359,"start":192,"enrollment":360,"conditions":361,"interventions":363},"NCT07435077","Examining Analgesic Synergy and Efficacy in Trauma Care",[92],"2026-12",282,[362],"Opioid Use Disorder",[364,328],"Buprenorphine",{"trials":366,"activeCount":101},[],{"intervention":368,"totalTrials":97,"cells":369},"Triamcinolone Acetonide",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":406},{"trials":371,"activeCount":101},[],{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":101},[],{"trials":379,"activeCount":228,"soonestReadout":396},[380,392],{"nctId":381,"briefTitle":382,"status":177,"phases":383,"primaryCompletion":384,"completion":385,"start":386,"enrollment":101,"conditions":387,"interventions":389},"NCT04075136","Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy",[92],"2024-11","2024-12","2023-03-30",[388],"Exudative Age Related Macular Degeneration",[390,368,391],"Ranibizumab","verteporfin",{"nctId":393,"briefTitle":394,"status":113,"phases":395,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT04207931","Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study",[92],"2026-11","2027-03","2018-04-30",250,[401],"Central Centrifugal Cicatricial Alopecia (CCCA)",[403,368,404,405],"Topical steroid class I-II","Doxycyline","Minoxidil",{"trials":407,"activeCount":101},[],{"intervention":73,"totalTrials":97,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":440},{"trials":411,"activeCount":101},[],{"trials":413,"activeCount":101},[],{"trials":415,"activeCount":101},[],{"trials":417,"activeCount":101},[],{"trials":419,"activeCount":228,"soonestReadout":72},[420,427],{"nctId":70,"briefTitle":71,"status":113,"phases":421,"primaryCompletion":72,"completion":72,"start":422,"enrollment":423,"conditions":424,"interventions":426},[92],"2018-06-21",50,[425],"Hernia, Paraesophageal",[73],{"nctId":428,"briefTitle":429,"status":158,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},"NCT04005859","Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane",[92],"2019-05-09","2021-07-20","2018-02-22",61,[436],"Colorectal Disorders",[438,439],"Exparel","IV Lidocaine",{"trials":441,"activeCount":101},[],{"intervention":443,"totalTrials":228,"cells":444},"Single dose of methadone",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":467},{"trials":446,"activeCount":101},[],{"trials":448,"activeCount":101},[],{"trials":450,"activeCount":101},[],{"trials":452,"activeCount":101},[],{"trials":454,"activeCount":228,"soonestReadout":459},[455],{"nctId":456,"briefTitle":457,"status":189,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT07226245","Methadone Pharmacokinetics in Cardiac Surgery",[92],"2026-12-30","2026-09",69,[463],"Postoperative Pain Management",[443,465,466],"Split dose of methadone","Balanced split dose of methadone",{"trials":468,"activeCount":101},[],{"intervention":465,"totalTrials":228,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":485},{"trials":472,"activeCount":101},[],{"trials":474,"activeCount":101},[],{"trials":476,"activeCount":101},[],{"trials":478,"activeCount":101},[],{"trials":480,"activeCount":228,"soonestReadout":459},[481],{"nctId":456,"briefTitle":457,"status":189,"phases":482,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":483,"interventions":484},[92],[463],[443,465,466],{"trials":486,"activeCount":101},[],{"intervention":466,"totalTrials":228,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":503},{"trials":490,"activeCount":101},[],{"trials":492,"activeCount":101},[],{"trials":494,"activeCount":101},[],{"trials":496,"activeCount":101},[],{"trials":498,"activeCount":228,"soonestReadout":459},[499],{"nctId":456,"briefTitle":457,"status":189,"phases":500,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":501,"interventions":502},[92],[463],[443,465,466],{"trials":504,"activeCount":101},[],{"intervention":506,"totalTrials":228,"cells":507},"Phentermine Hydrochloride 8 MG",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":529},{"trials":509,"activeCount":101},[],{"trials":511,"activeCount":101},[],{"trials":513,"activeCount":101},[],{"trials":515,"activeCount":101},[],{"trials":517,"activeCount":228,"soonestReadout":191},[518],{"nctId":519,"briefTitle":520,"status":521,"phases":522,"primaryCompletion":191,"completion":191,"start":523,"enrollment":524,"conditions":525,"interventions":528},"NCT05176626","Long-term Effectiveness of the Antiobesity Medication Phentermine","ACTIVE_NOT_RECRUITING",[92],"2022-06-30",870,[16,526,527],"Obesity; Drug","Lifestyle, Healthy",[506],{"trials":530,"activeCount":101},[],{"intervention":532,"totalTrials":228,"cells":533},"Fisetin followed by Placebo",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":553},{"trials":535,"activeCount":101},[],{"trials":537,"activeCount":101},[],{"trials":539,"activeCount":101},[],{"trials":541,"activeCount":101},[],{"trials":543,"activeCount":228,"soonestReadout":191},[544],{"nctId":545,"briefTitle":546,"status":113,"phases":547,"primaryCompletion":191,"completion":191,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT06819254","Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors",[92],"2025-12-09",60,[551],"Fatigue",[532],{"trials":554,"activeCount":101},[],{"intervention":197,"totalTrials":228,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":571},{"trials":558,"activeCount":101},[],{"trials":560,"activeCount":101},[],{"trials":562,"activeCount":101},[],{"trials":564,"activeCount":101},[],{"trials":566,"activeCount":228,"soonestReadout":191},[567],{"nctId":187,"briefTitle":188,"status":189,"phases":568,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":569,"interventions":570},[92],[195],[152,197],{"trials":572,"activeCount":101},[],{"intervention":574,"totalTrials":228,"cells":575},"Xeomin®",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":595},{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":101},[],{"trials":583,"activeCount":101},[],{"trials":585,"activeCount":228,"soonestReadout":590},[586],{"nctId":587,"briefTitle":588,"status":113,"phases":589,"primaryCompletion":590,"completion":590,"start":591,"enrollment":37,"conditions":592,"interventions":594},"NCT04908423","Xeomin® and Gait Related Mobility After Stroke",[92],"2027-04","2021-10-19",[593],"Stroke",[574],{"trials":596,"activeCount":101},[],{"intervention":130,"totalTrials":228,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":613},{"trials":600,"activeCount":101},[],{"trials":602,"activeCount":101},[],{"trials":604,"activeCount":101},[],{"trials":606,"activeCount":101},[],{"trials":608,"activeCount":228,"soonestReadout":126},[609],{"nctId":123,"briefTitle":124,"status":113,"phases":610,"primaryCompletion":126,"completion":126,"start":127,"enrollment":117,"conditions":611,"interventions":612},[92],[22],[130,131],{"trials":614,"activeCount":101},[],{"intervention":616,"totalTrials":228,"cells":617},"Exparel\u002Fbupivacaine mixture",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":637},{"trials":619,"activeCount":101},[],{"trials":621,"activeCount":101},[],{"trials":623,"activeCount":101},[],{"trials":625,"activeCount":101},[],{"trials":627,"activeCount":228,"soonestReadout":632},[628],{"nctId":629,"briefTitle":630,"status":189,"phases":631,"primaryCompletion":632,"completion":633,"start":460,"enrollment":117,"conditions":634,"interventions":636},"NCT07246642","IPP Placement & Intracavernosal Block",[92],"2027-09","2027-10",[635],"Erectile Dysfunction (ED)",[616],{"trials":638,"activeCount":101},[],{"intervention":640,"totalTrials":228,"cells":641},"Bisphosphonate",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":661},{"trials":643,"activeCount":101},[],{"trials":645,"activeCount":101},[],{"trials":647,"activeCount":101},[],{"trials":649,"activeCount":101},[],{"trials":651,"activeCount":228,"soonestReadout":632},[652],{"nctId":653,"briefTitle":654,"status":113,"phases":655,"primaryCompletion":632,"completion":632,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT05764733","Bone, Exercise, Alendronate, and Caloric Restriction",[92],"2023-06-08",900,[659],"Bone Loss",[640],{"trials":662,"activeCount":101},[],{"intervention":288,"totalTrials":228,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":679},{"trials":666,"activeCount":101},[],{"trials":668,"activeCount":101},[],{"trials":670,"activeCount":101},[],{"trials":672,"activeCount":101},[],{"trials":674,"activeCount":228,"soonestReadout":283},[675],{"nctId":280,"briefTitle":281,"status":189,"phases":676,"primaryCompletion":283,"completion":283,"start":77,"enrollment":284,"conditions":677,"interventions":678},[92],[286],[232,288],{"trials":680,"activeCount":101},[],{"intervention":324,"totalTrials":228,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":697},{"trials":684,"activeCount":101},[],{"trials":686,"activeCount":101},[],{"trials":688,"activeCount":101},[],{"trials":690,"activeCount":101},[],{"trials":692,"activeCount":228,"soonestReadout":318},[693],{"nctId":315,"briefTitle":316,"status":189,"phases":694,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":695,"interventions":696},[92],[247],[292,324],{"trials":698,"activeCount":101},[],{"intervention":403,"totalTrials":228,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":715},{"trials":702,"activeCount":101},[],{"trials":704,"activeCount":101},[],{"trials":706,"activeCount":101},[],{"trials":708,"activeCount":101},[],{"trials":710,"activeCount":228,"soonestReadout":396},[711],{"nctId":393,"briefTitle":394,"status":113,"phases":712,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":713,"interventions":714},[92],[401],[403,368,404,405],{"trials":716,"activeCount":101},[],{"intervention":404,"totalTrials":228,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":733},{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":101},[],{"trials":724,"activeCount":101},[],{"trials":726,"activeCount":101},[],{"trials":728,"activeCount":228,"soonestReadout":396},[729],{"nctId":393,"briefTitle":394,"status":113,"phases":730,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":731,"interventions":732},[92],[401],[403,368,404,405],{"trials":734,"activeCount":101},[],{"intervention":405,"totalTrials":228,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":751},{"trials":738,"activeCount":101},[],{"trials":740,"activeCount":101},[],{"trials":742,"activeCount":101},[],{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":228,"soonestReadout":396},[747],{"nctId":393,"briefTitle":394,"status":113,"phases":748,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":749,"interventions":750},[92],[401],[403,368,404,405],{"trials":752,"activeCount":101},[],{"intervention":754,"totalTrials":228,"cells":755},"Azithromycin Prophylaxis",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":777},{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":101},[],{"trials":763,"activeCount":101},[],{"trials":765,"activeCount":228,"soonestReadout":770},[766],{"nctId":767,"briefTitle":768,"status":189,"phases":769,"primaryCompletion":770,"completion":115,"start":77,"enrollment":771,"conditions":772,"interventions":774},"NCT07608562","Azithromycin for Cerclage Prophylaxis",[92],"2028-06",80,[773],"Cervical Insufficiency",[754,775,776],"Azithromycin Placebo","Cefazolin",{"trials":778,"activeCount":101},[],{"intervention":775,"totalTrials":228,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":795},{"trials":782,"activeCount":101},[],{"trials":784,"activeCount":101},[],{"trials":786,"activeCount":101},[],{"trials":788,"activeCount":101},[],{"trials":790,"activeCount":228,"soonestReadout":770},[791],{"nctId":767,"briefTitle":768,"status":189,"phases":792,"primaryCompletion":770,"completion":115,"start":77,"enrollment":771,"conditions":793,"interventions":794},[92],[773],[754,775,776],{"trials":796,"activeCount":101},[],{"intervention":776,"totalTrials":228,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":805,"PHASE4":807,"NA":813},{"trials":800,"activeCount":101},[],{"trials":802,"activeCount":101},[],{"trials":804,"activeCount":101},[],{"trials":806,"activeCount":101},[],{"trials":808,"activeCount":228,"soonestReadout":770},[809],{"nctId":767,"briefTitle":768,"status":189,"phases":810,"primaryCompletion":770,"completion":115,"start":77,"enrollment":771,"conditions":811,"interventions":812},[92],[773],[754,775,776],{"trials":814,"activeCount":101},[],{"intervention":816,"totalTrials":228,"cells":817},"Tirzepatide",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":826,"NA":837},{"trials":819,"activeCount":101},[],{"trials":821,"activeCount":101},[],{"trials":823,"activeCount":101},[],{"trials":825,"activeCount":101},[],{"trials":827,"activeCount":228,"soonestReadout":832},[828],{"nctId":829,"briefTitle":830,"status":521,"phases":831,"primaryCompletion":832,"completion":191,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT06861439","GLP-1s to Enhance Lasting Optimal Weight",[92],"2026-09-30","2025-07-07",40,[16],[816],{"trials":838,"activeCount":101},[],{"intervention":840,"totalTrials":228,"cells":841},"Antibiotic",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":860},{"trials":843,"activeCount":101},[],{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":101},[],{"trials":849,"activeCount":101},[],{"trials":851,"activeCount":228,"soonestReadout":115},[852],{"nctId":853,"briefTitle":854,"status":113,"phases":855,"primaryCompletion":115,"completion":115,"start":856,"enrollment":117,"conditions":857,"interventions":859},"NCT05206500","NextGen - Clinical Implication of Next Generation Sequencing",[92],"2022-05-17",[858],"Urinary Tract Infections",[840],{"trials":861,"activeCount":101},[],{"intervention":863,"totalTrials":228,"cells":864},"levetiracetam",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":885},{"trials":866,"activeCount":101},[],{"trials":868,"activeCount":101},[],{"trials":870,"activeCount":101},[],{"trials":872,"activeCount":101},[],{"trials":874,"activeCount":228,"soonestReadout":590},[875],{"nctId":876,"briefTitle":877,"status":113,"phases":878,"primaryCompletion":590,"completion":590,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT06866691","Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide",[92],"2025-04-18",600,[882],"Traumatic Brain Injury",[863,884],"lacosamide",{"trials":886,"activeCount":101},[],{"intervention":884,"totalTrials":228,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":903},{"trials":890,"activeCount":101},[],{"trials":892,"activeCount":101},[],{"trials":894,"activeCount":101},[],{"trials":896,"activeCount":101},[],{"trials":898,"activeCount":228,"soonestReadout":590},[899],{"nctId":876,"briefTitle":877,"status":113,"phases":900,"primaryCompletion":590,"completion":590,"start":879,"enrollment":880,"conditions":901,"interventions":902},[92],[882],[863,884],{"trials":904,"activeCount":101},[],{"intervention":906,"totalTrials":228,"cells":907},"Antibiotic coated intramedullary Nail",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":930},{"trials":909,"activeCount":101},[],{"trials":911,"activeCount":101},[],{"trials":913,"activeCount":101},[],{"trials":915,"activeCount":101},[],{"trials":917,"activeCount":228,"soonestReadout":359},[918],{"nctId":919,"briefTitle":920,"status":113,"phases":921,"primaryCompletion":359,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":929},"NCT05421741","Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial",[92],"2027-12","2023-05-15",484,[926,927,928],"Osteomyelitis Tibia","Tibial Fractures","Open Tibia Fracture",[906],{"trials":931,"activeCount":101},[],{"intervention":933,"totalTrials":228,"cells":934},"Estradiol vaginal cream",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":954},{"trials":936,"activeCount":101},[],{"trials":938,"activeCount":101},[],{"trials":940,"activeCount":101},[],{"trials":942,"activeCount":101},[],{"trials":944,"activeCount":228,"soonestReadout":283},[945],{"nctId":946,"briefTitle":947,"status":521,"phases":948,"primaryCompletion":283,"completion":283,"start":949,"enrollment":34,"conditions":950,"interventions":952},"NCT05723601","Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream",[92],"2024-01-12",[951],"Recurrent Urinary Tract Infection",[933,953],"Estradiol Vaginal",{"trials":955,"activeCount":101},[],{"intervention":953,"totalTrials":228,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":972},{"trials":959,"activeCount":101},[],{"trials":961,"activeCount":101},[],{"trials":963,"activeCount":101},[],{"trials":965,"activeCount":101},[],{"trials":967,"activeCount":228,"soonestReadout":283},[968],{"nctId":946,"briefTitle":947,"status":521,"phases":969,"primaryCompletion":283,"completion":283,"start":949,"enrollment":34,"conditions":970,"interventions":971},[92],[951],[933,953],{"trials":973,"activeCount":101},[],{"intervention":364,"totalTrials":228,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":990},{"trials":977,"activeCount":101},[],{"trials":979,"activeCount":101},[],{"trials":981,"activeCount":101},[],{"trials":983,"activeCount":101},[],{"trials":985,"activeCount":228,"soonestReadout":359},[986],{"nctId":356,"briefTitle":357,"status":189,"phases":987,"primaryCompletion":359,"completion":359,"start":192,"enrollment":360,"conditions":988,"interventions":989},[92],[362],[364,328],{"trials":991,"activeCount":101},[],{"intervention":993,"totalTrials":215,"cells":994},"Epinephrine",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1015,"NA":1039},{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":101},[],{"trials":1000,"activeCount":101},[],{"trials":1002,"activeCount":228,"soonestReadout":633},[1003],{"nctId":1004,"briefTitle":1005,"status":113,"phases":1006,"primaryCompletion":633,"completion":633,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1012},"NCT07092566","R.E.C.K vs Exparel in Robotic Nephrectomy",[91],"2025-11-14",170,[1010,1011,346],"Renal Carcinoma","Nephrectomy \u002F Methods",[1013,438,993,1014,352],"Ropivacaine HCL","Clonidine HCL",{"trials":1016,"activeCount":101},[1017,1028],{"nctId":1018,"briefTitle":1019,"status":158,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1026},"NCT02462148","Perineural Steroids for Peripheral Nerve Blocks",[92],"2017-08-31","2015-07",85,[1025],"Osteoarthritis, Knee",[1027,167,993],"Dexamethasone",{"nctId":1029,"briefTitle":1030,"status":158,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT02464176","Systemic Steroids for Peripheral Nerve Blocks",[92],"2017-01","2015-06",115,[1036],"Osteoarthritis, Hip",[1027,167,993,1038],"Saline",{"trials":1040,"activeCount":101},[],{"intervention":438,"totalTrials":97,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1055,"NA":1061},{"trials":1044,"activeCount":101},[],{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":101},[],{"trials":1050,"activeCount":228,"soonestReadout":633},[1051],{"nctId":1004,"briefTitle":1005,"status":113,"phases":1052,"primaryCompletion":633,"completion":633,"start":1007,"enrollment":1008,"conditions":1053,"interventions":1054},[91],[1010,1011,346],[1013,438,993,1014,352],{"trials":1056,"activeCount":101},[1057],{"nctId":428,"briefTitle":429,"status":158,"phases":1058,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":1059,"interventions":1060},[92],[436],[438,439],{"trials":1062,"activeCount":101},[],{"intervention":1064,"totalTrials":97,"cells":1065},"risedronate",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1082,"PHASE4":1094,"NA":1096},{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":101},[],{"trials":1071,"activeCount":101},[1072],{"nctId":1073,"briefTitle":1074,"status":158,"phases":1075,"primaryCompletion":1076,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1081},"NCT03861091","Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT",[90],"2022-03-02","2019-07-12",84,[1080],"Lung Neoplasm",[1064],{"trials":1083,"activeCount":228,"soonestReadout":1088},[1084],{"nctId":1085,"briefTitle":1086,"status":113,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT04922333","Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery",[91],"2028-04-30","2023-03-28",200,[659],[1093],"Risedronate",{"trials":1095,"activeCount":101},[],{"trials":1097,"activeCount":101},[],{"intervention":1099,"totalTrials":228,"cells":1100},"Magnesium Sulfate 2 G",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1121,"NA":1123},{"trials":1102,"activeCount":101},[],{"trials":1104,"activeCount":101},[],{"trials":1106,"activeCount":101},[],{"trials":1108,"activeCount":228,"soonestReadout":359},[1109],{"nctId":1110,"briefTitle":1111,"status":113,"phases":1112,"primaryCompletion":359,"completion":359,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1119},"NCT06376916","Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR",[91],"2024-10-07",153,[1116,1117,1118],"Tachycardia Atrial","Atrial Fibrillation","Atrial Flutter With Rapid Ventricular Response",[1099,1120,1038],"Magnesium Sulfate 4 G",{"trials":1122,"activeCount":101},[],{"trials":1124,"activeCount":101},[],{"intervention":1120,"totalTrials":228,"cells":1126},{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1133,"PHASE4":1139,"NA":1141},{"trials":1128,"activeCount":101},[],{"trials":1130,"activeCount":101},[],{"trials":1132,"activeCount":101},[],{"trials":1134,"activeCount":228,"soonestReadout":359},[1135],{"nctId":1110,"briefTitle":1111,"status":113,"phases":1136,"primaryCompletion":359,"completion":359,"start":1113,"enrollment":1114,"conditions":1137,"interventions":1138},[91],[1116,1117,1118],[1099,1120,1038],{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":101},[],{"intervention":1144,"totalTrials":228,"cells":1145},"Clonidine Pill",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1165,"NA":1167},{"trials":1147,"activeCount":101},[],{"trials":1149,"activeCount":101},[],{"trials":1151,"activeCount":101},[],{"trials":1153,"activeCount":228,"soonestReadout":1158},[1154],{"nctId":1155,"briefTitle":1156,"status":113,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":310,"conditions":1160,"interventions":1164},"NCT04877093","Repurposing Low-Dose Clonidine for PTSD in Veterans",[91],"2027-03-31","2023-06-01",[1161,1162,1163],"PTSD","Posttraumatic Stress Disorder","Sleep",[1144],{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[],{"intervention":1170,"totalTrials":228,"cells":1171},"Magnesium",{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1178,"PHASE4":1189,"NA":1191},{"trials":1173,"activeCount":101},[],{"trials":1175,"activeCount":101},[],{"trials":1177,"activeCount":101},[],{"trials":1179,"activeCount":228,"soonestReadout":1184},[1180],{"nctId":1181,"briefTitle":1182,"status":113,"phases":1183,"primaryCompletion":1184,"completion":1184,"start":1185,"enrollment":117,"conditions":1186,"interventions":1188},"NCT06904287","Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines",[91],"2027-06","2025-12-16",[1187],"Migraine",[1170],{"trials":1190,"activeCount":101},[],{"trials":1192,"activeCount":101},[],{"intervention":1194,"totalTrials":228,"cells":1195},"Vibegron",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1210,"NA":1212},{"trials":1197,"activeCount":101},[],{"trials":1199,"activeCount":101},[],{"trials":1201,"activeCount":101},[],{"trials":1203,"activeCount":228,"soonestReadout":318},[1204],{"nctId":1205,"briefTitle":1206,"status":189,"phases":1207,"primaryCompletion":318,"completion":318,"start":192,"enrollment":834,"conditions":1208,"interventions":1209},"NCT06987383","Vibegron for ENergy Thinking and Resilience in Aging",[91],[16],[1194],{"trials":1211,"activeCount":101},[],{"trials":1213,"activeCount":101},[],{"intervention":1215,"totalTrials":228,"cells":1216},"Suzetrigine",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1234,"NA":1236},{"trials":1218,"activeCount":101},[],{"trials":1220,"activeCount":101},[],{"trials":1222,"activeCount":101},[],{"trials":1224,"activeCount":228,"soonestReadout":1229},[1225],{"nctId":1226,"briefTitle":1227,"status":189,"phases":1228,"primaryCompletion":1229,"completion":1229,"start":320,"enrollment":771,"conditions":1230,"interventions":1232},"NCT07525219","Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen",[91],"2027-07",[1231],"Analgesic Efficacy",[1215,1233],"acetaminophen",{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"intervention":1013,"totalTrials":228,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1252,"NA":1254},{"trials":1241,"activeCount":101},[],{"trials":1243,"activeCount":101},[],{"trials":1245,"activeCount":101},[],{"trials":1247,"activeCount":228,"soonestReadout":633},[1248],{"nctId":1004,"briefTitle":1005,"status":113,"phases":1249,"primaryCompletion":633,"completion":633,"start":1007,"enrollment":1008,"conditions":1250,"interventions":1251},[91],[1010,1011,346],[1013,438,993,1014,352],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":101},[],{"intervention":1014,"totalTrials":228,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1270,"NA":1272},{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":101},[],{"trials":1263,"activeCount":101},[],{"trials":1265,"activeCount":228,"soonestReadout":633},[1266],{"nctId":1004,"briefTitle":1005,"status":113,"phases":1267,"primaryCompletion":633,"completion":633,"start":1007,"enrollment":1008,"conditions":1268,"interventions":1269},[91],[1010,1011,346],[1013,438,993,1014,352],{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[],{"intervention":1275,"totalTrials":228,"cells":1276},"Vancomycin Hydrochloride",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1295,"NA":1297},{"trials":1278,"activeCount":101},[],{"trials":1280,"activeCount":101},[],{"trials":1282,"activeCount":101},[],{"trials":1284,"activeCount":228,"soonestReadout":283},[1285],{"nctId":1286,"briefTitle":1287,"status":113,"phases":1288,"primaryCompletion":283,"completion":1289,"start":116,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT05766670","Intramedullary Calcium Sulfate Antibiotic Depot",[91],"2028-01",497,[1292,926,927],"Open tíbia Fracture",[1275,1294],"Gentamicin",{"trials":1296,"activeCount":101},[],{"trials":1298,"activeCount":101},[],{"intervention":1294,"totalTrials":228,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1313,"NA":1315},{"trials":1302,"activeCount":101},[],{"trials":1304,"activeCount":101},[],{"trials":1306,"activeCount":101},[],{"trials":1308,"activeCount":228,"soonestReadout":283},[1309],{"nctId":1286,"briefTitle":1287,"status":113,"phases":1310,"primaryCompletion":283,"completion":1289,"start":116,"enrollment":1290,"conditions":1311,"interventions":1312},[91],[1292,926,927],[1275,1294],{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[],{"intervention":1318,"totalTrials":228,"cells":1319},"Betamethasone dipropionate 0.05%",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1338,"NA":1340},{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":101},[],{"trials":1327,"activeCount":228,"soonestReadout":320},[1328],{"nctId":1329,"briefTitle":1330,"status":1331,"phases":1332,"primaryCompletion":320,"completion":359,"start":1333,"enrollment":834,"conditions":1334,"interventions":1336},"NCT05981118","Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)","ENROLLING_BY_INVITATION",[90,91],"2024-07-15",[1335],"ICD10 Code L40.9 for Psoriasis",[1318,1337],"Tapinarof",{"trials":1339,"activeCount":101},[],{"trials":1341,"activeCount":101},[],{"intervention":1337,"totalTrials":228,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1356,"NA":1358},{"trials":1345,"activeCount":101},[],{"trials":1347,"activeCount":101},[],{"trials":1349,"activeCount":101},[],{"trials":1351,"activeCount":228,"soonestReadout":320},[1352],{"nctId":1329,"briefTitle":1330,"status":1331,"phases":1353,"primaryCompletion":320,"completion":359,"start":1333,"enrollment":834,"conditions":1354,"interventions":1355},[90,91],[1335],[1318,1337],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"intervention":1361,"totalTrials":1362,"cells":1363},"ketorolac",6,{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1391,"PHASE4":1415,"NA":1417},{"trials":1365,"activeCount":101},[],{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":101},[1370,1383],{"nctId":1371,"briefTitle":1372,"status":143,"phases":1373,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1380},"NCT00693160","Effect of Spinal Ketorolac After Acute Opioid Exposure",[90],"2010-10","2011-01","2007-12",30,[1379],"Healthy",[1361,1381,1382],"remifentanil","Capsaicin",{"nctId":1384,"briefTitle":1385,"status":177,"phases":1386,"start":1387,"enrollment":101,"conditions":1388,"interventions":1389},"NCT00349401","Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation",[90],"2006-12",[25],[1361,1390],"morphine",{"trials":1392,"activeCount":228,"soonestReadout":633},[1393,1397,1401],{"nctId":339,"briefTitle":340,"status":143,"phases":1394,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":1395,"interventions":1396},[90,91],[346,347,348],[328,350,351,352,350],{"nctId":1004,"briefTitle":1005,"status":113,"phases":1398,"primaryCompletion":633,"completion":633,"start":1007,"enrollment":1008,"conditions":1399,"interventions":1400},[91],[1010,1011,346],[1013,438,993,1014,352],{"nctId":1402,"briefTitle":1403,"status":177,"phases":1404,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":1407,"interventions":1409},"NCT04939987","Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy",[90,91],"2022-10","2022-08",[1408],"Radical Prostatectomies",[1410,1411,1412,1413,352,350,1414,351],"Tramadol","Gabapentin","Hydrocodone-Acetaminophen","Oxycodone-Acetaminophen","Ketorolac tromethamine",{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[1419],{"nctId":1420,"briefTitle":1421,"status":158,"phases":1422,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":321,"conditions":1425,"interventions":1427},"NCT02112448","Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery",[93],"2016-05","2014-06",[1426],"Congenital Heart Disease",[1428,1429,350,1361],"continuous","as needed dosing",{"intervention":1038,"totalTrials":1362,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1445,"PHASE2":1447,"PHASE3":1462,"PHASE4":1468,"NA":1486},{"trials":1433,"activeCount":101},[1434],{"nctId":1435,"briefTitle":1436,"status":158,"phases":1437,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":37,"conditions":1440,"interventions":1442},"NCT05505630","The Effects of Sedatives on Tobacco Use Disorder Version 2",[88],"2025-12-10","2023-01-31",[1441],"Tobacco Smoking",[351,1443,1444,1038],"Midazolam","Dexmedetomidine",{"trials":1446,"activeCount":101},[],{"trials":1448,"activeCount":101},[1449],{"nctId":1450,"briefTitle":1451,"status":158,"phases":1452,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1459},"NCT01595646","Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)",[90],"2015-03-12","2011-11",37,[1457,1458],"Alzheimer's Disease","Mild Cognitive Impairment",[1038,1460,1461],"Insulin detemir","Insulin",{"trials":1463,"activeCount":228,"soonestReadout":359},[1464],{"nctId":1110,"briefTitle":1111,"status":113,"phases":1465,"primaryCompletion":359,"completion":359,"start":1113,"enrollment":1114,"conditions":1466,"interventions":1467},[91],[1116,1117,1118],[1099,1120,1038],{"trials":1469,"activeCount":101},[1470,1482],{"nctId":1471,"briefTitle":1472,"status":158,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1480},"NCT03935399","Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin",[92],"2020-03-15","2020-04-30","2019-08-08",10,[1479],"Chronic Pain",[1481,1038],"Oxytocin",{"nctId":1029,"briefTitle":1030,"status":158,"phases":1483,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1484,"interventions":1485},[92],[1036],[1027,167,993,1038],{"trials":1487,"activeCount":101},[1488],{"nctId":1489,"briefTitle":1490,"status":158,"phases":1491,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":310,"conditions":1494,"interventions":1496},"NCT01167907","Evaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery",[93],"2017-09-07","2010-07",[1495],"Orthopedic Surgery of Lower Extremity",[1497],"saline",{"intervention":350,"totalTrials":1362,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1520,"NA":1530},{"trials":1501,"activeCount":101},[],{"trials":1503,"activeCount":101},[],{"trials":1505,"activeCount":101},[],{"trials":1507,"activeCount":228,"soonestReadout":1229},[1508,1512,1516],{"nctId":339,"briefTitle":340,"status":143,"phases":1509,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":1510,"interventions":1511},[90,91],[346,347,348],[328,350,351,352,350],{"nctId":1226,"briefTitle":1227,"status":189,"phases":1513,"primaryCompletion":1229,"completion":1229,"start":320,"enrollment":771,"conditions":1514,"interventions":1515},[91],[1231],[1215,1233],{"nctId":1402,"briefTitle":1403,"status":177,"phases":1517,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":1518,"interventions":1519},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":1521,"activeCount":101},[1522],{"nctId":1523,"briefTitle":1524,"status":143,"phases":1525,"primaryCompletion":1424,"completion":1424,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1529},"NCT02181387","Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?",[92],"2013-09-05",33,[25],[350],{"trials":1531,"activeCount":101},[1532,1543],{"nctId":1533,"briefTitle":1534,"status":158,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":461,"conditions":1538,"interventions":1540},"NCT01298778","High Pain Intervention in Cesarean Sections",[93],"2011-07","2010-08",[1539],"Other Chronic Postoperative Pain",[1541,350,1542],"Duramorph 150","Duramorph 300",{"nctId":1420,"briefTitle":1421,"status":158,"phases":1544,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":321,"conditions":1545,"interventions":1546},[93],[1426],[1428,1429,350,1361],{"intervention":53,"totalTrials":1548,"cells":1549},15,{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1578,"PHASE3":1712,"PHASE4":1723,"NA":1725},{"trials":1551,"activeCount":101},[],{"trials":1553,"activeCount":101},[1554,1566],{"nctId":1555,"briefTitle":1556,"status":143,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":1548,"conditions":1561,"interventions":1563},"NCT00084890","Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix",[89],"2007-03","2010-04","2003-11",[1562],"Cervical Cancer",[1564,1565],"carboplatin","docetaxel",{"nctId":1567,"briefTitle":1568,"status":177,"phases":1569,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":101,"conditions":1572,"interventions":1573},"NCT04762901","LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer",[89],"2026-01","2021-04-01",[19],[1574,1575,58,1576,1577,53],"Niraparib","Doxorubicin","Paclitaxel","Pegfilgrastim",{"trials":1579,"activeCount":233,"soonestReadout":52},[1580,1591,1601,1612,1623,1636,1650,1663,1674,1686,1701],{"nctId":1581,"briefTitle":1582,"status":158,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1588},"NCT00025285","Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],"2004-09-29","2001-11-01",46,[33],[1564,1589,1590],"irinotecan hydrochloride","thalidomide",{"nctId":1592,"briefTitle":1593,"status":158,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1585,"enrollment":1596,"conditions":1597,"interventions":1598},"NCT00025272","Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[90],"2005-01-18",14,[33],[1564,1599,1600],"etoposide","topotecan hydrochloride",{"nctId":1602,"briefTitle":1603,"status":158,"phases":1604,"primaryCompletion":1605,"completion":1606,"start":1607,"enrollment":1608,"conditions":1609,"interventions":1610},"NCT02328105","LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer",[90],"2017-06-15","2019-12-06","2014-12",11,[33],[53,1611],"Abraxane",{"nctId":1613,"briefTitle":1614,"status":521,"phases":1615,"primaryCompletion":460,"completion":397,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT06027268","Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer",[90],"2024-01-10",36,[1619],"Metastatic Triple-Negative Breast Cancer",[1621,86,1622,53],"Trilaciclib","Gemcitabine",{"nctId":1624,"briefTitle":1625,"status":158,"phases":1626,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1635},"NCT02581943","Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer",[90],"2022-11-19","2022-12-28","2016-06-17",43,[1632,1633,1634],"Recurrent Non-Small Cell Lung Carcinoma","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[53,1576,86],{"nctId":1637,"briefTitle":1638,"status":158,"phases":1639,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":1608,"conditions":1643,"interventions":1648},"NCT00002943","Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer",[90],"2003-10","2007-08","1993-02",[1644,1645,1646,1647],"Extragonadal Germ Cell Tumor","Ovarian Cancer","Testicular Germ Cell Tumor","Unspecified Adult Solid Tumor, Protocol Specific",[1564,1649,1599],"cyclophosphamide",{"nctId":1651,"briefTitle":1652,"status":143,"phases":1653,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1596,"conditions":1657,"interventions":1660},"NCT01009983","Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer",[90],"2013-07","2013-12","2010-03",[19,1658,1659],"Recurrent Breast Cancer","Stage IV Breast Cancer",[1661,1662,1564],"panitumumab","paclitaxel",{"nctId":50,"briefTitle":51,"status":521,"phases":1664,"primaryCompletion":52,"completion":1229,"start":1665,"enrollment":434,"conditions":1666,"interventions":1670},[90],"2017-05-12",[1667,1668,1669],"Lung Cancer Stage II","Lung Cancer Stage III","Non Small Cell Lung Cancer",[53,1576,1671,1672,1673],"cis Platinum","Etoposide","Durvalumab",{"nctId":1675,"briefTitle":1676,"status":113,"phases":1677,"primaryCompletion":460,"completion":460,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1683},"NCT04253964","Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo\u002FImmunotherapy",[90],"2020-07-01",105,[1681,1682],"Nonsmall Cell Lung Cancer","Performance Status",[86,53,1576,1684,1685],"Nab paclitaxel","Pemetrexed",{"nctId":1687,"briefTitle":1688,"status":158,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":423,"conditions":1693,"interventions":1700},"NCT03188432","Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2024-01-31","2024-02-08","2019-01-02",[1694,1695,1696,1697,1698,1699],"Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer",[53],{"nctId":84,"briefTitle":85,"status":521,"phases":1702,"primaryCompletion":77,"completion":319,"start":1703,"enrollment":310,"conditions":1704,"interventions":1711},[90],"2021-05-27",[1705,1706,1707,1708,1709,1710],"Head Neck Cancer","Metastatic Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma","Oropharynx Squamous Cell Carcinoma","Hypopharynx Squamous Cell Carcinoma","Larynx Squamous Cell Carcinoma",[86,53,1576],{"trials":1713,"activeCount":101},[1714],{"nctId":1715,"briefTitle":1716,"status":158,"phases":1717,"primaryCompletion":1718,"completion":1718,"start":1719,"enrollment":228,"conditions":1720,"interventions":1721},"NCT00028938","Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer",[91],"2002-11-10","2002-01-01",[33],[1722,1564,1662],"epoetin alfa",{"trials":1724,"activeCount":101},[],{"trials":1726,"activeCount":101},[1727],{"nctId":1728,"briefTitle":1729,"status":158,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1737},"NCT01026467","Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer",[],"2014-05","2010-01",45,[1735,1736],"Recurrent Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[1738,1564],"cisplatin",{"intervention":86,"totalTrials":271,"cells":1740},{"EARLY_PHASE1":1741,"PHASE1":1752,"PHASE2":1754,"PHASE3":1842,"PHASE4":1855,"NA":1857},{"trials":1742,"activeCount":101},[1743],{"nctId":1744,"briefTitle":1745,"status":143,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":228,"conditions":1749,"interventions":1751},"NCT05204290","Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab",[88],"2022-10-07","2022-03-28",[1750,27],"Epidural Spinal Tumors",[86],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":215,"soonestReadout":77},[1756,1764,1775,1790,1794,1804,1808,1812,1823,1838],{"nctId":1757,"briefTitle":1758,"status":177,"phases":1759,"primaryCompletion":126,"completion":126,"start":1760,"enrollment":101,"conditions":1761,"interventions":1763},"NCT04361851","Study of Dara-Pembro for Multiple Myeloma Patients",[90],"2021-06-09",[1762],"Multiple Myeloma",[86],{"nctId":1765,"briefTitle":1766,"status":158,"phases":1767,"primaryCompletion":1768,"completion":1769,"start":1770,"enrollment":834,"conditions":1771,"interventions":1774},"NCT03018080","Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer",[90],"2021-07-29","2022-08-05","2017-06-12",[1772,1773],"Breast - Female","Male Breast Cancer",[86,1576],{"nctId":1776,"briefTitle":1777,"status":143,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1783,"interventions":1785},"NCT02949843","Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations",[90],"2018-01-08","2021-01-12","2017-03-10",19,[1784,1632,1634],"EGFR Activating Mutation",[1786,1787,68,86,1788,1789],"Chemotherapy","Immunotherapy","Targeted Molecular Therapy","Tyrosine Kinase Inhibitor",{"nctId":1613,"briefTitle":1614,"status":521,"phases":1791,"primaryCompletion":460,"completion":397,"start":1616,"enrollment":1617,"conditions":1792,"interventions":1793},[90],[1619],[1621,86,1622,53],{"nctId":1795,"briefTitle":1796,"status":158,"phases":1797,"primaryCompletion":1798,"completion":1799,"start":1800,"enrollment":23,"conditions":1801,"interventions":1803},"NCT02581982","Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer",[90],"2021-05-11","2022-12-19","2016-04-06",[1802],"Transitional Cell Carcinoma",[1576,86],{"nctId":1624,"briefTitle":1625,"status":158,"phases":1805,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":1806,"interventions":1807},[90],[1632,1633,1634],[53,1576,86],{"nctId":1675,"briefTitle":1676,"status":113,"phases":1809,"primaryCompletion":460,"completion":460,"start":1678,"enrollment":1679,"conditions":1810,"interventions":1811},[90],[1681,1682],[86,53,1576,1684,1685],{"nctId":1813,"briefTitle":1814,"status":158,"phases":1815,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":1377,"conditions":1819,"interventions":1822},"NCT03056001","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",[90],"2021-11-16","2022-11-15","2017-05-01",[1820,1821],"Soft Tissue Sarcoma, Adult","Soft Tissue Sarcoma, Child",[86,1575],{"nctId":1824,"briefTitle":1825,"status":158,"phases":1826,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":34,"conditions":1830,"interventions":1837},"NCT04454489","Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition",[90],"2025-02-18","2025-04-30","2021-02-25",[1831,1832,1833,1834,1835,1836],"Advanced Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head-and-neck Squamous-cell Carcinoma","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck","Locally Advanced Head and Neck Squamous Cell Carcinoma","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck",[86],{"nctId":84,"briefTitle":85,"status":521,"phases":1839,"primaryCompletion":77,"completion":319,"start":1703,"enrollment":310,"conditions":1840,"interventions":1841},[90],[1705,1706,1707,1708,1709,1710],[86,53,1576],{"trials":1843,"activeCount":101},[1844],{"nctId":1845,"briefTitle":1846,"status":158,"phases":1847,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":1850,"conditions":1851,"interventions":1854},"NCT03867175","Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer",[91],"2025-04-21","2019-06-24",5,[1852,1853],"Metastatic Lung Cancer","Stage IV Lung Cancer",[86],{"trials":1856,"activeCount":101},[],{"trials":1858,"activeCount":101},[],{"intervention":1576,"totalTrials":1608,"cells":1860},{"EARLY_PHASE1":1861,"PHASE1":1863,"PHASE2":1881,"PHASE3":1924,"PHASE4":1930,"NA":1932},{"trials":1862,"activeCount":101},[],{"trials":1864,"activeCount":101},[1865,1877],{"nctId":1866,"briefTitle":1867,"status":158,"phases":1868,"primaryCompletion":1454,"completion":1869,"start":1870,"enrollment":1871,"conditions":1872,"interventions":1873},"NCT00637897","Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer",[89],"2013-03","2008-03",24,[19],[1565,1874,1662,1875,1876],"ixabepilone","paclitaxel albumin-stabilized nanoparticle formulation","paricalcitol",{"nctId":1567,"briefTitle":1568,"status":177,"phases":1878,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":101,"conditions":1879,"interventions":1880},[89],[19],[1574,1575,58,1576,1577,53],{"trials":1882,"activeCount":215,"soonestReadout":52},[1883,1896,1900,1904,1908,1912,1916,1920],{"nctId":1884,"briefTitle":1885,"status":158,"phases":1886,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":1890,"conditions":1891,"interventions":1894},"NCT00310011","Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium",[90],"2005-10","2009-08","1998-06",71,[1892,1893],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter",[1738,1895,1662],"gemcitabine hydrochloride",{"nctId":1765,"briefTitle":1766,"status":158,"phases":1897,"primaryCompletion":1768,"completion":1769,"start":1770,"enrollment":834,"conditions":1898,"interventions":1899},[90],[1772,1773],[86,1576],{"nctId":1795,"briefTitle":1796,"status":158,"phases":1901,"primaryCompletion":1798,"completion":1799,"start":1800,"enrollment":23,"conditions":1902,"interventions":1903},[90],[1802],[1576,86],{"nctId":1624,"briefTitle":1625,"status":158,"phases":1905,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":1906,"interventions":1907},[90],[1632,1633,1634],[53,1576,86],{"nctId":1651,"briefTitle":1652,"status":143,"phases":1909,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1596,"conditions":1910,"interventions":1911},[90],[19,1658,1659],[1661,1662,1564],{"nctId":50,"briefTitle":51,"status":521,"phases":1913,"primaryCompletion":52,"completion":1229,"start":1665,"enrollment":434,"conditions":1914,"interventions":1915},[90],[1667,1668,1669],[53,1576,1671,1672,1673],{"nctId":1675,"briefTitle":1676,"status":113,"phases":1917,"primaryCompletion":460,"completion":460,"start":1678,"enrollment":1679,"conditions":1918,"interventions":1919},[90],[1681,1682],[86,53,1576,1684,1685],{"nctId":84,"briefTitle":85,"status":521,"phases":1921,"primaryCompletion":77,"completion":319,"start":1703,"enrollment":310,"conditions":1922,"interventions":1923},[90],[1705,1706,1707,1708,1709,1710],[86,53,1576],{"trials":1925,"activeCount":101},[1926],{"nctId":1715,"briefTitle":1716,"status":158,"phases":1927,"primaryCompletion":1718,"completion":1718,"start":1719,"enrollment":228,"conditions":1928,"interventions":1929},[91],[33],[1722,1564,1662],{"trials":1931,"activeCount":101},[],{"trials":1933,"activeCount":101},[],{"intervention":1622,"totalTrials":1850,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1950,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1937,"activeCount":101},[],{"trials":1939,"activeCount":101},[1940],{"nctId":1941,"briefTitle":1942,"status":143,"phases":1943,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1948},"NCT04037527","Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities",[89],"2024-06-18","2020-08-18",9,[148],[1622,1949],"Docetaxel",{"trials":1951,"activeCount":97,"soonestReadout":460},[1952,1965,1974,1986],{"nctId":1953,"briefTitle":1954,"status":143,"phases":1955,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":1596,"conditions":1959,"interventions":1964},"NCT03662074","Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer",[90],"2020-10-07","2022-02-03","2018-11-07",[1960,1961,1962,1963],"Small Cell Lung Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[1622,68],{"nctId":1966,"briefTitle":1967,"status":177,"phases":1968,"primaryCompletion":270,"completion":270,"start":1969,"enrollment":101,"conditions":1970,"interventions":1973},"NCT02850874","HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma",[90],"2016-02",[1971,1972],"Pancreatic Neoplasms","Pancreatic Adenocarcinoma",[1622],{"nctId":1975,"briefTitle":1976,"status":113,"phases":1977,"primaryCompletion":1184,"completion":318,"start":1978,"enrollment":1979,"conditions":1980,"interventions":1984},"NCT05825066","Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma",[90],"2023-08-01",64,[1981,1982,1983],"Pancreas Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma",[1684,1622,1985],"mFOLFIRINOX",{"nctId":1613,"briefTitle":1614,"status":521,"phases":1987,"primaryCompletion":460,"completion":397,"start":1616,"enrollment":1617,"conditions":1988,"interventions":1989},[90],[1619],[1621,86,1622,53],{"trials":1991,"activeCount":101},[],{"trials":1993,"activeCount":101},[],{"trials":1995,"activeCount":101},[],{"intervention":1997,"totalTrials":215,"cells":1998},"Intravenous Oxytocin",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2014,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[2003],{"nctId":2004,"briefTitle":2005,"status":158,"phases":2006,"primaryCompletion":2007,"completion":2007,"start":2008,"enrollment":204,"conditions":2009,"interventions":2011},"NCT05672667","A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects",[89],"2023-11-01","2023-02-27",[2010],"Healthy Volunteer Study",[2012,2013],"intravenous oxytocin","intranasal oxytocin",{"trials":2015,"activeCount":97,"soonestReadout":2031},[2016,2027],{"nctId":2017,"briefTitle":2018,"status":113,"phases":2019,"primaryCompletion":2020,"completion":2021,"start":2022,"enrollment":549,"conditions":2023,"interventions":2025},"NCT07409753","Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography",[90],"2027-06-01","2027-06-08","2025-10-22",[2024],"Acute Pain",[1997,2026],"Intravenous Placebo",{"nctId":2028,"briefTitle":2029,"status":113,"phases":2030,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":1871,"conditions":2033,"interventions":2035},"NCT07053774","Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain",[90],"2026-06-20","2025-11-05",[2034],"Pain, Acute",[2036,2037,2038,2039],"Intravenous oxytocin","Intravenous placebo","Intranasal oxytocin","Intranasal placebo",{"trials":2041,"activeCount":101},[],{"trials":2043,"activeCount":101},[],{"trials":2045,"activeCount":101},[],{"intervention":1673,"totalTrials":215,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2070,"PHASE2":2072,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2049,"activeCount":101},[2050],{"nctId":2051,"briefTitle":2052,"status":143,"phases":2053,"primaryCompletion":2054,"completion":2054,"start":1032,"enrollment":2055,"conditions":2056,"interventions":2069},"NCT02827838","Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer",[88],"2022-04-22",17,[2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068],"Human Papillomavirus Infection","Stage I Oral Cavity Squamous Cell Carcinoma","Stage I Oropharyngeal Squamous Cell Carcinoma","Stage II Oral Cavity Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Oral Cavity Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Oral Cavity Squamous Cell Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma",[1673],{"trials":2071,"activeCount":101},[],{"trials":2073,"activeCount":97,"soonestReadout":52},[2074,2086],{"nctId":2075,"briefTitle":2076,"status":113,"phases":2077,"primaryCompletion":2078,"completion":590,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2085},"NCT05696782","Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer",[90],"2027-02","2023-07-26",28,[2082,2083,2084],"Nonsmall Cell Lung Cancer Stage III","Unresectable Non-Small Cell Lung Carcinoma","Nonsmall Cell Lung Cancer, Stage II",[1673],{"nctId":50,"briefTitle":51,"status":521,"phases":2087,"primaryCompletion":52,"completion":1229,"start":1665,"enrollment":434,"conditions":2088,"interventions":2089},[90],[1667,1668,1669],[53,1576,1671,1672,1673],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":101},[],{"trials":2095,"activeCount":101},[],{"intervention":2026,"totalTrials":97,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":97,"soonestReadout":2031},[2104,2108],{"nctId":2017,"briefTitle":2018,"status":113,"phases":2105,"primaryCompletion":2020,"completion":2021,"start":2022,"enrollment":549,"conditions":2106,"interventions":2107},[90],[2024],[1997,2026],{"nctId":2028,"briefTitle":2029,"status":113,"phases":2109,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":1871,"conditions":2110,"interventions":2111},[90],[2034],[2036,2037,2038,2039],{"trials":2113,"activeCount":101},[],{"trials":2115,"activeCount":101},[],{"trials":2117,"activeCount":101},[],{"intervention":2119,"totalTrials":97,"cells":2120},"High-dose Methotrexate",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2122,"activeCount":101},[],{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":97,"soonestReadout":460},[2127,2135],{"nctId":2128,"briefTitle":2129,"status":189,"phases":2130,"primaryCompletion":115,"completion":115,"start":77,"enrollment":1586,"conditions":2131,"interventions":2134},"NCT07560826","The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma",[90],[2132,2133],"Osteosarcoma in Children","Osteosarcoma in Adolescents and Young Adults",[2119],{"nctId":2136,"briefTitle":2137,"status":113,"phases":2138,"primaryCompletion":460,"completion":1229,"start":2139,"enrollment":2140,"conditions":2141,"interventions":2144},"NCT02422641","Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis",[90],"2015-05",16,[2142,2143],"Metastatic Breast Cancer","Leptomeningeal Disease",[2119],{"trials":2146,"activeCount":101},[],{"trials":2148,"activeCount":101},[],{"trials":2150,"activeCount":101},[],{"intervention":1684,"totalTrials":97,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2154,"activeCount":101},[],{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":97,"soonestReadout":460},[2159,2163],{"nctId":1975,"briefTitle":1976,"status":113,"phases":2160,"primaryCompletion":1184,"completion":318,"start":1978,"enrollment":1979,"conditions":2161,"interventions":2162},[90],[1981,1982,1983],[1684,1622,1985],{"nctId":1675,"briefTitle":1676,"status":113,"phases":2164,"primaryCompletion":460,"completion":460,"start":1678,"enrollment":1679,"conditions":2165,"interventions":2166},[90],[1681,1682],[86,53,1576,1684,1685],{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[],{"intervention":58,"totalTrials":1362,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2183,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2176,"activeCount":101},[],{"trials":2178,"activeCount":101},[2179],{"nctId":1567,"briefTitle":1568,"status":177,"phases":2180,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":101,"conditions":2181,"interventions":2182},[89],[19],[1574,1575,58,1576,1577,53],{"trials":2184,"activeCount":228,"soonestReadout":57},[2185,2200,2220,2231],{"nctId":2186,"briefTitle":2187,"status":158,"phases":2188,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":23,"conditions":2192,"interventions":2195},"NCT02248597","Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases",[90],"2022-01-18","2023-01-18","2015-02-25",[2193,2194],"Graft Versus Host Disease","Hematopoietic\u002FLymphoid Cancer",[2196,2197,1649,2198,2199],"fludarabine phosphate","busulfan","tacrolimus","mycophenolate mofetil",{"nctId":2201,"briefTitle":2202,"status":158,"phases":2203,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":2207,"interventions":2209},"NCT00002865","High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia",[90],"2000-06","2001-08","1995-04",[2208],"Leukemia",[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],"filgrastim","cytarabine","dexamethasone","doxorubicin hydrochloride","ifosfamide","leucovorin calcium","mesna","methotrexate","therapeutic hydrocortisone","vincristine sulfate",{"nctId":55,"briefTitle":56,"status":521,"phases":2221,"primaryCompletion":57,"completion":2222,"start":2223,"enrollment":771,"conditions":2224,"interventions":2226},[90],"2025-11","2018-07-19",[2225],"B-Cell Non-Hodgkin Lymphoma",[58,2227,2228,2229,2230],"Doxorubicin Hydrochloride","Prednisone","Rituximab","Vincristine Sulfate",{"nctId":1637,"briefTitle":1638,"status":158,"phases":2232,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":1608,"conditions":2233,"interventions":2234},[90],[1644,1645,1646,1647],[1564,1649,1599],{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":228,"soonestReadout":2245},[2241],{"nctId":2242,"briefTitle":2243,"status":113,"phases":2244,"primaryCompletion":2245,"completion":2246,"start":2247,"enrollment":2248,"conditions":2249,"interventions":2252},"NCT03555851","Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy",[],"2033-10","2035-08","2018-07-13",120,[2250,2251],"Leukemia, Not Otherwise Specified","Leukemia, Other",[58],{"intervention":1481,"totalTrials":1596,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2350,"PHASE4":2352,"NA":2375},{"trials":2256,"activeCount":101},[],{"trials":2258,"activeCount":101},[],{"trials":2260,"activeCount":228,"soonestReadout":359},[2261,2268,2276,2285,2292,2301,2311,2318,2328,2334,2342],{"nctId":2262,"briefTitle":2263,"status":113,"phases":2264,"primaryCompletion":359,"completion":359,"start":2265,"enrollment":20,"conditions":2266,"interventions":2267},"NCT04427709","Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity",[90],"2020-11-30",[1479,1025],[1481],{"nctId":2269,"briefTitle":2270,"status":177,"phases":2271,"primaryCompletion":179,"completion":179,"start":2272,"enrollment":101,"conditions":2273,"interventions":2275},"NCT04433741","Apply the PD Model of Peripheral Oxytocin Action to a Multimodal Stimulus",[90],"2025-01",[2274],"Pain, Chronic",[1481],{"nctId":2277,"briefTitle":2278,"status":177,"phases":2279,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":101,"conditions":2283,"interventions":2284},"NCT04427540","Oxytocin Pharmacokinetics After Intramuscular Injection",[90],"2022-06","2022-12","2021-12",[1025],[1481],{"nctId":2286,"briefTitle":2287,"status":177,"phases":2288,"primaryCompletion":1570,"completion":1570,"start":2289,"enrollment":101,"conditions":2290,"interventions":2291},"NCT04493229","A Pilot Feasibility Study of IM OXT on Fear of Pain and Trust in Physical Therapist During OP Rehabilitation After TKA",[90],"2024-01",[1025],[1481],{"nctId":2293,"briefTitle":2294,"status":158,"phases":2295,"primaryCompletion":2296,"completion":2296,"start":2297,"enrollment":204,"conditions":2298,"interventions":2300},"NCT05929339","Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin",[90],"2024-10-02","2023-08-17",[2024,1479,2299],"Healthy Volunteer",[1481],{"nctId":2302,"briefTitle":2303,"status":143,"phases":2304,"primaryCompletion":2305,"completion":2306,"start":2307,"enrollment":2308,"conditions":2309,"interventions":2310},"NCT03011307","Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery",[90],"2020-10-23","2021-08-11","2017-01-12",126,[182],[1481],{"nctId":2312,"briefTitle":2313,"status":177,"phases":2314,"primaryCompletion":2289,"completion":2289,"start":2315,"enrollment":101,"conditions":2316,"interventions":2317},"NCT04429880","A Study of Oxytocin PK After IV Administration in Healthy Subjects and Advanced Knee Arthritis Subjects",[90],"2023-01",[1025],[1481],{"nctId":2319,"briefTitle":2320,"status":158,"phases":2321,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":20,"conditions":2324,"interventions":2326},"NCT06651476","A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn",[90],"2025-11-20","2024-12-05",[2325],"Sunburn",[2327],"oxytocin",{"nctId":2329,"briefTitle":2330,"status":177,"phases":2331,"primaryCompletion":283,"completion":283,"start":2272,"enrollment":101,"conditions":2332,"interventions":2333},"NCT04435704","Validate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects",[90],[1025],[1481],{"nctId":2335,"briefTitle":2336,"status":177,"phases":2337,"primaryCompletion":2272,"completion":2338,"start":2339,"enrollment":101,"conditions":2340,"interventions":2341},"NCT04431193","Estimate Serum Oxytocin PD Range in the Periphery",[90],"2025-03","2023-12",[1025],[1481],{"nctId":2343,"briefTitle":2344,"status":143,"phases":2345,"primaryCompletion":2346,"completion":2346,"start":2347,"enrollment":136,"conditions":2348,"interventions":2349},"NCT04431206","Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects",[90],"2020-11-25","2020-11-04",[1025,1379],[1481],{"trials":2351,"activeCount":101},[],{"trials":2353,"activeCount":101},[2354,2358,2367],{"nctId":1471,"briefTitle":1472,"status":158,"phases":2355,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":2356,"interventions":2357},[92],[1479],[1481,1038],{"nctId":2359,"briefTitle":2360,"status":158,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":31,"conditions":2364,"interventions":2366},"NCT04105998","Effects of Intramuscular (IM) Oxytocin on Pupil Diameter and Heart Rate Variability (HRV)",[92],"2021-11-01","2019-10-24",[2365],"Chronic Pain Due to Injury",[1481],{"nctId":2368,"briefTitle":2369,"status":158,"phases":2370,"primaryCompletion":2371,"completion":2371,"start":2372,"enrollment":1608,"conditions":2373,"interventions":2374},"NCT03929367","PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers",[92],"2020-03-01","2019-05-10",[1479],[1481],{"trials":2376,"activeCount":101},[],{"intervention":2229,"totalTrials":215,"cells":2378},{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2420,"PHASE3":2426,"PHASE4":2428,"NA":2439},{"trials":2380,"activeCount":101},[],{"trials":2382,"activeCount":101},[2383],{"nctId":2384,"briefTitle":2385,"status":143,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":1607,"enrollment":228,"conditions":2388,"interventions":2416},"NCT02168907","CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",[89],"2015-02",[2389,2390,2391,2392,2393,2394,2395,2396,2397,2398,2399,2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415],"B-cell Adult Acute Lymphoblastic Leukemia","B-cell Chronic Lymphocytic Leukemia","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia",[2417,2418,2419],"6,8-bis(benzylthio)octanoic acid","bendamustine hydrochloride","rituximab",{"trials":2421,"activeCount":228,"soonestReadout":57},[2422],{"nctId":55,"briefTitle":56,"status":521,"phases":2423,"primaryCompletion":57,"completion":2222,"start":2223,"enrollment":771,"conditions":2424,"interventions":2425},[90],[2225],[58,2227,2228,2229,2230],{"trials":2427,"activeCount":101},[],{"trials":2429,"activeCount":101},[2430],{"nctId":2431,"briefTitle":2432,"status":158,"phases":2433,"primaryCompletion":2434,"completion":2434,"start":2435,"enrollment":1782,"conditions":2436,"interventions":2438},"NCT02040116","Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases",[92],"2014-08","2013-02",[2437],"Multiple Sclerosis",[2229],{"trials":2440,"activeCount":101},[],{"intervention":2211,"totalTrials":258,"cells":2442},{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2500,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[2447,2457,2472,2483],{"nctId":2448,"briefTitle":2449,"status":158,"phases":2450,"primaryCompletion":2451,"completion":2451,"start":2452,"enrollment":2453,"conditions":2454,"interventions":2455},"NCT00295841","Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",[89],"2015-01-07","2005-02",53,[2208],[2456,2211],"clofarabine",{"nctId":2458,"briefTitle":2459,"status":158,"phases":2460,"primaryCompletion":2461,"completion":2462,"start":2463,"enrollment":2464,"conditions":2465,"interventions":2468},"NCT02484391","CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma",[89],"2018-10","2022-02-02","2015-09",48,[2466,2467],"Granulocytic Sarcoma","Recurrent Adult Acute Myeloid Leukemia",[2469,2470,2471],"6,8-Bis(benzylthio)octanoic Acid","Cytarabine","Mitoxantrone Hydrochloride",{"nctId":2473,"briefTitle":2474,"status":158,"phases":2475,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":834,"conditions":2479,"interventions":2481},"NCT02971397","Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[89],"2018-03","2018-08-08","2016-11",[2480],"Acute Myeloid Leukemia",[2470,2482],"Daunorubicin Hydrochloride",{"nctId":2484,"briefTitle":2485,"status":158,"phases":2486,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":2489,"conditions":2490,"interventions":2497},"NCT01768897","CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2016-01","2013-01",67,[2491,2492,2493,2494,2495,2496,2467],"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",[2498,2211,2499],"CPI-613","mitoxantrone hydrochloride",{"trials":2501,"activeCount":228,"soonestReadout":2527},[2502,2506,2514,2523],{"nctId":2201,"briefTitle":2202,"status":158,"phases":2503,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":2504,"interventions":2505},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"nctId":2507,"briefTitle":2508,"status":158,"phases":2509,"primaryCompletion":2510,"completion":2510,"start":2452,"enrollment":2511,"conditions":2512,"interventions":2513},"NCT01656031","A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia",[90],"2008-11",39,[2208],[2456,2211],{"nctId":2515,"briefTitle":2516,"status":177,"phases":2517,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":101,"conditions":2520,"interventions":2522},"NCT02472626","6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[89,90],"2016-07","2015-12",[2521],"Untreated Adult Acute Myeloid Leukemia",[2469,2470,2482],{"nctId":2524,"briefTitle":2525,"status":521,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2531},"NCT02835222","Selinexor With Combination With Induction\u002FConsolidation Therapy in Acute Myeloid Leukemia Patients",[90],"2027-02-26","2018-02-02",57,[2521],[2470,2482,2532],"Selinexor",{"trials":2534,"activeCount":101},[],{"trials":2536,"activeCount":101},[],{"trials":2538,"activeCount":101},[],{"intervention":68,"totalTrials":233,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2556,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2542,"activeCount":101},[],{"trials":2544,"activeCount":101},[2545],{"nctId":2546,"briefTitle":2547,"status":158,"phases":2548,"primaryCompletion":2549,"completion":2550,"start":2551,"enrollment":1596,"conditions":2552,"interventions":2555},"NCT04022980","Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma",[89],"2025-01-21","2025-12-22","2020-03-31",[2553,2554],"Brain and Nervous System","Eye and Orbit",[68],{"trials":2557,"activeCount":228,"soonestReadout":67},[2558,2562,2566],{"nctId":1953,"briefTitle":1954,"status":143,"phases":2559,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":1596,"conditions":2560,"interventions":2561},[90],[1960,1961,1962,1963],[1622,68],{"nctId":1776,"briefTitle":1777,"status":143,"phases":2563,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":2564,"interventions":2565},[90],[1784,1632,1634],[1786,1787,68,86,1788,1789],{"nctId":65,"briefTitle":66,"status":521,"phases":2567,"primaryCompletion":67,"completion":115,"start":2568,"enrollment":228,"conditions":2569,"interventions":2570},[90],"2025-02-28",[1762],[68],{"trials":2572,"activeCount":101},[],{"trials":2574,"activeCount":101},[],{"trials":2576,"activeCount":101},[],{"intervention":1599,"totalTrials":233,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[],{"trials":2584,"activeCount":228,"soonestReadout":52},[2585,2589,2593,2597],{"nctId":2201,"briefTitle":2202,"status":158,"phases":2586,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":2587,"interventions":2588},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"nctId":1592,"briefTitle":1593,"status":158,"phases":2590,"primaryCompletion":1595,"completion":1595,"start":1585,"enrollment":1596,"conditions":2591,"interventions":2592},[90],[33],[1564,1599,1600],{"nctId":1637,"briefTitle":1638,"status":158,"phases":2594,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":1608,"conditions":2595,"interventions":2596},[90],[1644,1645,1646,1647],[1564,1649,1599],{"nctId":50,"briefTitle":51,"status":521,"phases":2598,"primaryCompletion":52,"completion":1229,"start":1665,"enrollment":434,"conditions":2599,"interventions":2600},[90],[1667,1668,1669],[53,1576,1671,1672,1673],{"trials":2602,"activeCount":101},[],{"trials":2604,"activeCount":101},[],{"trials":2606,"activeCount":101},[],{"intervention":2213,"totalTrials":215,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2610,"activeCount":101},[],{"trials":2612,"activeCount":101},[],{"trials":2614,"activeCount":228,"soonestReadout":57},[2615,2619,2623],{"nctId":2201,"briefTitle":2202,"status":158,"phases":2616,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":2617,"interventions":2618},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"nctId":55,"briefTitle":56,"status":521,"phases":2620,"primaryCompletion":57,"completion":2222,"start":2223,"enrollment":771,"conditions":2621,"interventions":2622},[90],[2225],[58,2227,2228,2229,2230],{"nctId":2624,"briefTitle":2625,"status":158,"phases":2626,"primaryCompletion":2627,"start":2628,"enrollment":2629,"conditions":2630,"interventions":2631},"NCT00416533","Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy",[90],"2006-10","2004-08",47,[348],[1565,2213,2632],"prednisone",{"trials":2634,"activeCount":101},[],{"trials":2636,"activeCount":101},[],{"trials":2638,"activeCount":101},[],{"intervention":2482,"totalTrials":215,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2649,"PHASE3":2659,"PHASE4":2661,"NA":2663},{"trials":2642,"activeCount":101},[],{"trials":2644,"activeCount":101},[2645],{"nctId":2473,"briefTitle":2474,"status":158,"phases":2646,"primaryCompletion":2476,"completion":2477,"start":2478,"enrollment":834,"conditions":2647,"interventions":2648},[89],[2480],[2470,2482],{"trials":2650,"activeCount":228,"soonestReadout":2527},[2651,2655],{"nctId":2515,"briefTitle":2516,"status":177,"phases":2652,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":101,"conditions":2653,"interventions":2654},[89,90],[2521],[2469,2470,2482],{"nctId":2524,"briefTitle":2525,"status":521,"phases":2656,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2657,"interventions":2658},[90],[2521],[2470,2482,2532],{"trials":2660,"activeCount":101},[],{"trials":2662,"activeCount":101},[],{"trials":2664,"activeCount":101},[],{"intervention":2666,"totalTrials":97,"cells":2667},"Cetuximab",{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2672,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2669,"activeCount":101},[],{"trials":2671,"activeCount":101},[],{"trials":2673,"activeCount":228,"soonestReadout":359},[2674,2681],{"nctId":2675,"briefTitle":2676,"status":113,"phases":2677,"primaryCompletion":359,"completion":922,"start":1678,"enrollment":20,"conditions":2678,"interventions":2680},"NCT04375384","Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer",[90],[2679,1832,1833],"Head and Neck Squamous Cell Carcinoma",[2666],{"nctId":2682,"briefTitle":2683,"status":158,"phases":2684,"primaryCompletion":2434,"completion":2434,"start":2685,"enrollment":37,"conditions":2686,"interventions":2687},"NCT00721513","Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer",[90],"2008-09",[36],[2688,1738,1565,2689],"cetuximab","fluorouracil",{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[],{"trials":2695,"activeCount":101},[],{"intervention":2219,"totalTrials":97,"cells":2697},{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2702,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2699,"activeCount":101},[],{"trials":2701,"activeCount":101},[],{"trials":2703,"activeCount":228,"soonestReadout":57},[2704,2708],{"nctId":2201,"briefTitle":2202,"status":158,"phases":2705,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":2706,"interventions":2707},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"nctId":55,"briefTitle":56,"status":521,"phases":2709,"primaryCompletion":57,"completion":2222,"start":2223,"enrollment":771,"conditions":2710,"interventions":2711},[90],[2225],[58,2227,2228,2229,2230],{"trials":2713,"activeCount":101},[],{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[],{"intervention":2228,"totalTrials":97,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2721,"activeCount":101},[],{"trials":2723,"activeCount":101},[],{"trials":2725,"activeCount":228,"soonestReadout":57},[2726,2730],{"nctId":55,"briefTitle":56,"status":521,"phases":2727,"primaryCompletion":57,"completion":2222,"start":2223,"enrollment":771,"conditions":2728,"interventions":2729},[90],[2225],[58,2227,2228,2229,2230],{"nctId":2624,"briefTitle":2625,"status":158,"phases":2731,"primaryCompletion":2627,"start":2628,"enrollment":2629,"conditions":2732,"interventions":2733},[90],[348],[1565,2213,2632],{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"trials":2739,"activeCount":101},[],{"intervention":2038,"totalTrials":97,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2750,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2743,"activeCount":101},[],{"trials":2745,"activeCount":101},[2746],{"nctId":2004,"briefTitle":2005,"status":158,"phases":2747,"primaryCompletion":2007,"completion":2007,"start":2008,"enrollment":204,"conditions":2748,"interventions":2749},[89],[2010],[2012,2013],{"trials":2751,"activeCount":228,"soonestReadout":2031},[2752],{"nctId":2028,"briefTitle":2029,"status":113,"phases":2753,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":1871,"conditions":2754,"interventions":2755},[90],[2034],[2036,2037,2038,2039],{"trials":2757,"activeCount":101},[],{"trials":2759,"activeCount":101},[],{"trials":2761,"activeCount":101},[],{"intervention":2763,"totalTrials":228,"cells":2764},"Statin",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2785,"PHASE4":2787,"NA":2789},{"trials":2766,"activeCount":101},[],{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":228,"soonestReadout":2775},[2771],{"nctId":2772,"briefTitle":2773,"status":113,"phases":2774,"primaryCompletion":2775,"completion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2784},"NCT06488105","Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial",[90],"2027-11-30","2029-03-31","2024-08-05",130,[2780,2781,2782,2783],"Lipid Disorder","Hypercholesterolemia","Cardiovascular Diseases","Atherosclerosis",[2763],{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[],{"intervention":2792,"totalTrials":228,"cells":2793},"Omeprazole 80 mg twice daily",{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2795,"activeCount":101},[],{"trials":2797,"activeCount":101},[],{"trials":2799,"activeCount":228,"soonestReadout":2804},[2800],{"nctId":2801,"briefTitle":2802,"status":113,"phases":2803,"primaryCompletion":2804,"completion":2805,"start":2806,"enrollment":423,"conditions":2807,"interventions":2810},"NCT04337580","Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer",[90],"2028-02","2028-03","2021-03-05",[348,2808,2809],"Refractory Cancer","Castration Resistant Prostatic Cancer",[2792],{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":101},[],{"intervention":2818,"totalTrials":228,"cells":2819},"Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2836,"PHASE4":2838,"NA":2840},{"trials":2821,"activeCount":101},[],{"trials":2823,"activeCount":101},[],{"trials":2825,"activeCount":228,"soonestReadout":2830},[2826],{"nctId":2827,"briefTitle":2828,"status":521,"phases":2829,"primaryCompletion":2830,"completion":2831,"start":2832,"enrollment":2833,"conditions":2834,"interventions":2835},"NCT04822337","Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma",[89,90],"2029-04","2032-11","2021-05-19",70,[1762],[2818],{"trials":2837,"activeCount":101},[],{"trials":2839,"activeCount":101},[],{"trials":2841,"activeCount":101},[],{"intervention":2843,"totalTrials":228,"cells":2844},"intravenous administration of oxytocin",{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2849,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2846,"activeCount":101},[],{"trials":2848,"activeCount":101},[],{"trials":2850,"activeCount":228,"soonestReadout":922},[2851],{"nctId":2852,"briefTitle":2853,"status":1331,"phases":2854,"primaryCompletion":922,"completion":922,"start":77,"enrollment":771,"conditions":2855,"interventions":2857},"NCT07430228","Efficacy of Intravenous Oxytocin to Speed Recovery After THA",[90],[2856],"Total Hip Arthroplasty",[2843],{"trials":2859,"activeCount":101},[],{"trials":2861,"activeCount":101},[],{"trials":2863,"activeCount":101},[],{"intervention":2865,"totalTrials":228,"cells":2866},"Virgin Coconut Oil",{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[],{"trials":2872,"activeCount":228,"soonestReadout":2877},[2873],{"nctId":2874,"briefTitle":2875,"status":113,"phases":2876,"primaryCompletion":2877,"completion":2877,"start":2878,"enrollment":549,"conditions":2879,"interventions":2881},"NCT05441813","Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy",[90],"2036-07","2023-02-15",[2880],"Oral Mucositis",[2865],{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[],{"trials":2887,"activeCount":101},[],{"intervention":1985,"totalTrials":228,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2900,"PHASE4":2902,"NA":2904},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":228,"soonestReadout":1184},[2896],{"nctId":1975,"briefTitle":1976,"status":113,"phases":2897,"primaryCompletion":1184,"completion":318,"start":1978,"enrollment":1979,"conditions":2898,"interventions":2899},[90],[1981,1982,1983],[1684,1622,1985],{"trials":2901,"activeCount":101},[],{"trials":2903,"activeCount":101},[],{"trials":2905,"activeCount":101},[],{"intervention":2039,"totalTrials":228,"cells":2907},{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2909,"activeCount":101},[],{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":228,"soonestReadout":2031},[2914],{"nctId":2028,"briefTitle":2029,"status":113,"phases":2915,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":1871,"conditions":2916,"interventions":2917},[90],[2034],[2036,2037,2038,2039],{"trials":2919,"activeCount":101},[],{"trials":2921,"activeCount":101},[],{"trials":2923,"activeCount":101},[],{"intervention":43,"totalTrials":228,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2927,"activeCount":101},[],{"trials":2929,"activeCount":101},[],{"trials":2931,"activeCount":228,"soonestReadout":42},[2932],{"nctId":40,"briefTitle":41,"status":521,"phases":2933,"primaryCompletion":42,"completion":2805,"start":2934,"enrollment":834,"conditions":2935,"interventions":2937},[90],"2017-08-23",[348,2936],"Prostate Adenocarcinoma",[43],{"trials":2939,"activeCount":101},[],{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"intervention":1621,"totalTrials":228,"cells":2945},{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2950,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2947,"activeCount":101},[],{"trials":2949,"activeCount":101},[],{"trials":2951,"activeCount":228,"soonestReadout":460},[2952],{"nctId":1613,"briefTitle":1614,"status":521,"phases":2953,"primaryCompletion":460,"completion":397,"start":1616,"enrollment":1617,"conditions":2954,"interventions":2955},[90],[1619],[1621,86,1622,53],{"trials":2957,"activeCount":101},[],{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[],{"intervention":2963,"totalTrials":228,"cells":2964},"Standard of Care Neoadjuvant Chemotherapy",{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2981,"PHASE4":2983,"NA":2985},{"trials":2966,"activeCount":101},[],{"trials":2968,"activeCount":101},[],{"trials":2970,"activeCount":228,"soonestReadout":192},[2971],{"nctId":2972,"briefTitle":2973,"status":113,"phases":2974,"primaryCompletion":192,"completion":192,"start":2975,"enrollment":423,"conditions":2976,"interventions":2980},"NCT04677816","Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients",[90],"2021-10-22",[2977,2978,2979],"Triple Negative Breast Cancer","Vitamin D Deficiency","Invasive Breast Cancer",[2963],{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"intervention":2988,"totalTrials":228,"cells":2989},"Gadolinium",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":2991,"activeCount":101},[],{"trials":2993,"activeCount":101},[],{"trials":2995,"activeCount":228,"soonestReadout":3000},[2996],{"nctId":2997,"briefTitle":2998,"status":113,"phases":2999,"primaryCompletion":3000,"completion":3000,"start":3001,"enrollment":549,"conditions":3002,"interventions":3004},"NCT05692635","Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance",[90],"2028-04","2023-08-30",[3003,2082],"Brain Metastases",[2988],{"trials":3006,"activeCount":101},[],{"trials":3008,"activeCount":101},[],{"trials":3010,"activeCount":101},[],{"intervention":3012,"totalTrials":228,"cells":3013},"Metformin Hydrochloride ER",{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":101},[],{"trials":3019,"activeCount":228,"soonestReadout":3024},[3020],{"nctId":3021,"briefTitle":3022,"status":113,"phases":3023,"primaryCompletion":3024,"completion":2245,"start":3025,"enrollment":423,"conditions":3026,"interventions":3029},"NCT07291297","Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma",[90],"2028-10","2026-03-04",[3027,3028],"Sarcoma Metastatic","Sarcoma, Soft Tissue",[3012],{"trials":3031,"activeCount":101},[],{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"intervention":3037,"totalTrials":228,"cells":3038},"\"Neo-Bladder\" Construct",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3040,"activeCount":101},[],{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":228,"soonestReadout":1184},[3045],{"nctId":3046,"briefTitle":3047,"status":189,"phases":3048,"primaryCompletion":1184,"completion":1184,"start":77,"enrollment":1477,"conditions":3049,"interventions":3051},"NCT05054790","Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct",[90],[3050],"Contracted Bladder",[3037],{"trials":3053,"activeCount":101},[],{"trials":3055,"activeCount":101},[],{"trials":3057,"activeCount":101},[],{"intervention":3059,"totalTrials":228,"cells":3060},"Intra-arterial Tenecteplase",{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3062,"activeCount":101},[],{"trials":3064,"activeCount":101},[],{"trials":3066,"activeCount":228,"soonestReadout":460},[3067],{"nctId":3068,"briefTitle":3069,"status":1331,"phases":3070,"primaryCompletion":460,"completion":359,"start":3071,"enrollment":834,"conditions":3072,"interventions":3074},"NCT06781385","Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke",[90],"2025-09-22",[3073],"Acute Ischemic Stroke",[3059,3075],"Intra-arterial Saline",{"trials":3077,"activeCount":101},[],{"trials":3079,"activeCount":101},[],{"trials":3081,"activeCount":101},[],{"intervention":3075,"totalTrials":228,"cells":3083},{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3085,"activeCount":101},[],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":228,"soonestReadout":460},[3090],{"nctId":3068,"briefTitle":3069,"status":1331,"phases":3091,"primaryCompletion":460,"completion":359,"start":3071,"enrollment":834,"conditions":3092,"interventions":3093},[90],[3073],[3059,3075],{"trials":3095,"activeCount":101},[],{"trials":3097,"activeCount":101},[],{"trials":3099,"activeCount":101},[],{"intervention":1671,"totalTrials":228,"cells":3101},{"EARLY_PHASE1":3102,"PHASE1":3104,"PHASE2":3106,"PHASE3":3112,"PHASE4":3114,"NA":3116},{"trials":3103,"activeCount":101},[],{"trials":3105,"activeCount":101},[],{"trials":3107,"activeCount":228,"soonestReadout":52},[3108],{"nctId":50,"briefTitle":51,"status":521,"phases":3109,"primaryCompletion":52,"completion":1229,"start":1665,"enrollment":434,"conditions":3110,"interventions":3111},[90],[1667,1668,1669],[53,1576,1671,1672,1673],{"trials":3113,"activeCount":101},[],{"trials":3115,"activeCount":101},[],{"trials":3117,"activeCount":101},[],{"intervention":1685,"totalTrials":228,"cells":3119},{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3124,"PHASE3":3130,"PHASE4":3132,"NA":3134},{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":101},[],{"trials":3125,"activeCount":228,"soonestReadout":460},[3126],{"nctId":1675,"briefTitle":1676,"status":113,"phases":3127,"primaryCompletion":460,"completion":460,"start":1678,"enrollment":1679,"conditions":3128,"interventions":3129},[90],[1681,1682],[86,53,1576,1684,1685],{"trials":3131,"activeCount":101},[],{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[],{"intervention":3137,"totalTrials":228,"cells":3138},"anastrozole",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"trials":3144,"activeCount":228,"soonestReadout":3149},[3145],{"nctId":3146,"briefTitle":3147,"status":521,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":834,"conditions":3151,"interventions":3153},"NCT02942355","Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer",[90],"2028-06-30","2016-12-07",[3152,19],"Female Breast Carcinoma",[3137,3154],"Palbociclib",{"trials":3156,"activeCount":101},[],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"intervention":3154,"totalTrials":228,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3164,"activeCount":101},[],{"trials":3166,"activeCount":101},[],{"trials":3168,"activeCount":228,"soonestReadout":3149},[3169],{"nctId":3146,"briefTitle":3147,"status":521,"phases":3170,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":834,"conditions":3171,"interventions":3172},[90],[3152,19],[3137,3154],{"trials":3174,"activeCount":101},[],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[],{"intervention":48,"totalTrials":228,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":228,"soonestReadout":47},[3187],{"nctId":45,"briefTitle":46,"status":521,"phases":3188,"primaryCompletion":47,"completion":633,"start":3189,"enrollment":2511,"conditions":3190,"interventions":3191},[90],"2020-01-10",[1762],[48],{"trials":3193,"activeCount":101},[],{"trials":3195,"activeCount":101},[],{"trials":3197,"activeCount":101},[],{"intervention":2532,"totalTrials":228,"cells":3199},{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"trials":3205,"activeCount":228,"soonestReadout":2527},[3206],{"nctId":2524,"briefTitle":2525,"status":521,"phases":3207,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":3208,"interventions":3209},[90],[2521],[2470,2482,2532],{"trials":3211,"activeCount":101},[],{"trials":3213,"activeCount":101},[],{"trials":3215,"activeCount":101},[],{"intervention":3217,"totalTrials":228,"cells":3218},"Low-dose ASA",{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":228,"soonestReadout":3229},[3225],{"nctId":3226,"briefTitle":3227,"status":113,"phases":3228,"primaryCompletion":3229,"completion":3230,"start":3231,"enrollment":3232,"conditions":3233,"interventions":3236},"NCT06866964","A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy",[90],"2029-08","2031-01","2025-08-28",35,[3234,3235],"Germ Cell Tumor","Testicular Cancer",[3217],{"trials":3238,"activeCount":101},[],{"trials":3240,"activeCount":101},[],{"trials":3242,"activeCount":101},[],{"intervention":3244,"totalTrials":228,"cells":3245},"Vaccine",{"EARLY_PHASE1":3246,"PHASE1":3248,"PHASE2":3250,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3247,"activeCount":101},[],{"trials":3249,"activeCount":101},[],{"trials":3251,"activeCount":228,"soonestReadout":3256},[3252],{"nctId":3253,"briefTitle":3254,"status":113,"phases":3255,"primaryCompletion":3256,"completion":3256,"start":3257,"enrollment":1979,"conditions":3258,"interventions":3260},"NCT04948619","Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients",[90],"2030-10","2022-08-08",[3259],"Pediatric Cancer",[3244],{"trials":3262,"activeCount":101},[],{"trials":3264,"activeCount":101},[],{"trials":3266,"activeCount":101},[],{"intervention":3268,"totalTrials":228,"cells":3269},"iNO",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3285,"PHASE3":3287,"PHASE4":3289,"NA":3291},{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":228,"soonestReadout":3278},[3274],{"nctId":3275,"briefTitle":3276,"status":113,"phases":3277,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":1617,"conditions":3281,"interventions":3284},"NCT05871606","Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy",[89],"2028-08-01","2028-12-01","2026-04-16",[3282,3283],"Cerebrovascular Disorders","Acute Cerebrovascular Disease",[3268],{"trials":3286,"activeCount":101},[],{"trials":3288,"activeCount":101},[],{"trials":3290,"activeCount":101},[],{"trials":3292,"activeCount":101},[],{"intervention":3294,"totalTrials":228,"cells":3295},"Autologous Engineered Urethral Construct",{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3311,"PHASE3":3313,"PHASE4":3315,"NA":3317},{"trials":3297,"activeCount":101},[],{"trials":3299,"activeCount":228,"soonestReadout":115},[3300],{"nctId":3301,"briefTitle":3302,"status":113,"phases":3303,"primaryCompletion":115,"completion":3304,"start":72,"enrollment":1477,"conditions":3305,"interventions":3310},"NCT03258658","Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures",[89],"2029-12",[3306,3307,3308,3309],"Urologic Diseases","Male Urogenital Diseases","Urethral Stricture","Urethral Injury",[3294],{"trials":3312,"activeCount":101},[],{"trials":3314,"activeCount":101},[],{"trials":3316,"activeCount":101},[],{"trials":3318,"activeCount":101},[],{"intervention":3320,"totalTrials":228,"cells":3321},"biologic vaginal-construct implantation",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3333,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3323,"activeCount":101},[],{"trials":3325,"activeCount":228,"soonestReadout":3304},[3326],{"nctId":3327,"briefTitle":3328,"status":113,"phases":3329,"primaryCompletion":3304,"completion":3304,"start":1159,"enrollment":1477,"conditions":3330,"interventions":3332},"NCT05675722","Implantation Of Vaginal Construct For Patients With Vaginal Aplasia",[89],[3331],"Congenital Mullerian Duct Anomaly",[3320],{"trials":3334,"activeCount":101},[],{"trials":3336,"activeCount":101},[],{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"intervention":3342,"totalTrials":228,"cells":3343},"LP-118",{"EARLY_PHASE1":3344,"PHASE1":3346,"PHASE2":3358,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":228,"soonestReadout":3352},[3348],{"nctId":3349,"briefTitle":3350,"status":189,"phases":3351,"primaryCompletion":3352,"completion":3352,"start":3353,"enrollment":3354,"conditions":3355,"interventions":3357},"NCT07614022","A Phase I Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive ALL",[89],"2030-03","2026-10",26,[3356],"Philadelphia Positive Acute Lymphoblastic Leukemia",[3342],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"intervention":3367,"totalTrials":228,"cells":3368},"Autologous tissue engineered corpora",{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3384,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3370,"activeCount":101},[],{"trials":3372,"activeCount":228,"soonestReadout":3377},[3373],{"nctId":3374,"briefTitle":3375,"status":189,"phases":3376,"primaryCompletion":3377,"completion":3377,"start":3353,"enrollment":1477,"conditions":3378,"interventions":3383},"NCT03463239","Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora",[89],"2030-12",[3306,3307,3379,3380,3381,3382],"Penile Diseases","Corpus Callosum Malformation","Corpora Cavernosa; Inflammation","Trauma Injury",[3367],{"trials":3385,"activeCount":101},[],{"trials":3387,"activeCount":101},[],{"trials":3389,"activeCount":101},[],{"trials":3391,"activeCount":101},[],{"intervention":63,"totalTrials":228,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3404,"PHASE2":3406,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3395,"activeCount":228,"soonestReadout":62},[3396],{"nctId":60,"briefTitle":61,"status":521,"phases":3397,"primaryCompletion":62,"completion":396,"start":3398,"enrollment":162,"conditions":3399,"interventions":3401},[88],"2024-02-15",[3400],"Acne",[63,3402,3403],"adapalene 0.3%\u002FBPO 2.5% gel and compounded clindamycin phosphate 1.2% gel","Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel",{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"trials":3409,"activeCount":101},[],{"trials":3411,"activeCount":101},[],{"trials":3413,"activeCount":101},[],{"intervention":3402,"totalTrials":228,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3422,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3417,"activeCount":228,"soonestReadout":62},[3418],{"nctId":60,"briefTitle":61,"status":521,"phases":3419,"primaryCompletion":62,"completion":396,"start":3398,"enrollment":162,"conditions":3420,"interventions":3421},[88],[3400],[63,3402,3403],{"trials":3423,"activeCount":101},[],{"trials":3425,"activeCount":101},[],{"trials":3427,"activeCount":101},[],{"trials":3429,"activeCount":101},[],{"trials":3431,"activeCount":101},[],{"intervention":3403,"totalTrials":228,"cells":3433},{"EARLY_PHASE1":3434,"PHASE1":3440,"PHASE2":3442,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3435,"activeCount":228,"soonestReadout":62},[3436],{"nctId":60,"briefTitle":61,"status":521,"phases":3437,"primaryCompletion":62,"completion":396,"start":3398,"enrollment":162,"conditions":3438,"interventions":3439},[88],[3400],[63,3402,3403],{"trials":3441,"activeCount":101},[],{"trials":3443,"activeCount":101},[],{"trials":3445,"activeCount":101},[],{"trials":3447,"activeCount":101},[],{"trials":3449,"activeCount":101},[],{"intervention":3451,"totalTrials":228,"cells":3452},"SPECTRUM cigarettes",{"EARLY_PHASE1":3453,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3454,"activeCount":228,"soonestReadout":359},[3455],{"nctId":3456,"briefTitle":3457,"status":113,"phases":3458,"primaryCompletion":359,"completion":359,"start":3459,"enrollment":3460,"conditions":3461,"interventions":3463},"NCT05707871","Cardiovascular Effects of Very Low Nicotine Content Cigarettes",[88],"2023-04-04",49,[3462],"Tobacco Use",[3451],{"trials":3465,"activeCount":101},[],{"trials":3467,"activeCount":101},[],{"trials":3469,"activeCount":101},[],{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":101},[],{"intervention":3475,"totalTrials":228,"cells":3476},"Desert Harvest Aloe Vera",{"EARLY_PHASE1":3477,"PHASE1":3488,"PHASE2":3490,"PHASE3":3492,"PHASE4":3494,"NA":3496},{"trials":3478,"activeCount":228,"soonestReadout":590},[3479],{"nctId":3480,"briefTitle":3481,"status":113,"phases":3482,"primaryCompletion":590,"completion":1229,"start":1827,"enrollment":1377,"conditions":3483,"interventions":3487},"NCT04734106","Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis",[88],[3484,3485,3486],"Interstitial Cystitis","Chronic Interstitial Cystitis","Bladder Pain Syndrome",[3475],{"trials":3489,"activeCount":101},[],{"trials":3491,"activeCount":101},[],{"trials":3493,"activeCount":101},[],{"trials":3495,"activeCount":101},[],{"trials":3497,"activeCount":101},[],{"intervention":82,"totalTrials":228,"cells":3499},{"EARLY_PHASE1":3500,"PHASE1":3509,"PHASE2":3511,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3501,"activeCount":228,"soonestReadout":77},[3502],{"nctId":80,"briefTitle":81,"status":113,"phases":3503,"primaryCompletion":77,"completion":77,"start":3504,"enrollment":2248,"conditions":3505,"interventions":3508},[88],"2020-09-02",[3506,3507],"Salt; Excess","Blood Pressure Disorders",[82],{"trials":3510,"activeCount":101},[],{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[],{"trials":3516,"activeCount":101},[],{"trials":3518,"activeCount":101},[],{"intervention":3520,"totalTrials":228,"cells":3521},"Platelet-rich Plasma Left Side",{"EARLY_PHASE1":3522,"PHASE1":3533,"PHASE2":3535,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3523,"activeCount":228,"soonestReadout":1184},[3524],{"nctId":3525,"briefTitle":3526,"status":189,"phases":3527,"primaryCompletion":1184,"completion":1184,"start":3528,"enrollment":2140,"conditions":3529,"interventions":3531},"NCT03474718","Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia",[88],"2026-04",[3530],"Androgenic Alopecia",[3520,3532],"Platelet-rich Plasma Right Side",{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[],{"trials":3540,"activeCount":101},[],{"trials":3542,"activeCount":101},[],{"intervention":3532,"totalTrials":228,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3546,"activeCount":228,"soonestReadout":1184},[3547],{"nctId":3525,"briefTitle":3526,"status":189,"phases":3548,"primaryCompletion":1184,"completion":1184,"start":3528,"enrollment":2140,"conditions":3549,"interventions":3550},[88],[3530],[3520,3532],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[],{"trials":3556,"activeCount":101},[],{"trials":3558,"activeCount":101},[],{"trials":3560,"activeCount":101},[],{"intervention":3562,"totalTrials":215,"cells":3563},"Azelaic acid",{"EARLY_PHASE1":3564,"PHASE1":3573,"PHASE2":3575,"PHASE3":3577,"PHASE4":3588,"NA":3590},{"trials":3565,"activeCount":228,"soonestReadout":77},[3566],{"nctId":75,"briefTitle":76,"status":521,"phases":3567,"primaryCompletion":77,"completion":359,"start":3568,"enrollment":3569,"conditions":3570,"interventions":3572},[88],"2024-08-12",18,[3571],"Central Centrifugal Cicatricial Alopecia",[78],{"trials":3574,"activeCount":101},[],{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[3579],{"nctId":3580,"briefTitle":3581,"status":158,"phases":3582,"primaryCompletion":3583,"completion":3583,"start":3584,"enrollment":37,"conditions":3585,"interventions":3587},"NCT03035955","Azelaic Acid on Demodex Counts in Rosacea",[90,91],"2012-02-02","2010-12",[3586],"Rosacea",[3562],{"trials":3589,"activeCount":101},[],{"trials":3591,"activeCount":101},[3592],{"nctId":3593,"briefTitle":3594,"status":158,"phases":3595,"primaryCompletion":3596,"completion":3596,"start":1493,"enrollment":1477,"conditions":3597,"interventions":3598},"NCT01631656","Combination Gel and Vascular ND in Mild to Moderate Rosacea",[93],"2011-02",[3586],[3562],{"intervention":3600,"totalTrials":215,"cells":3601},"pegfilgrastim",{"EARLY_PHASE1":3602,"PHASE1":3604,"PHASE2":3610,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3603,"activeCount":101},[],{"trials":3605,"activeCount":101},[3606],{"nctId":1567,"briefTitle":1568,"status":177,"phases":3607,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":101,"conditions":3608,"interventions":3609},[89],[19],[1574,1575,58,1576,1577,53],{"trials":3611,"activeCount":101},[3612],{"nctId":3613,"briefTitle":3614,"status":158,"phases":3615,"primaryCompletion":3596,"completion":3596,"start":3616,"enrollment":1733,"conditions":3617,"interventions":3625},"NCT01557959","Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],"2007-07",[3618,3619,3620,3621,3622,1735,3623,3624,1736],"Adenocarcinoma of the Lung","Adenosquamous Cell Lung Cancer","Bronchoalveolar Cell Lung Cancer","Large Cell Lung Cancer","Non-small Cell Lung Cancer","Squamous Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[1738,3600,3626,3627,3628,1565],"erlotinib hydrochloride","polymorphism analysis","genetic linkage analysis",{"trials":3630,"activeCount":101},[],{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":228,"soonestReadout":3639},[3635],{"nctId":3636,"briefTitle":3637,"status":113,"phases":3638,"primaryCompletion":3639,"completion":3639,"start":3640,"enrollment":1034,"conditions":3641,"interventions":3643},"NCT04174742","Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer",[],"2041-01","2019-12-17",[3642,19],"Breast",[3600],{"intervention":3645,"totalTrials":228,"cells":3646},"Fecal swab collection",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"trials":3654,"activeCount":101},[],{"trials":3656,"activeCount":101},[],{"trials":3658,"activeCount":228,"soonestReadout":320},[3659],{"nctId":3660,"briefTitle":3661,"status":113,"phases":3662,"primaryCompletion":320,"completion":320,"start":3663,"enrollment":204,"conditions":3664,"interventions":3665},"NCT05030038","Oral Aromatase Inhibitors Modify the Gut Microbiome",[],"2022-03-29",[19],[3645,3666],"Blood samples",{"intervention":3666,"totalTrials":228,"cells":3668},{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3670,"activeCount":101},[],{"trials":3672,"activeCount":101},[],{"trials":3674,"activeCount":101},[],{"trials":3676,"activeCount":101},[],{"trials":3678,"activeCount":101},[],{"trials":3680,"activeCount":228,"soonestReadout":320},[3681],{"nctId":3660,"briefTitle":3661,"status":113,"phases":3682,"primaryCompletion":320,"completion":320,"start":3663,"enrollment":204,"conditions":3683,"interventions":3684},[],[19],[3645,3666],{"intervention":3686,"totalTrials":228,"cells":3687},"Pharmacogenomic Testing with the \"Global Diversity Array with Enhanced PGx\"",{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3694,"PHASE4":3696,"NA":3698},{"trials":3689,"activeCount":101},[],{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[],{"trials":3695,"activeCount":101},[],{"trials":3697,"activeCount":101},[],{"trials":3699,"activeCount":228,"soonestReadout":359},[3700],{"nctId":3701,"briefTitle":3702,"status":113,"phases":3703,"primaryCompletion":359,"completion":359,"start":3704,"enrollment":2248,"conditions":3705,"interventions":3707},"NCT06489041","Evaluating Microarray Pharmacogenetic Testing in Cancer Patients",[93],"2025-07-18",[27,3706],"Gastrointestinal Cancer",[3686],{"intervention":3709,"totalTrials":228,"cells":3710},"KeraStat cream",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[],{"trials":3718,"activeCount":101},[],{"trials":3720,"activeCount":101},[],{"trials":3722,"activeCount":228,"soonestReadout":320},[3723],{"nctId":3724,"briefTitle":3725,"status":521,"phases":3726,"primaryCompletion":320,"completion":320,"start":3727,"enrollment":2140,"conditions":3728,"interventions":3730},"NCT06441266","M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis",[93],"2025-05-08",[3729],"Radiation Dermatitis",[3709],{"intervention":1027,"totalTrials":1850,"cells":3732},{"EARLY_PHASE1":3733,"PHASE1":3745,"PHASE2":3747,"PHASE3":3764,"PHASE4":3766,"NA":3776},{"trials":3734,"activeCount":101},[3735],{"nctId":3736,"briefTitle":3737,"status":177,"phases":3738,"primaryCompletion":2282,"completion":2282,"start":3739,"enrollment":101,"conditions":3740,"interventions":3744},"NCT03979664","Iontophoresis in Psoriasis",[88],"2021-03",[3741,3742,3743],"Psoriasis","Psoriasis Vulgaris","Skin Diseases",[1027],{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[3749,3753],{"nctId":2201,"briefTitle":2202,"status":158,"phases":3750,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":3751,"interventions":3752},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"nctId":3754,"briefTitle":3755,"status":158,"phases":3756,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":271,"conditions":3760,"interventions":3761},"NCT03773107","LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma",[89,90],"2022-11-07","2024-02-21","2019-01-03",[1762],[3762,3763,1027],"Carfilzomib","Ruxolitinib",{"trials":3765,"activeCount":101},[],{"trials":3767,"activeCount":101},[3768,3772],{"nctId":1018,"briefTitle":1019,"status":158,"phases":3769,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":3770,"interventions":3771},[92],[1025],[1027,167,993],{"nctId":1029,"briefTitle":1030,"status":158,"phases":3773,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":3774,"interventions":3775},[92],[1036],[1027,167,993,1038],{"trials":3777,"activeCount":101},[],{"intervention":1411,"totalTrials":233,"cells":3779},{"EARLY_PHASE1":3780,"PHASE1":3782,"PHASE2":3784,"PHASE3":3786,"PHASE4":3792,"NA":3829},{"trials":3781,"activeCount":101},[],{"trials":3783,"activeCount":101},[],{"trials":3785,"activeCount":101},[],{"trials":3787,"activeCount":101},[3788],{"nctId":1402,"briefTitle":1403,"status":177,"phases":3789,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":3790,"interventions":3791},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":3793,"activeCount":101},[3794,3804,3815],{"nctId":3795,"briefTitle":3796,"status":158,"phases":3797,"primaryCompletion":3798,"completion":3798,"start":3799,"enrollment":1377,"conditions":3800,"interventions":3802},"NCT02155257","Pain Expectations in Subjects With Osteoarthritis",[92],"2017-10","2014-07",[3801],"Osteoarthritis",[3803,1411],"Modafinil",{"nctId":3805,"briefTitle":3806,"status":143,"phases":3807,"primaryCompletion":3808,"completion":3808,"start":3809,"enrollment":3810,"conditions":3811,"interventions":3814},"NCT02685735","Predicting, Understanding and Speeding Recovery After TKA",[92],"2022-02-09","2016-06-02",350,[25,3812,3813],"Total Knee Replacement","Total Hip Replacement",[1411],{"nctId":3816,"briefTitle":3817,"status":143,"phases":3818,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":31,"conditions":3821,"interventions":3824},"NCT00619983","Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",[92],"2013-05","2008-02",[3822,3823],"Diabetic Neuropathic Pain","Chronic Low Back Pain",[3825,3826,3827,3828],"donepezil","duloxetine","donepezil 2.5 mg and duloxetine 30mg","gabapentin",{"trials":3830,"activeCount":101},[],{"intervention":1382,"totalTrials":215,"cells":3832},{"EARLY_PHASE1":3833,"PHASE1":3835,"PHASE2":3837,"PHASE3":3843,"PHASE4":3845,"NA":3863},{"trials":3834,"activeCount":101},[],{"trials":3836,"activeCount":101},[],{"trials":3838,"activeCount":101},[3839],{"nctId":1371,"briefTitle":1372,"status":143,"phases":3840,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":3841,"interventions":3842},[90],[1379],[1361,1381,1382],{"trials":3844,"activeCount":101},[],{"trials":3846,"activeCount":101},[3847,3855],{"nctId":3848,"briefTitle":3849,"status":143,"phases":3850,"primaryCompletion":1641,"completion":3851,"start":3852,"enrollment":271,"conditions":3853,"interventions":3854},"NCT00697034","Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin",[92],"2008-12","2006-06",[3741],[1382],{"nctId":3856,"briefTitle":3857,"status":158,"phases":3858,"primaryCompletion":3859,"completion":3860,"start":3820,"enrollment":834,"conditions":3861,"interventions":3862},"NCT00655811","Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects",[92],"2008-08","2009-10",[1379],[1382],{"trials":3864,"activeCount":101},[],{"intervention":3866,"totalTrials":215,"cells":3867},"Metformin",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3896,"PHASE4":3898,"NA":3910},{"trials":3869,"activeCount":101},[],{"trials":3871,"activeCount":101},[],{"trials":3873,"activeCount":101},[3874,3884],{"nctId":3875,"briefTitle":3876,"status":158,"phases":3877,"primaryCompletion":3878,"completion":3280,"start":3879,"enrollment":3880,"conditions":3881,"interventions":3883},"NCT05093959","Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction",[90],"2025-12-18","2022-01-04",86,[3882],"Heart Failure With Preserved Ejection Fraction",[3866],{"nctId":3885,"briefTitle":3886,"status":177,"phases":3887,"primaryCompletion":3888,"completion":3889,"start":385,"enrollment":101,"conditions":3890,"interventions":3893},"NCT05854966","CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[90],"2025-04","2025-09",[3891,3892,2466],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory",[3894,3866,3895],"CPI 613","Blood draws",{"trials":3897,"activeCount":101},[],{"trials":3899,"activeCount":101},[3900],{"nctId":3901,"briefTitle":3902,"status":158,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":3905,"enrollment":1377,"conditions":3906,"interventions":3909},"NCT02986659","Genomic Outcomes of Metformin",[92],"2018-11-15","2016-08-03",[3907,1458,3908,312],"Coronary Artery Disease","Obesity, Abdominal",[3866],{"trials":3911,"activeCount":101},[],{"intervention":3913,"totalTrials":215,"cells":3914},"adalimumab",{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3935,"PHASE4":3937,"NA":3949},{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[],{"trials":3920,"activeCount":101},[3921,3928],{"nctId":3922,"briefTitle":3923,"status":177,"phases":3924,"enrollment":101,"conditions":3925,"interventions":3927},"NCT00690911","Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis",[90],[3926],"Sarcoidosis",[3913],{"nctId":3929,"briefTitle":3930,"status":177,"phases":3931,"primaryCompletion":3616,"completion":3616,"start":3616,"enrollment":101,"conditions":3932,"interventions":3934},"NCT00690846","Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum",[90],[3933],"Pyoderma Gangrenosum",[3913],{"trials":3936,"activeCount":101},[],{"trials":3938,"activeCount":101},[3939],{"nctId":3940,"briefTitle":3941,"status":177,"phases":3942,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":101,"conditions":3945,"interventions":3947},"NCT04132388","Hidradenitis Suppurativa Patient Experience With Humira Treatment",[92],"2022-09-07","2020-08-20",[3946],"Hidradenitis Suppurativa",[3948],"Adalimumab",{"trials":3950,"activeCount":101},[],{"intervention":3952,"totalTrials":215,"cells":3953},"Donepezil",{"EARLY_PHASE1":3954,"PHASE1":3969,"PHASE2":3971,"PHASE3":3973,"PHASE4":3975,"NA":3989},{"trials":3955,"activeCount":101},[3956],{"nctId":3957,"briefTitle":3958,"status":158,"phases":3959,"primaryCompletion":3960,"completion":3960,"start":3852,"enrollment":1596,"conditions":3961,"interventions":3968},"NCT00452868","Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain",[88],"2010-02",[3962,3963,3964,3965,3966,3967],"Brain and Central Nervous System Tumors","Cognitive\u002FFunctional Effects","Long-term Effects Secondary to Cancer Therapy in Children","Neurotoxicity","Psychosocial Effects of Cancer and Its Treatment","Radiation Toxicity",[3952],{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[3977,3985],{"nctId":3978,"briefTitle":3979,"status":143,"phases":3980,"primaryCompletion":3981,"completion":3981,"start":3982,"enrollment":1850,"conditions":3983,"interventions":3984},"NCT01743976","Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain",[92],"2013-10-23","2012-12",[260],[3952],{"nctId":3816,"briefTitle":3817,"status":143,"phases":3986,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":31,"conditions":3987,"interventions":3988},[92],[3822,3823],[3825,3826,3827,3828],{"trials":3990,"activeCount":101},[],{"intervention":3992,"totalTrials":97,"cells":3993},"Propofol",{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4012,"PHASE4":4014,"NA":4027},{"trials":3995,"activeCount":101},[],{"trials":3997,"activeCount":101},[],{"trials":3999,"activeCount":101},[4000],{"nctId":4001,"briefTitle":4002,"status":158,"phases":4003,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":1527,"conditions":4006,"interventions":4008},"NCT01516684","Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures",[90],"2018-06-26","2012-05-14",[4007],"Malignant Neoplasm",[4009,4010,4011],"EMLA","propofol","fentanyl citrate",{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[4016],{"nctId":4017,"briefTitle":4018,"status":158,"phases":4019,"primaryCompletion":4020,"completion":4020,"start":4021,"enrollment":4022,"conditions":4023,"interventions":4025},"NCT04187196","Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion",[92],"2022-09-28","2020-04-29",73,[1117,4024],"Atrial Flutter",[3992,4026],"Methohexital",{"trials":4028,"activeCount":101},[],{"intervention":4030,"totalTrials":97,"cells":4031},"Escitalopram 10mg",{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4058},{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[4042,4051],{"nctId":4043,"briefTitle":4044,"status":158,"phases":4045,"primaryCompletion":4046,"completion":4046,"start":4047,"enrollment":461,"conditions":4048,"interventions":4050},"NCT03464383","Anxiety and Depression in Epilepsy: A Treatment Study",[92],"2019-09-20","2018-05-07",[30,22,4049],"Epilepsy",[4030],{"nctId":4052,"briefTitle":4053,"status":177,"phases":4054,"primaryCompletion":4055,"completion":4055,"start":4055,"enrollment":101,"conditions":4056,"interventions":4057},"NCT03522987","Anxiety and Depression in Epilepsy: A Pilot Treatment Study",[92],"2018-05",[30,22,4049],[4030],{"trials":4059,"activeCount":101},[],{"intervention":4061,"totalTrials":97,"cells":4062},"pioglitazone",{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4079,"PHASE3":4081,"PHASE4":4083,"NA":4095},{"trials":4064,"activeCount":101},[],{"trials":4066,"activeCount":101},[4067],{"nctId":4068,"briefTitle":4069,"status":158,"phases":4070,"primaryCompletion":2434,"completion":2434,"start":1537,"enrollment":3569,"conditions":4071,"interventions":4077},"NCT01151670","Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors",[89],[4072,4073,4074,4075,4076],"Brain Neoplasms, Malignant","Brain Neoplasms, Benign","Malignant Meningioma","Glioblastoma Multiforme","Anaplastic Astrocytoma",[4061,4078],"Pioglitazone",{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[],{"trials":4084,"activeCount":101},[4085],{"nctId":4086,"briefTitle":4087,"status":158,"phases":4088,"primaryCompletion":4089,"completion":4089,"start":4090,"enrollment":4091,"conditions":4092,"interventions":4094},"NCT00315146","Optimizing Body Composition for Function in Older Adults",[92],"2007-04","2006-04",88,[16,4093],"Overweight With Indications for Weight Loss",[4078],{"trials":4096,"activeCount":101},[],{"intervention":4098,"totalTrials":97,"cells":4099},"Tropicamide",{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4114,"PHASE3":4116,"PHASE4":4118,"NA":4130},{"trials":4101,"activeCount":101},[],{"trials":4103,"activeCount":101},[4104],{"nctId":4105,"briefTitle":4106,"status":158,"phases":4107,"primaryCompletion":3798,"completion":3798,"start":4108,"enrollment":1850,"conditions":4109,"interventions":4111},"NCT03139708","The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients",[89],"2016-09",[4110],"Intraocular Pressure",[4112,4113,4098],"Alphagan","Phenylephrine",{"trials":4115,"activeCount":101},[],{"trials":4117,"activeCount":101},[],{"trials":4119,"activeCount":101},[4120],{"nctId":4121,"briefTitle":4122,"status":158,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":4124,"enrollment":4125,"conditions":4126,"interventions":4127},"NCT03959176","The Effect of Brimonidine",[92],"2019-07-20",13,[4110],[4128,4098,4129],"Brimonidine","Phenylephrine Ophthalmic Product",{"trials":4131,"activeCount":101},[],{"intervention":4133,"totalTrials":97,"cells":4134},"Spironolactone",{"EARLY_PHASE1":4135,"PHASE1":4137,"PHASE2":4139,"PHASE3":4141,"PHASE4":4153,"NA":4163},{"trials":4136,"activeCount":101},[],{"trials":4138,"activeCount":101},[],{"trials":4140,"activeCount":101},[],{"trials":4142,"activeCount":101},[4143],{"nctId":4144,"briefTitle":4145,"status":158,"phases":4146,"primaryCompletion":4147,"completion":3982,"start":4148,"enrollment":771,"conditions":4149,"interventions":4152},"NCT00123955","PIE II: Pharmacological Intervention in the Elderly II",[91],"2009-06","2005-04",[4150,4151],"Diastolic Heart Failure","Heart Failure, Congestive",[4133],{"trials":4154,"activeCount":101},[4155],{"nctId":4156,"briefTitle":4157,"status":158,"phases":4158,"primaryCompletion":4159,"completion":4159,"start":1607,"enrollment":1377,"conditions":4160,"interventions":4162},"NCT02883400","Spironolactone After Liver Transplant",[92],"2018-01",[4161],"Transplant, Liver",[4133],{"trials":4164,"activeCount":101},[],{"intervention":4166,"totalTrials":97,"cells":4167},"Tranexamic acid",{"EARLY_PHASE1":4168,"PHASE1":4170,"PHASE2":4172,"PHASE3":4174,"PHASE4":4188,"NA":4200},{"trials":4169,"activeCount":101},[],{"trials":4171,"activeCount":101},[],{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":101},[4176],{"nctId":4177,"briefTitle":4178,"status":158,"phases":4179,"primaryCompletion":4180,"completion":4181,"start":4182,"enrollment":4183,"conditions":4184,"interventions":4186},"NCT02684851","The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery",[91],"2016-07-25","2017-07-25","2012-10",87,[4185],"Acetabular Fractures",[4187],"Tranexamic Acid",{"trials":4189,"activeCount":101},[4190],{"nctId":4191,"briefTitle":4192,"status":158,"phases":4193,"primaryCompletion":4194,"completion":4194,"start":1969,"enrollment":31,"conditions":4195,"interventions":4198},"NCT02656472","A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery",[92],"2017-04",[4196,4197],"Pediatric Cardiac Surgery","Complication of Extracorporeal Circulation",[4166,4199],"Epsilon Aminocaproic Acid",{"trials":4201,"activeCount":101},[],{"intervention":3826,"totalTrials":97,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4227},{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":101},[],{"trials":4213,"activeCount":101},[4214,4218],{"nctId":3816,"briefTitle":3817,"status":143,"phases":4215,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":31,"conditions":4216,"interventions":4217},[92],[3822,3823],[3825,3826,3827,3828],{"nctId":4219,"briefTitle":4220,"status":158,"phases":4221,"primaryCompletion":4222,"completion":4222,"start":4223,"enrollment":4224,"conditions":4225,"interventions":4226},"NCT04395001","Pain Response Evaluation of a Combined Intervention to Cope Effectively",[92],"2024-07-18","2021-02-24",280,[1479],[3826],{"trials":4228,"activeCount":101},[],{"intervention":4230,"totalTrials":228,"cells":4231},"Solution For Thoracic epidural block",{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4238,"PHASE4":4240,"NA":4251},{"trials":4233,"activeCount":101},[],{"trials":4235,"activeCount":101},[],{"trials":4237,"activeCount":101},[],{"trials":4239,"activeCount":101},[],{"trials":4241,"activeCount":101},[4242],{"nctId":4243,"briefTitle":4244,"status":158,"phases":4245,"primaryCompletion":4246,"completion":4246,"start":4247,"enrollment":117,"conditions":4248,"interventions":4250},"NCT03087604","Loss of Resistance, w\u002Fwo Stimulation, For Epidural Placement",[92],"2017-10-11","2017-03-17",[4249],"Anesthesia",[4230],{"trials":4252,"activeCount":101},[],{"intervention":4254,"totalTrials":228,"cells":4255},"Extended Release Epidural Morphine",{"EARLY_PHASE1":4256,"PHASE1":4258,"PHASE2":4260,"PHASE3":4262,"PHASE4":4264,"NA":4273},{"trials":4257,"activeCount":101},[],{"trials":4259,"activeCount":101},[],{"trials":4261,"activeCount":101},[],{"trials":4263,"activeCount":101},[],{"trials":4265,"activeCount":101},[4266],{"nctId":4267,"briefTitle":4268,"status":143,"phases":4269,"primaryCompletion":1869,"completion":1869,"start":1732,"enrollment":834,"conditions":4270,"interventions":4272},"NCT00934661","Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing",[92],[4271],"Hip Arthroplasty",[4254],{"trials":4274,"activeCount":101},[],{"intervention":4276,"totalTrials":228,"cells":4277},"Quercetin",{"EARLY_PHASE1":4278,"PHASE1":4280,"PHASE2":4282,"PHASE3":4284,"PHASE4":4286,"NA":4296},{"trials":4279,"activeCount":101},[],{"trials":4281,"activeCount":101},[],{"trials":4283,"activeCount":101},[],{"trials":4285,"activeCount":101},[],{"trials":4287,"activeCount":101},[4288],{"nctId":4289,"briefTitle":4290,"status":177,"phases":4291,"primaryCompletion":2339,"completion":2289,"start":4292,"enrollment":101,"conditions":4293,"interventions":4295},"NCT04258410","Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency",[92],"2022-09",[4294],"Menopause Related Conditions",[4276],{"trials":4297,"activeCount":101},[],{"intervention":4299,"totalTrials":228,"cells":4300},"Adapalene + benzoyl peroxide samples",{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4321},{"trials":4302,"activeCount":101},[],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"trials":4310,"activeCount":101},[4311],{"nctId":4312,"briefTitle":4313,"status":158,"phases":4314,"primaryCompletion":4315,"completion":4315,"start":4316,"enrollment":37,"conditions":4317,"interventions":4319},"NCT01504204","Effect of Samples on Acne Treatment With Epiduo® Gel",[92],"2012-11","2011-12",[4318],"Acne Vulgaris",[4299,4320],"Adapalene + benzoyl peroxide from standard tube",{"trials":4322,"activeCount":101},[],{"intervention":4320,"totalTrials":228,"cells":4324},{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4329,"PHASE3":4331,"PHASE4":4333,"NA":4339},{"trials":4326,"activeCount":101},[],{"trials":4328,"activeCount":101},[],{"trials":4330,"activeCount":101},[],{"trials":4332,"activeCount":101},[],{"trials":4334,"activeCount":101},[4335],{"nctId":4312,"briefTitle":4313,"status":158,"phases":4336,"primaryCompletion":4315,"completion":4315,"start":4316,"enrollment":37,"conditions":4337,"interventions":4338},[92],[4318],[4299,4320],{"trials":4340,"activeCount":101},[],{"intervention":4342,"totalTrials":228,"cells":4343},"Meropenem",{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4350,"PHASE4":4352,"NA":4363},{"trials":4345,"activeCount":101},[],{"trials":4347,"activeCount":101},[],{"trials":4349,"activeCount":101},[],{"trials":4351,"activeCount":101},[],{"trials":4353,"activeCount":101},[4354],{"nctId":4355,"briefTitle":4356,"status":177,"phases":4357,"primaryCompletion":3888,"completion":3888,"start":4358,"enrollment":101,"conditions":4359,"interventions":4361},"NCT05784844","Antimicrobial Revision in Persistent Febrile Neutropenia",[92],"2024-08",[4360],"Febrile Neutropenia",[4342,4362],"Micafungin",{"trials":4364,"activeCount":101},[],{"intervention":4362,"totalTrials":228,"cells":4366},{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4373,"PHASE4":4375,"NA":4381},{"trials":4368,"activeCount":101},[],{"trials":4370,"activeCount":101},[],{"trials":4372,"activeCount":101},[],{"trials":4374,"activeCount":101},[],{"trials":4376,"activeCount":101},[4377],{"nctId":4355,"briefTitle":4356,"status":177,"phases":4378,"primaryCompletion":3888,"completion":3888,"start":4358,"enrollment":101,"conditions":4379,"interventions":4380},[92],[4360],[4342,4362],{"trials":4382,"activeCount":101},[],{"intervention":185,"totalTrials":228,"cells":4384},{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4389,"PHASE3":4391,"PHASE4":4393,"NA":4399},{"trials":4386,"activeCount":101},[],{"trials":4388,"activeCount":101},[],{"trials":4390,"activeCount":101},[],{"trials":4392,"activeCount":101},[],{"trials":4394,"activeCount":101},[4395],{"nctId":175,"briefTitle":176,"status":177,"phases":4396,"primaryCompletion":179,"completion":179,"start":180,"enrollment":101,"conditions":4397,"interventions":4398},[92],[182,183],[135,185],{"trials":4400,"activeCount":101},[],{"intervention":4402,"totalTrials":228,"cells":4403},"Brovana",{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4410,"PHASE4":4412,"NA":4428},{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[4414],{"nctId":4415,"briefTitle":4416,"status":143,"phases":4417,"primaryCompletion":4418,"completion":4418,"start":4419,"enrollment":834,"conditions":4420,"interventions":4423},"NCT03219866","Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)",[92],"2020-04-01","2017-10-03",[4421,4422],"COPD","COPD Exacerbation",[4402,4424,4425,4426,4427],"Pulmicort","Atrovent","Advair Diskus","Spiriva HandiHaler",{"trials":4429,"activeCount":101},[],{"intervention":4424,"totalTrials":228,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4446},{"trials":4433,"activeCount":101},[],{"trials":4435,"activeCount":101},[],{"trials":4437,"activeCount":101},[],{"trials":4439,"activeCount":101},[],{"trials":4441,"activeCount":101},[4442],{"nctId":4415,"briefTitle":4416,"status":143,"phases":4443,"primaryCompletion":4418,"completion":4418,"start":4419,"enrollment":834,"conditions":4444,"interventions":4445},[92],[4421,4422],[4402,4424,4425,4426,4427],{"trials":4447,"activeCount":101},[],{"intervention":4425,"totalTrials":228,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4456,"PHASE4":4458,"NA":4464},{"trials":4451,"activeCount":101},[],{"trials":4453,"activeCount":101},[],{"trials":4455,"activeCount":101},[],{"trials":4457,"activeCount":101},[],{"trials":4459,"activeCount":101},[4460],{"nctId":4415,"briefTitle":4416,"status":143,"phases":4461,"primaryCompletion":4418,"completion":4418,"start":4419,"enrollment":834,"conditions":4462,"interventions":4463},[92],[4421,4422],[4402,4424,4425,4426,4427],{"trials":4465,"activeCount":101},[],{"intervention":4426,"totalTrials":228,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4476,"NA":4482},{"trials":4469,"activeCount":101},[],{"trials":4471,"activeCount":101},[],{"trials":4473,"activeCount":101},[],{"trials":4475,"activeCount":101},[],{"trials":4477,"activeCount":101},[4478],{"nctId":4415,"briefTitle":4416,"status":143,"phases":4479,"primaryCompletion":4418,"completion":4418,"start":4419,"enrollment":834,"conditions":4480,"interventions":4481},[92],[4421,4422],[4402,4424,4425,4426,4427],{"trials":4483,"activeCount":101},[],{"intervention":4427,"totalTrials":228,"cells":4485},{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4492,"PHASE4":4494,"NA":4500},{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"trials":4491,"activeCount":101},[],{"trials":4493,"activeCount":101},[],{"trials":4495,"activeCount":101},[4496],{"nctId":4415,"briefTitle":4416,"status":143,"phases":4497,"primaryCompletion":4418,"completion":4418,"start":4419,"enrollment":834,"conditions":4498,"interventions":4499},[92],[4421,4422],[4402,4424,4425,4426,4427],{"trials":4501,"activeCount":101},[],{"intervention":4503,"totalTrials":228,"cells":4504},"Peri-capsular Nerve Group",{"EARLY_PHASE1":4505,"PHASE1":4507,"PHASE2":4509,"PHASE3":4511,"PHASE4":4513,"NA":4526},{"trials":4506,"activeCount":101},[],{"trials":4508,"activeCount":101},[],{"trials":4510,"activeCount":101},[],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[4515],{"nctId":4516,"briefTitle":4517,"status":158,"phases":4518,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":4521,"conditions":4522,"interventions":4525},"NCT05261009","PENG Block Versus LP Block for THA Postop Pain",[92],"2023-07-20","2022-06-13",154,[4523,4524],"Pain, Postoperative","Hip Pain Chronic",[4503],{"trials":4527,"activeCount":101},[],{"intervention":4529,"totalTrials":228,"cells":4530},"hydrocortisone 17-butyrate 0.1% Cream preparation",{"EARLY_PHASE1":4531,"PHASE1":4533,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4551},{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[4541],{"nctId":4542,"briefTitle":4543,"status":158,"phases":4544,"primaryCompletion":2685,"completion":2685,"start":4545,"enrollment":3354,"conditions":4546,"interventions":4548},"NCT00693693","Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis",[92],"2006-11",[4547],"Atopic Dermatitis",[4529,4549,4550],"hydrocortisone 17-butyrate 0.1% Ointment preparation","hydrocortisone 17-butyrate 0.1% Lipocream preparation",{"trials":4552,"activeCount":101},[],{"intervention":4549,"totalTrials":228,"cells":4554},{"EARLY_PHASE1":4555,"PHASE1":4557,"PHASE2":4559,"PHASE3":4561,"PHASE4":4563,"NA":4569},{"trials":4556,"activeCount":101},[],{"trials":4558,"activeCount":101},[],{"trials":4560,"activeCount":101},[],{"trials":4562,"activeCount":101},[],{"trials":4564,"activeCount":101},[4565],{"nctId":4542,"briefTitle":4543,"status":158,"phases":4566,"primaryCompletion":2685,"completion":2685,"start":4545,"enrollment":3354,"conditions":4567,"interventions":4568},[92],[4547],[4529,4549,4550],{"trials":4570,"activeCount":101},[],{"intervention":4550,"totalTrials":228,"cells":4572},{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4587},{"trials":4574,"activeCount":101},[],{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":101},[],{"trials":4582,"activeCount":101},[4583],{"nctId":4542,"briefTitle":4543,"status":158,"phases":4584,"primaryCompletion":2685,"completion":2685,"start":4545,"enrollment":3354,"conditions":4585,"interventions":4586},[92],[4547],[4529,4549,4550],{"trials":4588,"activeCount":101},[],{"intervention":3803,"totalTrials":228,"cells":4590},{"EARLY_PHASE1":4591,"PHASE1":4593,"PHASE2":4595,"PHASE3":4597,"PHASE4":4599,"NA":4605},{"trials":4592,"activeCount":101},[],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[4601],{"nctId":3795,"briefTitle":3796,"status":158,"phases":4602,"primaryCompletion":3798,"completion":3798,"start":3799,"enrollment":1377,"conditions":4603,"interventions":4604},[92],[3801],[3803,1411],{"trials":4606,"activeCount":101},[],{"intervention":4608,"totalTrials":228,"cells":4609},"Risedronate Sodium 150 MG",{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4614,"PHASE3":4616,"PHASE4":4618,"NA":4629},{"trials":4611,"activeCount":101},[],{"trials":4613,"activeCount":101},[],{"trials":4615,"activeCount":101},[],{"trials":4617,"activeCount":101},[],{"trials":4619,"activeCount":101},[4620],{"nctId":4621,"briefTitle":4622,"status":158,"phases":4623,"primaryCompletion":4624,"completion":4624,"start":4625,"enrollment":1871,"conditions":4626,"interventions":4628},"NCT03411902","Weight Loss With Risedronate for Bone Health",[92],"2020-07-22","2018-06-15",[165,659,4627],"Weight Loss",[4608],{"trials":4630,"activeCount":101},[],{"intervention":4632,"totalTrials":228,"cells":4633},"Midazolam + Ketamine 10 MG\u002FML: 0.5 ML",{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4640,"PHASE4":4642,"NA":4657},{"trials":4635,"activeCount":101},[],{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":101},[4644],{"nctId":4645,"briefTitle":4646,"status":158,"phases":4647,"primaryCompletion":4648,"completion":4649,"start":4650,"enrollment":1679,"conditions":4651,"interventions":4654},"NCT03054103","Sedation Methods During Cataract Surgery",[92],"2016-11-05","2016-11-11","2016-05-03",[4652,4653],"Phacoemulsification","Cataract",[4632,4655,4656],"Midazolam + Ketamine 10 MG\u002FML: 1 ML","Midazolam + Normal saline",{"trials":4658,"activeCount":101},[],{"intervention":4655,"totalTrials":228,"cells":4660},{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4667,"PHASE4":4669,"NA":4675},{"trials":4662,"activeCount":101},[],{"trials":4664,"activeCount":101},[],{"trials":4666,"activeCount":101},[],{"trials":4668,"activeCount":101},[],{"trials":4670,"activeCount":101},[4671],{"nctId":4645,"briefTitle":4646,"status":158,"phases":4672,"primaryCompletion":4648,"completion":4649,"start":4650,"enrollment":1679,"conditions":4673,"interventions":4674},[92],[4652,4653],[4632,4655,4656],{"trials":4676,"activeCount":101},[],{"intervention":4656,"totalTrials":228,"cells":4678},{"EARLY_PHASE1":4679,"PHASE1":4681,"PHASE2":4683,"PHASE3":4685,"PHASE4":4687,"NA":4693},{"trials":4680,"activeCount":101},[],{"trials":4682,"activeCount":101},[],{"trials":4684,"activeCount":101},[],{"trials":4686,"activeCount":101},[],{"trials":4688,"activeCount":101},[4689],{"nctId":4645,"briefTitle":4646,"status":158,"phases":4690,"primaryCompletion":4648,"completion":4649,"start":4650,"enrollment":1679,"conditions":4691,"interventions":4692},[92],[4652,4653],[4632,4655,4656],{"trials":4694,"activeCount":101},[],{"intervention":4696,"totalTrials":228,"cells":4697},"Tamsulosin",{"EARLY_PHASE1":4698,"PHASE1":4700,"PHASE2":4702,"PHASE3":4704,"PHASE4":4706,"NA":4716},{"trials":4699,"activeCount":101},[],{"trials":4701,"activeCount":101},[],{"trials":4703,"activeCount":101},[],{"trials":4705,"activeCount":101},[],{"trials":4707,"activeCount":101},[4708],{"nctId":4709,"briefTitle":4710,"status":143,"phases":4711,"primaryCompletion":4712,"completion":4712,"start":591,"enrollment":233,"conditions":4713,"interventions":4715},"NCT04682366","The Effect of Tamsulosin on Postoperative Urinary Retention",[92],"2022-11-10",[4714],"Urinary Retention",[4696],{"trials":4717,"activeCount":101},[],{"intervention":4026,"totalTrials":228,"cells":4719},{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4726,"PHASE4":4728,"NA":4734},{"trials":4721,"activeCount":101},[],{"trials":4723,"activeCount":101},[],{"trials":4725,"activeCount":101},[],{"trials":4727,"activeCount":101},[],{"trials":4729,"activeCount":101},[4730],{"nctId":4017,"briefTitle":4018,"status":158,"phases":4731,"primaryCompletion":4020,"completion":4020,"start":4021,"enrollment":4022,"conditions":4732,"interventions":4733},[92],[1117,4024],[3992,4026],{"trials":4735,"activeCount":101},[],{"intervention":4737,"totalTrials":228,"cells":4738},"Spironolactone 50 mg",{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4743,"PHASE3":4745,"PHASE4":4747,"NA":4757},{"trials":4740,"activeCount":101},[],{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"trials":4746,"activeCount":101},[],{"trials":4748,"activeCount":101},[4749],{"nctId":4750,"briefTitle":4751,"status":177,"phases":4752,"primaryCompletion":4292,"completion":1405,"start":4753,"enrollment":101,"conditions":4754,"interventions":4756},"NCT04853355","Non-Responsive Diabetic Macular Edema and Spironolactone",[92],"2022-07",[4755],"Diabetic Maculopathy",[4737],{"trials":4758,"activeCount":101},[],{"intervention":4760,"totalTrials":228,"cells":4761},"clindamycin phosphate 1.2% and tretinoin 0.025%",{"EARLY_PHASE1":4762,"PHASE1":4764,"PHASE2":4766,"PHASE3":4768,"PHASE4":4770,"NA":4781},{"trials":4763,"activeCount":101},[],{"trials":4765,"activeCount":101},[],{"trials":4767,"activeCount":101},[],{"trials":4769,"activeCount":101},[],{"trials":4771,"activeCount":101},[4772],{"nctId":4773,"briefTitle":4774,"status":158,"phases":4775,"primaryCompletion":3860,"completion":3860,"start":4776,"enrollment":3354,"conditions":4777,"interventions":4778},"NCT01047189","Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris",[92],"2009-03",[4318],[4760,4779,4780],"clindamycin 1% gel","tretinoin 0.025% cream",{"trials":4782,"activeCount":101},[],{"intervention":4779,"totalTrials":228,"cells":4784},{"EARLY_PHASE1":4785,"PHASE1":4787,"PHASE2":4789,"PHASE3":4791,"PHASE4":4793,"NA":4799},{"trials":4786,"activeCount":101},[],{"trials":4788,"activeCount":101},[],{"trials":4790,"activeCount":101},[],{"trials":4792,"activeCount":101},[],{"trials":4794,"activeCount":101},[4795],{"nctId":4773,"briefTitle":4774,"status":158,"phases":4796,"primaryCompletion":3860,"completion":3860,"start":4776,"enrollment":3354,"conditions":4797,"interventions":4798},[92],[4318],[4760,4779,4780],{"trials":4800,"activeCount":101},[],{"intervention":4780,"totalTrials":228,"cells":4802},{"EARLY_PHASE1":4803,"PHASE1":4805,"PHASE2":4807,"PHASE3":4809,"PHASE4":4811,"NA":4817},{"trials":4804,"activeCount":101},[],{"trials":4806,"activeCount":101},[],{"trials":4808,"activeCount":101},[],{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[4813],{"nctId":4773,"briefTitle":4774,"status":158,"phases":4814,"primaryCompletion":3860,"completion":3860,"start":4776,"enrollment":3354,"conditions":4815,"interventions":4816},[92],[4318],[4760,4779,4780],{"trials":4818,"activeCount":101},[],{"intervention":4820,"totalTrials":228,"cells":4821},"Norco 5milligram-325milligram",{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4828,"PHASE4":4830,"NA":4842},{"trials":4823,"activeCount":101},[],{"trials":4825,"activeCount":101},[],{"trials":4827,"activeCount":101},[],{"trials":4829,"activeCount":101},[],{"trials":4831,"activeCount":101},[4832],{"nctId":4833,"briefTitle":4834,"status":158,"phases":4835,"primaryCompletion":4836,"completion":4836,"start":4837,"enrollment":31,"conditions":4838,"interventions":4840},"NCT03872843","Opioid Free Management After Ureteroscopy",[92],"2020-02-26","2019-09-19",[4839],"Kidney Stone",[4820,4841],"Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED",{"trials":4843,"activeCount":101},[],{"intervention":4841,"totalTrials":228,"cells":4845},{"EARLY_PHASE1":4846,"PHASE1":4848,"PHASE2":4850,"PHASE3":4852,"PHASE4":4854,"NA":4860},{"trials":4847,"activeCount":101},[],{"trials":4849,"activeCount":101},[],{"trials":4851,"activeCount":101},[],{"trials":4853,"activeCount":101},[],{"trials":4855,"activeCount":101},[4856],{"nctId":4833,"briefTitle":4834,"status":158,"phases":4857,"primaryCompletion":4836,"completion":4836,"start":4837,"enrollment":31,"conditions":4858,"interventions":4859},[92],[4839],[4820,4841],{"trials":4861,"activeCount":101},[],{"intervention":4863,"totalTrials":228,"cells":4864},"Vancomycin CI",{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4869,"PHASE3":4871,"PHASE4":4873,"NA":4885},{"trials":4866,"activeCount":101},[],{"trials":4868,"activeCount":101},[],{"trials":4870,"activeCount":101},[],{"trials":4872,"activeCount":101},[],{"trials":4874,"activeCount":101},[4875],{"nctId":4876,"briefTitle":4877,"status":143,"phases":4878,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":258,"conditions":4881,"interventions":4883},"NCT04648696","Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin",[92],"2022-10-31","2021-03-03",[4882],"Infection",[4863,4884],"Vancomycin II",{"trials":4886,"activeCount":101},[],{"intervention":4884,"totalTrials":228,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4895,"PHASE4":4897,"NA":4903},{"trials":4890,"activeCount":101},[],{"trials":4892,"activeCount":101},[],{"trials":4894,"activeCount":101},[],{"trials":4896,"activeCount":101},[],{"trials":4898,"activeCount":101},[4899],{"nctId":4876,"briefTitle":4877,"status":143,"phases":4900,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":258,"conditions":4901,"interventions":4902},[92],[4882],[4863,4884],{"trials":4904,"activeCount":101},[],{"intervention":4906,"totalTrials":228,"cells":4907},"Pecto-intercostal Fascial Block",{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4914,"PHASE4":4916,"NA":4930},{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[],{"trials":4915,"activeCount":101},[],{"trials":4917,"activeCount":101},[4918],{"nctId":4919,"briefTitle":4920,"status":158,"phases":4921,"primaryCompletion":4922,"completion":4923,"start":4924,"enrollment":245,"conditions":4925,"interventions":4928},"NCT05676814","Pecto-intercostal Fascial Block (PIFB) for Postop Analgesia Following Sternotomy in Cardiac Surgery Patients",[92],"2023-06-23","2023-06-24","2023-03-24",[4926,4927],"Analgesia","Sternotomy",[4906,4929],"PIFB with adjuvants",{"trials":4931,"activeCount":101},[],{"intervention":4929,"totalTrials":228,"cells":4933},{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4938,"PHASE3":4940,"PHASE4":4942,"NA":4948},{"trials":4935,"activeCount":101},[],{"trials":4937,"activeCount":101},[],{"trials":4939,"activeCount":101},[],{"trials":4941,"activeCount":101},[],{"trials":4943,"activeCount":101},[4944],{"nctId":4919,"briefTitle":4920,"status":158,"phases":4945,"primaryCompletion":4922,"completion":4923,"start":4924,"enrollment":245,"conditions":4946,"interventions":4947},[92],[4926,4927],[4906,4929],{"trials":4949,"activeCount":101},[],{"intervention":4951,"totalTrials":228,"cells":4952},"duramorph",{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4959,"PHASE4":4961,"NA":4971},{"trials":4954,"activeCount":101},[],{"trials":4956,"activeCount":101},[],{"trials":4958,"activeCount":101},[],{"trials":4960,"activeCount":101},[],{"trials":4962,"activeCount":101},[4963],{"nctId":4964,"briefTitle":4965,"status":143,"phases":4966,"primaryCompletion":2434,"completion":2434,"start":1454,"enrollment":4125,"conditions":4967,"interventions":4970},"NCT02143141","Low Pain Prediction in Cesarean Section Patients",[92],[4968,463,4969],"Scheduled Cesarean Sections","Side Effects",[4951],{"trials":4972,"activeCount":101},[],{"intervention":208,"totalTrials":228,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4989},{"trials":4976,"activeCount":101},[],{"trials":4978,"activeCount":101},[],{"trials":4980,"activeCount":101},[],{"trials":4982,"activeCount":101},[],{"trials":4984,"activeCount":101},[4985],{"nctId":199,"briefTitle":200,"status":143,"phases":4986,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":4987,"interventions":4988},[92],[206],[135,208],{"trials":4990,"activeCount":101},[],{"intervention":4992,"totalTrials":228,"cells":4993},"clomiphene plus gonadotropins",{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5013},{"trials":4995,"activeCount":101},[],{"trials":4997,"activeCount":101},[],{"trials":4999,"activeCount":101},[],{"trials":5001,"activeCount":101},[],{"trials":5003,"activeCount":101},[5004],{"nctId":5005,"briefTitle":5006,"status":158,"phases":5007,"primaryCompletion":1454,"completion":5008,"start":1375,"enrollment":28,"conditions":5009,"interventions":5011},"NCT01921166","Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study",[92],"2014-03",[5010],"Infertility",[4992,5012],"Leuprolide flare",{"trials":5014,"activeCount":101},[],{"intervention":5012,"totalTrials":228,"cells":5016},{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5021,"PHASE3":5023,"PHASE4":5025,"NA":5031},{"trials":5018,"activeCount":101},[],{"trials":5020,"activeCount":101},[],{"trials":5022,"activeCount":101},[],{"trials":5024,"activeCount":101},[],{"trials":5026,"activeCount":101},[5027],{"nctId":5005,"briefTitle":5006,"status":158,"phases":5028,"primaryCompletion":1454,"completion":5008,"start":1375,"enrollment":28,"conditions":5029,"interventions":5030},[92],[5010],[4992,5012],{"trials":5032,"activeCount":101},[],{"intervention":5034,"totalTrials":228,"cells":5035},"Atopiclair Nonsteroidal Cream",{"EARLY_PHASE1":5036,"PHASE1":5038,"PHASE2":5040,"PHASE3":5042,"PHASE4":5044,"NA":5055},{"trials":5037,"activeCount":101},[],{"trials":5039,"activeCount":101},[],{"trials":5041,"activeCount":101},[],{"trials":5043,"activeCount":101},[],{"trials":5045,"activeCount":101},[5046],{"nctId":5047,"briefTitle":5048,"status":158,"phases":5049,"primaryCompletion":5050,"completion":3960,"start":5051,"enrollment":2511,"conditions":5052,"interventions":5053},"NCT01093469","Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis",[92],"2009-12","2009-09",[4547],[5034,5054],"EpiCeram",{"trials":5056,"activeCount":101},[],{"intervention":5054,"totalTrials":228,"cells":5058},{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5063,"PHASE3":5065,"PHASE4":5067,"NA":5073},{"trials":5060,"activeCount":101},[],{"trials":5062,"activeCount":101},[],{"trials":5064,"activeCount":101},[],{"trials":5066,"activeCount":101},[],{"trials":5068,"activeCount":101},[5069],{"nctId":5047,"briefTitle":5048,"status":158,"phases":5070,"primaryCompletion":5050,"completion":3960,"start":5051,"enrollment":2511,"conditions":5071,"interventions":5072},[92],[4547],[5034,5054],{"trials":5074,"activeCount":101},[],{"intervention":5076,"totalTrials":228,"cells":5077},"Alefacept",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5086,"NA":5095},{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[],{"trials":5085,"activeCount":101},[],{"trials":5087,"activeCount":101},[5088],{"nctId":5089,"briefTitle":5090,"status":158,"phases":5091,"primaryCompletion":5050,"completion":1732,"start":5092,"enrollment":1548,"conditions":5093,"interventions":5094},"NCT00655564","Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis",[92],"2008-05",[3741],[5076],{"trials":5096,"activeCount":101},[],{"intervention":5098,"totalTrials":228,"cells":5099},"Tetracaine",{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5104,"PHASE3":5106,"PHASE4":5108,"NA":5118},{"trials":5101,"activeCount":101},[],{"trials":5103,"activeCount":101},[],{"trials":5105,"activeCount":101},[],{"trials":5107,"activeCount":101},[],{"trials":5109,"activeCount":101},[5110],{"nctId":5111,"briefTitle":5112,"status":143,"phases":5113,"primaryCompletion":5114,"completion":5114,"start":1888,"enrollment":1586,"conditions":5115,"interventions":5117},"NCT01005459","Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE",[92],"2011-12-12",[5116],"Labor Pain",[5098,167],{"trials":5119,"activeCount":101},[],{"intervention":5121,"totalTrials":228,"cells":5122},"l-Histidine",{"EARLY_PHASE1":5123,"PHASE1":5125,"PHASE2":5127,"PHASE3":5129,"PHASE4":5131,"NA":5140},{"trials":5124,"activeCount":101},[],{"trials":5126,"activeCount":101},[],{"trials":5128,"activeCount":101},[],{"trials":5130,"activeCount":101},[],{"trials":5132,"activeCount":101},[5133],{"nctId":5134,"briefTitle":5135,"status":177,"phases":5136,"primaryCompletion":3528,"completion":3528,"start":3888,"enrollment":101,"conditions":5137,"interventions":5139},"NCT06169826","Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease",[92],[5138],"Alzheimer Disease",[5121],{"trials":5141,"activeCount":101},[],{"intervention":5143,"totalTrials":228,"cells":5144},"Cilostazol",{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5153,"NA":5164},{"trials":5146,"activeCount":101},[],{"trials":5148,"activeCount":101},[],{"trials":5150,"activeCount":101},[],{"trials":5152,"activeCount":101},[],{"trials":5154,"activeCount":101},[5155],{"nctId":5156,"briefTitle":5157,"status":143,"phases":5158,"primaryCompletion":5159,"completion":5159,"start":2387,"enrollment":37,"conditions":5160,"interventions":5163},"NCT02374957","Cilostazol After Lower Extremity Arterial Revascularization Trial",[92],"2017-06-30",[5161,5162],"Peripheral Arterial Disease","Claudication (Finding)",[5143],{"trials":5165,"activeCount":101},[],{"intervention":5167,"totalTrials":228,"cells":5168},"Fluocinonide Cream 0.1%",{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5175,"PHASE4":5177,"NA":5185},{"trials":5170,"activeCount":101},[],{"trials":5172,"activeCount":101},[],{"trials":5174,"activeCount":101},[],{"trials":5176,"activeCount":101},[],{"trials":5178,"activeCount":101},[5179],{"nctId":5180,"briefTitle":5181,"status":158,"phases":5182,"primaryCompletion":5051,"completion":3860,"start":4776,"enrollment":37,"conditions":5183,"interventions":5184},"NCT01049243","A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis",[92],[4547],[5167],{"trials":5186,"activeCount":101},[],{"intervention":5188,"totalTrials":228,"cells":5189},"imiquimod",{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5194,"PHASE3":5196,"PHASE4":5198,"NA":5209},{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[],{"trials":5195,"activeCount":101},[],{"trials":5197,"activeCount":101},[],{"trials":5199,"activeCount":101},[5200],{"nctId":5201,"briefTitle":5202,"status":158,"phases":5203,"completion":5204,"start":5205,"enrollment":1548,"conditions":5206,"interventions":5208},"NCT00314756","Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage",[92],"2005-11","2005-03",[5207],"Basal Cell Carcinoma",[5188],{"trials":5210,"activeCount":101},[],{"intervention":5212,"totalTrials":228,"cells":5213},"Enoxaparin",{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5222,"NA":5236},{"trials":5215,"activeCount":101},[],{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[],{"trials":5221,"activeCount":101},[],{"trials":5223,"activeCount":101},[5224],{"nctId":5225,"briefTitle":5226,"status":143,"phases":5227,"primaryCompletion":5228,"completion":5228,"start":5229,"enrollment":5230,"conditions":5231,"interventions":5235},"NCT03296033","Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin",[92],"2022-01-14","2017-10-24",122,[5232,5233,5234],"Anticoagulants and Bleeding Disorders","Surgery","Regional Anesthesia Morbidity",[5212,5212],{"trials":5237,"activeCount":101},[],{"intervention":390,"totalTrials":228,"cells":5239},{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5244,"PHASE3":5246,"PHASE4":5248,"NA":5254},{"trials":5241,"activeCount":101},[],{"trials":5243,"activeCount":101},[],{"trials":5245,"activeCount":101},[],{"trials":5247,"activeCount":101},[],{"trials":5249,"activeCount":101},[5250],{"nctId":381,"briefTitle":382,"status":177,"phases":5251,"primaryCompletion":384,"completion":385,"start":386,"enrollment":101,"conditions":5252,"interventions":5253},[92],[388],[390,368,391],{"trials":5255,"activeCount":101},[],{"intervention":391,"totalTrials":228,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5262,"PHASE3":5264,"PHASE4":5266,"NA":5272},{"trials":5259,"activeCount":101},[],{"trials":5261,"activeCount":101},[],{"trials":5263,"activeCount":101},[],{"trials":5265,"activeCount":101},[],{"trials":5267,"activeCount":101},[5268],{"nctId":381,"briefTitle":382,"status":177,"phases":5269,"primaryCompletion":384,"completion":385,"start":386,"enrollment":101,"conditions":5270,"interventions":5271},[92],[388],[390,368,391],{"trials":5273,"activeCount":101},[],{"intervention":4199,"totalTrials":228,"cells":5275},{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5282,"PHASE4":5284,"NA":5290},{"trials":5277,"activeCount":101},[],{"trials":5279,"activeCount":101},[],{"trials":5281,"activeCount":101},[],{"trials":5283,"activeCount":101},[],{"trials":5285,"activeCount":101},[5286],{"nctId":4191,"briefTitle":4192,"status":158,"phases":5287,"primaryCompletion":4194,"completion":4194,"start":1969,"enrollment":31,"conditions":5288,"interventions":5289},[92],[4196,4197],[4166,4199],{"trials":5291,"activeCount":101},[],{"intervention":5293,"totalTrials":228,"cells":5294},"Onabotulinumtoxin A",{"EARLY_PHASE1":5295,"PHASE1":5297,"PHASE2":5299,"PHASE3":5301,"PHASE4":5303,"NA":5312},{"trials":5296,"activeCount":101},[],{"trials":5298,"activeCount":101},[],{"trials":5300,"activeCount":101},[],{"trials":5302,"activeCount":101},[],{"trials":5304,"activeCount":101},[5305],{"nctId":5306,"briefTitle":5307,"status":158,"phases":5308,"primaryCompletion":5309,"completion":5309,"start":1607,"enrollment":23,"conditions":5310,"interventions":5311},"NCT02297100","Intravesicular Onabotulinumtoxin A in Interstitial Cystitis",[92],"2018-01-10",[3484],[5293],{"trials":5313,"activeCount":101},[],{"intervention":5315,"totalTrials":228,"cells":5316},"Baclofen",{"EARLY_PHASE1":5317,"PHASE1":5319,"PHASE2":5321,"PHASE3":5323,"PHASE4":5325,"NA":5336},{"trials":5318,"activeCount":101},[],{"trials":5320,"activeCount":101},[],{"trials":5322,"activeCount":101},[],{"trials":5324,"activeCount":101},[],{"trials":5326,"activeCount":101},[5327],{"nctId":5328,"briefTitle":5329,"status":143,"phases":5330,"primaryCompletion":1869,"completion":1869,"start":5051,"enrollment":271,"conditions":5331,"interventions":5335},"NCT01003249","Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen",[92],[5332,5333,5334],"Overactive Bladder","Constipation","Lower Urinary Tract Symptoms",[5315],{"trials":5337,"activeCount":101},[],{"intervention":3827,"totalTrials":228,"cells":5339},{"EARLY_PHASE1":5340,"PHASE1":5342,"PHASE2":5344,"PHASE3":5346,"PHASE4":5348,"NA":5354},{"trials":5341,"activeCount":101},[],{"trials":5343,"activeCount":101},[],{"trials":5345,"activeCount":101},[],{"trials":5347,"activeCount":101},[],{"trials":5349,"activeCount":101},[5350],{"nctId":3816,"briefTitle":3817,"status":143,"phases":5351,"primaryCompletion":3819,"completion":3819,"start":3820,"enrollment":31,"conditions":5352,"interventions":5353},[92],[3822,3823],[3825,3826,3827,3828],{"trials":5355,"activeCount":101},[],{"intervention":5357,"totalTrials":228,"cells":5358},"Progesterone",{"EARLY_PHASE1":5359,"PHASE1":5361,"PHASE2":5363,"PHASE3":5365,"PHASE4":5367,"NA":5377},{"trials":5360,"activeCount":101},[],{"trials":5362,"activeCount":101},[],{"trials":5364,"activeCount":101},[],{"trials":5366,"activeCount":101},[],{"trials":5368,"activeCount":101},[5369],{"nctId":5370,"briefTitle":5371,"status":158,"phases":5372,"primaryCompletion":2519,"completion":2519,"start":5373,"enrollment":204,"conditions":5374,"interventions":5376},"NCT01809639","Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion",[92],"2013-06",[5375],"Concussion",[5357],{"trials":5378,"activeCount":101},[],{"intervention":5380,"totalTrials":228,"cells":5381},"Benzoyl Peroxide",{"EARLY_PHASE1":5382,"PHASE1":5384,"PHASE2":5386,"PHASE3":5388,"PHASE4":5390,"NA":5399},{"trials":5383,"activeCount":101},[],{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[5392],{"nctId":5393,"briefTitle":5394,"status":158,"phases":5395,"primaryCompletion":5092,"completion":5092,"start":5396,"enrollment":37,"conditions":5397,"interventions":5398},"NCT00658112","Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne",[92],"2006-07",[4318],[5380],{"trials":5400,"activeCount":101},[],{"intervention":4128,"totalTrials":228,"cells":5402},{"EARLY_PHASE1":5403,"PHASE1":5405,"PHASE2":5407,"PHASE3":5409,"PHASE4":5411,"NA":5417},{"trials":5404,"activeCount":101},[],{"trials":5406,"activeCount":101},[],{"trials":5408,"activeCount":101},[],{"trials":5410,"activeCount":101},[],{"trials":5412,"activeCount":101},[5413],{"nctId":4121,"briefTitle":4122,"status":158,"phases":5414,"primaryCompletion":4124,"completion":4124,"start":4124,"enrollment":4125,"conditions":5415,"interventions":5416},[92],[4110],[4128,4098,4129],{"trials":5418,"activeCount":101},[],{"intervention":4129,"totalTrials":228,"cells":5420},{"EARLY_PHASE1":5421,"PHASE1":5423,"PHASE2":5425,"PHASE3":5427,"PHASE4":5429,"NA":5435},{"trials":5422,"activeCount":101},[],{"trials":5424,"activeCount":101},[],{"trials":5426,"activeCount":101},[],{"trials":5428,"activeCount":101},[],{"trials":5430,"activeCount":101},[5431],{"nctId":4121,"briefTitle":4122,"status":158,"phases":5432,"primaryCompletion":4124,"completion":4124,"start":4124,"enrollment":4125,"conditions":5433,"interventions":5434},[92],[4110],[4128,4098,4129],{"trials":5436,"activeCount":101},[],{"intervention":5438,"totalTrials":228,"cells":5439},"Fluorouracil 0.5%",{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5458},{"trials":5441,"activeCount":101},[],{"trials":5443,"activeCount":101},[],{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":101},[],{"trials":5449,"activeCount":101},[5450],{"nctId":5451,"briefTitle":5452,"status":158,"phases":5453,"primaryCompletion":1641,"completion":5454,"start":4089,"enrollment":37,"conditions":5455,"interventions":5457},"NCT00696488","Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population",[92],"2008-10",[5456],"Actinic Keratosis",[5438],{"trials":5459,"activeCount":101},[],{"intervention":5461,"totalTrials":228,"cells":5462},"Dalbavancin",{"EARLY_PHASE1":5463,"PHASE1":5465,"PHASE2":5467,"PHASE3":5469,"PHASE4":5471,"NA":5483},{"trials":5464,"activeCount":101},[],{"trials":5466,"activeCount":101},[],{"trials":5468,"activeCount":101},[],{"trials":5470,"activeCount":101},[],{"trials":5472,"activeCount":101},[5473],{"nctId":5474,"briefTitle":5475,"status":177,"phases":5476,"primaryCompletion":3888,"completion":5477,"start":5478,"enrollment":101,"conditions":5479,"interventions":5482},"NCT03982030","Dalbavancin Outpatient Pilot",[92],"2025-07","2023-04",[5480,5481],"Gram-Positive Bacterial Infections","Soft Tissue Infections",[5461],{"trials":5484,"activeCount":101},[],{"intervention":5486,"totalTrials":228,"cells":5487},"moderate- or high-intensity statin\u002F rosuvastatin",{"EARLY_PHASE1":5488,"PHASE1":5490,"PHASE2":5492,"PHASE3":5494,"PHASE4":5496,"NA":5506},{"trials":5489,"activeCount":101},[],{"trials":5491,"activeCount":101},[],{"trials":5493,"activeCount":101},[],{"trials":5495,"activeCount":101},[],{"trials":5497,"activeCount":101},[5498],{"nctId":5499,"briefTitle":5500,"status":158,"phases":5501,"primaryCompletion":1159,"completion":5502,"start":5503,"enrollment":31,"conditions":5504,"interventions":5505},"NCT05742841","EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)",[92],"2023-07-15","2023-03-08",[2780],[5486],{"trials":5507,"activeCount":101},[],{"intervention":5509,"totalTrials":228,"cells":5510},"Adapalene",{"EARLY_PHASE1":5511,"PHASE1":5513,"PHASE2":5515,"PHASE3":5517,"PHASE4":5519,"NA":5528},{"trials":5512,"activeCount":101},[],{"trials":5514,"activeCount":101},[],{"trials":5516,"activeCount":101},[],{"trials":5518,"activeCount":101},[],{"trials":5520,"activeCount":101},[5521],{"nctId":5522,"briefTitle":5523,"status":158,"phases":5524,"primaryCompletion":5525,"completion":3860,"start":3852,"enrollment":434,"conditions":5526,"interventions":5527},"NCT00696449","Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris",[92],"2007-05",[4318],[5509],{"trials":5529,"activeCount":101},[],{"intervention":5531,"totalTrials":228,"cells":5532},"Omidria",{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5539,"PHASE4":5541,"NA":5553},{"trials":5534,"activeCount":101},[],{"trials":5536,"activeCount":101},[],{"trials":5538,"activeCount":101},[],{"trials":5540,"activeCount":101},[],{"trials":5542,"activeCount":101},[5543],{"nctId":5544,"briefTitle":5545,"status":158,"phases":5546,"primaryCompletion":5547,"completion":5548,"start":5549,"enrollment":5550,"conditions":5551,"interventions":5552},"NCT03864133","No Drop Post-Op Cataract Surgery",[92],"2021-06-30","2021-08-16","2019-07-08",94,[4653],[5531],{"trials":5554,"activeCount":101},[],{"intervention":5556,"totalTrials":228,"cells":5557},"brimonidine topical gel 0.33% & survey",{"EARLY_PHASE1":5558,"PHASE1":5560,"PHASE2":5562,"PHASE3":5564,"PHASE4":5566,"NA":5577},{"trials":5559,"activeCount":101},[],{"trials":5561,"activeCount":101},[],{"trials":5563,"activeCount":101},[],{"trials":5565,"activeCount":101},[],{"trials":5567,"activeCount":101},[5568],{"nctId":5569,"briefTitle":5570,"status":158,"phases":5571,"primaryCompletion":5572,"completion":5572,"start":5573,"enrollment":37,"conditions":5574,"interventions":5575},"NCT03048058","Internet Surveys and Their Impact on Adherence for Rosacea",[92],"2017-06","2016-05-05",[3586],[5556,5576],"brimonidine topical gel 0.33% & SOC",{"trials":5578,"activeCount":101},[],{"intervention":5576,"totalTrials":228,"cells":5580},{"EARLY_PHASE1":5581,"PHASE1":5583,"PHASE2":5585,"PHASE3":5587,"PHASE4":5589,"NA":5595},{"trials":5582,"activeCount":101},[],{"trials":5584,"activeCount":101},[],{"trials":5586,"activeCount":101},[],{"trials":5588,"activeCount":101},[],{"trials":5590,"activeCount":101},[5591],{"nctId":5569,"briefTitle":5570,"status":158,"phases":5592,"primaryCompletion":5572,"completion":5572,"start":5573,"enrollment":37,"conditions":5593,"interventions":5594},[92],[3586],[5556,5576],{"trials":5596,"activeCount":101},[],{"intervention":5598,"totalTrials":228,"cells":5599},"OnabotulinumtoxinA 100 Units",{"EARLY_PHASE1":5600,"PHASE1":5602,"PHASE2":5604,"PHASE3":5606,"PHASE4":5608,"NA":5619},{"trials":5601,"activeCount":101},[],{"trials":5603,"activeCount":101},[],{"trials":5605,"activeCount":101},[],{"trials":5607,"activeCount":101},[],{"trials":5609,"activeCount":101},[5610],{"nctId":5611,"briefTitle":5612,"status":158,"phases":5613,"primaryCompletion":5614,"completion":5615,"start":5616,"enrollment":17,"conditions":5617,"interventions":5618},"NCT04124939","Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?",[92],"2022-11-09","2023-02-23","2019-11-10",[5332],[5598],{"trials":5620,"activeCount":101},[],{"intervention":5622,"totalTrials":228,"cells":5623},"Imipenem+Relebactam",{"EARLY_PHASE1":5624,"PHASE1":5626,"PHASE2":5628,"PHASE3":5630,"PHASE4":5632,"NA":5646},{"trials":5625,"activeCount":101},[],{"trials":5627,"activeCount":101},[],{"trials":5629,"activeCount":101},[],{"trials":5631,"activeCount":101},[],{"trials":5633,"activeCount":101},[5634],{"nctId":5635,"briefTitle":5636,"status":177,"phases":5637,"primaryCompletion":5638,"completion":5638,"start":5639,"enrollment":101,"conditions":5640,"interventions":5645},"NCT04785924","Imipenem\u002FCilastatin\u002FRelebactam (IMI\u002FREL) in Treatment of CRE Infections",[92],"2023-01-12","2021-06-07",[5641,5642,5643,5644],"Carbapenem-Resistant Enterobacteriaceae Infection","KPC","Gram-Negative Bacterial Infections","Antibiotic Resistant Infection",[5622],{"trials":5647,"activeCount":101},[],{"intervention":5649,"totalTrials":228,"cells":5650},"Desoximetasone 0.25% spray",{"EARLY_PHASE1":5651,"PHASE1":5653,"PHASE2":5655,"PHASE3":5657,"PHASE4":5659,"NA":5669},{"trials":5652,"activeCount":101},[],{"trials":5654,"activeCount":101},[],{"trials":5656,"activeCount":101},[],{"trials":5658,"activeCount":101},[],{"trials":5660,"activeCount":101},[5661],{"nctId":5662,"briefTitle":5663,"status":158,"phases":5664,"primaryCompletion":5665,"completion":5665,"start":5666,"enrollment":1871,"conditions":5667,"interventions":5668},"NCT03050294","Evaluating Treatment Resistant Dermatitis TaroIIR",[92],"2017-06-01","2017-02-01",[4547,3741],[5649],{"trials":5670,"activeCount":101},[],{"intervention":5672,"totalTrials":228,"cells":5673},"Crotaline Polyvalent Immune Fab",{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5678,"PHASE3":5680,"PHASE4":5682,"NA":5692},{"trials":5675,"activeCount":101},[],{"trials":5677,"activeCount":101},[],{"trials":5679,"activeCount":101},[],{"trials":5681,"activeCount":101},[],{"trials":5683,"activeCount":101},[5684],{"nctId":5685,"briefTitle":5686,"status":143,"phases":5687,"primaryCompletion":5092,"completion":5092,"start":4148,"enrollment":4125,"conditions":5688,"interventions":5690},"NCT00303303","The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations",[92],[5689],"Snake Envenomation",[5672,5691],"Crotaline Immune Fab",{"trials":5693,"activeCount":101},[],{"intervention":5691,"totalTrials":228,"cells":5695},{"EARLY_PHASE1":5696,"PHASE1":5698,"PHASE2":5700,"PHASE3":5702,"PHASE4":5704,"NA":5710},{"trials":5697,"activeCount":101},[],{"trials":5699,"activeCount":101},[],{"trials":5701,"activeCount":101},[],{"trials":5703,"activeCount":101},[],{"trials":5705,"activeCount":101},[5706],{"nctId":5685,"briefTitle":5686,"status":143,"phases":5707,"primaryCompletion":5092,"completion":5092,"start":4148,"enrollment":4125,"conditions":5708,"interventions":5709},[92],[5689],[5672,5691],{"trials":5711,"activeCount":101},[],{"intervention":5713,"totalTrials":228,"cells":5714},"topical desonide hydrogel 0.05%",{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5719,"PHASE3":5721,"PHASE4":5723,"NA":5732},{"trials":5716,"activeCount":101},[],{"trials":5718,"activeCount":101},[],{"trials":5720,"activeCount":101},[],{"trials":5722,"activeCount":101},[],{"trials":5724,"activeCount":101},[5725],{"nctId":5726,"briefTitle":5727,"status":158,"phases":5728,"primaryCompletion":1376,"completion":5729,"start":1641,"enrollment":17,"conditions":5730,"interventions":5731},"NCT00690833","Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis",[92],"2009-11",[4547],[5713],{"trials":5733,"activeCount":101},[],{"intervention":5735,"totalTrials":228,"cells":5736},"Ticagrelor",{"EARLY_PHASE1":5737,"PHASE1":5739,"PHASE2":5741,"PHASE3":5743,"PHASE4":5745,"NA":5758},{"trials":5738,"activeCount":101},[],{"trials":5740,"activeCount":101},[],{"trials":5742,"activeCount":101},[],{"trials":5744,"activeCount":101},[],{"trials":5746,"activeCount":101},[5747],{"nctId":5748,"briefTitle":5749,"status":158,"phases":5750,"primaryCompletion":5751,"completion":5752,"start":5753,"enrollment":5754,"conditions":5755,"interventions":5757},"NCT03708588","Chewed Versus Integral Pill of Ticagrelor",[92],"2020-12-31","2021-07-31","2018-09-19",112,[5756],"Percutaneous Coronary Intervention",[5735,5735],{"trials":5759,"activeCount":101},[],{"intervention":5761,"totalTrials":228,"cells":5762},"Lidocaine injection flushed",{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5769,"PHASE4":5771,"NA":5783},{"trials":5764,"activeCount":101},[],{"trials":5766,"activeCount":101},[],{"trials":5768,"activeCount":101},[],{"trials":5770,"activeCount":101},[],{"trials":5772,"activeCount":101},[5773],{"nctId":5774,"briefTitle":5775,"status":158,"phases":5776,"primaryCompletion":5777,"completion":5777,"start":5778,"enrollment":423,"conditions":5779,"interventions":5781},"NCT03057704","Comparison of Two Techniques of IV Lidocaine on Propofol Injection Pain",[92],"2017-01-20","2016-12-05",[5780],"Injections, Intravenous",[5761,5782],"Lidocaine injection tourniquet",{"trials":5784,"activeCount":101},[],{"intervention":5782,"totalTrials":228,"cells":5786},{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5795,"NA":5801},{"trials":5788,"activeCount":101},[],{"trials":5790,"activeCount":101},[],{"trials":5792,"activeCount":101},[],{"trials":5794,"activeCount":101},[],{"trials":5796,"activeCount":101},[5797],{"nctId":5774,"briefTitle":5775,"status":158,"phases":5798,"primaryCompletion":5777,"completion":5777,"start":5778,"enrollment":423,"conditions":5799,"interventions":5800},[92],[5780],[5761,5782],{"trials":5802,"activeCount":101},[],{"intervention":5804,"totalTrials":228,"cells":5805},"ReCell",{"EARLY_PHASE1":5806,"PHASE1":5808,"PHASE2":5810,"PHASE3":5812,"PHASE4":5814,"NA":5827},{"trials":5807,"activeCount":101},[],{"trials":5809,"activeCount":101},[],{"trials":5811,"activeCount":101},[],{"trials":5813,"activeCount":101},[],{"trials":5815,"activeCount":101},[5816],{"nctId":5817,"briefTitle":5818,"status":143,"phases":5819,"primaryCompletion":5820,"completion":5821,"start":5822,"enrollment":228,"conditions":5823,"interventions":5826},"NCT05386368","RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients",[92],"2023-07-07","2024-05-06","2023-03-22",[5824,5825],"Carbon Dioxide Laser","Photoaging",[5804],{"trials":5828,"activeCount":101},[],{"intervention":5830,"totalTrials":228,"cells":5831},"aliskiren",{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5836,"PHASE3":5838,"PHASE4":5840,"NA":5852},{"trials":5833,"activeCount":101},[],{"trials":5835,"activeCount":101},[],{"trials":5837,"activeCount":101},[],{"trials":5839,"activeCount":101},[],{"trials":5841,"activeCount":101},[5842],{"nctId":5843,"briefTitle":5844,"status":158,"phases":5845,"primaryCompletion":5846,"completion":4316,"start":5847,"enrollment":5848,"conditions":5849,"interventions":5851},"NCT00982033","Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction",[92],"2011-09","2009-07",52,[5850],"Heart Failure",[5830],{"trials":5853,"activeCount":101},[],{"intervention":5855,"totalTrials":228,"cells":5856},"Adductor canal block",{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5861,"PHASE3":5863,"PHASE4":5865,"NA":5878},{"trials":5858,"activeCount":101},[],{"trials":5860,"activeCount":101},[],{"trials":5862,"activeCount":101},[],{"trials":5864,"activeCount":101},[],{"trials":5866,"activeCount":101},[5867],{"nctId":5868,"briefTitle":5869,"status":158,"phases":5870,"primaryCompletion":2139,"completion":2139,"start":5871,"enrollment":5872,"conditions":5873,"interventions":5876},"NCT01818531","Adductor Canal Block for Medial Compartment Knee Arthroplasty",[92],"2013-04",150,[5874,5875],"Postoperative Analgesia","Medial Unicompartmental Knee Arthroplasty",[5855,5877],"Lumbar plexus block",{"trials":5879,"activeCount":101},[],{"intervention":5877,"totalTrials":228,"cells":5881},{"EARLY_PHASE1":5882,"PHASE1":5884,"PHASE2":5886,"PHASE3":5888,"PHASE4":5890,"NA":5896},{"trials":5883,"activeCount":101},[],{"trials":5885,"activeCount":101},[],{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[],{"trials":5891,"activeCount":101},[5892],{"nctId":5868,"briefTitle":5869,"status":158,"phases":5893,"primaryCompletion":2139,"completion":2139,"start":5871,"enrollment":5872,"conditions":5894,"interventions":5895},[92],[5874,5875],[5855,5877],{"trials":5897,"activeCount":101},[],{"intervention":5899,"totalTrials":228,"cells":5900},"Sarna",{"EARLY_PHASE1":5901,"PHASE1":5903,"PHASE2":5905,"PHASE3":5907,"PHASE4":5909,"NA":5919},{"trials":5902,"activeCount":101},[],{"trials":5904,"activeCount":101},[],{"trials":5906,"activeCount":101},[],{"trials":5908,"activeCount":101},[],{"trials":5910,"activeCount":101},[5911],{"nctId":5912,"briefTitle":5913,"status":158,"phases":5914,"primaryCompletion":4545,"completion":5454,"start":4545,"enrollment":2080,"conditions":5915,"interventions":5917},"NCT00693654","Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients",[92],[5916],"Pruritis",[5899,5918],"Cetaphil",{"trials":5920,"activeCount":101},[],{"intervention":5918,"totalTrials":228,"cells":5922},{"EARLY_PHASE1":5923,"PHASE1":5925,"PHASE2":5927,"PHASE3":5929,"PHASE4":5931,"NA":5937},{"trials":5924,"activeCount":101},[],{"trials":5926,"activeCount":101},[],{"trials":5928,"activeCount":101},[],{"trials":5930,"activeCount":101},[],{"trials":5932,"activeCount":101},[5933],{"nctId":5912,"briefTitle":5913,"status":158,"phases":5934,"primaryCompletion":4545,"completion":5454,"start":4545,"enrollment":2080,"conditions":5935,"interventions":5936},[92],[5916],[5899,5918],{"trials":5938,"activeCount":101},[],{"intervention":5940,"totalTrials":228,"cells":5941},"Eszopiclone",{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5946,"PHASE3":5948,"PHASE4":5950,"NA":5960},{"trials":5943,"activeCount":101},[],{"trials":5945,"activeCount":101},[],{"trials":5947,"activeCount":101},[],{"trials":5949,"activeCount":101},[],{"trials":5951,"activeCount":101},[5952],{"nctId":5953,"briefTitle":5954,"status":158,"phases":5955,"primaryCompletion":5454,"completion":3851,"start":1887,"enrollment":549,"conditions":5956,"interventions":5958},"NCT00247624","Improving Sleep and Psychological Functioning in People With Depression and Insomnia",[92],[5957,22],"Sleep Initiation and Maintenance Disorders",[5940,5959],"Fluoxetine",{"trials":5961,"activeCount":101},[],{"intervention":5959,"totalTrials":228,"cells":5963},{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5970,"PHASE4":5972,"NA":5978},{"trials":5965,"activeCount":101},[],{"trials":5967,"activeCount":101},[],{"trials":5969,"activeCount":101},[],{"trials":5971,"activeCount":101},[],{"trials":5973,"activeCount":101},[5974],{"nctId":5953,"briefTitle":5954,"status":158,"phases":5975,"primaryCompletion":5454,"completion":3851,"start":1887,"enrollment":549,"conditions":5976,"interventions":5977},[92],[5957,22],[5940,5959],{"trials":5979,"activeCount":101},[],{"intervention":5981,"totalTrials":228,"cells":5982},"Biafine",{"EARLY_PHASE1":5983,"PHASE1":5985,"PHASE2":5987,"PHASE3":5989,"PHASE4":5991,"NA":6001},{"trials":5984,"activeCount":101},[],{"trials":5986,"activeCount":101},[],{"trials":5988,"activeCount":101},[],{"trials":5990,"activeCount":101},[],{"trials":5992,"activeCount":101},[5993],{"nctId":5994,"briefTitle":5995,"status":158,"phases":5996,"primaryCompletion":5997,"completion":3820,"start":2627,"enrollment":37,"conditions":5998,"interventions":5999},"NCT00695578","Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy",[92],"2007-06",[5456],[5981,6000],"Polysporin",{"trials":6002,"activeCount":101},[],{"intervention":6000,"totalTrials":228,"cells":6004},{"EARLY_PHASE1":6005,"PHASE1":6007,"PHASE2":6009,"PHASE3":6011,"PHASE4":6013,"NA":6019},{"trials":6006,"activeCount":101},[],{"trials":6008,"activeCount":101},[],{"trials":6010,"activeCount":101},[],{"trials":6012,"activeCount":101},[],{"trials":6014,"activeCount":101},[6015],{"nctId":5994,"briefTitle":5995,"status":158,"phases":6016,"primaryCompletion":5997,"completion":3820,"start":2627,"enrollment":37,"conditions":6017,"interventions":6018},[92],[5456],[5981,6000],{"trials":6020,"activeCount":101},[],{"intervention":6022,"totalTrials":228,"cells":6023},"tacrolimus ointment",{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6028,"PHASE3":6030,"PHASE4":6032,"NA":6041},{"trials":6025,"activeCount":101},[],{"trials":6027,"activeCount":101},[],{"trials":6029,"activeCount":101},[],{"trials":6031,"activeCount":101},[],{"trials":6033,"activeCount":101},[6034],{"nctId":6035,"briefTitle":6036,"status":158,"phases":6037,"primaryCompletion":5051,"completion":5051,"start":6038,"enrollment":1377,"conditions":6039,"interventions":6040},"NCT00654355","Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit",[92],"2008-04",[4547],[6022],{"trials":6042,"activeCount":101},[],{"intervention":6044,"totalTrials":228,"cells":6045},"Alemtuzumab",{"EARLY_PHASE1":6046,"PHASE1":6048,"PHASE2":6050,"PHASE3":6052,"PHASE4":6054,"NA":6066},{"trials":6047,"activeCount":101},[],{"trials":6049,"activeCount":101},[],{"trials":6051,"activeCount":101},[],{"trials":6053,"activeCount":101},[],{"trials":6055,"activeCount":101},[6056],{"nctId":6057,"briefTitle":6058,"status":158,"phases":6059,"primaryCompletion":6060,"completion":6060,"start":2452,"enrollment":6061,"conditions":6062,"interventions":6064},"NCT00331162","Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation",[92],"2011-11-28",222,[6063],"Graft Rejection",[6044,6065],"Anti-Thymocyte Globulin",{"trials":6067,"activeCount":101},[],{"intervention":6065,"totalTrials":228,"cells":6069},{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6074,"PHASE3":6076,"PHASE4":6078,"NA":6084},{"trials":6071,"activeCount":101},[],{"trials":6073,"activeCount":101},[],{"trials":6075,"activeCount":101},[],{"trials":6077,"activeCount":101},[],{"trials":6079,"activeCount":101},[6080],{"nctId":6057,"briefTitle":6058,"status":158,"phases":6081,"primaryCompletion":6060,"completion":6060,"start":2452,"enrollment":6061,"conditions":6082,"interventions":6083},[92],[6063],[6044,6065],{"trials":6085,"activeCount":101},[],{"intervention":6087,"totalTrials":228,"cells":6088},"Alfentanil",{"EARLY_PHASE1":6089,"PHASE1":6091,"PHASE2":6093,"PHASE3":6095,"PHASE4":6097,"NA":6110},{"trials":6090,"activeCount":101},[],{"trials":6092,"activeCount":101},[],{"trials":6094,"activeCount":101},[],{"trials":6096,"activeCount":101},[],{"trials":6098,"activeCount":101},[6099],{"nctId":6100,"briefTitle":6101,"status":158,"phases":6102,"primaryCompletion":6103,"completion":6103,"start":6104,"enrollment":117,"conditions":6105,"interventions":6108},"NCT03359395","Pre-medication With Alfentanil vs Placebo During ECT",[92],"2020-02-17","2018-06-04",[6106,6107],"Blood Pressure","Electroconvulsive Therapy",[6087,6109],"Placebos",{"trials":6111,"activeCount":101},[],{"intervention":6109,"totalTrials":228,"cells":6113},{"EARLY_PHASE1":6114,"PHASE1":6116,"PHASE2":6118,"PHASE3":6120,"PHASE4":6122,"NA":6128},{"trials":6115,"activeCount":101},[],{"trials":6117,"activeCount":101},[],{"trials":6119,"activeCount":101},[],{"trials":6121,"activeCount":101},[],{"trials":6123,"activeCount":101},[6124],{"nctId":6100,"briefTitle":6101,"status":158,"phases":6125,"primaryCompletion":6103,"completion":6103,"start":6104,"enrollment":117,"conditions":6126,"interventions":6127},[92],[6106,6107],[6087,6109],{"trials":6129,"activeCount":101},[],{"intervention":6131,"totalTrials":228,"cells":6132},"Omadacycline",{"EARLY_PHASE1":6133,"PHASE1":6135,"PHASE2":6137,"PHASE3":6139,"PHASE4":6141,"NA":6152},{"trials":6134,"activeCount":101},[],{"trials":6136,"activeCount":101},[],{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[],{"trials":6142,"activeCount":101},[6143],{"nctId":6144,"briefTitle":6145,"status":158,"phases":6146,"primaryCompletion":6147,"completion":6147,"start":6148,"enrollment":258,"conditions":6149,"interventions":6151},"NCT05515562","Effects of Intravenous (IV) Omadacycline on Gut Microbiome",[92],"2023-07-11","2023-03-20",[6150],"Microbial Colonization",[6131],{"trials":6153,"activeCount":101},[],{"intervention":6155,"totalTrials":228,"cells":6156},"Nitrofurantoin 100 MG",{"EARLY_PHASE1":6157,"PHASE1":6159,"PHASE2":6161,"PHASE3":6163,"PHASE4":6165,"NA":6178},{"trials":6158,"activeCount":101},[],{"trials":6160,"activeCount":101},[],{"trials":6162,"activeCount":101},[],{"trials":6164,"activeCount":101},[],{"trials":6166,"activeCount":101},[6167],{"nctId":6168,"briefTitle":6169,"status":158,"phases":6170,"primaryCompletion":6171,"completion":6172,"start":6173,"enrollment":6174,"conditions":6175,"interventions":6177},"NCT03287089","Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery",[92],"2019-05-30","2019-06-01","2017-09-29",164,[6176],"Catheter-Associated Urinary Tract Infection",[6155],{"trials":6179,"activeCount":101},[],{"intervention":6181,"totalTrials":228,"cells":6182},"Aflibercept Ophthalmic",{"EARLY_PHASE1":6183,"PHASE1":6185,"PHASE2":6187,"PHASE3":6189,"PHASE4":6191,"NA":6202},{"trials":6184,"activeCount":101},[],{"trials":6186,"activeCount":101},[],{"trials":6188,"activeCount":101},[],{"trials":6190,"activeCount":101},[],{"trials":6192,"activeCount":101},[6193],{"nctId":6194,"briefTitle":6195,"status":143,"phases":6196,"primaryCompletion":6197,"completion":6197,"start":6198,"enrollment":2055,"conditions":6199,"interventions":6201},"NCT04707625","Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment",[92],"2023-12-18","2021-10-06",[6200],"Retinal Vein Occlusion",[6181],{"trials":6203,"activeCount":101},[],{"intervention":6205,"totalTrials":228,"cells":6206},"Crinone vaginal progesterone gel",{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6213,"PHASE4":6215,"NA":6224},{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[],{"trials":6214,"activeCount":101},[],{"trials":6216,"activeCount":101},[6217],{"nctId":6218,"briefTitle":6219,"status":158,"phases":6220,"primaryCompletion":244,"completion":244,"start":2510,"enrollment":37,"conditions":6221,"interventions":6223},"NCT01959464","Sexual Absorption of Vaginal Progesterone",[92],[5010,6222],"Pregnancy",[6205],{"trials":6225,"activeCount":101},[],{"intervention":6227,"totalTrials":228,"cells":6228},"Taclonex",{"EARLY_PHASE1":6229,"PHASE1":6231,"PHASE2":6233,"PHASE3":6235,"PHASE4":6237,"NA":6247},{"trials":6230,"activeCount":101},[],{"trials":6232,"activeCount":101},[],{"trials":6234,"activeCount":101},[],{"trials":6236,"activeCount":101},[],{"trials":6238,"activeCount":101},[6239],{"nctId":6240,"briefTitle":6241,"status":158,"phases":6242,"primaryCompletion":6243,"completion":1655,"start":4182,"enrollment":37,"conditions":6244,"interventions":6246},"NCT01707043","Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris",[92],"2013-09",[6245],"Plaque Psoriasis",[6227],{"trials":6248,"activeCount":101},[],{"intervention":6250,"totalTrials":228,"cells":6251},"Isotonix OPC-3",{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6256,"PHASE3":6258,"PHASE4":6260,"NA":6269},{"trials":6253,"activeCount":101},[],{"trials":6255,"activeCount":101},[],{"trials":6257,"activeCount":101},[],{"trials":6259,"activeCount":101},[],{"trials":6261,"activeCount":101},[6262],{"nctId":6263,"briefTitle":6264,"status":158,"phases":6265,"completion":1387,"start":6266,"enrollment":204,"conditions":6267,"interventions":6268},"NCT00331227","Flavonoid Supplementation and Endothelial Function",[92],"2006-05",[1379],[6250],{"trials":6270,"activeCount":101},[],{"intervention":6272,"totalTrials":228,"cells":6273},"Calcium pre-treatment",{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6278,"PHASE3":6280,"PHASE4":6282,"NA":6295},{"trials":6275,"activeCount":101},[],{"trials":6277,"activeCount":101},[],{"trials":6279,"activeCount":101},[],{"trials":6281,"activeCount":101},[],{"trials":6283,"activeCount":101},[6284],{"nctId":6285,"briefTitle":6286,"status":158,"phases":6287,"primaryCompletion":6288,"completion":6288,"start":6289,"enrollment":6290,"conditions":6291,"interventions":6294},"NCT05661942","Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate",[92],"2024-11-20","2022-11-30",92,[6292,6293],"Atrial Fibrillation With Rapid Ventricular Response","Hypotension Drug-Induced",[6272],{"trials":6296,"activeCount":101},[],{"intervention":6298,"totalTrials":228,"cells":6299},"Letrozole",{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6306,"PHASE4":6308,"NA":6318},{"trials":6301,"activeCount":101},[],{"trials":6303,"activeCount":101},[],{"trials":6305,"activeCount":101},[],{"trials":6307,"activeCount":101},[],{"trials":6309,"activeCount":101},[6310],{"nctId":6311,"briefTitle":6312,"status":158,"phases":6313,"primaryCompletion":5092,"completion":5092,"start":4089,"enrollment":1477,"conditions":6314,"interventions":6317},"NCT01999569","The Role of Estrogen in Luteinizing Hormone Surge and Ovulation",[92],[6315,6316],"Ovulation Disorder","Ovarian Cysts",[6298],{"trials":6319,"activeCount":101},[],{"intervention":6321,"totalTrials":233,"cells":6322},"megestrol acetate",{"EARLY_PHASE1":6323,"PHASE1":6325,"PHASE2":6327,"PHASE3":6329,"PHASE4":6372,"NA":6374},{"trials":6324,"activeCount":101},[],{"trials":6326,"activeCount":101},[],{"trials":6328,"activeCount":101},[],{"trials":6330,"activeCount":101},[6331,6341,6352,6363],{"nctId":6332,"briefTitle":6333,"status":158,"phases":6334,"primaryCompletion":6335,"completion":6335,"start":6336,"enrollment":204,"conditions":6337,"interventions":6340},"NCT00031785","Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer",[91],"2002-09-11","2000-09-01",[6338,6339,33],"Anorexia","Cachexia",[6321],{"nctId":6342,"briefTitle":6343,"status":177,"phases":6344,"primaryCompletion":6345,"completion":396,"start":6346,"enrollment":101,"conditions":6347,"interventions":6349},"NCT04897217","Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia",[91],"2024-10","2023-06-30",[6348],"Endometrial Hyperplasia",[6350,6351],"Megestrol Acetate","Levonorgestrel Drug Implant",{"nctId":6353,"briefTitle":6354,"status":158,"phases":6355,"primaryCompletion":6356,"completion":6356,"start":6357,"enrollment":6358,"conditions":6359,"interventions":6361},"NCT00070148","Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer",[91],"2007-08-01","2004-03-01",155,[1647,6360],"Weight Changes",[6350,6362],"Oxandrolone 20 mg",{"nctId":6364,"briefTitle":6365,"status":158,"phases":6366,"primaryCompletion":6367,"completion":6367,"start":6368,"enrollment":4125,"conditions":6369,"interventions":6371},"NCT00006799","Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer",[91],"2002-09-06","2000-10-01",[6338,6339,36,6370],"Quality of Life",[6321],{"trials":6373,"activeCount":101},[],{"trials":6375,"activeCount":101},[],{"intervention":351,"totalTrials":233,"cells":6377},{"EARLY_PHASE1":6378,"PHASE1":6384,"PHASE2":6386,"PHASE3":6398,"PHASE4":6408,"NA":6410},{"trials":6379,"activeCount":101},[6380],{"nctId":1435,"briefTitle":1436,"status":158,"phases":6381,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":37,"conditions":6382,"interventions":6383},[88],[1441],[351,1443,1444,1038],{"trials":6385,"activeCount":101},[],{"trials":6387,"activeCount":101},[6388],{"nctId":6389,"briefTitle":6390,"status":158,"phases":6391,"primaryCompletion":2478,"completion":2478,"start":2519,"enrollment":4183,"conditions":6392,"interventions":6394},"NCT02521415","IN Sub-Dissociative Ketamine vs IN Fentanyl",[90],[6393],"Bone Fracture",[6395,6396,6397],"ketamine","fentanyl","ibuprofen or acetaminophen",{"trials":6399,"activeCount":101},[6400,6404],{"nctId":339,"briefTitle":340,"status":143,"phases":6401,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":6402,"interventions":6403},[90,91],[346,347,348],[328,350,351,352,350],{"nctId":1402,"briefTitle":1403,"status":177,"phases":6405,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":6406,"interventions":6407},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":6409,"activeCount":101},[],{"trials":6411,"activeCount":101},[],{"intervention":6413,"totalTrials":215,"cells":6414},"donepezil hydrochloride",{"EARLY_PHASE1":6415,"PHASE1":6417,"PHASE2":6419,"PHASE3":6443,"PHASE4":6455,"NA":6457},{"trials":6416,"activeCount":101},[],{"trials":6418,"activeCount":101},[],{"trials":6420,"activeCount":101},[6421,6433],{"nctId":6422,"briefTitle":6423,"status":158,"phases":6424,"primaryCompletion":6425,"completion":6425,"start":6426,"enrollment":6427,"conditions":6428,"interventions":6432},"NCT01466270","Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction",[90],"2013-10-01","2012-07",62,[6429,19,6430,22,551,6431],"Anxiety Disorder","Cognition Disorders","Sleep Disorders",[6413],{"nctId":6434,"briefTitle":6435,"status":158,"phases":6436,"primaryCompletion":6437,"completion":6438,"start":6439,"enrollment":6440,"conditions":6441,"interventions":6442},"NCT00070161","Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor",[90],"2005-05-01","2012-08-01","2001-07-01",68,[3962,3967],[6413],{"trials":6444,"activeCount":101},[6445],{"nctId":6446,"briefTitle":6447,"status":158,"phases":6448,"primaryCompletion":6449,"completion":6449,"start":3820,"enrollment":6450,"conditions":6451,"interventions":6454},"NCT00369785","Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors",[91],"2012-07-01",198,[6452,6453],"Brain Tumors","Metastatic Disease",[6413],{"trials":6456,"activeCount":101},[],{"trials":6458,"activeCount":101},[],{"intervention":6460,"totalTrials":228,"cells":6461},"Zoloft 50 mg",{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6478,"NA":6480},{"trials":6463,"activeCount":101},[],{"trials":6465,"activeCount":101},[],{"trials":6467,"activeCount":101},[],{"trials":6469,"activeCount":101},[6470],{"nctId":6471,"briefTitle":6472,"status":158,"phases":6473,"primaryCompletion":6474,"completion":6475,"start":6357,"enrollment":97,"conditions":6476,"interventions":6477},"NCT00066859","Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression",[91],"2005-04-01","2005-11-01",[22,1647],[6460],{"trials":6479,"activeCount":101},[],{"trials":6481,"activeCount":101},[],{"intervention":6483,"totalTrials":228,"cells":6484},"Rifaximin 550 MG Oral Tablet [XIFAXAN]",{"EARLY_PHASE1":6485,"PHASE1":6487,"PHASE2":6489,"PHASE3":6491,"PHASE4":6502,"NA":6504},{"trials":6486,"activeCount":101},[],{"trials":6488,"activeCount":101},[],{"trials":6490,"activeCount":101},[],{"trials":6492,"activeCount":101},[6493],{"nctId":6494,"briefTitle":6495,"status":177,"phases":6496,"primaryCompletion":3889,"completion":3889,"start":5477,"enrollment":101,"conditions":6497,"interventions":6501},"NCT05408910","Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis",[90,91],[6498,6499,6500],"Cystic Fibrosis","Abdominal Pain","Small Bowel Disease",[6483],{"trials":6503,"activeCount":101},[],{"trials":6505,"activeCount":101},[],{"intervention":1722,"totalTrials":228,"cells":6507},{"EARLY_PHASE1":6508,"PHASE1":6510,"PHASE2":6512,"PHASE3":6514,"PHASE4":6520,"NA":6522},{"trials":6509,"activeCount":101},[],{"trials":6511,"activeCount":101},[],{"trials":6513,"activeCount":101},[],{"trials":6515,"activeCount":101},[6516],{"nctId":1715,"briefTitle":1716,"status":158,"phases":6517,"primaryCompletion":1718,"completion":1718,"start":1719,"enrollment":228,"conditions":6518,"interventions":6519},[91],[33],[1722,1564,1662],{"trials":6521,"activeCount":101},[],{"trials":6523,"activeCount":101},[],{"intervention":6351,"totalTrials":228,"cells":6525},{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6532,"PHASE4":6538,"NA":6540},{"trials":6527,"activeCount":101},[],{"trials":6529,"activeCount":101},[],{"trials":6531,"activeCount":101},[],{"trials":6533,"activeCount":101},[6534],{"nctId":6342,"briefTitle":6343,"status":177,"phases":6535,"primaryCompletion":6345,"completion":396,"start":6346,"enrollment":101,"conditions":6536,"interventions":6537},[91],[6348],[6350,6351],{"trials":6539,"activeCount":101},[],{"trials":6541,"activeCount":101},[],{"intervention":6362,"totalTrials":228,"cells":6543},{"EARLY_PHASE1":6544,"PHASE1":6546,"PHASE2":6548,"PHASE3":6550,"PHASE4":6556,"NA":6558},{"trials":6545,"activeCount":101},[],{"trials":6547,"activeCount":101},[],{"trials":6549,"activeCount":101},[],{"trials":6551,"activeCount":101},[6552],{"nctId":6353,"briefTitle":6354,"status":158,"phases":6553,"primaryCompletion":6356,"completion":6356,"start":6357,"enrollment":6358,"conditions":6554,"interventions":6555},[91],[1647,6360],[6350,6362],{"trials":6557,"activeCount":101},[],{"trials":6559,"activeCount":101},[],{"intervention":6561,"totalTrials":228,"cells":6562},"Sugammadex",{"EARLY_PHASE1":6563,"PHASE1":6565,"PHASE2":6567,"PHASE3":6569,"PHASE4":6581,"NA":6583},{"trials":6564,"activeCount":101},[],{"trials":6566,"activeCount":101},[],{"trials":6568,"activeCount":101},[],{"trials":6570,"activeCount":101},[6571],{"nctId":6572,"briefTitle":6573,"status":158,"phases":6574,"primaryCompletion":6575,"completion":6575,"start":6576,"enrollment":6577,"conditions":6578,"interventions":6580},"NCT05276804","The POUR (Postoperative Urinary Retention) Study",[91],"2024-09-03","2022-04-13",171,[6579],"Postoperative Urinary Retention",[6561],{"trials":6582,"activeCount":101},[],{"trials":6584,"activeCount":101},[],{"intervention":6586,"totalTrials":228,"cells":6587},"Enalapril",{"EARLY_PHASE1":6588,"PHASE1":6590,"PHASE2":6592,"PHASE3":6594,"PHASE4":6605,"NA":6607},{"trials":6589,"activeCount":101},[],{"trials":6591,"activeCount":101},[],{"trials":6593,"activeCount":101},[],{"trials":6595,"activeCount":101},[6596],{"nctId":6597,"briefTitle":6598,"status":158,"phases":6599,"primaryCompletion":6600,"completion":6601,"start":6602,"enrollment":1890,"conditions":6603,"interventions":6604},"NCT01411735","Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure",[91],"2004-06","2008-07","2003-07",[3882,4151],[6586],{"trials":6606,"activeCount":101},[],{"trials":6608,"activeCount":101},[],{"intervention":6610,"totalTrials":228,"cells":6611},"Magnesium Sulfate",{"EARLY_PHASE1":6612,"PHASE1":6614,"PHASE2":6616,"PHASE3":6618,"PHASE4":6632,"NA":6634},{"trials":6613,"activeCount":101},[],{"trials":6615,"activeCount":101},[],{"trials":6617,"activeCount":101},[],{"trials":6619,"activeCount":101},[6620],{"nctId":6621,"briefTitle":6622,"status":158,"phases":6623,"primaryCompletion":2551,"completion":6624,"start":6625,"enrollment":6626,"conditions":6627,"interventions":6629},"NCT05967442","Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines",[91],"2023-04-06","2019-08-23",157,[1187,6628],"Headache",[6610,6630,6631],"Metoclopramide 10mg","Prochlorperazine (Compazine)",{"trials":6633,"activeCount":101},[],{"trials":6635,"activeCount":101},[],{"intervention":6630,"totalTrials":228,"cells":6637},{"EARLY_PHASE1":6638,"PHASE1":6640,"PHASE2":6642,"PHASE3":6644,"PHASE4":6650,"NA":6652},{"trials":6639,"activeCount":101},[],{"trials":6641,"activeCount":101},[],{"trials":6643,"activeCount":101},[],{"trials":6645,"activeCount":101},[6646],{"nctId":6621,"briefTitle":6622,"status":158,"phases":6647,"primaryCompletion":2551,"completion":6624,"start":6625,"enrollment":6626,"conditions":6648,"interventions":6649},[91],[1187,6628],[6610,6630,6631],{"trials":6651,"activeCount":101},[],{"trials":6653,"activeCount":101},[],{"intervention":6631,"totalTrials":228,"cells":6655},{"EARLY_PHASE1":6656,"PHASE1":6658,"PHASE2":6660,"PHASE3":6662,"PHASE4":6668,"NA":6670},{"trials":6657,"activeCount":101},[],{"trials":6659,"activeCount":101},[],{"trials":6661,"activeCount":101},[],{"trials":6663,"activeCount":101},[6664],{"nctId":6621,"briefTitle":6622,"status":158,"phases":6665,"primaryCompletion":2551,"completion":6624,"start":6625,"enrollment":6626,"conditions":6666,"interventions":6667},[91],[1187,6628],[6610,6630,6631],{"trials":6669,"activeCount":101},[],{"trials":6671,"activeCount":101},[],{"intervention":6673,"totalTrials":228,"cells":6674},"0.625 mg of conjugated equine estrogen",{"EARLY_PHASE1":6675,"PHASE1":6677,"PHASE2":6679,"PHASE3":6681,"PHASE4":6694,"NA":6696},{"trials":6676,"activeCount":101},[],{"trials":6678,"activeCount":101},[],{"trials":6680,"activeCount":101},[],{"trials":6682,"activeCount":101},[6683],{"nctId":6684,"briefTitle":6685,"status":158,"phases":6686,"primaryCompletion":6687,"completion":6687,"start":6688,"enrollment":6689,"conditions":6690,"interventions":6692},"NCT03097120","The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.",[91],"2001-01","1995-01",309,[6691],"Heart Disease",[6673,6693],"0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate",{"trials":6695,"activeCount":101},[],{"trials":6697,"activeCount":101},[],{"intervention":6693,"totalTrials":228,"cells":6699},{"EARLY_PHASE1":6700,"PHASE1":6702,"PHASE2":6704,"PHASE3":6706,"PHASE4":6712,"NA":6714},{"trials":6701,"activeCount":101},[],{"trials":6703,"activeCount":101},[],{"trials":6705,"activeCount":101},[],{"trials":6707,"activeCount":101},[6708],{"nctId":6684,"briefTitle":6685,"status":158,"phases":6709,"primaryCompletion":6687,"completion":6687,"start":6688,"enrollment":6689,"conditions":6710,"interventions":6711},[91],[6691],[6673,6693],{"trials":6713,"activeCount":101},[],{"trials":6715,"activeCount":101},[],{"intervention":6717,"totalTrials":228,"cells":6718},"Solution for Injection in Interscalene Block",{"EARLY_PHASE1":6719,"PHASE1":6721,"PHASE2":6723,"PHASE3":6725,"PHASE4":6738,"NA":6740},{"trials":6720,"activeCount":101},[],{"trials":6722,"activeCount":101},[],{"trials":6724,"activeCount":101},[],{"trials":6726,"activeCount":101},[6727],{"nctId":6728,"briefTitle":6729,"status":158,"phases":6730,"primaryCompletion":6731,"completion":6731,"start":6732,"enrollment":834,"conditions":6733,"interventions":6735},"NCT02741713","Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery",[91],"2017-06-29","2016-04",[6734],"Biceps Tendonitis",[6717,6736,6737],"Solution for Injection in Sham Block","Solution for Injection PECS Blocks",{"trials":6739,"activeCount":101},[],{"trials":6741,"activeCount":101},[],{"intervention":6736,"totalTrials":228,"cells":6743},{"EARLY_PHASE1":6744,"PHASE1":6746,"PHASE2":6748,"PHASE3":6750,"PHASE4":6756,"NA":6758},{"trials":6745,"activeCount":101},[],{"trials":6747,"activeCount":101},[],{"trials":6749,"activeCount":101},[],{"trials":6751,"activeCount":101},[6752],{"nctId":6728,"briefTitle":6729,"status":158,"phases":6753,"primaryCompletion":6731,"completion":6731,"start":6732,"enrollment":834,"conditions":6754,"interventions":6755},[91],[6734],[6717,6736,6737],{"trials":6757,"activeCount":101},[],{"trials":6759,"activeCount":101},[],{"intervention":6737,"totalTrials":228,"cells":6761},{"EARLY_PHASE1":6762,"PHASE1":6764,"PHASE2":6766,"PHASE3":6768,"PHASE4":6774,"NA":6776},{"trials":6763,"activeCount":101},[],{"trials":6765,"activeCount":101},[],{"trials":6767,"activeCount":101},[],{"trials":6769,"activeCount":101},[6770],{"nctId":6728,"briefTitle":6729,"status":158,"phases":6771,"primaryCompletion":6731,"completion":6731,"start":6732,"enrollment":834,"conditions":6772,"interventions":6773},[91],[6734],[6717,6736,6737],{"trials":6775,"activeCount":101},[],{"trials":6777,"activeCount":101},[],{"intervention":6779,"totalTrials":228,"cells":6780},"Patiromer Oral Product",{"EARLY_PHASE1":6781,"PHASE1":6783,"PHASE2":6785,"PHASE3":6787,"PHASE4":6799,"NA":6801},{"trials":6782,"activeCount":101},[],{"trials":6784,"activeCount":101},[],{"trials":6786,"activeCount":101},[],{"trials":6788,"activeCount":101},[6789],{"nctId":6790,"briefTitle":6791,"status":158,"phases":6792,"primaryCompletion":6793,"completion":6793,"start":6794,"enrollment":6795,"conditions":6796,"interventions":6798},"NCT03740048","A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease",[91],"2021-11-04","2019-06-19",51,[6797],"End Stage Renal Failure on Dialysis",[6779],{"trials":6800,"activeCount":101},[],{"trials":6802,"activeCount":101},[],{"intervention":6804,"totalTrials":228,"cells":6805},"Consolidation chemotherapy",{"EARLY_PHASE1":6806,"PHASE1":6808,"PHASE2":6810,"PHASE3":6812,"PHASE4":6822,"NA":6824},{"trials":6807,"activeCount":101},[],{"trials":6809,"activeCount":101},[],{"trials":6811,"activeCount":101},[],{"trials":6813,"activeCount":101},[6814],{"nctId":6815,"briefTitle":6816,"status":143,"phases":6817,"primaryCompletion":6818,"completion":6818,"start":4108,"enrollment":3569,"conditions":6819,"interventions":6821},"NCT02927938","Leukemia Stem Cell Detection in Acute Myeloid Leukemia",[91],"2018-10-05",[6820],"Acute Myeloid Leukemia (AML)",[6804],{"trials":6823,"activeCount":101},[],{"trials":6825,"activeCount":101},[],{"intervention":6827,"totalTrials":228,"cells":6828},"Tenecteplase + Enoxaparin",{"EARLY_PHASE1":6829,"PHASE1":6831,"PHASE2":6833,"PHASE3":6835,"PHASE4":6847,"NA":6849},{"trials":6830,"activeCount":101},[],{"trials":6832,"activeCount":101},[],{"trials":6834,"activeCount":101},[],{"trials":6836,"activeCount":101},[6837],{"nctId":6838,"briefTitle":6839,"status":143,"phases":6840,"primaryCompletion":6841,"completion":4182,"start":5092,"enrollment":6842,"conditions":6843,"interventions":6845},"NCT00680628","Clot Dissolving Treatment for Blood Clots in the Lungs",[91],"2012-05",83,[6844],"Pulmonary Embolism",[6827,6846],"0.9% Saline + Enoxaparin",{"trials":6848,"activeCount":101},[],{"trials":6850,"activeCount":101},[],{"intervention":6846,"totalTrials":228,"cells":6852},{"EARLY_PHASE1":6853,"PHASE1":6855,"PHASE2":6857,"PHASE3":6859,"PHASE4":6865,"NA":6867},{"trials":6854,"activeCount":101},[],{"trials":6856,"activeCount":101},[],{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[6861],{"nctId":6838,"briefTitle":6839,"status":143,"phases":6862,"primaryCompletion":6841,"completion":4182,"start":5092,"enrollment":6842,"conditions":6863,"interventions":6864},[91],[6844],[6827,6846],{"trials":6866,"activeCount":101},[],{"trials":6868,"activeCount":101},[],{"intervention":6870,"totalTrials":228,"cells":6871},"Carac Cream",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6878,"PHASE4":6888,"NA":6890},{"trials":6873,"activeCount":101},[],{"trials":6875,"activeCount":101},[],{"trials":6877,"activeCount":101},[],{"trials":6879,"activeCount":101},[6880],{"nctId":6881,"briefTitle":6882,"status":158,"phases":6883,"primaryCompletion":6884,"completion":6884,"start":6885,"enrollment":549,"conditions":6886,"interventions":6887},"NCT03037541","Cryosurgery and Cream Combination for Actinic Keratosis",[91],"2013-10-29","2011-01-05",[5456],[6870],{"trials":6889,"activeCount":101},[],{"trials":6891,"activeCount":101},[],{"intervention":6893,"totalTrials":228,"cells":6894},"methylphenidate hydrochloride",{"EARLY_PHASE1":6895,"PHASE1":6897,"PHASE2":6899,"PHASE3":6901,"PHASE4":6912,"NA":6914},{"trials":6896,"activeCount":101},[],{"trials":6898,"activeCount":101},[],{"trials":6900,"activeCount":101},[],{"trials":6902,"activeCount":101},[6903],{"nctId":6904,"briefTitle":6905,"status":143,"phases":6906,"primaryCompletion":6907,"completion":6908,"start":6909,"conditions":6910,"interventions":6911},"NCT00031798","Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors",[91],"2005-03-01","2006-05-01","2002-04-01",[3962,3963,22,551,6370],[6893],{"trials":6913,"activeCount":101},[],{"trials":6915,"activeCount":101},[],{"intervention":276,"totalTrials":228,"cells":6917},{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":6922,"PHASE3":6924,"PHASE4":6930,"NA":6932},{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[],{"trials":6923,"activeCount":101},[],{"trials":6925,"activeCount":101},[6926],{"nctId":266,"briefTitle":267,"status":158,"phases":6927,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":6928,"interventions":6929},[90,91],[273,274],[276,232],{"trials":6931,"activeCount":101},[],{"trials":6933,"activeCount":101},[],{"intervention":1410,"totalTrials":228,"cells":6935},{"EARLY_PHASE1":6936,"PHASE1":6938,"PHASE2":6940,"PHASE3":6942,"PHASE4":6948,"NA":6950},{"trials":6937,"activeCount":101},[],{"trials":6939,"activeCount":101},[],{"trials":6941,"activeCount":101},[],{"trials":6943,"activeCount":101},[6944],{"nctId":1402,"briefTitle":1403,"status":177,"phases":6945,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":6946,"interventions":6947},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":6949,"activeCount":101},[],{"trials":6951,"activeCount":101},[],{"intervention":1412,"totalTrials":228,"cells":6953},{"EARLY_PHASE1":6954,"PHASE1":6956,"PHASE2":6958,"PHASE3":6960,"PHASE4":6966,"NA":6968},{"trials":6955,"activeCount":101},[],{"trials":6957,"activeCount":101},[],{"trials":6959,"activeCount":101},[],{"trials":6961,"activeCount":101},[6962],{"nctId":1402,"briefTitle":1403,"status":177,"phases":6963,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":6964,"interventions":6965},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":6967,"activeCount":101},[],{"trials":6969,"activeCount":101},[],{"intervention":1413,"totalTrials":228,"cells":6971},{"EARLY_PHASE1":6972,"PHASE1":6974,"PHASE2":6976,"PHASE3":6978,"PHASE4":6984,"NA":6986},{"trials":6973,"activeCount":101},[],{"trials":6975,"activeCount":101},[],{"trials":6977,"activeCount":101},[],{"trials":6979,"activeCount":101},[6980],{"nctId":1402,"briefTitle":1403,"status":177,"phases":6981,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":6982,"interventions":6983},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":6985,"activeCount":101},[],{"trials":6987,"activeCount":101},[],{"intervention":1414,"totalTrials":228,"cells":6989},{"EARLY_PHASE1":6990,"PHASE1":6992,"PHASE2":6994,"PHASE3":6996,"PHASE4":7002,"NA":7004},{"trials":6991,"activeCount":101},[],{"trials":6993,"activeCount":101},[],{"trials":6995,"activeCount":101},[],{"trials":6997,"activeCount":101},[6998],{"nctId":1402,"briefTitle":1403,"status":177,"phases":6999,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":101,"conditions":7000,"interventions":7001},[90,91],[1408],[1410,1411,1412,1413,352,350,1414,351],{"trials":7003,"activeCount":101},[],{"trials":7005,"activeCount":101},[],{"intervention":7007,"totalTrials":228,"cells":7008},"tamoxifen",{"EARLY_PHASE1":7009,"PHASE1":7011,"PHASE2":7013,"PHASE3":7015,"PHASE4":7028,"NA":7030},{"trials":7010,"activeCount":101},[],{"trials":7012,"activeCount":101},[],{"trials":7014,"activeCount":101},[],{"trials":7016,"activeCount":101},[7017],{"nctId":7018,"briefTitle":7019,"status":158,"phases":7020,"primaryCompletion":1870,"completion":1870,"start":7021,"enrollment":7022,"conditions":7023,"interventions":7026},"NCT00687102","Cognition in the Study of Tamoxifen and Raloxifene",[91],"2001-10",1498,[7024,7025],"Cognition","Aging",[7007,7027],"raloxifene",{"trials":7029,"activeCount":101},[],{"trials":7031,"activeCount":101},[],{"intervention":7027,"totalTrials":228,"cells":7033},{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7038,"PHASE3":7040,"PHASE4":7046,"NA":7048},{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[],{"trials":7039,"activeCount":101},[],{"trials":7041,"activeCount":101},[7042],{"nctId":7018,"briefTitle":7019,"status":158,"phases":7043,"primaryCompletion":1870,"completion":1870,"start":7021,"enrollment":7022,"conditions":7044,"interventions":7045},[91],[7024,7025],[7007,7027],{"trials":7047,"activeCount":101},[],{"trials":7049,"activeCount":101},[],{"intervention":7051,"totalTrials":228,"cells":7052},"Lidocaine",{"EARLY_PHASE1":7053,"PHASE1":7055,"PHASE2":7057,"PHASE3":7059,"PHASE4":7071,"NA":7073},{"trials":7054,"activeCount":101},[],{"trials":7056,"activeCount":101},[],{"trials":7058,"activeCount":101},[],{"trials":7060,"activeCount":101},[7061],{"nctId":7062,"briefTitle":7063,"status":143,"phases":7064,"primaryCompletion":7065,"completion":7065,"start":7066,"enrollment":1527,"conditions":7067,"interventions":7069},"NCT04356352","Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain",[90,91],"2023-08-25","2020-09-09",[7068,25],"Injection Site Irritation",[7051,7070],"Esmolol",{"trials":7072,"activeCount":101},[],{"trials":7074,"activeCount":101},[],{"intervention":7070,"totalTrials":228,"cells":7076},{"EARLY_PHASE1":7077,"PHASE1":7079,"PHASE2":7081,"PHASE3":7083,"PHASE4":7089,"NA":7091},{"trials":7078,"activeCount":101},[],{"trials":7080,"activeCount":101},[],{"trials":7082,"activeCount":101},[],{"trials":7084,"activeCount":101},[7085],{"nctId":7062,"briefTitle":7063,"status":143,"phases":7086,"primaryCompletion":7065,"completion":7065,"start":7066,"enrollment":1527,"conditions":7087,"interventions":7088},[90,91],[7068,25],[7051,7070],{"trials":7090,"activeCount":101},[],{"trials":7092,"activeCount":101},[],{"intervention":7094,"totalTrials":228,"cells":7095},"Donepezil 5 mg",{"EARLY_PHASE1":7096,"PHASE1":7098,"PHASE2":7100,"PHASE3":7102,"PHASE4":7115,"NA":7117},{"trials":7097,"activeCount":101},[],{"trials":7099,"activeCount":101},[],{"trials":7101,"activeCount":101},[],{"trials":7103,"activeCount":101},[7104],{"nctId":7105,"briefTitle":7106,"status":158,"phases":7107,"primaryCompletion":7108,"completion":7108,"start":7109,"enrollment":7110,"conditions":7111,"interventions":7114},"NCT02822573","Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil",[91],"2022-07-29","2017-05-30",276,[7112,7113],"Cognitive Dysfunction","Memory Impairment",[7094],{"trials":7116,"activeCount":101},[],{"trials":7118,"activeCount":101},[],{"intervention":7120,"totalTrials":228,"cells":7121},"Nitroglycerin",{"EARLY_PHASE1":7122,"PHASE1":7124,"PHASE2":7126,"PHASE3":7128,"PHASE4":7138,"NA":7140},{"trials":7123,"activeCount":101},[],{"trials":7125,"activeCount":101},[],{"trials":7127,"activeCount":101},[],{"trials":7129,"activeCount":101},[7130],{"nctId":7131,"briefTitle":7132,"status":143,"phases":7133,"primaryCompletion":223,"completion":223,"start":7134,"enrollment":2055,"conditions":7135,"interventions":7137},"NCT03716050","The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems",[90,91],"2018-01-30",[7136],"Perfusion; Complications",[7120],{"trials":7139,"activeCount":101},[],{"trials":7141,"activeCount":101},[],{"intervention":7143,"totalTrials":228,"cells":7144},"Venlafaxine",{"EARLY_PHASE1":7145,"PHASE1":7147,"PHASE2":7149,"PHASE3":7151,"PHASE4":7162,"NA":7164},{"trials":7146,"activeCount":101},[],{"trials":7148,"activeCount":101},[],{"trials":7150,"activeCount":101},[],{"trials":7152,"activeCount":101},[7153],{"nctId":7154,"briefTitle":7155,"status":143,"phases":7156,"primaryCompletion":7157,"completion":7157,"start":7158,"enrollment":2248,"conditions":7159,"interventions":7161},"NCT00354432","Soy Protein\u002FEffexor Hormone Therapy for Prostate Cancer",[91],"2010-08-01","2007-02-01",[7160,348],"Hot Flashes",[7143],{"trials":7163,"activeCount":101},[],{"trials":7165,"activeCount":101},[],{"intervention":7167,"totalTrials":228,"cells":7168},"acyclovir sodium",{"EARLY_PHASE1":7169,"PHASE1":7171,"PHASE2":7173,"PHASE3":7175,"PHASE4":7185,"NA":7187},{"trials":7170,"activeCount":101},[],{"trials":7172,"activeCount":101},[],{"trials":7174,"activeCount":101},[],{"trials":7176,"activeCount":101},[7177],{"nctId":7178,"briefTitle":7179,"status":158,"phases":7180,"primaryCompletion":7181,"completion":7181,"start":2510,"enrollment":5754,"conditions":7182,"interventions":7184},"NCT00855309","Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia",[91],"2013-11",[7183],"Herpes Simplex",[7167],{"trials":7186,"activeCount":101},[],{"trials":7188,"activeCount":101},[],{"intervention":2417,"totalTrials":1608,"cells":7190},{"EARLY_PHASE1":7191,"PHASE1":7193,"PHASE2":7281,"PHASE3":7323,"PHASE4":7325,"NA":7327},{"trials":7192,"activeCount":101},[],{"trials":7194,"activeCount":101},[7195,7219,7223,7236,7244,7248,7273],{"nctId":7196,"briefTitle":7197,"status":158,"phases":7198,"primaryCompletion":7199,"completion":7200,"start":7201,"enrollment":2140,"conditions":7202,"interventions":7218},"NCT02168140","CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma",[89],"2019-04-18","2022-09-15","2014-09",[7203,7204,7205,7206,7207,7208,7209,7210,7211,7212,2395,7213,7214,7215,2408,7216,7217],"Adult Lymphocyte Depletion Hodgkin Lymphoma","Adult Lymphocyte Predominant Hodgkin Lymphoma","Adult Mixed Cellularity Hodgkin Lymphoma","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Adult Nodular Sclerosis Hodgkin Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic T-cell Lymphoma","Noncutaneous Extranodal Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","T-cell Adult Acute Lymphoblastic Leukemia","T-cell Large Granular Lymphocyte Leukemia",[2417,2418],{"nctId":2458,"briefTitle":2459,"status":158,"phases":7220,"primaryCompletion":2461,"completion":2462,"start":2463,"enrollment":2464,"conditions":7221,"interventions":7222},[89],[2466,2467],[2469,2470,2471],{"nctId":7224,"briefTitle":7225,"status":158,"phases":7226,"primaryCompletion":7227,"completion":7228,"start":5871,"enrollment":34,"conditions":7229,"interventions":7234},"NCT01835041","CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer",[89],"2017-02-28","2023-03-16",[7230,7231,7232,7233],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage IV Pancreatic Cancer",[2417,7235,2215,1589,2689],"oxaliplatin",{"nctId":7237,"briefTitle":7238,"status":158,"phases":7239,"primaryCompletion":7240,"completion":7240,"start":1654,"enrollment":1477,"conditions":7241,"interventions":7243},"NCT01839981","CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[89],"2015-10",[7230,7231,7232,7242,7233],"Stage III Pancreatic Cancer",[2417],{"nctId":2384,"briefTitle":2385,"status":143,"phases":7245,"primaryCompletion":2387,"completion":2387,"start":1607,"enrollment":228,"conditions":7246,"interventions":7247},[89],[2389,2390,2391,2392,2393,2394,2395,2396,2397,2398,2399,2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415],[2417,2418,2419],{"nctId":7249,"briefTitle":7250,"status":158,"phases":7251,"primaryCompletion":7252,"completion":7253,"start":7254,"enrollment":1782,"conditions":7255,"interventions":7272},"NCT02232152","CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery",[89],"2019-02-19","2023-01-11","2015-01-06",[7256,7257,7258,7259,7260,7261,7262,7263,7264,7265,7266,7267,7268,7269,7270,7271],"Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum","Recurrent Colon Cancer","Recurrent Rectal Cancer","Signet Ring Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Rectum","Stage IIIA Colon Cancer","Stage IIIA Rectal Cancer","Stage IIIB Colon Cancer","Stage IIIB Rectal Cancer","Stage IIIC Colon Cancer","Stage IIIC Rectal Cancer","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[2417,2689],{"nctId":7274,"briefTitle":7275,"status":158,"phases":7276,"primaryCompletion":2519,"completion":2519,"start":7277,"enrollment":1548,"conditions":7278,"interventions":7280},"NCT01931787","CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer",[89],"2013-10",[7279],"Recurrent Small Cell Lung Cancer",[2417],{"trials":7282,"activeCount":101},[7283,7292,7296,7306],{"nctId":7284,"briefTitle":7285,"status":143,"phases":7286,"primaryCompletion":7287,"completion":7287,"start":7288,"enrollment":271,"conditions":7289,"interventions":7291},"NCT01902381","CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy",[90],"2018-11-26","2013-08",[7290],"Previously Treated Myelodysplastic Syndromes",[2417],{"nctId":2515,"briefTitle":2516,"status":177,"phases":7293,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":101,"conditions":7294,"interventions":7295},[89,90],[2521],[2469,2470,2482],{"nctId":7297,"briefTitle":7298,"status":177,"phases":7299,"primaryCompletion":7300,"completion":2371,"start":7301,"enrollment":101,"conditions":7302,"interventions":7305},"NCT03370159","CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer",[89,90],"2019-03-01","2018-06",[7303,7304],"Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IV Non-Small Cell Lung Cancer AJCC v7",[2469,1949],{"nctId":7307,"briefTitle":7308,"status":158,"phases":7309,"primaryCompletion":7310,"completion":7311,"start":3819,"enrollment":2055,"conditions":7312,"interventions":7322},"NCT01766219","CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery",[89,90],"2018-04","2018-05-18",[7313,7314,7315,7316,7317,7318,7319,7320,7321],"Adult Primary Cholangiocellular Carcinoma","Advanced Adult Primary Liver Cancer","Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma of the Gallbladder","Localized Unresectable Adult Primary Liver Cancer","Metastatic Extrahepatic Bile Duct Cancer","Recurrent Adult Primary Liver Cancer","Recurrent Extrahepatic Bile Duct Cancer","Unresectable Extrahepatic Bile Duct Cancer",[2417],{"trials":7324,"activeCount":101},[],{"trials":7326,"activeCount":101},[],{"trials":7328,"activeCount":101},[],{"intervention":1565,"totalTrials":1608,"cells":7330},{"EARLY_PHASE1":7331,"PHASE1":7333,"PHASE2":7354,"PHASE3":7399,"PHASE4":7401,"NA":7403},{"trials":7332,"activeCount":101},[],{"trials":7334,"activeCount":101},[7335,7339,7343,7350],{"nctId":1941,"briefTitle":1942,"status":143,"phases":7336,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":7337,"interventions":7338},[89],[148],[1622,1949],{"nctId":1555,"briefTitle":1556,"status":143,"phases":7340,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":1548,"conditions":7341,"interventions":7342},[89],[1562],[1564,1565],{"nctId":7344,"briefTitle":7345,"status":158,"phases":7346,"primaryCompletion":3616,"completion":1537,"start":1560,"enrollment":1733,"conditions":7347,"interventions":7348},"NCT00310154","Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",[89],[33],[1565,7349],"gefitinib",{"nctId":1866,"briefTitle":1867,"status":158,"phases":7351,"primaryCompletion":1454,"completion":1869,"start":1870,"enrollment":1871,"conditions":7352,"interventions":7353},[89],[19],[1565,1874,1662,1875,1876],{"trials":7355,"activeCount":101},[7356,7364,7368,7372,7382,7391,7395],{"nctId":7357,"briefTitle":7358,"status":158,"phases":7359,"primaryCompletion":7360,"completion":5847,"start":7361,"enrollment":204,"conditions":7362,"interventions":7363},"NCT00015886","Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery",[90],"2002-05","1997-01",[19],[1565,2689],{"nctId":7297,"briefTitle":7298,"status":177,"phases":7365,"primaryCompletion":7300,"completion":2371,"start":7301,"enrollment":101,"conditions":7366,"interventions":7367},[89,90],[7303,7304],[2469,1949],{"nctId":3613,"briefTitle":3614,"status":158,"phases":7369,"primaryCompletion":3596,"completion":3596,"start":3616,"enrollment":1733,"conditions":7370,"interventions":7371},[90],[3618,3619,3620,3621,3622,1735,3623,3624,1736],[1738,3600,3626,3627,3628,1565],{"nctId":7373,"briefTitle":7374,"status":143,"phases":7375,"primaryCompletion":5092,"completion":6601,"start":7376,"enrollment":97,"conditions":7377,"interventions":7380},"NCT00354601","Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer",[90],"2006-01",[7378,1645,7379],"Fallopian Tube Cancer","Peritoneal Cavity Cancer",[7381,1565],"capecitabine",{"nctId":7383,"briefTitle":7384,"status":158,"phases":7385,"primaryCompletion":7386,"completion":7387,"start":7388,"enrollment":3460,"conditions":7389,"interventions":7390},"NCT00278460","Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer",[90],"2006-02","2007-09","2000-11",[33],[1565,1895],{"nctId":2682,"briefTitle":2683,"status":158,"phases":7392,"primaryCompletion":2434,"completion":2434,"start":2685,"enrollment":37,"conditions":7393,"interventions":7394},[90],[36],[2688,1738,1565,2689],{"nctId":2624,"briefTitle":2625,"status":158,"phases":7396,"primaryCompletion":2627,"start":2628,"enrollment":2629,"conditions":7397,"interventions":7398},[90],[348],[1565,2213,2632],{"trials":7400,"activeCount":101},[],{"trials":7402,"activeCount":101},[],{"trials":7404,"activeCount":101},[],{"intervention":2689,"totalTrials":136,"cells":7406},{"EARLY_PHASE1":7407,"PHASE1":7409,"PHASE2":7444,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7408,"activeCount":101},[],{"trials":7410,"activeCount":101},[7411,7415,7430,7440],{"nctId":7224,"briefTitle":7225,"status":158,"phases":7412,"primaryCompletion":7227,"completion":7228,"start":5871,"enrollment":34,"conditions":7413,"interventions":7414},[89],[7230,7231,7232,7233],[2417,7235,2215,1589,2689],{"nctId":7416,"briefTitle":7417,"status":158,"phases":7418,"primaryCompletion":4776,"completion":4776,"start":4089,"enrollment":1946,"conditions":7419,"interventions":7428},"NCT01561014","Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction",[89],[7420,7421,7422,7423,7424,7425,7426,7427],"Adenocarcinoma of the Esophagus","Adenocarcinoma of the Gastroesophageal Junction","Adenocarcinoma of the Stomach","Squamous Cell Carcinoma of the Esophagus","Stage II Esophageal Cancer","Stage II Gastric Cancer","Stage III Esophageal Cancer","Stage III Gastric Cancer",[3626,7235,2689,7429],"gene expression analysis",{"nctId":7431,"briefTitle":7432,"status":143,"phases":7433,"primaryCompletion":6426,"completion":7434,"start":1537,"enrollment":97,"conditions":7435,"interventions":7439},"NCT01197664","Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery",[89],"2014-04",[7257,7436,7437,7438,7265,7267],"Stage IIA Rectal Cancer","Stage IIB Rectal Cancer","Stage IIC Rectal Cancer",[1876,2689],{"nctId":7249,"briefTitle":7250,"status":158,"phases":7441,"primaryCompletion":7252,"completion":7253,"start":7254,"enrollment":1782,"conditions":7442,"interventions":7443},[89],[7256,7257,7258,7259,7260,7261,7262,7263,7264,7265,7266,7267,7268,7269,7270,7271],[2417,2689],{"trials":7445,"activeCount":101},[7446,7450,7454],{"nctId":7357,"briefTitle":7358,"status":158,"phases":7447,"primaryCompletion":7360,"completion":5847,"start":7361,"enrollment":204,"conditions":7448,"interventions":7449},[90],[19],[1565,2689],{"nctId":2682,"briefTitle":2683,"status":158,"phases":7451,"primaryCompletion":2434,"completion":2434,"start":2685,"enrollment":37,"conditions":7452,"interventions":7453},[90],[36],[2688,1738,1565,2689],{"nctId":7455,"briefTitle":7456,"status":158,"phases":7457,"primaryCompletion":5050,"completion":7458,"start":7459,"enrollment":31,"conditions":7460,"interventions":7465},"NCT01534637","Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer",[90],"2012-08","2006-08",[7461,7462,7463,7464,7242,7233],"Extrahepatic Bile Duct Cancer","Nausea","Vomiting","Stage II Pancreatic Cancer",[7466,1895,7381,2689],"aprepitant",{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[],{"trials":7472,"activeCount":101},[],{"intervention":1895,"totalTrials":136,"cells":7474},{"EARLY_PHASE1":7475,"PHASE1":7477,"PHASE2":7479,"PHASE3":7525,"PHASE4":7527,"NA":7529},{"trials":7476,"activeCount":101},[],{"trials":7478,"activeCount":101},[],{"trials":7480,"activeCount":101},[7481,7490,7494,7502,7510,7517,7521],{"nctId":7482,"briefTitle":7483,"status":158,"phases":7484,"primaryCompletion":7485,"completion":7485,"start":7486,"enrollment":3354,"conditions":7487,"interventions":7489},"NCT00010166","Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas",[90],"2003-10-03","2000-12-01",[7488],"Pancreatic Cancer",[1895],{"nctId":1884,"briefTitle":1885,"status":158,"phases":7491,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":1890,"conditions":7492,"interventions":7493},[90],[1892,1893],[1738,1895,1662],{"nctId":7495,"briefTitle":7496,"status":158,"phases":7497,"primaryCompletion":7498,"completion":5396,"start":7499,"enrollment":834,"conditions":7500,"interventions":7501},"NCT00003202","Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer",[89,90],"2002-04","1998-01",[33],[1738,1895],{"nctId":7503,"briefTitle":7504,"status":158,"phases":7505,"primaryCompletion":7506,"completion":7506,"start":6336,"enrollment":1548,"conditions":7507,"interventions":7509},"NCT00007943","Gemcitabine in Treating Patients With Advanced Colorectal Cancer",[90],"2001-02-27",[7508],"Colorectal Cancer",[1895],{"nctId":7511,"briefTitle":7512,"status":158,"phases":7513,"primaryCompletion":7514,"completion":7514,"start":1585,"enrollment":37,"conditions":7515,"interventions":7516},"NCT00025168","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer",[90],"2003-08-29",[7488],[1895,1589],{"nctId":7383,"briefTitle":7384,"status":158,"phases":7518,"primaryCompletion":7386,"completion":7387,"start":7388,"enrollment":3460,"conditions":7519,"interventions":7520},[90],[33],[1565,1895],{"nctId":7455,"briefTitle":7456,"status":158,"phases":7522,"primaryCompletion":5050,"completion":7458,"start":7459,"enrollment":31,"conditions":7523,"interventions":7524},[90],[7461,7462,7463,7464,7242,7233],[7466,1895,7381,2689],{"trials":7526,"activeCount":101},[],{"trials":7528,"activeCount":101},[],{"trials":7530,"activeCount":101},[],{"intervention":1590,"totalTrials":1850,"cells":7532},{"EARLY_PHASE1":7533,"PHASE1":7535,"PHASE2":7537,"PHASE3":7580,"PHASE4":7582,"NA":7584},{"trials":7534,"activeCount":101},[],{"trials":7536,"activeCount":101},[],{"trials":7538,"activeCount":101},[7539,7543,7553,7562,7572],{"nctId":1581,"briefTitle":1582,"status":158,"phases":7540,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":7541,"interventions":7542},[90],[33],[1564,1589,1590],{"nctId":7544,"briefTitle":7545,"status":158,"phases":7546,"primaryCompletion":1536,"completion":7547,"start":7548,"enrollment":7549,"conditions":7550,"interventions":7552},"NCT00310076","Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer",[90],"2012-09","2002-10",29,[7551,7508],"Carcinoma of the Appendix",[1590],{"nctId":7554,"briefTitle":7555,"status":158,"phases":7556,"primaryCompletion":7557,"completion":7557,"start":7558,"enrollment":3569,"conditions":7559,"interventions":7560},"NCT00079092","Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma",[90],"2006-03-21","2004-01-01",[3962],[7561,1590],"procarbazine hydrochloride",{"nctId":7563,"briefTitle":7564,"status":158,"phases":7565,"primaryCompletion":7566,"completion":4147,"start":7567,"enrollment":34,"conditions":7568,"interventions":7570},"NCT01891019","Thalidomide in the Treatment of Chronic Plaque Psoriasis.",[90],"2005-09","2003-04",[7569],"Psoriasis, Plaque-type",[7571],"Thalidomide",{"nctId":7573,"briefTitle":7574,"status":158,"phases":7575,"primaryCompletion":7576,"completion":7576,"start":7558,"conditions":7577,"interventions":7578},"NCT00049361","Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases",[90],"2004-12-07",[3962,1647],[7579,1590],"temozolomide",{"trials":7581,"activeCount":101},[],{"trials":7583,"activeCount":101},[],{"trials":7585,"activeCount":101},[],{"intervention":3626,"totalTrials":1850,"cells":7587},{"EARLY_PHASE1":7588,"PHASE1":7599,"PHASE2":7623,"PHASE3":7637,"PHASE4":7639,"NA":7641},{"trials":7589,"activeCount":101},[7590],{"nctId":7591,"briefTitle":7592,"status":158,"phases":7593,"primaryCompletion":7594,"completion":7594,"start":1870,"enrollment":1871,"conditions":7595,"interventions":7596},"NCT00601913","Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery",[88],"2014-10",[36],[3626,7597,7598],"protein analysis","western blotting",{"trials":7600,"activeCount":101},[7601,7605],{"nctId":7416,"briefTitle":7417,"status":158,"phases":7602,"primaryCompletion":4776,"completion":4776,"start":4089,"enrollment":1946,"conditions":7603,"interventions":7604},[89],[7420,7421,7422,7423,7424,7425,7426,7427],[3626,7235,2689,7429],{"nctId":7606,"briefTitle":7607,"status":143,"phases":7608,"primaryCompletion":2488,"completion":1869,"start":7609,"enrollment":1850,"conditions":7610,"interventions":7620},"NCT01103375","Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma",[89],"2010-05",[7611,7612,7613,7614,7615,7616,7617,7618,7619],"Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Diffuse Astrocytoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Adult Oligodendroglioma","Recurrent Adult Brain Tumor",[3626,7621,7622],"isotretinoin","protein expression analysis",{"trials":7624,"activeCount":101},[7625,7633],{"nctId":7626,"briefTitle":7627,"status":143,"phases":7628,"primaryCompletion":7629,"completion":7629,"start":1870,"enrollment":23,"conditions":7630,"interventions":7631},"NCT00573989","Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",[89,90],"2017-03",[36],[3626,7632],"pemetrexed disodium",{"nctId":3613,"briefTitle":3614,"status":158,"phases":7634,"primaryCompletion":3596,"completion":3596,"start":3616,"enrollment":1733,"conditions":7635,"interventions":7636},[90],[3618,3619,3620,3621,3622,1735,3623,3624,1736],[1738,3600,3626,3627,3628,1565],{"trials":7638,"activeCount":101},[],{"trials":7640,"activeCount":101},[],{"trials":7642,"activeCount":101},[],{"intervention":1461,"totalTrials":233,"cells":7644},{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7649,"PHASE3":7684,"PHASE4":7686,"NA":7688},{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[7651,7662,7671,7675],{"nctId":7652,"briefTitle":7653,"status":177,"phases":7654,"primaryCompletion":7655,"completion":7656,"start":7657,"enrollment":101,"conditions":7658,"interventions":7661},"NCT05006599","SNIFF - 3-Week Aptar CPS Device",[90],"2029-05","2031-05","2025-05",[1458,7659,7660],"Cognitive Impairment","Alzheimer Disease, Early Onset",[1461],{"nctId":7663,"briefTitle":7664,"status":158,"phases":7665,"primaryCompletion":7666,"completion":7666,"start":7667,"enrollment":2629,"conditions":7668,"interventions":7669},"NCT05081219","SNIFF - Combo INI+EMPA Trial",[90],"2024-09-17","2021-09-14",[1458,7659,5138],[1461,7670],"Empagliflozin 10 MG",{"nctId":1450,"briefTitle":1451,"status":158,"phases":7672,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1455,"conditions":7673,"interventions":7674},[90],[1457,1458],[1038,1460,1461],{"nctId":7676,"briefTitle":7677,"status":158,"phases":7678,"primaryCompletion":7679,"completion":7680,"start":7681,"enrollment":37,"conditions":7682,"interventions":7683},"NCT03857321","Study of Nasal Insulin to Fight Forgetfulness - Device Study",[90],"2019-09-27","2019-09-30","2019-04-12",[1458,7659],[1461],{"trials":7685,"activeCount":101},[],{"trials":7687,"activeCount":101},[],{"trials":7689,"activeCount":101},[],{"intervention":7235,"totalTrials":233,"cells":7691},{"EARLY_PHASE1":7692,"PHASE1":7694,"PHASE2":7712,"PHASE3":7724,"PHASE4":7726,"NA":7728},{"trials":7693,"activeCount":101},[],{"trials":7695,"activeCount":101},[7696,7700,7704],{"nctId":7224,"briefTitle":7225,"status":158,"phases":7697,"primaryCompletion":7227,"completion":7228,"start":5871,"enrollment":34,"conditions":7698,"interventions":7699},[89],[7230,7231,7232,7233],[2417,7235,2215,1589,2689],{"nctId":7416,"briefTitle":7417,"status":158,"phases":7701,"primaryCompletion":4776,"completion":4776,"start":4089,"enrollment":1946,"conditions":7702,"interventions":7703},[89],[7420,7421,7422,7423,7424,7425,7426,7427],[3626,7235,2689,7429],{"nctId":7705,"briefTitle":7706,"status":158,"phases":7707,"primaryCompletion":7708,"completion":7708,"start":1558,"enrollment":2140,"conditions":7709,"interventions":7711},"NCT00458809","Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer",[89],"2007-11",[7551,7508,7710],"Primary Peritoneal Cavity Cancer",[7235],{"trials":7713,"activeCount":101},[7714],{"nctId":7715,"briefTitle":7716,"status":158,"phases":7717,"primaryCompletion":7240,"completion":2478,"start":7718,"enrollment":7719,"conditions":7720,"interventions":7721},"NCT01580410","Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix",[90],"2009-05",136,[7551,7710],[7722,7235,7723],"mitomycin C","hyperthermic intraperitoneal chemotherapy",{"trials":7725,"activeCount":101},[],{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[],{"intervention":7632,"totalTrials":215,"cells":7731},{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7742,"PHASE3":7756,"PHASE4":7758,"NA":7760},{"trials":7733,"activeCount":101},[],{"trials":7735,"activeCount":101},[7736],{"nctId":7737,"briefTitle":7738,"status":143,"phases":7739,"primaryCompletion":5092,"completion":5092,"start":1887,"enrollment":233,"conditions":7740,"interventions":7741},"NCT00310050","Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",[89],[7488],[7632],{"trials":7743,"activeCount":101},[7744,7748],{"nctId":7626,"briefTitle":7627,"status":143,"phases":7745,"primaryCompletion":7629,"completion":7629,"start":1870,"enrollment":23,"conditions":7746,"interventions":7747},[89,90],[36],[3626,7632],{"nctId":7749,"briefTitle":7750,"status":158,"phases":7751,"primaryCompletion":7752,"completion":1747,"start":2139,"enrollment":2140,"conditions":7753,"interventions":7754},"NCT02426658","Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3",[90],"2018-04-19",[1634],[7755],"Pemetrexed Disodium",{"trials":7757,"activeCount":101},[],{"trials":7759,"activeCount":101},[],{"trials":7761,"activeCount":101},[],{"intervention":7763,"totalTrials":215,"cells":7764},"Regorafenib",{"EARLY_PHASE1":7765,"PHASE1":7767,"PHASE2":7769,"PHASE3":7798,"PHASE4":7800,"NA":7802},{"trials":7766,"activeCount":101},[],{"trials":7768,"activeCount":101},[],{"trials":7770,"activeCount":101},[7771,7780,7789],{"nctId":7772,"briefTitle":7773,"status":143,"phases":7774,"primaryCompletion":7775,"completion":7775,"start":6732,"enrollment":1477,"conditions":7776,"interventions":7779},"NCT02581059","Efficacy of Ginseng for Patients on Regorafenib",[90],"2018-06-22",[7508,7777,7778],"Palliative Medicine","Supportive Care",[7763],{"nctId":7781,"briefTitle":7782,"status":158,"phases":7783,"primaryCompletion":7784,"completion":7784,"start":7785,"enrollment":37,"conditions":7786,"interventions":7787},"NCT02080260","A Study of Regorafenib in Advanced Pancreatic Cancer Patients",[90],"2017-06-28","2014-06-06",[7488],[7788],"regorafenib",{"nctId":7790,"briefTitle":7791,"status":143,"phases":7792,"primaryCompletion":7793,"completion":7793,"start":7794,"enrollment":97,"conditions":7795,"interventions":7797},"NCT04327700","Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib",[90],"2024-05-31","2021-01-26",[7796],"Hepatocellular Carcinoma",[7763],{"trials":7799,"activeCount":101},[],{"trials":7801,"activeCount":101},[],{"trials":7803,"activeCount":101},[],{"intervention":1589,"totalTrials":215,"cells":7805},{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7814,"PHASE3":7824,"PHASE4":7826,"NA":7828},{"trials":7807,"activeCount":101},[],{"trials":7809,"activeCount":101},[7810],{"nctId":7224,"briefTitle":7225,"status":158,"phases":7811,"primaryCompletion":7227,"completion":7228,"start":5871,"enrollment":34,"conditions":7812,"interventions":7813},[89],[7230,7231,7232,7233],[2417,7235,2215,1589,2689],{"trials":7815,"activeCount":101},[7816,7820],{"nctId":1581,"briefTitle":1582,"status":158,"phases":7817,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":7818,"interventions":7819},[90],[33],[1564,1589,1590],{"nctId":7511,"briefTitle":7512,"status":158,"phases":7821,"primaryCompletion":7514,"completion":7514,"start":1585,"enrollment":37,"conditions":7822,"interventions":7823},[90],[7488],[1895,1589],{"trials":7825,"activeCount":101},[],{"trials":7827,"activeCount":101},[],{"trials":7829,"activeCount":101},[],{"intervention":2498,"totalTrials":215,"cells":7831},{"EARLY_PHASE1":7832,"PHASE1":7834,"PHASE2":7847,"PHASE3":7859,"PHASE4":7861,"NA":7863},{"trials":7833,"activeCount":101},[],{"trials":7835,"activeCount":101},[7836,7843],{"nctId":7837,"briefTitle":7838,"status":158,"phases":7839,"primaryCompletion":5373,"completion":2434,"start":1656,"enrollment":3354,"conditions":7840,"interventions":7842},"NCT01034475","Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies",[89],[7841],"Advanced Hematologic Malignancies",[2498],{"nctId":2484,"briefTitle":2485,"status":158,"phases":7844,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":2489,"conditions":7845,"interventions":7846},[89],[2491,2492,2493,2494,2495,2496,2467],[2498,2211,2499],{"trials":7848,"activeCount":101},[7849],{"nctId":7850,"briefTitle":7851,"status":177,"phases":7852,"primaryCompletion":4292,"completion":1229,"start":7853,"enrollment":101,"conditions":7854,"interventions":7857},"NCT03929211","CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome",[89,90],"2021-05",[7855,7856],"Myelodysplastic Syndromes","Progressive Disease",[2498,7858],"Hydroxychloroquine",{"trials":7860,"activeCount":101},[],{"trials":7862,"activeCount":101},[],{"trials":7864,"activeCount":101},[],{"intervention":1876,"totalTrials":215,"cells":7866},{"EARLY_PHASE1":7867,"PHASE1":7869,"PHASE2":7879,"PHASE3":7889,"PHASE4":7891,"NA":7893},{"trials":7868,"activeCount":101},[],{"trials":7870,"activeCount":101},[7871,7875],{"nctId":1866,"briefTitle":1867,"status":158,"phases":7872,"primaryCompletion":1454,"completion":1869,"start":1870,"enrollment":1871,"conditions":7873,"interventions":7874},[89],[19],[1565,1874,1662,1875,1876],{"nctId":7431,"briefTitle":7432,"status":143,"phases":7876,"primaryCompletion":6426,"completion":7434,"start":1537,"enrollment":97,"conditions":7877,"interventions":7878},[89],[7257,7436,7437,7438,7265,7267],[1876,2689],{"trials":7880,"activeCount":101},[7881],{"nctId":7882,"briefTitle":7883,"status":143,"phases":7884,"primaryCompletion":2488,"completion":1033,"start":7885,"enrollment":97,"conditions":7886,"interventions":7888},"NCT00634582","Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases",[90],"2009-01",[7887,348],"Metastatic Cancer",[1876],{"trials":7890,"activeCount":101},[],{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":101},[],{"intervention":7896,"totalTrials":215,"cells":7897},"Temozolomide",{"EARLY_PHASE1":7898,"PHASE1":7900,"PHASE2":7902,"PHASE3":7928,"PHASE4":7930,"NA":7932},{"trials":7899,"activeCount":101},[],{"trials":7901,"activeCount":101},[],{"trials":7903,"activeCount":101},[7904,7914,7924],{"nctId":7905,"briefTitle":7906,"status":143,"phases":7907,"primaryCompletion":7908,"completion":7908,"start":7909,"enrollment":1548,"conditions":7910,"interventions":7912},"NCT03363659","Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme",[90],"2022-01-13","2018-03-28",[7911,4075],"Glioblastoma",[7913,7896],"Disulfiram",{"nctId":7915,"briefTitle":7916,"status":143,"phases":7917,"primaryCompletion":7918,"completion":7918,"start":7919,"enrollment":4125,"conditions":7920,"interventions":7922},"NCT02343549","A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)",[90],"2020-07-11","2015-01",[7921],"Cancer of Brain and Nervous System",[7923,7896],"Bevacizumab",{"nctId":7573,"briefTitle":7574,"status":158,"phases":7925,"primaryCompletion":7576,"completion":7576,"start":7558,"conditions":7926,"interventions":7927},[90],[3962,1647],[7579,1590],{"trials":7929,"activeCount":101},[],{"trials":7931,"activeCount":101},[],{"trials":7933,"activeCount":101},[],{"intervention":7935,"totalTrials":97,"cells":7936},"clonidine",{"EARLY_PHASE1":7937,"PHASE1":7939,"PHASE2":7941,"PHASE3":7958,"PHASE4":7960,"NA":7962},{"trials":7938,"activeCount":101},[],{"trials":7940,"activeCount":101},[],{"trials":7942,"activeCount":101},[7943,7950],{"nctId":7944,"briefTitle":7945,"status":158,"phases":7946,"primaryCompletion":1870,"completion":1870,"start":7947,"enrollment":1630,"conditions":7948,"interventions":7949},"NCT00350532","Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain",[90],"2004-09",[25],[7935,7935],{"nctId":7951,"briefTitle":7952,"status":158,"phases":7953,"primaryCompletion":7954,"completion":7954,"start":2628,"enrollment":1871,"conditions":7955,"interventions":7956},"NCT00349921","Clonidine Versus Adenosine to Treat Neuropathic Pain",[90],"2008-01",[25],[7935,7957],"adenosine",{"trials":7959,"activeCount":101},[],{"trials":7961,"activeCount":101},[],{"trials":7963,"activeCount":101},[],{"intervention":2456,"totalTrials":97,"cells":7965},{"EARLY_PHASE1":7966,"PHASE1":7968,"PHASE2":7974,"PHASE3":7980,"PHASE4":7982,"NA":7984},{"trials":7967,"activeCount":101},[],{"trials":7969,"activeCount":101},[7970],{"nctId":2448,"briefTitle":2449,"status":158,"phases":7971,"primaryCompletion":2451,"completion":2451,"start":2452,"enrollment":2453,"conditions":7972,"interventions":7973},[89],[2208],[2456,2211],{"trials":7975,"activeCount":101},[7976],{"nctId":2507,"briefTitle":2508,"status":158,"phases":7977,"primaryCompletion":2510,"completion":2510,"start":2452,"enrollment":2511,"conditions":7978,"interventions":7979},[90],[2208],[2456,2211],{"trials":7981,"activeCount":101},[],{"trials":7983,"activeCount":101},[],{"trials":7985,"activeCount":101},[],{"intervention":2198,"totalTrials":97,"cells":7987},{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":8003,"PHASE3":8009,"PHASE4":8011,"NA":8013},{"trials":7989,"activeCount":101},[],{"trials":7991,"activeCount":101},[7992],{"nctId":7993,"briefTitle":7994,"status":177,"phases":7995,"primaryCompletion":2281,"completion":179,"start":1032,"enrollment":101,"conditions":7996,"interventions":8000},"NCT03240822","Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma",[89],[7997,7998,7999],"Urologic Injuries","Genital Diseases, Male","Amputation",[8001,8002],"Monoclonal Antibody","Tacrolimus",{"trials":8004,"activeCount":101},[8005],{"nctId":2186,"briefTitle":2187,"status":158,"phases":8006,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":23,"conditions":8007,"interventions":8008},[90],[2193,2194],[2196,2197,1649,2198,2199],{"trials":8010,"activeCount":101},[],{"trials":8012,"activeCount":101},[],{"trials":8014,"activeCount":101},[],{"intervention":2215,"totalTrials":97,"cells":8016},{"EARLY_PHASE1":8017,"PHASE1":8019,"PHASE2":8025,"PHASE3":8031,"PHASE4":8033,"NA":8035},{"trials":8018,"activeCount":101},[],{"trials":8020,"activeCount":101},[8021],{"nctId":7224,"briefTitle":7225,"status":158,"phases":8022,"primaryCompletion":7227,"completion":7228,"start":5871,"enrollment":34,"conditions":8023,"interventions":8024},[89],[7230,7231,7232,7233],[2417,7235,2215,1589,2689],{"trials":8026,"activeCount":101},[8027],{"nctId":2201,"briefTitle":2202,"status":158,"phases":8028,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":8029,"interventions":8030},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"trials":8032,"activeCount":101},[],{"trials":8034,"activeCount":101},[],{"trials":8036,"activeCount":101},[],{"intervention":8038,"totalTrials":97,"cells":8039},"therapeutic angiotensin-",{"EARLY_PHASE1":8040,"PHASE1":8042,"PHASE2":8050,"PHASE3":8070,"PHASE4":8072,"NA":8074},{"trials":8041,"activeCount":101},[],{"trials":8043,"activeCount":101},[8044],{"nctId":8045,"briefTitle":8046,"status":158,"phases":8047,"primaryCompletion":3860,"completion":3860,"start":1558,"enrollment":3569,"conditions":8048,"interventions":8049},"NCT00471562","Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors",[89],[1647],[8038],{"trials":8051,"activeCount":101},[8052],{"nctId":8053,"briefTitle":8054,"status":158,"phases":8055,"primaryCompletion":2488,"completion":2488,"start":3860,"enrollment":37,"conditions":8056,"interventions":8069},"NCT01553539","Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery",[90],[8057,8058,8059,8060,8061,8062,8063,8064,8065,8066,8067,8068],"Bone Cancer","Chondrosarcoma","Clear Cell Sarcoma of the Kidney","Metastatic Osteosarcoma","Ovarian Sarcoma","Recurrent Adult Soft Tissue Sarcoma","Recurrent Osteosarcoma","Recurrent Uterine Sarcoma","Stage III Adult Soft Tissue Sarcoma","Stage III Uterine Sarcoma","Stage IV Adult Soft Tissue Sarcoma","Stage IV Uterine Sarcoma",[8038],{"trials":8071,"activeCount":101},[],{"trials":8073,"activeCount":101},[],{"trials":8075,"activeCount":101},[],{"intervention":8077,"totalTrials":97,"cells":8078},"Nitric Oxide",{"EARLY_PHASE1":8079,"PHASE1":8081,"PHASE2":8092,"PHASE3":8101,"PHASE4":8103,"NA":8105},{"trials":8080,"activeCount":101},[],{"trials":8082,"activeCount":101},[8083],{"nctId":8084,"briefTitle":8085,"status":158,"phases":8086,"primaryCompletion":8087,"completion":8087,"start":8088,"enrollment":204,"conditions":8089,"interventions":8090},"NCT00848731","Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism",[89],"2011-05","2009-02",[6844],[8091],"nitric oxide",{"trials":8093,"activeCount":101},[8094],{"nctId":8095,"briefTitle":8096,"status":158,"phases":8097,"primaryCompletion":5846,"completion":5846,"start":244,"enrollment":1477,"conditions":8098,"interventions":8100},"NCT01165047","Nitric Oxide, GeNO Nitrosyl Delivery System",[90],[8099],"Pulmonary Arterial Hypertension",[8077],{"trials":8102,"activeCount":101},[],{"trials":8104,"activeCount":101},[],{"trials":8106,"activeCount":101},[],{"intervention":6396,"totalTrials":97,"cells":8108},{"EARLY_PHASE1":8109,"PHASE1":8111,"PHASE2":8120,"PHASE3":8126,"PHASE4":8128,"NA":8130},{"trials":8110,"activeCount":101},[],{"trials":8112,"activeCount":101},[8113],{"nctId":8114,"briefTitle":8115,"status":158,"phases":8116,"primaryCompletion":7181,"completion":7181,"start":5454,"enrollment":1090,"conditions":8117,"interventions":8118},"NCT00779467","Epidural Neostigmine for Labor Pain",[89],[5116],[8119,167,6396],"Neostigmine",{"trials":8121,"activeCount":101},[8122],{"nctId":6389,"briefTitle":6390,"status":158,"phases":8123,"primaryCompletion":2478,"completion":2478,"start":2519,"enrollment":4183,"conditions":8124,"interventions":8125},[90],[6393],[6395,6396,6397],{"trials":8127,"activeCount":101},[],{"trials":8129,"activeCount":101},[],{"trials":8131,"activeCount":101},[],{"intervention":3894,"totalTrials":97,"cells":8133},{"EARLY_PHASE1":8134,"PHASE1":8136,"PHASE2":8138,"PHASE3":8157,"PHASE4":8159,"NA":8161},{"trials":8135,"activeCount":101},[],{"trials":8137,"activeCount":101},[],{"trials":8139,"activeCount":101},[8140,8153],{"nctId":8141,"briefTitle":8142,"status":143,"phases":8143,"primaryCompletion":8144,"completion":8145,"start":8146,"enrollment":1362,"conditions":8147,"interventions":8151},"NCT04217317","CPI-613 in Combination With Bendamustine in Patients With Relapsed\u002FRefractory T-Cell Non-Hodgkin Lymphoma",[90],"2023-04-21","2024-07-11","2020-09-16",[8148,8149,8150],"Relapsed T-Cell Lymphoma","Refractory T-Cell Lymphoma","Non Hodgkin Lymphoma",[3894,8152],"Bendamustine",{"nctId":3885,"briefTitle":3886,"status":177,"phases":8154,"primaryCompletion":3888,"completion":3889,"start":385,"enrollment":101,"conditions":8155,"interventions":8156},[90],[3891,3892,2466],[3894,3866,3895],{"trials":8158,"activeCount":101},[],{"trials":8160,"activeCount":101},[],{"trials":8162,"activeCount":101},[],{"intervention":7381,"totalTrials":97,"cells":8164},{"EARLY_PHASE1":8165,"PHASE1":8167,"PHASE2":8169,"PHASE3":8179,"PHASE4":8181,"NA":8183},{"trials":8166,"activeCount":101},[],{"trials":8168,"activeCount":101},[],{"trials":8170,"activeCount":101},[8171,8175],{"nctId":7373,"briefTitle":7374,"status":143,"phases":8172,"primaryCompletion":5092,"completion":6601,"start":7376,"enrollment":97,"conditions":8173,"interventions":8174},[90],[7378,1645,7379],[7381,1565],{"nctId":7455,"briefTitle":7456,"status":158,"phases":8176,"primaryCompletion":5050,"completion":7458,"start":7459,"enrollment":31,"conditions":8177,"interventions":8178},[90],[7461,7462,7463,7464,7242,7233],[7466,1895,7381,2689],{"trials":8180,"activeCount":101},[],{"trials":8182,"activeCount":101},[],{"trials":8184,"activeCount":101},[],{"intervention":1575,"totalTrials":97,"cells":8186},{"EARLY_PHASE1":8187,"PHASE1":8189,"PHASE2":8195,"PHASE3":8201,"PHASE4":8203,"NA":8205},{"trials":8188,"activeCount":101},[],{"trials":8190,"activeCount":101},[8191],{"nctId":1567,"briefTitle":1568,"status":177,"phases":8192,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":101,"conditions":8193,"interventions":8194},[89],[19],[1574,1575,58,1576,1577,53],{"trials":8196,"activeCount":101},[8197],{"nctId":1813,"briefTitle":1814,"status":158,"phases":8198,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":1377,"conditions":8199,"interventions":8200},[90],[1820,1821],[86,1575],{"trials":8202,"activeCount":101},[],{"trials":8204,"activeCount":101},[],{"trials":8206,"activeCount":101},[],{"intervention":8208,"totalTrials":97,"cells":8209},"ramipril",{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8214,"PHASE3":8238,"PHASE4":8240,"NA":8242},{"trials":8211,"activeCount":101},[],{"trials":8213,"activeCount":101},[],{"trials":8215,"activeCount":101},[8216,8225],{"nctId":8217,"briefTitle":8218,"status":143,"phases":8219,"primaryCompletion":1655,"completion":7434,"start":3596,"enrollment":1362,"conditions":8220,"interventions":8221},"NCT01234922","Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors",[90],[312,1647],[8222,8223,8224,8208],"lisinopril","losartan potassium","benazepril hydrochloride",{"nctId":8226,"briefTitle":8227,"status":158,"phases":8228,"primaryCompletion":8229,"completion":8229,"start":8230,"enrollment":8231,"conditions":8232,"interventions":8236},"NCT03475186","Testing Ramipril to Prevent Memory Loss in People With Glioblastoma",[90],"2025-03-25","2019-03-25",75,[7911,8233,8234,8235],"Radiotherapy; Complications","Cognitive Decline","Chemoradiation",[8237],"Ramipril",{"trials":8239,"activeCount":101},[],{"trials":8241,"activeCount":101},[],{"trials":8243,"activeCount":101},[],{"intervention":1381,"totalTrials":228,"cells":8245},{"EARLY_PHASE1":8246,"PHASE1":8248,"PHASE2":8250,"PHASE3":8256,"PHASE4":8258,"NA":8260},{"trials":8247,"activeCount":101},[],{"trials":8249,"activeCount":101},[],{"trials":8251,"activeCount":101},[8252],{"nctId":1371,"briefTitle":1372,"status":143,"phases":8253,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":8254,"interventions":8255},[90],[1379],[1361,1381,1382],{"trials":8257,"activeCount":101},[],{"trials":8259,"activeCount":101},[],{"trials":8261,"activeCount":101},[],{"intervention":8263,"totalTrials":228,"cells":8264},"Investigational Agent",{"EARLY_PHASE1":8265,"PHASE1":8267,"PHASE2":8269,"PHASE3":8283,"PHASE4":8285,"NA":8287},{"trials":8266,"activeCount":101},[],{"trials":8268,"activeCount":101},[],{"trials":8270,"activeCount":101},[8271],{"nctId":8272,"briefTitle":8273,"status":143,"phases":8274,"primaryCompletion":8275,"completion":8276,"start":8277,"enrollment":1733,"conditions":8278,"interventions":8282},"NCT04111107","Precision Medicine for Patients With Identified Actionable Mutations",[90],"2022-12-09","2023-02-09","2020-04-22",[8279,8280,1762,4007,8281],"Solid Tumor","Lymphoma","Mutation Abnormality",[8263],{"trials":8284,"activeCount":101},[],{"trials":8286,"activeCount":101},[],{"trials":8288,"activeCount":101},[],{"intervention":8290,"totalTrials":228,"cells":8291},"Lucanthone",{"EARLY_PHASE1":8292,"PHASE1":8294,"PHASE2":8296,"PHASE3":8305,"PHASE4":8307,"NA":8309},{"trials":8293,"activeCount":101},[],{"trials":8295,"activeCount":101},[],{"trials":8297,"activeCount":101},[8298],{"nctId":8299,"briefTitle":8300,"status":177,"phases":8301,"primaryCompletion":8302,"completion":8302,"start":2487,"enrollment":101,"conditions":8303,"interventions":8304},"NCT02014545","Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer",[90],"2017-11-29",[3003,3622],[8290],{"trials":8306,"activeCount":101},[],{"trials":8308,"activeCount":101},[],{"trials":8310,"activeCount":101},[],{"intervention":8312,"totalTrials":228,"cells":8313},"beet juice",{"EARLY_PHASE1":8314,"PHASE1":8316,"PHASE2":8318,"PHASE3":8329,"PHASE4":8331,"NA":8333},{"trials":8315,"activeCount":101},[],{"trials":8317,"activeCount":101},[],{"trials":8319,"activeCount":101},[8320],{"nctId":8321,"briefTitle":8322,"status":177,"phases":8323,"primaryCompletion":8324,"completion":8325,"start":7201,"enrollment":101,"conditions":8326,"interventions":8328},"NCT02162225","Study of Beet Juice for Patients With Sickle Cell Anemia",[90],"2019-02","2019-04",[8327],"Sickle Cell Anemia",[8312],{"trials":8330,"activeCount":101},[],{"trials":8332,"activeCount":101},[],{"trials":8334,"activeCount":101},[],{"intervention":8336,"totalTrials":228,"cells":8337},"Harvoni",{"EARLY_PHASE1":8338,"PHASE1":8340,"PHASE2":8342,"PHASE3":8354,"PHASE4":8356,"NA":8358},{"trials":8339,"activeCount":101},[],{"trials":8341,"activeCount":101},[],{"trials":8343,"activeCount":101},[8344],{"nctId":8345,"briefTitle":8346,"status":158,"phases":8347,"primaryCompletion":8348,"completion":8348,"start":8349,"enrollment":28,"conditions":8350,"interventions":8353},"NCT03118674","Harvoni Treatment Porphyria Cutanea Tarda",[90],"2022-03-04","2017-09-06",[8351,8352],"Porphyria Cutanea Tarda","Hepatitis C",[8336],{"trials":8355,"activeCount":101},[],{"trials":8357,"activeCount":101},[],{"trials":8359,"activeCount":101},[],{"intervention":8361,"totalTrials":228,"cells":8362},"Phentermine\u002Ftopiramate",{"EARLY_PHASE1":8363,"PHASE1":8365,"PHASE2":8367,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[],{"trials":8368,"activeCount":101},[8369],{"nctId":8370,"briefTitle":8371,"status":158,"phases":8372,"primaryCompletion":8373,"completion":8373,"start":1607,"enrollment":204,"conditions":8374,"interventions":8377},"NCT02301416","Qsymia as an Adjunct to Surgical Therapy in the Superobese",[90],"2018-06-27",[16,8375,4627,8376],"Metabolic Surgery","Bariatric Surgery Procedures",[8361],{"trials":8379,"activeCount":101},[],{"trials":8381,"activeCount":101},[],{"trials":8383,"activeCount":101},[],{"intervention":8385,"totalTrials":228,"cells":8386},"Atorvastatin",{"EARLY_PHASE1":8387,"PHASE1":8389,"PHASE2":8391,"PHASE3":8402,"PHASE4":8404,"NA":8406},{"trials":8388,"activeCount":101},[],{"trials":8390,"activeCount":101},[],{"trials":8392,"activeCount":101},[8393],{"nctId":8394,"briefTitle":8395,"status":158,"phases":8396,"primaryCompletion":8397,"completion":8397,"start":8398,"enrollment":8399,"conditions":8400,"interventions":8401},"NCT01988571","Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)",[90],"2020-09-24","2014-02-01",279,[19,8280],[8385],{"trials":8403,"activeCount":101},[],{"trials":8405,"activeCount":101},[],{"trials":8407,"activeCount":101},[],{"intervention":8409,"totalTrials":228,"cells":8410},"Daratumumab",{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8415,"PHASE3":8424,"PHASE4":8426,"NA":8428},{"trials":8412,"activeCount":101},[],{"trials":8414,"activeCount":101},[],{"trials":8416,"activeCount":101},[8417],{"nctId":8418,"briefTitle":8419,"status":177,"phases":8420,"primaryCompletion":283,"completion":283,"start":8421,"enrollment":101,"conditions":8422,"interventions":8423},"NCT04230031","Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma",[90],"2021-07-02",[1762],[8409],{"trials":8425,"activeCount":101},[],{"trials":8427,"activeCount":101},[],{"trials":8429,"activeCount":101},[],{"intervention":8431,"totalTrials":228,"cells":8432},"Vincristine Sulfate Liposome",{"EARLY_PHASE1":8433,"PHASE1":8435,"PHASE2":8437,"PHASE3":8448,"PHASE4":8450,"NA":8452},{"trials":8434,"activeCount":101},[],{"trials":8436,"activeCount":101},[],{"trials":8438,"activeCount":101},[8439],{"nctId":8440,"briefTitle":8441,"status":143,"phases":8442,"primaryCompletion":8443,"completion":8444,"start":8445,"enrollment":1850,"conditions":8446,"interventions":8447},"NCT02337478","Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],"2016-03-31","2017-09-04","2015-06-05",[2467],[8431],{"trials":8449,"activeCount":101},[],{"trials":8451,"activeCount":101},[],{"trials":8453,"activeCount":101},[],{"intervention":8455,"totalTrials":228,"cells":8456},"omega-3 fatty acid",{"EARLY_PHASE1":8457,"PHASE1":8459,"PHASE2":8461,"PHASE3":8478,"PHASE4":8480,"NA":8482},{"trials":8458,"activeCount":101},[],{"trials":8460,"activeCount":101},[],{"trials":8462,"activeCount":101},[8463],{"nctId":8464,"briefTitle":8465,"status":158,"phases":8466,"primaryCompletion":8467,"completion":8467,"start":7181,"enrollment":2529,"conditions":8468,"interventions":8477},"NCT01869764","Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer",[90],"2018-07",[8469,8470,1773,8471,8472,8473,8474,8475,8476],"Ductal Breast Carcinoma in Situ","Lobular Breast Carcinoma in Situ","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[8455],{"trials":8479,"activeCount":101},[],{"trials":8481,"activeCount":101},[],{"trials":8483,"activeCount":101},[],{"intervention":8485,"totalTrials":228,"cells":8486},"ketorolac tromethamine opthalmic solution",{"EARLY_PHASE1":8487,"PHASE1":8489,"PHASE2":8491,"PHASE3":8499,"PHASE4":8501,"NA":8503},{"trials":8488,"activeCount":101},[],{"trials":8490,"activeCount":101},[],{"trials":8492,"activeCount":101},[8493],{"nctId":8494,"briefTitle":8495,"status":143,"phases":8496,"primaryCompletion":5373,"completion":5373,"start":1870,"enrollment":6427,"conditions":8497,"interventions":8498},"NCT00621530","Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement",[90],[4271],[8485],{"trials":8500,"activeCount":101},[],{"trials":8502,"activeCount":101},[],{"trials":8504,"activeCount":101},[],{"intervention":7670,"totalTrials":228,"cells":8506},{"EARLY_PHASE1":8507,"PHASE1":8509,"PHASE2":8511,"PHASE3":8517,"PHASE4":8519,"NA":8521},{"trials":8508,"activeCount":101},[],{"trials":8510,"activeCount":101},[],{"trials":8512,"activeCount":101},[8513],{"nctId":7663,"briefTitle":7664,"status":158,"phases":8514,"primaryCompletion":7666,"completion":7666,"start":7667,"enrollment":2629,"conditions":8515,"interventions":8516},[90],[1458,7659,5138],[1461,7670],{"trials":8518,"activeCount":101},[],{"trials":8520,"activeCount":101},[],{"trials":8522,"activeCount":101},[],{"intervention":2196,"totalTrials":228,"cells":8524},{"EARLY_PHASE1":8525,"PHASE1":8527,"PHASE2":8529,"PHASE3":8535,"PHASE4":8537,"NA":8539},{"trials":8526,"activeCount":101},[],{"trials":8528,"activeCount":101},[],{"trials":8530,"activeCount":101},[8531],{"nctId":2186,"briefTitle":2187,"status":158,"phases":8532,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":23,"conditions":8533,"interventions":8534},[90],[2193,2194],[2196,2197,1649,2198,2199],{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[],{"trials":8540,"activeCount":101},[],{"intervention":2197,"totalTrials":228,"cells":8542},{"EARLY_PHASE1":8543,"PHASE1":8545,"PHASE2":8547,"PHASE3":8553,"PHASE4":8555,"NA":8557},{"trials":8544,"activeCount":101},[],{"trials":8546,"activeCount":101},[],{"trials":8548,"activeCount":101},[8549],{"nctId":2186,"briefTitle":2187,"status":158,"phases":8550,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":23,"conditions":8551,"interventions":8552},[90],[2193,2194],[2196,2197,1649,2198,2199],{"trials":8554,"activeCount":101},[],{"trials":8556,"activeCount":101},[],{"trials":8558,"activeCount":101},[],{"intervention":2199,"totalTrials":228,"cells":8560},{"EARLY_PHASE1":8561,"PHASE1":8563,"PHASE2":8565,"PHASE3":8571,"PHASE4":8573,"NA":8575},{"trials":8562,"activeCount":101},[],{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[8567],{"nctId":2186,"briefTitle":2187,"status":158,"phases":8568,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":23,"conditions":8569,"interventions":8570},[90],[2193,2194],[2196,2197,1649,2198,2199],{"trials":8572,"activeCount":101},[],{"trials":8574,"activeCount":101},[],{"trials":8576,"activeCount":101},[],{"intervention":8578,"totalTrials":228,"cells":8579},"Suboxone® SL",{"EARLY_PHASE1":8580,"PHASE1":8582,"PHASE2":8584,"PHASE3":8593,"PHASE4":8595,"NA":8597},{"trials":8581,"activeCount":101},[],{"trials":8583,"activeCount":101},[],{"trials":8585,"activeCount":101},[8586],{"nctId":8587,"briefTitle":8588,"status":177,"phases":8589,"primaryCompletion":2281,"completion":2281,"start":2280,"enrollment":101,"conditions":8590,"interventions":8591},"NCT03744663","Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine\u002FNaloxone Films",[90],[347],[8578,8592],"Sublocade®",{"trials":8594,"activeCount":101},[],{"trials":8596,"activeCount":101},[],{"trials":8598,"activeCount":101},[],{"intervention":8592,"totalTrials":228,"cells":8600},{"EARLY_PHASE1":8601,"PHASE1":8603,"PHASE2":8605,"PHASE3":8611,"PHASE4":8613,"NA":8615},{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":101},[8607],{"nctId":8587,"briefTitle":8588,"status":177,"phases":8608,"primaryCompletion":2281,"completion":2281,"start":2280,"enrollment":101,"conditions":8609,"interventions":8610},[90],[347],[8578,8592],{"trials":8612,"activeCount":101},[],{"trials":8614,"activeCount":101},[],{"trials":8616,"activeCount":101},[],{"intervention":262,"totalTrials":228,"cells":8618},{"EARLY_PHASE1":8619,"PHASE1":8621,"PHASE2":8623,"PHASE3":8629,"PHASE4":8631,"NA":8633},{"trials":8620,"activeCount":101},[],{"trials":8622,"activeCount":101},[],{"trials":8624,"activeCount":101},[8625],{"nctId":253,"briefTitle":254,"status":143,"phases":8626,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":8627,"interventions":8628},[90],[260],[262,232],{"trials":8630,"activeCount":101},[],{"trials":8632,"activeCount":101},[],{"trials":8634,"activeCount":101},[],{"intervention":2210,"totalTrials":228,"cells":8636},{"EARLY_PHASE1":8637,"PHASE1":8639,"PHASE2":8641,"PHASE3":8647,"PHASE4":8649,"NA":8651},{"trials":8638,"activeCount":101},[],{"trials":8640,"activeCount":101},[],{"trials":8642,"activeCount":101},[8643],{"nctId":2201,"briefTitle":2202,"status":158,"phases":8644,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":8645,"interventions":8646},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"trials":8648,"activeCount":101},[],{"trials":8650,"activeCount":101},[],{"trials":8652,"activeCount":101},[],{"intervention":2214,"totalTrials":228,"cells":8654},{"EARLY_PHASE1":8655,"PHASE1":8657,"PHASE2":8659,"PHASE3":8665,"PHASE4":8667,"NA":8669},{"trials":8656,"activeCount":101},[],{"trials":8658,"activeCount":101},[],{"trials":8660,"activeCount":101},[8661],{"nctId":2201,"briefTitle":2202,"status":158,"phases":8662,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":8663,"interventions":8664},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"trials":8666,"activeCount":101},[],{"trials":8668,"activeCount":101},[],{"trials":8670,"activeCount":101},[],{"intervention":2216,"totalTrials":228,"cells":8672},{"EARLY_PHASE1":8673,"PHASE1":8675,"PHASE2":8677,"PHASE3":8683,"PHASE4":8685,"NA":8687},{"trials":8674,"activeCount":101},[],{"trials":8676,"activeCount":101},[],{"trials":8678,"activeCount":101},[8679],{"nctId":2201,"briefTitle":2202,"status":158,"phases":8680,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":8681,"interventions":8682},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"trials":8684,"activeCount":101},[],{"trials":8686,"activeCount":101},[],{"trials":8688,"activeCount":101},[],{"intervention":2217,"totalTrials":228,"cells":8690},{"EARLY_PHASE1":8691,"PHASE1":8693,"PHASE2":8695,"PHASE3":8701,"PHASE4":8703,"NA":8705},{"trials":8692,"activeCount":101},[],{"trials":8694,"activeCount":101},[],{"trials":8696,"activeCount":101},[8697],{"nctId":2201,"briefTitle":2202,"status":158,"phases":8698,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":8699,"interventions":8700},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"trials":8702,"activeCount":101},[],{"trials":8704,"activeCount":101},[],{"trials":8706,"activeCount":101},[],{"intervention":2218,"totalTrials":228,"cells":8708},{"EARLY_PHASE1":8709,"PHASE1":8711,"PHASE2":8713,"PHASE3":8719,"PHASE4":8721,"NA":8723},{"trials":8710,"activeCount":101},[],{"trials":8712,"activeCount":101},[],{"trials":8714,"activeCount":101},[8715],{"nctId":2201,"briefTitle":2202,"status":158,"phases":8716,"primaryCompletion":2204,"completion":2205,"start":2206,"enrollment":204,"conditions":8717,"interventions":8718},[90],[2208],[2210,1649,2211,2212,2213,1599,2214,2215,2216,2217,2218,2219],{"trials":8720,"activeCount":101},[],{"trials":8722,"activeCount":101},[],{"trials":8724,"activeCount":101},[],{"intervention":8726,"totalTrials":228,"cells":8727},"secukinumab 150 mg (2 injections per dose",{"EARLY_PHASE1":8728,"PHASE1":8730,"PHASE2":8732,"PHASE3":8741,"PHASE4":8743,"NA":8745},{"trials":8729,"activeCount":101},[],{"trials":8731,"activeCount":101},[],{"trials":8733,"activeCount":101},[8734],{"nctId":8735,"briefTitle":8736,"status":177,"phases":8737,"primaryCompletion":2282,"completion":8738,"start":7853,"enrollment":101,"conditions":8739,"interventions":8740},"NCT04274166","Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum",[90],"2022-04",[3933],[8726],{"trials":8742,"activeCount":101},[],{"trials":8744,"activeCount":101},[],{"trials":8746,"activeCount":101},[],{"intervention":8748,"totalTrials":228,"cells":8749},"MGE",{"EARLY_PHASE1":8750,"PHASE1":8752,"PHASE2":8754,"PHASE3":8767,"PHASE4":8769,"NA":8771},{"trials":8751,"activeCount":101},[],{"trials":8753,"activeCount":101},[],{"trials":8755,"activeCount":101},[8756],{"nctId":8757,"briefTitle":8758,"status":158,"phases":8759,"primaryCompletion":8760,"completion":8761,"start":8762,"enrollment":8763,"conditions":8764,"interventions":8766},"NCT03496805","Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy",[90],"2025-02-20","2025-08-14","2019-01-29",106,[8765],"Recurrent Prostate Cancer",[8748],{"trials":8768,"activeCount":101},[],{"trials":8770,"activeCount":101},[],{"trials":8772,"activeCount":101},[],{"intervention":8774,"totalTrials":228,"cells":8775},"midazolam intravenous",{"EARLY_PHASE1":8776,"PHASE1":8778,"PHASE2":8780,"PHASE3":8791,"PHASE4":8793,"NA":8795},{"trials":8777,"activeCount":101},[],{"trials":8779,"activeCount":101},[],{"trials":8781,"activeCount":101},[8782],{"nctId":8783,"briefTitle":8784,"status":158,"phases":8785,"primaryCompletion":8786,"completion":8786,"start":6172,"enrollment":1477,"conditions":8787,"interventions":8789},"NCT03813121","The Effects of Sedatives on Tobacco Use Disorder",[89,90],"2021-08-31",[8788],"Tobacco Use Disorder",[8774,8790],"ketamine intravenous",{"trials":8792,"activeCount":101},[],{"trials":8794,"activeCount":101},[],{"trials":8796,"activeCount":101},[],{"intervention":8790,"totalTrials":228,"cells":8798},{"EARLY_PHASE1":8799,"PHASE1":8801,"PHASE2":8803,"PHASE3":8809,"PHASE4":8811,"NA":8813},{"trials":8800,"activeCount":101},[],{"trials":8802,"activeCount":101},[],{"trials":8804,"activeCount":101},[8805],{"nctId":8783,"briefTitle":8784,"status":158,"phases":8806,"primaryCompletion":8786,"completion":8786,"start":6172,"enrollment":1477,"conditions":8807,"interventions":8808},[89,90],[8788],[8774,8790],{"trials":8810,"activeCount":101},[],{"trials":8812,"activeCount":101},[],{"trials":8814,"activeCount":101},[],{"intervention":8816,"totalTrials":228,"cells":8817},"Fluocinonide cream",{"EARLY_PHASE1":8818,"PHASE1":8820,"PHASE2":8822,"PHASE3":8832,"PHASE4":8834,"NA":8836},{"trials":8819,"activeCount":101},[],{"trials":8821,"activeCount":101},[],{"trials":8823,"activeCount":101},[8824],{"nctId":8825,"briefTitle":8826,"status":158,"phases":8827,"primaryCompletion":8828,"completion":8828,"start":8829,"enrollment":1477,"conditions":8830,"interventions":8831},"NCT01469767","Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis",[90],"2013-08-17","2012-02-01",[4547],[8816],{"trials":8833,"activeCount":101},[],{"trials":8835,"activeCount":101},[],{"trials":8837,"activeCount":101},[],{"intervention":8839,"totalTrials":228,"cells":8840},"Omegaven®",{"EARLY_PHASE1":8841,"PHASE1":8843,"PHASE2":8845,"PHASE3":8855,"PHASE4":8857,"NA":8859},{"trials":8842,"activeCount":101},[],{"trials":8844,"activeCount":101},[],{"trials":8846,"activeCount":101},[8847],{"nctId":8848,"briefTitle":8849,"status":158,"phases":8850,"primaryCompletion":8851,"completion":8851,"start":1493,"enrollment":1608,"conditions":8852,"interventions":8854},"NCT01845116","Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury",[90],"2020-07",[8853],"Total Parenteral Nutrition-induced Cholestasis",[8839],{"trials":8856,"activeCount":101},[],{"trials":8858,"activeCount":101},[],{"trials":8860,"activeCount":101},[],{"intervention":8862,"totalTrials":228,"cells":8863},"Gentian Violet",{"EARLY_PHASE1":8864,"PHASE1":8866,"PHASE2":8868,"PHASE3":8877,"PHASE4":8879,"NA":8881},{"trials":8865,"activeCount":101},[],{"trials":8867,"activeCount":101},[],{"trials":8869,"activeCount":101},[8870],{"nctId":8871,"briefTitle":8872,"status":177,"phases":8873,"primaryCompletion":359,"completion":359,"start":8874,"enrollment":101,"conditions":8875,"interventions":8876},"NCT04388163","Gentian Violet Treatment for Hidradenitis Suppurativa",[90],"2025-08",[3946],[8862],{"trials":8878,"activeCount":101},[],{"trials":8880,"activeCount":101},[],{"trials":8882,"activeCount":101},[],{"intervention":8884,"totalTrials":228,"cells":8885},"Red Heart Pill 2b",{"EARLY_PHASE1":8886,"PHASE1":8888,"PHASE2":8890,"PHASE3":8900,"PHASE4":8902,"NA":8904},{"trials":8887,"activeCount":101},[],{"trials":8889,"activeCount":101},[],{"trials":8891,"activeCount":101},[8892],{"nctId":8893,"briefTitle":8894,"status":158,"phases":8895,"primaryCompletion":5050,"completion":1732,"start":7885,"enrollment":8896,"conditions":8897,"interventions":8899},"NCT00567307","Polypill For Prevention of Cardiovascular Disease",[90],216,[8898],"Cardiovascular Disease",[8884],{"trials":8901,"activeCount":101},[],{"trials":8903,"activeCount":101},[],{"trials":8905,"activeCount":101},[],{"intervention":8907,"totalTrials":228,"cells":8908},"Standard of care radiation therapy",{"EARLY_PHASE1":8909,"PHASE1":8911,"PHASE2":8913,"PHASE3":8923,"PHASE4":8925,"NA":8927},{"trials":8910,"activeCount":101},[],{"trials":8912,"activeCount":101},[],{"trials":8914,"activeCount":101},[8915],{"nctId":8916,"briefTitle":8917,"status":177,"phases":8918,"primaryCompletion":8919,"completion":8919,"start":2347,"enrollment":101,"conditions":8920,"interventions":8922},"NCT04485026","Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma",[90],"2024-05-09",[1669,8921],"Oligoprogressive",[8907],{"trials":8924,"activeCount":101},[],{"trials":8926,"activeCount":101},[],{"trials":8928,"activeCount":101},[],{"intervention":8930,"totalTrials":228,"cells":8931},"Elotuzumab",{"EARLY_PHASE1":8932,"PHASE1":8934,"PHASE2":8936,"PHASE3":8947,"PHASE4":8949,"NA":8951},{"trials":8933,"activeCount":101},[],{"trials":8935,"activeCount":101},[],{"trials":8937,"activeCount":101},[8938],{"nctId":8939,"briefTitle":8940,"status":158,"phases":8941,"primaryCompletion":8942,"completion":8943,"start":8944,"enrollment":1548,"conditions":8945,"interventions":8946},"NCT03361306","LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed\u002FRefractory Multiple Myeloma",[90],"2021-06-04","2025-02-14","2018-01-09",[1762],[8930],{"trials":8948,"activeCount":101},[],{"trials":8950,"activeCount":101},[],{"trials":8952,"activeCount":101},[],{"intervention":1600,"totalTrials":228,"cells":8954},{"EARLY_PHASE1":8955,"PHASE1":8957,"PHASE2":8959,"PHASE3":8965,"PHASE4":8967,"NA":8969},{"trials":8956,"activeCount":101},[],{"trials":8958,"activeCount":101},[],{"trials":8960,"activeCount":101},[8961],{"nctId":1592,"briefTitle":1593,"status":158,"phases":8962,"primaryCompletion":1595,"completion":1595,"start":1585,"enrollment":1596,"conditions":8963,"interventions":8964},[90],[33],[1564,1599,1600],{"trials":8966,"activeCount":101},[],{"trials":8968,"activeCount":101},[],{"trials":8970,"activeCount":101},[],{"intervention":8972,"totalTrials":228,"cells":8973},"Low dose oxytocin",{"EARLY_PHASE1":8974,"PHASE1":8976,"PHASE2":8978,"PHASE3":8989,"PHASE4":8991,"NA":8993},{"trials":8975,"activeCount":101},[],{"trials":8977,"activeCount":101},[],{"trials":8979,"activeCount":101},[8980],{"nctId":8981,"briefTitle":8982,"status":158,"phases":8983,"primaryCompletion":8984,"completion":8984,"start":8985,"enrollment":204,"conditions":8986,"interventions":8987},"NCT05179421","Dose Ranging Study of Intravenous Oxytocin for Analgesia to Heat Pain",[90],"2023-02-10","2022-05-09",[2010],[8972,8988],"High dose oxytocin",{"trials":8990,"activeCount":101},[],{"trials":8992,"activeCount":101},[],{"trials":8994,"activeCount":101},[],{"intervention":8988,"totalTrials":228,"cells":8996},{"EARLY_PHASE1":8997,"PHASE1":8999,"PHASE2":9001,"PHASE3":9007,"PHASE4":9009,"NA":9011},{"trials":8998,"activeCount":101},[],{"trials":9000,"activeCount":101},[],{"trials":9002,"activeCount":101},[9003],{"nctId":8981,"briefTitle":8982,"status":158,"phases":9004,"primaryCompletion":8984,"completion":8984,"start":8985,"enrollment":204,"conditions":9005,"interventions":9006},[90],[2010],[8972,8988],{"trials":9008,"activeCount":101},[],{"trials":9010,"activeCount":101},[],{"trials":9012,"activeCount":101},[],{"intervention":9014,"totalTrials":228,"cells":9015},"Azacitadine and Hematopoietic Growth Factors",{"EARLY_PHASE1":9016,"PHASE1":9018,"PHASE2":9020,"PHASE3":9029,"PHASE4":9031,"NA":9033},{"trials":9017,"activeCount":101},[],{"trials":9019,"activeCount":101},[],{"trials":9021,"activeCount":101},[9022],{"nctId":9023,"briefTitle":9024,"status":143,"phases":9025,"primaryCompletion":5051,"completion":5051,"start":9026,"enrollment":215,"conditions":9027,"interventions":9028},"NCT00398047","Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes",[90],"2006-09",[2208,7855],[9014],{"trials":9030,"activeCount":101},[],{"trials":9032,"activeCount":101},[],{"trials":9034,"activeCount":101},[],{"intervention":9036,"totalTrials":228,"cells":9037},"N-Acetyl-L-Cysteine dietary supplement",{"EARLY_PHASE1":9038,"PHASE1":9040,"PHASE2":9042,"PHASE3":9051,"PHASE4":9053,"NA":9055},{"trials":9039,"activeCount":101},[],{"trials":9041,"activeCount":101},[],{"trials":9043,"activeCount":101},[9044],{"nctId":9045,"briefTitle":9046,"status":177,"phases":9047,"primaryCompletion":9048,"completion":9048,"start":9048,"enrollment":101,"conditions":9049,"interventions":9050},"NCT03982537","Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome",[90],"2020-06-18",[36],[9036],{"trials":9052,"activeCount":101},[],{"trials":9054,"activeCount":101},[],{"trials":9056,"activeCount":101},[],{"intervention":9058,"totalTrials":228,"cells":9059},"deferasirox",{"EARLY_PHASE1":9060,"PHASE1":9062,"PHASE2":9064,"PHASE3":9169,"PHASE4":9171,"NA":9173},{"trials":9061,"activeCount":101},[],{"trials":9063,"activeCount":101},[],{"trials":9065,"activeCount":101},[9066],{"nctId":9067,"briefTitle":9068,"status":158,"phases":9069,"primaryCompletion":9070,"completion":1607,"start":1375,"enrollment":2140,"conditions":9071,"interventions":9168},"NCT01273766","Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies",[90],"2012-03",[9072,9073,9074,2491,2492,2493,2494,2495,2496,9075,9076,7206,7208,7209,9077,9078,9079,9080,9081,9082,9083,9084,9085,9086,9087,9088,2391,9089,2392,7210,2393,9090,9091,9092,9093,2394,9094,9095,9096,9097,9098,9099,9100,9101,9102,9103,9104,9105,7211,7212,7290,9106,2395,2467,2396,2397,2398,2399,2400,7213,2401,2402,7214,7215,2403,2404,2405,2406,2407,2408,2409,9107,9108,9109,9110,2412,2413,9111,9112,9113,9114,9115,9116,9117,9118,9119,9120,9121,9122,9123,9124,9125,9126,9127,9128,9129,9130,9131,9132,9133,9134,9135,9136,9137,9138,9139,9140,9141,9142,9143,9144,9145,9146,9147,9148,9149,9150,9151,9152,9153,9154,9155,9156,9157,9158,9159,9160,9161,9162,9163,9164,9165,2414,9166,2521,9167],"Acute Undifferentiated Leukemia","Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","Adult Grade III Lymphomatoid Granulomatosis","Adult Langerhans Cell Histiocytosis","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","de Novo Myelodysplastic Syndromes","Mast Cell Leukemia","Myelodysplastic Syndrome With Isolated Del(5q)","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Myeloid\u002FNK-cell Acute Leukemia","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Primary Myelofibrosis","Refractory Anemia","Refractory Multiple Myeloma","Secondary Acute Myeloid Leukemia","Secondary Myelofibrosis","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Adult T-cell Leukemia\u002FLymphoma","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Multiple Myeloma","Stage I Mycosis Fungoides\u002FSezary Syndrome","Stage I Small Lymphocytic Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Adult T-cell Leukemia\u002FLymphoma","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage II Multiple Myeloma","Stage II Mycosis Fungoides\u002FSezary Syndrome","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Multiple Myeloma","Stage III Mycosis Fungoides\u002FSezary Syndrome","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Mycosis Fungoides\u002FSezary Syndrome","Stage IV Small Lymphocytic Lymphoma","Untreated Adult Acute Lymphoblastic Leukemia","Waldenstrom Macroglobulinemia",[9058],{"trials":9170,"activeCount":101},[],{"trials":9172,"activeCount":101},[],{"trials":9174,"activeCount":101},[],{"intervention":9176,"totalTrials":228,"cells":9177},"Pharmacogenomic Testing",{"EARLY_PHASE1":9178,"PHASE1":9180,"PHASE2":9182,"PHASE3":9192,"PHASE4":9194,"NA":9196},{"trials":9179,"activeCount":101},[],{"trials":9181,"activeCount":101},[],{"trials":9183,"activeCount":101},[9184],{"nctId":9185,"briefTitle":9186,"status":143,"phases":9187,"primaryCompletion":9188,"completion":9188,"start":2463,"enrollment":8231,"conditions":9189,"interventions":9191},"NCT02542397","LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients",[90],"2019-06",[9190],"Malignant Tumor of Ill-defined Site",[9176],{"trials":9193,"activeCount":101},[],{"trials":9195,"activeCount":101},[],{"trials":9197,"activeCount":101},[],{"intervention":9199,"totalTrials":228,"cells":9200},"nintedanib",{"EARLY_PHASE1":9201,"PHASE1":9203,"PHASE2":9205,"PHASE3":9217,"PHASE4":9219,"NA":9221},{"trials":9202,"activeCount":101},[],{"trials":9204,"activeCount":101},[],{"trials":9206,"activeCount":101},[9207],{"nctId":9208,"briefTitle":9209,"status":143,"phases":9210,"primaryCompletion":9211,"completion":9212,"start":9213,"enrollment":1850,"conditions":9214,"interventions":9216},"NCT03287947","LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma",[90],"2019-09-03","2019-10-27","2017-11-10",[9215],"Appendix Cancer",[9199],{"trials":9218,"activeCount":101},[],{"trials":9220,"activeCount":101},[],{"trials":9222,"activeCount":101},[],{"intervention":9224,"totalTrials":228,"cells":9225},"sargramostim",{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9230,"PHASE3":9239,"PHASE4":9241,"NA":9243},{"trials":9227,"activeCount":101},[],{"trials":9229,"activeCount":101},[],{"trials":9231,"activeCount":101},[9232],{"nctId":9233,"briefTitle":9234,"status":158,"phases":9235,"primaryCompletion":4090,"completion":1376,"start":9236,"conditions":9237,"interventions":9238},"NCT00072579","Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment",[90],"2003-05",[2208],[9224],{"trials":9240,"activeCount":101},[],{"trials":9242,"activeCount":101},[],{"trials":9244,"activeCount":101},[],{"intervention":9246,"totalTrials":228,"cells":9247},"Bupivacaine 0.25%",{"EARLY_PHASE1":9248,"PHASE1":9250,"PHASE2":9252,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9249,"activeCount":101},[],{"trials":9251,"activeCount":101},[],{"trials":9253,"activeCount":101},[9254],{"nctId":9255,"briefTitle":9256,"status":158,"phases":9257,"primaryCompletion":9258,"completion":9258,"start":9259,"enrollment":549,"conditions":9260,"interventions":9264},"NCT03007966","IINB vs. QLB for Elective Open Inguinal Herniorrhaphy",[90],"2018-02-17","2017-01-30",[9261,9262,9263],"Nerve Block","Herniorrhaphy","Regional Anesthesia",[9246,9265,9266],"Epinephrine 1:200k","Clonidine 1.66mcg\u002Fcc",{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"trials":9272,"activeCount":101},[],{"intervention":9265,"totalTrials":228,"cells":9274},{"EARLY_PHASE1":9275,"PHASE1":9277,"PHASE2":9279,"PHASE3":9285,"PHASE4":9287,"NA":9289},{"trials":9276,"activeCount":101},[],{"trials":9278,"activeCount":101},[],{"trials":9280,"activeCount":101},[9281],{"nctId":9255,"briefTitle":9256,"status":158,"phases":9282,"primaryCompletion":9258,"completion":9258,"start":9259,"enrollment":549,"conditions":9283,"interventions":9284},[90],[9261,9262,9263],[9246,9265,9266],{"trials":9286,"activeCount":101},[],{"trials":9288,"activeCount":101},[],{"trials":9290,"activeCount":101},[],{"intervention":9266,"totalTrials":228,"cells":9292},{"EARLY_PHASE1":9293,"PHASE1":9295,"PHASE2":9297,"PHASE3":9303,"PHASE4":9305,"NA":9307},{"trials":9294,"activeCount":101},[],{"trials":9296,"activeCount":101},[],{"trials":9298,"activeCount":101},[9299],{"nctId":9255,"briefTitle":9256,"status":158,"phases":9300,"primaryCompletion":9258,"completion":9258,"start":9259,"enrollment":549,"conditions":9301,"interventions":9302},[90],[9261,9262,9263],[9246,9265,9266],{"trials":9304,"activeCount":101},[],{"trials":9306,"activeCount":101},[],{"trials":9308,"activeCount":101},[],{"intervention":9310,"totalTrials":228,"cells":9311},"0.5% bupivacaine",{"EARLY_PHASE1":9312,"PHASE1":9314,"PHASE2":9316,"PHASE3":9326,"PHASE4":9328,"NA":9330},{"trials":9313,"activeCount":101},[],{"trials":9315,"activeCount":101},[],{"trials":9317,"activeCount":101},[9318],{"nctId":9319,"briefTitle":9320,"status":143,"phases":9321,"primaryCompletion":2518,"completion":2518,"start":7277,"enrollment":28,"conditions":9322,"interventions":9324},"NCT01785459","Bupivacaine for Benign Headache in the ED",[90],[9323],"Benign Headache",[9310,9325],"Standard Care",{"trials":9327,"activeCount":101},[],{"trials":9329,"activeCount":101},[],{"trials":9331,"activeCount":101},[],{"intervention":9325,"totalTrials":228,"cells":9333},{"EARLY_PHASE1":9334,"PHASE1":9336,"PHASE2":9338,"PHASE3":9344,"PHASE4":9346,"NA":9348},{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[9340],{"nctId":9319,"briefTitle":9320,"status":143,"phases":9341,"primaryCompletion":2518,"completion":2518,"start":7277,"enrollment":28,"conditions":9342,"interventions":9343},[90],[9323],[9310,9325],{"trials":9345,"activeCount":101},[],{"trials":9347,"activeCount":101},[],{"trials":9349,"activeCount":101},[],{"intervention":9351,"totalTrials":228,"cells":9352},"memantine hydrochloride",{"EARLY_PHASE1":9353,"PHASE1":9355,"PHASE2":9357,"PHASE3":9365,"PHASE4":9367,"NA":9369},{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[9359],{"nctId":9360,"briefTitle":9361,"status":158,"phases":9362,"primaryCompletion":8398,"completion":8398,"start":6438,"enrollment":2778,"conditions":9363,"interventions":9364},"NCT01535040","Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking",[90],[19,7508,33,348,8788],[9351],{"trials":9366,"activeCount":101},[],{"trials":9368,"activeCount":101},[],{"trials":9370,"activeCount":101},[],{"intervention":6397,"totalTrials":228,"cells":9372},{"EARLY_PHASE1":9373,"PHASE1":9375,"PHASE2":9377,"PHASE3":9383,"PHASE4":9385,"NA":9387},{"trials":9374,"activeCount":101},[],{"trials":9376,"activeCount":101},[],{"trials":9378,"activeCount":101},[9379],{"nctId":6389,"briefTitle":6390,"status":158,"phases":9380,"primaryCompletion":2478,"completion":2478,"start":2519,"enrollment":4183,"conditions":9381,"interventions":9382},[90],[6393],[6395,6396,6397],{"trials":9384,"activeCount":101},[],{"trials":9386,"activeCount":101},[],{"trials":9388,"activeCount":101},[],{"intervention":8152,"totalTrials":228,"cells":9390},{"EARLY_PHASE1":9391,"PHASE1":9393,"PHASE2":9395,"PHASE3":9401,"PHASE4":9403,"NA":9405},{"trials":9392,"activeCount":101},[],{"trials":9394,"activeCount":101},[],{"trials":9396,"activeCount":101},[9397],{"nctId":8141,"briefTitle":8142,"status":143,"phases":9398,"primaryCompletion":8144,"completion":8145,"start":8146,"enrollment":1362,"conditions":9399,"interventions":9400},[90],[8148,8149,8150],[3894,8152],{"trials":9402,"activeCount":101},[],{"trials":9404,"activeCount":101},[],{"trials":9406,"activeCount":101},[],{"intervention":1786,"totalTrials":228,"cells":9408},{"EARLY_PHASE1":9409,"PHASE1":9411,"PHASE2":9413,"PHASE3":9419,"PHASE4":9421,"NA":9423},{"trials":9410,"activeCount":101},[],{"trials":9412,"activeCount":101},[],{"trials":9414,"activeCount":101},[9415],{"nctId":1776,"briefTitle":1777,"status":143,"phases":9416,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":9417,"interventions":9418},[90],[1784,1632,1634],[1786,1787,68,86,1788,1789],{"trials":9420,"activeCount":101},[],{"trials":9422,"activeCount":101},[],{"trials":9424,"activeCount":101},[],{"intervention":1787,"totalTrials":228,"cells":9426},{"EARLY_PHASE1":9427,"PHASE1":9429,"PHASE2":9431,"PHASE3":9437,"PHASE4":9439,"NA":9441},{"trials":9428,"activeCount":101},[],{"trials":9430,"activeCount":101},[],{"trials":9432,"activeCount":101},[9433],{"nctId":1776,"briefTitle":1777,"status":143,"phases":9434,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":9435,"interventions":9436},[90],[1784,1632,1634],[1786,1787,68,86,1788,1789],{"trials":9438,"activeCount":101},[],{"trials":9440,"activeCount":101},[],{"trials":9442,"activeCount":101},[],{"intervention":1788,"totalTrials":228,"cells":9444},{"EARLY_PHASE1":9445,"PHASE1":9447,"PHASE2":9449,"PHASE3":9455,"PHASE4":9457,"NA":9459},{"trials":9446,"activeCount":101},[],{"trials":9448,"activeCount":101},[],{"trials":9450,"activeCount":101},[9451],{"nctId":1776,"briefTitle":1777,"status":143,"phases":9452,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":9453,"interventions":9454},[90],[1784,1632,1634],[1786,1787,68,86,1788,1789],{"trials":9456,"activeCount":101},[],{"trials":9458,"activeCount":101},[],{"trials":9460,"activeCount":101},[],{"intervention":1789,"totalTrials":228,"cells":9462},{"EARLY_PHASE1":9463,"PHASE1":9465,"PHASE2":9467,"PHASE3":9473,"PHASE4":9475,"NA":9477},{"trials":9464,"activeCount":101},[],{"trials":9466,"activeCount":101},[],{"trials":9468,"activeCount":101},[9469],{"nctId":1776,"briefTitle":1777,"status":143,"phases":9470,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":9471,"interventions":9472},[90],[1784,1632,1634],[1786,1787,68,86,1788,1789],{"trials":9474,"activeCount":101},[],{"trials":9476,"activeCount":101},[],{"trials":9478,"activeCount":101},[],{"intervention":9480,"totalTrials":228,"cells":9481},"ivermectin",{"EARLY_PHASE1":9482,"PHASE1":9484,"PHASE2":9486,"PHASE3":9497,"PHASE4":9499,"NA":9501},{"trials":9483,"activeCount":101},[],{"trials":9485,"activeCount":101},[],{"trials":9487,"activeCount":101},[9488],{"nctId":9489,"briefTitle":9490,"status":158,"phases":9491,"primaryCompletion":9492,"completion":9493,"start":9494,"enrollment":1377,"conditions":9495,"interventions":9496},"NCT04275999","Rosacea and Ivermectin",[90],"2024-01-17","2025-01-17","2021-04-16",[3586],[9480],{"trials":9498,"activeCount":101},[],{"trials":9500,"activeCount":101},[],{"trials":9502,"activeCount":101},[],{"intervention":9504,"totalTrials":228,"cells":9505},"St. John's Wort",{"EARLY_PHASE1":9506,"PHASE1":9508,"PHASE2":9510,"PHASE3":9520,"PHASE4":9522,"NA":9524},{"trials":9507,"activeCount":101},[],{"trials":9509,"activeCount":101},[],{"trials":9511,"activeCount":101},[9512],{"nctId":9513,"briefTitle":9514,"status":143,"phases":9515,"primaryCompletion":9516,"completion":9516,"start":9517,"enrollment":1946,"conditions":9518,"interventions":9519},"NCT00110136","St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer",[90],"2008-04-01","2006-03-16",[19,7160],[9504],{"trials":9521,"activeCount":101},[],{"trials":9523,"activeCount":101},[],{"trials":9525,"activeCount":101},[],{"intervention":9527,"totalTrials":228,"cells":9528},"DTGM fusion protein",{"EARLY_PHASE1":9529,"PHASE1":9531,"PHASE2":9533,"PHASE3":9544,"PHASE4":9546,"NA":9548},{"trials":9530,"activeCount":101},[],{"trials":9532,"activeCount":101},[],{"trials":9534,"activeCount":101},[9535],{"nctId":9536,"briefTitle":9537,"status":158,"phases":9538,"primaryCompletion":9539,"completion":9540,"start":9541,"conditions":9542,"interventions":9543},"NCT00003840","DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia",[89,90],"2002-09","2005-07","2000-10",[2208],[9527],{"trials":9545,"activeCount":101},[],{"trials":9547,"activeCount":101},[],{"trials":9549,"activeCount":101},[],{"intervention":1611,"totalTrials":228,"cells":9551},{"EARLY_PHASE1":9552,"PHASE1":9554,"PHASE2":9556,"PHASE3":9562,"PHASE4":9564,"NA":9566},{"trials":9553,"activeCount":101},[],{"trials":9555,"activeCount":101},[],{"trials":9557,"activeCount":101},[9558],{"nctId":1602,"briefTitle":1603,"status":158,"phases":9559,"primaryCompletion":1605,"completion":1606,"start":1607,"enrollment":1608,"conditions":9560,"interventions":9561},[90],[33],[53,1611],{"trials":9563,"activeCount":101},[],{"trials":9565,"activeCount":101},[],{"trials":9567,"activeCount":101},[],{"intervention":3895,"totalTrials":228,"cells":9569},{"EARLY_PHASE1":9570,"PHASE1":9572,"PHASE2":9574,"PHASE3":9580,"PHASE4":9582,"NA":9584},{"trials":9571,"activeCount":101},[],{"trials":9573,"activeCount":101},[],{"trials":9575,"activeCount":101},[9576],{"nctId":3885,"briefTitle":3886,"status":177,"phases":9577,"primaryCompletion":3888,"completion":3889,"start":385,"enrollment":101,"conditions":9578,"interventions":9579},[90],[3891,3892,2466],[3894,3866,3895],{"trials":9581,"activeCount":101},[],{"trials":9583,"activeCount":101},[],{"trials":9585,"activeCount":101},[],{"intervention":3762,"totalTrials":228,"cells":9587},{"EARLY_PHASE1":9588,"PHASE1":9590,"PHASE2":9592,"PHASE3":9598,"PHASE4":9600,"NA":9602},{"trials":9589,"activeCount":101},[],{"trials":9591,"activeCount":101},[],{"trials":9593,"activeCount":101},[9594],{"nctId":3754,"briefTitle":3755,"status":158,"phases":9595,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":271,"conditions":9596,"interventions":9597},[89,90],[1762],[3762,3763,1027],{"trials":9599,"activeCount":101},[],{"trials":9601,"activeCount":101},[],{"trials":9603,"activeCount":101},[],{"intervention":3763,"totalTrials":228,"cells":9605},{"EARLY_PHASE1":9606,"PHASE1":9608,"PHASE2":9610,"PHASE3":9616,"PHASE4":9618,"NA":9620},{"trials":9607,"activeCount":101},[],{"trials":9609,"activeCount":101},[],{"trials":9611,"activeCount":101},[9612],{"nctId":3754,"briefTitle":3755,"status":158,"phases":9613,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":271,"conditions":9614,"interventions":9615},[89,90],[1762],[3762,3763,1027],{"trials":9617,"activeCount":101},[],{"trials":9619,"activeCount":101},[],{"trials":9621,"activeCount":101},[],{"intervention":7722,"totalTrials":228,"cells":9623},{"EARLY_PHASE1":9624,"PHASE1":9626,"PHASE2":9628,"PHASE3":9634,"PHASE4":9636,"NA":9638},{"trials":9625,"activeCount":101},[],{"trials":9627,"activeCount":101},[],{"trials":9629,"activeCount":101},[9630],{"nctId":7715,"briefTitle":7716,"status":158,"phases":9631,"primaryCompletion":7240,"completion":2478,"start":7718,"enrollment":7719,"conditions":9632,"interventions":9633},[90],[7551,7710],[7722,7235,7723],{"trials":9635,"activeCount":101},[],{"trials":9637,"activeCount":101},[],{"trials":9639,"activeCount":101},[],{"intervention":7723,"totalTrials":228,"cells":9641},{"EARLY_PHASE1":9642,"PHASE1":9644,"PHASE2":9646,"PHASE3":9652,"PHASE4":9654,"NA":9656},{"trials":9643,"activeCount":101},[],{"trials":9645,"activeCount":101},[],{"trials":9647,"activeCount":101},[9648],{"nctId":7715,"briefTitle":7716,"status":158,"phases":9649,"primaryCompletion":7240,"completion":2478,"start":7718,"enrollment":7719,"conditions":9650,"interventions":9651},[90],[7551,7710],[7722,7235,7723],{"trials":9653,"activeCount":101},[],{"trials":9655,"activeCount":101},[],{"trials":9657,"activeCount":101},[],{"intervention":9659,"totalTrials":228,"cells":9660},"Amniotic fluid or placental CD117 stem cells",{"EARLY_PHASE1":9661,"PHASE1":9663,"PHASE2":9665,"PHASE3":9675,"PHASE4":9677,"NA":9679},{"trials":9662,"activeCount":101},[],{"trials":9664,"activeCount":101},[],{"trials":9666,"activeCount":101},[9667],{"nctId":9668,"briefTitle":9669,"status":177,"phases":9670,"primaryCompletion":192,"completion":396,"start":9671,"enrollment":101,"conditions":9672,"interventions":9674},"NCT06841068","Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis",[89,90],"2026-02",[9673],"Multiple Sclerosis, Progressive",[9659],{"trials":9676,"activeCount":101},[],{"trials":9678,"activeCount":101},[],{"trials":9680,"activeCount":101},[],{"intervention":3628,"totalTrials":228,"cells":9682},{"EARLY_PHASE1":9683,"PHASE1":9685,"PHASE2":9687,"PHASE3":9693,"PHASE4":9695,"NA":9697},{"trials":9684,"activeCount":101},[],{"trials":9686,"activeCount":101},[],{"trials":9688,"activeCount":101},[9689],{"nctId":3613,"briefTitle":3614,"status":158,"phases":9690,"primaryCompletion":3596,"completion":3596,"start":3616,"enrollment":1733,"conditions":9691,"interventions":9692},[90],[3618,3619,3620,3621,3622,1735,3623,3624,1736],[1738,3600,3626,3627,3628,1565],{"trials":9694,"activeCount":101},[],{"trials":9696,"activeCount":101},[],{"trials":9698,"activeCount":101},[],{"intervention":9700,"totalTrials":228,"cells":9701},"Soliramfetol",{"EARLY_PHASE1":9702,"PHASE1":9704,"PHASE2":9706,"PHASE3":9717,"PHASE4":9719,"NA":9721},{"trials":9703,"activeCount":101},[],{"trials":9705,"activeCount":101},[],{"trials":9707,"activeCount":101},[9708],{"nctId":9709,"briefTitle":9710,"status":143,"phases":9711,"primaryCompletion":9712,"completion":9712,"start":9713,"enrollment":97,"conditions":9714,"interventions":9716},"NCT03868943","Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma",[90],"2021-11-22","2021-01-27",[9715,7911],"Glioma",[9700],{"trials":9718,"activeCount":101},[],{"trials":9720,"activeCount":101},[],{"trials":9722,"activeCount":101},[],{"intervention":9724,"totalTrials":228,"cells":9725},"Vitamin D",{"EARLY_PHASE1":9726,"PHASE1":9728,"PHASE2":9730,"PHASE3":9739,"PHASE4":9741,"NA":9743},{"trials":9727,"activeCount":101},[],{"trials":9729,"activeCount":101},[],{"trials":9731,"activeCount":101},[9732],{"nctId":9733,"briefTitle":9734,"status":158,"phases":9735,"primaryCompletion":4316,"completion":1655,"start":8088,"enrollment":1586,"conditions":9736,"interventions":9738},"NCT01331148","High Dose Vitamin D for Sickle Cell Disease",[90],[9737],"Sickle Cell Disease",[9724],{"trials":9740,"activeCount":101},[],{"trials":9742,"activeCount":101},[],{"trials":9744,"activeCount":101},[],{"intervention":7858,"totalTrials":228,"cells":9746},{"EARLY_PHASE1":9747,"PHASE1":9749,"PHASE2":9751,"PHASE3":9757,"PHASE4":9759,"NA":9761},{"trials":9748,"activeCount":101},[],{"trials":9750,"activeCount":101},[],{"trials":9752,"activeCount":101},[9753],{"nctId":7850,"briefTitle":7851,"status":177,"phases":9754,"primaryCompletion":4292,"completion":1229,"start":7853,"enrollment":101,"conditions":9755,"interventions":9756},[89,90],[7855,7856],[2498,7858],{"trials":9758,"activeCount":101},[],{"trials":9760,"activeCount":101},[],{"trials":9762,"activeCount":101},[],{"intervention":9764,"totalTrials":228,"cells":9765},"Armodafinil",{"EARLY_PHASE1":9766,"PHASE1":9768,"PHASE2":9770,"PHASE3":9781,"PHASE4":9783,"NA":9785},{"trials":9767,"activeCount":101},[],{"trials":9769,"activeCount":101},[],{"trials":9771,"activeCount":101},[9772],{"nctId":9773,"briefTitle":9774,"status":158,"phases":9775,"primaryCompletion":9776,"completion":9776,"start":7157,"enrollment":9777,"conditions":9778,"interventions":9780},"NCT01032200","Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors",[90],"2013-01-08",54,[6452,9779,6430,551],"Nervous System Tumors",[9764],{"trials":9782,"activeCount":101},[],{"trials":9784,"activeCount":101},[],{"trials":9786,"activeCount":101},[],{"intervention":9788,"totalTrials":228,"cells":9789},"arsenic trioxide",{"EARLY_PHASE1":9790,"PHASE1":9792,"PHASE2":9794,"PHASE3":9804,"PHASE4":9806,"NA":9808},{"trials":9791,"activeCount":101},[],{"trials":9793,"activeCount":101},[],{"trials":9795,"activeCount":101},[9796],{"nctId":9797,"briefTitle":9798,"status":143,"phases":9799,"primaryCompletion":7376,"completion":7609,"start":9800,"enrollment":1850,"conditions":9801,"interventions":9803},"NCT00104806","Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes",[90],"2004-11",[2208,7855,9802],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[9788],{"trials":9805,"activeCount":101},[],{"trials":9807,"activeCount":101},[],{"trials":9809,"activeCount":101},[],{"intervention":9811,"totalTrials":228,"cells":9812},"Hypofractionated Radiation Therapy",{"EARLY_PHASE1":9813,"PHASE1":9815,"PHASE2":9817,"PHASE3":9827,"PHASE4":9829,"NA":9831},{"trials":9814,"activeCount":101},[],{"trials":9816,"activeCount":101},[],{"trials":9818,"activeCount":101},[9819],{"nctId":9820,"briefTitle":9821,"status":143,"phases":9822,"primaryCompletion":9823,"completion":9823,"start":9824,"enrollment":228,"conditions":9825,"interventions":9826},"NCT04398199","Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients",[90],"2020-11-20","2020-10-16",[2084,2082],[9811],{"trials":9828,"activeCount":101},[],{"trials":9830,"activeCount":101},[],{"trials":9832,"activeCount":101},[],{"intervention":9834,"totalTrials":228,"cells":9835},"EX-527",{"EARLY_PHASE1":9836,"PHASE1":9838,"PHASE2":9840,"PHASE3":9854,"PHASE4":9856,"NA":9858},{"trials":9837,"activeCount":101},[],{"trials":9839,"activeCount":101},[],{"trials":9841,"activeCount":101},[9842],{"nctId":9843,"briefTitle":9844,"status":177,"phases":9845,"primaryCompletion":2339,"completion":2339,"start":9846,"enrollment":101,"conditions":9847,"interventions":9853},"NCT04184323","SIRT-1 Antagonism for Endometrial Receptivity",[90],"2022-01",[9848,9849,9850,9851,9852],"Endometriosis","Uterine Diseases","Endometrial Diseases","Infertility Unexplained","Infertility; Female, Nonimplantation",[9834],{"trials":9855,"activeCount":101},[],{"trials":9857,"activeCount":101},[],{"trials":9859,"activeCount":101},[],{"intervention":7561,"totalTrials":228,"cells":9861},{"EARLY_PHASE1":9862,"PHASE1":9864,"PHASE2":9866,"PHASE3":9872,"PHASE4":9874,"NA":9876},{"trials":9863,"activeCount":101},[],{"trials":9865,"activeCount":101},[],{"trials":9867,"activeCount":101},[9868],{"nctId":7554,"briefTitle":7555,"status":158,"phases":9869,"primaryCompletion":7557,"completion":7557,"start":7558,"enrollment":3569,"conditions":9870,"interventions":9871},[90],[3962],[7561,1590],{"trials":9873,"activeCount":101},[],{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[],{"intervention":9879,"totalTrials":228,"cells":9880},"Intranasal Insulin",{"EARLY_PHASE1":9881,"PHASE1":9883,"PHASE2":9885,"PHASE3":9895,"PHASE4":9897,"NA":9899},{"trials":9882,"activeCount":101},[],{"trials":9884,"activeCount":101},[],{"trials":9886,"activeCount":101},[9887],{"nctId":9888,"briefTitle":9889,"status":158,"phases":9890,"primaryCompletion":9891,"completion":9891,"start":6732,"enrollment":37,"conditions":9892,"interventions":9893},"NCT02810392","Intranasal Insulin and Post-stroke Cognition: A Pilot Study",[90],"2020-03-04",[593],[9879,9894],"Intranasal saline",{"trials":9896,"activeCount":101},[],{"trials":9898,"activeCount":101},[],{"trials":9900,"activeCount":101},[],{"intervention":9894,"totalTrials":228,"cells":9902},{"EARLY_PHASE1":9903,"PHASE1":9905,"PHASE2":9907,"PHASE3":9913,"PHASE4":9915,"NA":9917},{"trials":9904,"activeCount":101},[],{"trials":9906,"activeCount":101},[],{"trials":9908,"activeCount":101},[9909],{"nctId":9888,"briefTitle":9889,"status":158,"phases":9910,"primaryCompletion":9891,"completion":9891,"start":6732,"enrollment":37,"conditions":9911,"interventions":9912},[90],[593],[9879,9894],{"trials":9914,"activeCount":101},[],{"trials":9916,"activeCount":101},[],{"trials":9918,"activeCount":101},[],{"intervention":8222,"totalTrials":228,"cells":9920},{"EARLY_PHASE1":9921,"PHASE1":9923,"PHASE2":9925,"PHASE3":9931,"PHASE4":9933,"NA":9935},{"trials":9922,"activeCount":101},[],{"trials":9924,"activeCount":101},[],{"trials":9926,"activeCount":101},[9927],{"nctId":8217,"briefTitle":8218,"status":143,"phases":9928,"primaryCompletion":1655,"completion":7434,"start":3596,"enrollment":1362,"conditions":9929,"interventions":9930},[90],[312,1647],[8222,8223,8224,8208],{"trials":9932,"activeCount":101},[],{"trials":9934,"activeCount":101},[],{"trials":9936,"activeCount":101},[],{"intervention":8223,"totalTrials":228,"cells":9938},{"EARLY_PHASE1":9939,"PHASE1":9941,"PHASE2":9943,"PHASE3":9949,"PHASE4":9951,"NA":9953},{"trials":9940,"activeCount":101},[],{"trials":9942,"activeCount":101},[],{"trials":9944,"activeCount":101},[9945],{"nctId":8217,"briefTitle":8218,"status":143,"phases":9946,"primaryCompletion":1655,"completion":7434,"start":3596,"enrollment":1362,"conditions":9947,"interventions":9948},[90],[312,1647],[8222,8223,8224,8208],{"trials":9950,"activeCount":101},[],{"trials":9952,"activeCount":101},[],{"trials":9954,"activeCount":101},[],{"intervention":8224,"totalTrials":228,"cells":9956},{"EARLY_PHASE1":9957,"PHASE1":9959,"PHASE2":9961,"PHASE3":9967,"PHASE4":9969,"NA":9971},{"trials":9958,"activeCount":101},[],{"trials":9960,"activeCount":101},[],{"trials":9962,"activeCount":101},[9963],{"nctId":8217,"briefTitle":8218,"status":143,"phases":9964,"primaryCompletion":1655,"completion":7434,"start":3596,"enrollment":1362,"conditions":9965,"interventions":9966},[90],[312,1647],[8222,8223,8224,8208],{"trials":9968,"activeCount":101},[],{"trials":9970,"activeCount":101},[],{"trials":9972,"activeCount":101},[],{"intervention":1661,"totalTrials":228,"cells":9974},{"EARLY_PHASE1":9975,"PHASE1":9977,"PHASE2":9979,"PHASE3":9985,"PHASE4":9987,"NA":9989},{"trials":9976,"activeCount":101},[],{"trials":9978,"activeCount":101},[],{"trials":9980,"activeCount":101},[9981],{"nctId":1651,"briefTitle":1652,"status":143,"phases":9982,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1596,"conditions":9983,"interventions":9984},[90],[19,1658,1659],[1661,1662,1564],{"trials":9986,"activeCount":101},[],{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[],{"intervention":1460,"totalTrials":228,"cells":9992},{"EARLY_PHASE1":9993,"PHASE1":9995,"PHASE2":9997,"PHASE3":10003,"PHASE4":10005,"NA":10007},{"trials":9994,"activeCount":101},[],{"trials":9996,"activeCount":101},[],{"trials":9998,"activeCount":101},[9999],{"nctId":1450,"briefTitle":1451,"status":158,"phases":10000,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":1455,"conditions":10001,"interventions":10002},[90],[1457,1458],[1038,1460,1461],{"trials":10004,"activeCount":101},[],{"trials":10006,"activeCount":101},[],{"trials":10008,"activeCount":101},[],{"intervention":10010,"totalTrials":228,"cells":10011},"Progesterone Pill",{"EARLY_PHASE1":10012,"PHASE1":10014,"PHASE2":10016,"PHASE3":10027,"PHASE4":10029,"NA":10031},{"trials":10013,"activeCount":101},[],{"trials":10015,"activeCount":101},[],{"trials":10017,"activeCount":101},[10018],{"nctId":10019,"briefTitle":10020,"status":177,"phases":10021,"primaryCompletion":179,"completion":179,"start":10022,"enrollment":101,"conditions":10023,"interventions":10025},"NCT05365464","HOPE Trial hCG or Progesterone Effect on Recurrent Pregnancy Loss",[90],"2022-05",[10024],"Recurrent Pregnancy Loss Without Current Pregnancy",[10010,10026],"hCG",{"trials":10028,"activeCount":101},[],{"trials":10030,"activeCount":101},[],{"trials":10032,"activeCount":101},[],{"intervention":10026,"totalTrials":228,"cells":10034},{"EARLY_PHASE1":10035,"PHASE1":10037,"PHASE2":10039,"PHASE3":10045,"PHASE4":10047,"NA":10049},{"trials":10036,"activeCount":101},[],{"trials":10038,"activeCount":101},[],{"trials":10040,"activeCount":101},[10041],{"nctId":10019,"briefTitle":10020,"status":177,"phases":10042,"primaryCompletion":179,"completion":179,"start":10022,"enrollment":101,"conditions":10043,"interventions":10044},[90],[10024],[10010,10026],{"trials":10046,"activeCount":101},[],{"trials":10048,"activeCount":101},[],{"trials":10050,"activeCount":101},[],{"intervention":10052,"totalTrials":228,"cells":10053},"Aspirin",{"EARLY_PHASE1":10054,"PHASE1":10056,"PHASE2":10058,"PHASE3":10068,"PHASE4":10070,"NA":10072},{"trials":10055,"activeCount":101},[],{"trials":10057,"activeCount":101},[],{"trials":10059,"activeCount":101},[10060],{"nctId":10061,"briefTitle":10062,"status":158,"phases":10063,"completion":10064,"start":9236,"enrollment":1617,"conditions":10065,"interventions":10067},"NCT00405613","Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population",[90],"2005-12",[10066],"Bleeding Complication",[10052],{"trials":10069,"activeCount":101},[],{"trials":10071,"activeCount":101},[],{"trials":10073,"activeCount":101},[],{"intervention":10075,"totalTrials":228,"cells":10076},"20 IU Humulin® R U-100",{"EARLY_PHASE1":10077,"PHASE1":10079,"PHASE2":10081,"PHASE3":10092,"PHASE4":10094,"NA":10096},{"trials":10078,"activeCount":101},[],{"trials":10080,"activeCount":101},[],{"trials":10082,"activeCount":101},[10083],{"nctId":10084,"briefTitle":10085,"status":158,"phases":10086,"primaryCompletion":10087,"completion":10087,"start":10088,"enrollment":4125,"conditions":10089,"interventions":10090},"NCT04199767","SNIFF Multi-Device Study 2",[90],"2020-11-03","2020-07-16",[1458,7659],[10075,10091],"40 IU Humulin® R U-100",{"trials":10093,"activeCount":101},[],{"trials":10095,"activeCount":101},[],{"trials":10097,"activeCount":101},[],{"intervention":10091,"totalTrials":228,"cells":10099},{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10104,"PHASE3":10110,"PHASE4":10112,"NA":10114},{"trials":10101,"activeCount":101},[],{"trials":10103,"activeCount":101},[],{"trials":10105,"activeCount":101},[10106],{"nctId":10084,"briefTitle":10085,"status":158,"phases":10107,"primaryCompletion":10087,"completion":10087,"start":10088,"enrollment":4125,"conditions":10108,"interventions":10109},[90],[1458,7659],[10075,10091],{"trials":10111,"activeCount":101},[],{"trials":10113,"activeCount":101},[],{"trials":10115,"activeCount":101},[],{"intervention":10117,"totalTrials":228,"cells":10118},"Biaxin",{"EARLY_PHASE1":10119,"PHASE1":10121,"PHASE2":10123,"PHASE3":10133,"PHASE4":10135,"NA":10137},{"trials":10120,"activeCount":101},[],{"trials":10122,"activeCount":101},[],{"trials":10124,"activeCount":101},[10125],{"nctId":10126,"briefTitle":10127,"status":158,"phases":10128,"primaryCompletion":10129,"completion":10129,"start":10130,"enrollment":423,"conditions":10131,"interventions":10132},"NCT00205634","Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis",[90],"2004-10","2000-12",[6498],[10117],{"trials":10134,"activeCount":101},[],{"trials":10136,"activeCount":101},[],{"trials":10138,"activeCount":101},[],{"intervention":10140,"totalTrials":228,"cells":10141},"Poly ICLC",{"EARLY_PHASE1":10142,"PHASE1":10144,"PHASE2":10146,"PHASE3":10155,"PHASE4":10157,"NA":10159},{"trials":10143,"activeCount":101},[],{"trials":10145,"activeCount":101},[],{"trials":10147,"activeCount":101},[10148],{"nctId":10149,"briefTitle":10150,"status":158,"phases":10151,"primaryCompletion":10152,"completion":10152,"start":1537,"enrollment":28,"conditions":10153,"interventions":10154},"NCT01188096","A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas",[90],"2019-07",[6452],[10140],{"trials":10156,"activeCount":101},[],{"trials":10158,"activeCount":101},[],{"trials":10160,"activeCount":101},[],{"intervention":10162,"totalTrials":228,"cells":10163},"Effect of Amoxicillin on bacteremia following a single-tooth extraction",{"EARLY_PHASE1":10164,"PHASE1":10166,"PHASE2":10168,"PHASE3":10179,"PHASE4":10181,"NA":10183},{"trials":10165,"activeCount":101},[],{"trials":10167,"activeCount":101},[],{"trials":10169,"activeCount":101},[10170],{"nctId":10171,"briefTitle":10172,"status":158,"phases":10173,"primaryCompletion":5204,"completion":3852,"start":10174,"enrollment":10175,"conditions":10176,"interventions":10178},"NCT00454285","Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing",[90],"2003-01",290,[10177],"Bacteremia",[10162],{"trials":10180,"activeCount":101},[],{"trials":10182,"activeCount":101},[],{"trials":10184,"activeCount":101},[],{"intervention":4009,"totalTrials":228,"cells":10186},{"EARLY_PHASE1":10187,"PHASE1":10189,"PHASE2":10191,"PHASE3":10197,"PHASE4":10199,"NA":10201},{"trials":10188,"activeCount":101},[],{"trials":10190,"activeCount":101},[],{"trials":10192,"activeCount":101},[10193],{"nctId":4001,"briefTitle":4002,"status":158,"phases":10194,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":1527,"conditions":10195,"interventions":10196},[90],[4007],[4009,4010,4011],{"trials":10198,"activeCount":101},[],{"trials":10200,"activeCount":101},[],{"trials":10202,"activeCount":101},[],{"intervention":4011,"totalTrials":228,"cells":10204},{"EARLY_PHASE1":10205,"PHASE1":10207,"PHASE2":10209,"PHASE3":10215,"PHASE4":10217,"NA":10219},{"trials":10206,"activeCount":101},[],{"trials":10208,"activeCount":101},[],{"trials":10210,"activeCount":101},[10211],{"nctId":4001,"briefTitle":4002,"status":158,"phases":10212,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":1527,"conditions":10213,"interventions":10214},[90],[4007],[4009,4010,4011],{"trials":10216,"activeCount":101},[],{"trials":10218,"activeCount":101},[],{"trials":10220,"activeCount":101},[],{"intervention":10222,"totalTrials":228,"cells":10223},"HIPEC with Carboplatin",{"EARLY_PHASE1":10224,"PHASE1":10226,"PHASE2":10228,"PHASE3":10246,"PHASE4":10248,"NA":10250},{"trials":10225,"activeCount":101},[],{"trials":10227,"activeCount":101},[],{"trials":10229,"activeCount":101},[10230],{"nctId":10231,"briefTitle":10232,"status":158,"phases":10233,"primaryCompletion":10234,"completion":10235,"start":10236,"enrollment":1477,"conditions":10237,"interventions":10245},"NCT04415944","Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy",[90],"2025-09-19","2026-01-23","2021-05-20",[10238,10239,10240,10241,10242,10243,10244],"Ovarian Epithelial Cancer Stage I","Ovarian Epithelial Cancer Stage II","Ovarian Epithelial Cancer Stage III","Stage I Fallopian Tube Cancer","Stage II Fallopian Tube Cancer","Stage III Fallopian Tube Cancer","Peritoneal Carcinoma",[10222],{"trials":10247,"activeCount":101},[],{"trials":10249,"activeCount":101},[],{"trials":10251,"activeCount":101},[],{"intervention":10253,"totalTrials":228,"cells":10254},"Botox",{"EARLY_PHASE1":10255,"PHASE1":10257,"PHASE2":10259,"PHASE3":10270,"PHASE4":10272,"NA":10274},{"trials":10256,"activeCount":101},[],{"trials":10258,"activeCount":101},[],{"trials":10260,"activeCount":101},[10261],{"nctId":10262,"briefTitle":10263,"status":158,"phases":10264,"primaryCompletion":10265,"completion":10265,"start":10266,"enrollment":258,"conditions":10267,"interventions":10269},"NCT02058836","Botulinum Toxin for the Management of Chronic Orchialgia",[90],"2016-10-18","2014-11",[10268],"Chronic Testicular Pain",[10253],{"trials":10271,"activeCount":101},[],{"trials":10273,"activeCount":101},[],{"trials":10275,"activeCount":101},[],{"intervention":7466,"totalTrials":228,"cells":10277},{"EARLY_PHASE1":10278,"PHASE1":10280,"PHASE2":10282,"PHASE3":10288,"PHASE4":10290,"NA":10292},{"trials":10279,"activeCount":101},[],{"trials":10281,"activeCount":101},[],{"trials":10283,"activeCount":101},[10284],{"nctId":7455,"briefTitle":7456,"status":158,"phases":10285,"primaryCompletion":5050,"completion":7458,"start":7459,"enrollment":31,"conditions":10286,"interventions":10287},[90],[7461,7462,7463,7464,7242,7233],[7466,1895,7381,2689],{"trials":10289,"activeCount":101},[],{"trials":10291,"activeCount":101},[],{"trials":10293,"activeCount":101},[],{"intervention":10295,"totalTrials":228,"cells":10296},"Tumor Infiltrating Lymphocytes",{"EARLY_PHASE1":10297,"PHASE1":10299,"PHASE2":10301,"PHASE3":10310,"PHASE4":10312,"NA":10314},{"trials":10298,"activeCount":101},[],{"trials":10300,"activeCount":101},[],{"trials":10302,"activeCount":101},[10303],{"nctId":10304,"briefTitle":10305,"status":143,"phases":10306,"primaryCompletion":6426,"completion":6426,"start":8088,"enrollment":1596,"conditions":10307,"interventions":10309},"NCT00863330","Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma",[90],[10308],"Melanoma (Skin)",[10295],{"trials":10311,"activeCount":101},[],{"trials":10313,"activeCount":101},[],{"trials":10315,"activeCount":101},[],{"intervention":10317,"totalTrials":228,"cells":10318},"Oral N-acetycystein",{"EARLY_PHASE1":10319,"PHASE1":10321,"PHASE2":10323,"PHASE3":10334,"PHASE4":10336,"NA":10338},{"trials":10320,"activeCount":101},[],{"trials":10322,"activeCount":101},[],{"trials":10324,"activeCount":101},[10325],{"nctId":10326,"briefTitle":10327,"status":158,"phases":10328,"completion":10329,"start":7361,"enrollment":10330,"conditions":10331,"interventions":10333},"NCT00205647","Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis",[90],"2000-03",240,[10332],"Chronic Bronchitis",[10317],{"trials":10335,"activeCount":101},[],{"trials":10337,"activeCount":101},[],{"trials":10339,"activeCount":101},[],{"intervention":7913,"totalTrials":228,"cells":10341},{"EARLY_PHASE1":10342,"PHASE1":10344,"PHASE2":10346,"PHASE3":10352,"PHASE4":10354,"NA":10356},{"trials":10343,"activeCount":101},[],{"trials":10345,"activeCount":101},[],{"trials":10347,"activeCount":101},[10348],{"nctId":7905,"briefTitle":7906,"status":143,"phases":10349,"primaryCompletion":7908,"completion":7908,"start":7909,"enrollment":1548,"conditions":10350,"interventions":10351},[90],[7911,4075],[7913,7896],{"trials":10353,"activeCount":101},[],{"trials":10355,"activeCount":101},[],{"trials":10357,"activeCount":101},[],{"intervention":10359,"totalTrials":228,"cells":10360},"denileukin diftitox",{"EARLY_PHASE1":10361,"PHASE1":10363,"PHASE2":10365,"PHASE3":10376,"PHASE4":10378,"NA":10380},{"trials":10362,"activeCount":101},[],{"trials":10364,"activeCount":101},[],{"trials":10366,"activeCount":101},[10367],{"nctId":10368,"briefTitle":10369,"status":158,"phases":10370,"primaryCompletion":10371,"completion":10372,"start":10373,"conditions":10374,"interventions":10375},"NCT00082940","Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia",[90],"2005-01","2005-06","2002-08",[2208],[10359],{"trials":10377,"activeCount":101},[],{"trials":10379,"activeCount":101},[],{"trials":10381,"activeCount":101},[],{"intervention":10383,"totalTrials":228,"cells":10384},"Beet it Beetroot juice",{"EARLY_PHASE1":10385,"PHASE1":10387,"PHASE2":10389,"PHASE3":10402,"PHASE4":10404,"NA":10406},{"trials":10386,"activeCount":101},[],{"trials":10388,"activeCount":101},[],{"trials":10390,"activeCount":101},[10391],{"nctId":10392,"briefTitle":10393,"status":158,"phases":10394,"primaryCompletion":10395,"completion":10395,"start":10396,"enrollment":3569,"conditions":10397,"interventions":10400},"NCT02838901","Dietary Nitrate Supplements and Ischemic Stroke Recovery",[90],"2016-06","2012-06",[593,10398,10399],"Ischemic Stroke","Cerebrovascular Accident",[10383,10401],"Beet It Placebo Beetroot juice",{"trials":10403,"activeCount":101},[],{"trials":10405,"activeCount":101},[],{"trials":10407,"activeCount":101},[],{"intervention":10401,"totalTrials":228,"cells":10409},{"EARLY_PHASE1":10410,"PHASE1":10412,"PHASE2":10414,"PHASE3":10420,"PHASE4":10422,"NA":10424},{"trials":10411,"activeCount":101},[],{"trials":10413,"activeCount":101},[],{"trials":10415,"activeCount":101},[10416],{"nctId":10392,"briefTitle":10393,"status":158,"phases":10417,"primaryCompletion":10395,"completion":10395,"start":10396,"enrollment":3569,"conditions":10418,"interventions":10419},[90],[593,10398,10399],[10383,10401],{"trials":10421,"activeCount":101},[],{"trials":10423,"activeCount":101},[],{"trials":10425,"activeCount":101},[],{"intervention":10427,"totalTrials":228,"cells":10428},"Budesonide",{"EARLY_PHASE1":10429,"PHASE1":10431,"PHASE2":10433,"PHASE3":10444,"PHASE4":10446,"NA":10448},{"trials":10430,"activeCount":101},[],{"trials":10432,"activeCount":101},[],{"trials":10434,"activeCount":101},[10435],{"nctId":10436,"briefTitle":10437,"status":177,"phases":10438,"primaryCompletion":2518,"completion":2518,"start":7240,"enrollment":101,"conditions":10439,"interventions":10442},"NCT02425813","Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract",[90],[10440,10441],"Acute Graft Versus Host Disease","Intestinal Graft Versus Host Disease",[10427,10443],"Methylprednisolone Sodium Succinate",{"trials":10445,"activeCount":101},[],{"trials":10447,"activeCount":101},[],{"trials":10449,"activeCount":101},[],{"intervention":10443,"totalTrials":228,"cells":10451},{"EARLY_PHASE1":10452,"PHASE1":10454,"PHASE2":10456,"PHASE3":10462,"PHASE4":10464,"NA":10466},{"trials":10453,"activeCount":101},[],{"trials":10455,"activeCount":101},[],{"trials":10457,"activeCount":101},[10458],{"nctId":10436,"briefTitle":10437,"status":177,"phases":10459,"primaryCompletion":2518,"completion":2518,"start":7240,"enrollment":101,"conditions":10460,"interventions":10461},[90],[10440,10441],[10427,10443],{"trials":10463,"activeCount":101},[],{"trials":10465,"activeCount":101},[],{"trials":10467,"activeCount":101},[],{"intervention":10469,"totalTrials":228,"cells":10470},"combined spinal epidural",{"EARLY_PHASE1":10471,"PHASE1":10473,"PHASE2":10475,"PHASE3":10485,"PHASE4":10487,"NA":10489},{"trials":10472,"activeCount":101},[],{"trials":10474,"activeCount":101},[],{"trials":10476,"activeCount":101},[10477],{"nctId":10478,"briefTitle":10479,"status":158,"phases":10480,"primaryCompletion":10481,"completion":10481,"start":10482,"enrollment":344,"conditions":10483,"interventions":10484},"NCT02020304","Combined Spinal-Epidural Temperature and Duration of Action",[90],"2014-05-04","2013-08-29",[25],[10469],{"trials":10486,"activeCount":101},[],{"trials":10488,"activeCount":101},[],{"trials":10490,"activeCount":101},[],{"intervention":10492,"totalTrials":228,"cells":10493},"cinacalcet hydrochloride",{"EARLY_PHASE1":10494,"PHASE1":10496,"PHASE2":10498,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10495,"activeCount":101},[],{"trials":10497,"activeCount":101},[],{"trials":10499,"activeCount":101},[10500],{"nctId":10501,"briefTitle":10502,"status":158,"phases":10503,"primaryCompletion":2434,"completion":2434,"start":5846,"enrollment":37,"conditions":10504,"interventions":10506},"NCT01054079","Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer",[90],[10505,8765],"Adenocarcinoma of the Prostate",[10492],{"trials":10508,"activeCount":101},[],{"trials":10510,"activeCount":101},[],{"trials":10512,"activeCount":101},[],{"intervention":10514,"totalTrials":228,"cells":10515},"ciprofloxacin",{"EARLY_PHASE1":10516,"PHASE1":10518,"PHASE2":10520,"PHASE3":10528,"PHASE4":10530,"NA":10532},{"trials":10517,"activeCount":101},[],{"trials":10519,"activeCount":101},[],{"trials":10521,"activeCount":101},[10522],{"nctId":10523,"briefTitle":10524,"status":177,"phases":10525,"primaryCompletion":2518,"completion":2518,"start":2518,"enrollment":101,"conditions":10526,"interventions":10527},"NCT02252978","Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy",[90],[348],[10514],{"trials":10529,"activeCount":101},[],{"trials":10531,"activeCount":101},[],{"trials":10533,"activeCount":101},[],{"intervention":10535,"totalTrials":228,"cells":10536},"methylene blue, gentian violet, and ovine forestomach wound dressings",{"EARLY_PHASE1":10537,"PHASE1":10539,"PHASE2":10541,"PHASE3":10552,"PHASE4":10554,"NA":10556},{"trials":10538,"activeCount":101},[],{"trials":10540,"activeCount":101},[],{"trials":10542,"activeCount":101},[10543],{"nctId":10544,"briefTitle":10545,"status":158,"phases":10546,"primaryCompletion":10547,"completion":10547,"start":10548,"enrollment":1850,"conditions":10549,"interventions":10551},"NCT04354012","Hidradenitis Suppurativa Wound Care",[90],"2024-08-28","2021-02-04",[10550],"Hidradenitis Suppurativa (HS)",[10535],{"trials":10553,"activeCount":101},[],{"trials":10555,"activeCount":101},[],{"trials":10557,"activeCount":101},[],{"intervention":10559,"totalTrials":228,"cells":10560},"senna\u002Fdocusate",{"EARLY_PHASE1":10561,"PHASE1":10563,"PHASE2":10565,"PHASE3":10576,"PHASE4":10578,"NA":10580},{"trials":10562,"activeCount":101},[],{"trials":10564,"activeCount":101},[],{"trials":10566,"activeCount":101},[10567],{"nctId":10568,"briefTitle":10569,"status":143,"phases":10570,"primaryCompletion":10571,"completion":10571,"start":10572,"enrollment":97,"conditions":10573,"interventions":10575},"NCT03342157","Docusate\u002FSenna for the Treatment of Diabetic Gastroparesis",[90],"2018-08-17","2018-04-02",[10574],"Diabetic Gastroparesis",[10559],{"trials":10577,"activeCount":101},[],{"trials":10579,"activeCount":101},[],{"trials":10581,"activeCount":101},[],{"intervention":10583,"totalTrials":228,"cells":10584},"Oxytocin 15 mcg",{"EARLY_PHASE1":10585,"PHASE1":10587,"PHASE2":10589,"PHASE3":10599,"PHASE4":10601,"NA":10603},{"trials":10586,"activeCount":101},[],{"trials":10588,"activeCount":101},[],{"trials":10590,"activeCount":101},[10591],{"nctId":10592,"briefTitle":10593,"status":143,"phases":10594,"primaryCompletion":256,"completion":256,"start":10595,"enrollment":37,"conditions":10596,"interventions":10597},"NCT01996605","Efficacy of Spinal Oxytocin in Healthy Volunteers",[90],"2014-01-02",[2010],[10583,10598],"Oxytocin 150 mcg",{"trials":10600,"activeCount":101},[],{"trials":10602,"activeCount":101},[],{"trials":10604,"activeCount":101},[],{"intervention":10598,"totalTrials":228,"cells":10606},{"EARLY_PHASE1":10607,"PHASE1":10609,"PHASE2":10611,"PHASE3":10617,"PHASE4":10619,"NA":10621},{"trials":10608,"activeCount":101},[],{"trials":10610,"activeCount":101},[],{"trials":10612,"activeCount":101},[10613],{"nctId":10592,"briefTitle":10593,"status":143,"phases":10614,"primaryCompletion":256,"completion":256,"start":10595,"enrollment":37,"conditions":10615,"interventions":10616},[90],[2010],[10583,10598],{"trials":10618,"activeCount":101},[],{"trials":10620,"activeCount":101},[],{"trials":10622,"activeCount":101},[],{"intervention":10624,"totalTrials":228,"cells":10625},"Infusion of donor lymphocytes",{"EARLY_PHASE1":10626,"PHASE1":10628,"PHASE2":10630,"PHASE3":10639,"PHASE4":10641,"NA":10643},{"trials":10627,"activeCount":101},[],{"trials":10629,"activeCount":101},[],{"trials":10631,"activeCount":101},[10632],{"nctId":10633,"briefTitle":10634,"status":143,"phases":10635,"primaryCompletion":2478,"completion":2478,"start":1888,"enrollment":20,"conditions":10636,"interventions":10638},"NCT01027702","Donor Lymphocyte Infusion After Alternative Donor Transplantation",[89,90],[10637],"Immunodeficiency",[10624],{"trials":10640,"activeCount":101},[],{"trials":10642,"activeCount":101},[],{"trials":10644,"activeCount":101},[],{"intervention":1390,"totalTrials":228,"cells":10646},{"EARLY_PHASE1":10647,"PHASE1":10649,"PHASE2":10651,"PHASE3":10657,"PHASE4":10659,"NA":10661},{"trials":10648,"activeCount":101},[],{"trials":10650,"activeCount":101},[],{"trials":10652,"activeCount":101},[10653],{"nctId":1384,"briefTitle":1385,"status":177,"phases":10654,"start":1387,"enrollment":101,"conditions":10655,"interventions":10656},[90],[25],[1361,1390],{"trials":10658,"activeCount":101},[],{"trials":10660,"activeCount":101},[],{"trials":10662,"activeCount":101},[],{"intervention":10664,"totalTrials":228,"cells":10665},"Propranolol Hydrochloride",{"EARLY_PHASE1":10666,"PHASE1":10668,"PHASE2":10670,"PHASE3":10682,"PHASE4":10684,"NA":10686},{"trials":10667,"activeCount":101},[],{"trials":10669,"activeCount":101},[],{"trials":10671,"activeCount":101},[10672],{"nctId":10673,"briefTitle":10674,"status":143,"phases":10675,"primaryCompletion":10676,"completion":10677,"start":10678,"enrollment":1586,"conditions":10679,"interventions":10681},"NCT03152786","Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery",[90],"2021-06-15","2023-02-28","2019-01-15",[10680],"Prostate Carcinoma",[10664],{"trials":10683,"activeCount":101},[],{"trials":10685,"activeCount":101},[],{"trials":10687,"activeCount":101},[],{"intervention":10689,"totalTrials":228,"cells":10690},"Elagolix",{"EARLY_PHASE1":10691,"PHASE1":10693,"PHASE2":10695,"PHASE3":10707,"PHASE4":10709,"NA":10711},{"trials":10692,"activeCount":101},[],{"trials":10694,"activeCount":101},[],{"trials":10696,"activeCount":101},[10697],{"nctId":10698,"briefTitle":10699,"status":158,"phases":10700,"primaryCompletion":10701,"completion":10701,"start":10702,"enrollment":1477,"conditions":10703,"interventions":10705},"NCT04039204","Elagolix for Fertility Enhancement Clinical Trial",[90],"2023-08-09","2022-01-15",[9848,10704],"Unexplained Infertility",[10689,10706],"Ortho Cyclen",{"trials":10708,"activeCount":101},[],{"trials":10710,"activeCount":101},[],{"trials":10712,"activeCount":101},[],{"intervention":10706,"totalTrials":228,"cells":10714},{"EARLY_PHASE1":10715,"PHASE1":10717,"PHASE2":10719,"PHASE3":10725,"PHASE4":10727,"NA":10729},{"trials":10716,"activeCount":101},[],{"trials":10718,"activeCount":101},[],{"trials":10720,"activeCount":101},[10721],{"nctId":10698,"briefTitle":10699,"status":158,"phases":10722,"primaryCompletion":10701,"completion":10701,"start":10702,"enrollment":1477,"conditions":10723,"interventions":10724},[90],[9848,10704],[10689,10706],{"trials":10726,"activeCount":101},[],{"trials":10728,"activeCount":101},[],{"trials":10730,"activeCount":101},[],{"intervention":7923,"totalTrials":228,"cells":10732},{"EARLY_PHASE1":10733,"PHASE1":10735,"PHASE2":10737,"PHASE3":10743,"PHASE4":10745,"NA":10747},{"trials":10734,"activeCount":101},[],{"trials":10736,"activeCount":101},[],{"trials":10738,"activeCount":101},[10739],{"nctId":7915,"briefTitle":7916,"status":143,"phases":10740,"primaryCompletion":7918,"completion":7918,"start":7919,"enrollment":4125,"conditions":10741,"interventions":10742},[90],[7921],[7923,7896],{"trials":10744,"activeCount":101},[],{"trials":10746,"activeCount":101},[],{"trials":10748,"activeCount":101},[],{"intervention":10750,"totalTrials":228,"cells":10751},"Oral L-Arginine",{"EARLY_PHASE1":10752,"PHASE1":10754,"PHASE2":10756,"PHASE3":10768,"PHASE4":10770,"NA":10772},{"trials":10753,"activeCount":101},[],{"trials":10755,"activeCount":101},[],{"trials":10757,"activeCount":101},[10758],{"nctId":10759,"briefTitle":10760,"status":158,"phases":10761,"primaryCompletion":10762,"completion":10762,"start":10763,"enrollment":10764,"conditions":10765,"interventions":10767},"NCT01105130","L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors",[90],"2014-02-04","2010-10-01",140,[10766,348,3967],"Male Erectile Disorder",[10750,10750],{"trials":10769,"activeCount":101},[],{"trials":10771,"activeCount":101},[],{"trials":10773,"activeCount":101},[],{"intervention":10775,"totalTrials":228,"cells":10776},"borage\u002Fechium oil combination",{"EARLY_PHASE1":10777,"PHASE1":10779,"PHASE2":10781,"PHASE3":10792,"PHASE4":10794,"NA":10796},{"trials":10778,"activeCount":101},[],{"trials":10780,"activeCount":101},[],{"trials":10782,"activeCount":101},[10783],{"nctId":10784,"briefTitle":10785,"status":158,"phases":10786,"primaryCompletion":10787,"completion":10787,"start":7718,"enrollment":771,"conditions":10788,"interventions":10791},"NCT01145066","Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects",[90],"2011-03",[10789,10790],"Diabetes","Metabolic Syndrome x",[10775],{"trials":10793,"activeCount":101},[],{"trials":10795,"activeCount":101},[],{"trials":10797,"activeCount":101},[],{"intervention":10799,"totalTrials":228,"cells":10800},"Crizotinib",{"EARLY_PHASE1":10801,"PHASE1":10803,"PHASE2":10805,"PHASE3":10819,"PHASE4":10821,"NA":10823},{"trials":10802,"activeCount":101},[],{"trials":10804,"activeCount":101},[],{"trials":10806,"activeCount":101},[10807],{"nctId":10808,"briefTitle":10809,"status":143,"phases":10810,"primaryCompletion":10811,"completion":10812,"start":10813,"enrollment":258,"conditions":10814,"interventions":10818},"NCT02612194","LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer",[90],"2019-09-17","2019-11-21","2016-09-27",[10815,10816,10817],"Urinary Bladder Neoplasms","Ureteral Neoplasms","Urethral Neoplasms",[10799],{"trials":10820,"activeCount":101},[],{"trials":10822,"activeCount":101},[],{"trials":10824,"activeCount":101},[],{"intervention":10826,"totalTrials":228,"cells":10827},"Sodium bicarbonate",{"EARLY_PHASE1":10828,"PHASE1":10830,"PHASE2":10832,"PHASE3":10843,"PHASE4":10845,"NA":10847},{"trials":10829,"activeCount":101},[],{"trials":10831,"activeCount":101},[],{"trials":10833,"activeCount":101},[10834],{"nctId":10835,"briefTitle":10836,"status":158,"phases":10837,"primaryCompletion":4316,"completion":1655,"start":6266,"enrollment":10838,"conditions":10839,"interventions":10842},"NCT00484354","Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery",[90],123,[10840,10841],"Kidney Failure, Acute","Renal Replacement Therapy",[10826],{"trials":10844,"activeCount":101},[],{"trials":10846,"activeCount":101},[],{"trials":10848,"activeCount":101},[],{"intervention":2418,"totalTrials":97,"cells":10850},{"EARLY_PHASE1":10851,"PHASE1":10853,"PHASE2":10863,"PHASE3":10865,"PHASE4":10867,"NA":10869},{"trials":10852,"activeCount":101},[],{"trials":10854,"activeCount":101},[10855,10859],{"nctId":7196,"briefTitle":7197,"status":158,"phases":10856,"primaryCompletion":7199,"completion":7200,"start":7201,"enrollment":2140,"conditions":10857,"interventions":10858},[89],[7203,7204,7205,7206,7207,7208,7209,7210,7211,7212,2395,7213,7214,7215,2408,7216,7217],[2417,2418],{"nctId":2384,"briefTitle":2385,"status":143,"phases":10860,"primaryCompletion":2387,"completion":2387,"start":1607,"enrollment":228,"conditions":10861,"interventions":10862},[89],[2389,2390,2391,2392,2393,2394,2395,2396,2397,2398,2399,2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415],[2417,2418,2419],{"trials":10864,"activeCount":101},[],{"trials":10866,"activeCount":101},[],{"trials":10868,"activeCount":101},[],{"trials":10870,"activeCount":101},[],{"intervention":2471,"totalTrials":97,"cells":10872},{"EARLY_PHASE1":10873,"PHASE1":10875,"PHASE2":10885,"PHASE3":10887,"PHASE4":10889,"NA":10891},{"trials":10874,"activeCount":101},[],{"trials":10876,"activeCount":101},[10877,10881],{"nctId":2458,"briefTitle":2459,"status":158,"phases":10878,"primaryCompletion":2461,"completion":2462,"start":2463,"enrollment":2464,"conditions":10879,"interventions":10880},[89],[2466,2467],[2469,2470,2471],{"nctId":2484,"briefTitle":2485,"status":158,"phases":10882,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":2489,"conditions":10883,"interventions":10884},[89],[2491,2492,2493,2494,2495,2496,2467],[2498,2211,2499],{"trials":10886,"activeCount":101},[],{"trials":10888,"activeCount":101},[],{"trials":10890,"activeCount":101},[],{"trials":10892,"activeCount":101},[],{"intervention":10894,"totalTrials":228,"cells":10895},"GIK",{"EARLY_PHASE1":10896,"PHASE1":10898,"PHASE2":10906,"PHASE3":10908,"PHASE4":10910,"NA":10912},{"trials":10897,"activeCount":101},[],{"trials":10899,"activeCount":101},[10900],{"nctId":10901,"briefTitle":10902,"status":158,"phases":10903,"primaryCompletion":1374,"completion":1374,"start":4776,"enrollment":37,"conditions":10904,"interventions":10905},"NCT00823108","Rapid Administration of Insulin in Sepsis",[89],[247],[10894],{"trials":10907,"activeCount":101},[],{"trials":10909,"activeCount":101},[],{"trials":10911,"activeCount":101},[],{"trials":10913,"activeCount":101},[],{"intervention":10915,"totalTrials":228,"cells":10916},"Dermabond",{"EARLY_PHASE1":10917,"PHASE1":10919,"PHASE2":10929,"PHASE3":10931,"PHASE4":10933,"NA":10935},{"trials":10918,"activeCount":101},[],{"trials":10920,"activeCount":101},[10921],{"nctId":10922,"briefTitle":10923,"status":177,"phases":10924,"primaryCompletion":5871,"completion":5871,"start":3860,"enrollment":101,"conditions":10925,"interventions":10927},"NCT01008111","Wound Healing of Incisional Wounds for Bilateral Hernia Repair",[89],[10926],"Wound Healing",[10915,10928],"Hydrogen Peroxide Oxygen producing gel",{"trials":10930,"activeCount":101},[],{"trials":10932,"activeCount":101},[],{"trials":10934,"activeCount":101},[],{"trials":10936,"activeCount":101},[],{"intervention":10928,"totalTrials":228,"cells":10938},{"EARLY_PHASE1":10939,"PHASE1":10941,"PHASE2":10947,"PHASE3":10949,"PHASE4":10951,"NA":10953},{"trials":10940,"activeCount":101},[],{"trials":10942,"activeCount":101},[10943],{"nctId":10922,"briefTitle":10923,"status":177,"phases":10944,"primaryCompletion":5871,"completion":5871,"start":3860,"enrollment":101,"conditions":10945,"interventions":10946},[89],[10926],[10915,10928],{"trials":10948,"activeCount":101},[],{"trials":10950,"activeCount":101},[],{"trials":10952,"activeCount":101},[],{"trials":10954,"activeCount":101},[],{"intervention":10956,"totalTrials":228,"cells":10957},"cefepime hydrochloride",{"EARLY_PHASE1":10958,"PHASE1":10960,"PHASE2":10999,"PHASE3":11001,"PHASE4":11003,"NA":11005},{"trials":10959,"activeCount":101},[],{"trials":10961,"activeCount":101},[10962],{"nctId":10963,"briefTitle":10964,"status":158,"phases":10965,"primaryCompletion":10396,"completion":4182,"start":3596,"enrollment":2833,"conditions":10966,"interventions":10998},"NCT01484015","Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia",[89],[10967,10968,10969,10970,10971,10972,10973,10974,10975,10976,19,10977,10978,10979,10980,10981,10982,10983,2392,10984,10985,10986,10987,10988,10989,1762,10990,7855,9802,10991,2394,10992,10993,10994,10995,9106,10996,10997,2413],"Adult Acute Lymphoblastic Leukemia","Adult Acute Myeloid Leukemia","Adult Burkitt Lymphoma","Adult Diffuse Large Cell Lymphoma","Adult Diffuse Mixed Cell Lymphoma","Adult Diffuse Small Cleaved Cell Lymphoma","Adult Hodgkin Lymphoma","Adult Immunoblastic Large Cell Lymphoma","Adult Lymphoblastic Lymphoma","Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Chronic Eosinophilic Leukemia","Chronic Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Chronic Myelomonocytic Leukemia","Chronic Neutrophilic Leukemia","Cutaneous T-cell Non-Hodgkin Lymphoma","Disseminated Neuroblastoma","Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3 Follicular Lymphoma","Malignant Testicular Germ Cell Tumor","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Mycosis Fungoides\u002FSezary Syndrome","Neutropenia","Ovarian Epithelial Cancer","Ovarian Germ Cell Tumor","Plasma Cell Neoplasm","Poor Prognosis Metastatic Gestational Trophoblastic Tumor","Prolymphocytic Leukemia","Small Lymphocytic Lymphoma",[10956],{"trials":11000,"activeCount":101},[],{"trials":11002,"activeCount":101},[],{"trials":11004,"activeCount":101},[],{"trials":11006,"activeCount":101},[],{"intervention":249,"totalTrials":228,"cells":11008},{"EARLY_PHASE1":11009,"PHASE1":11011,"PHASE2":11017,"PHASE3":11019,"PHASE4":11021,"NA":11023},{"trials":11010,"activeCount":101},[],{"trials":11012,"activeCount":101},[11013],{"nctId":240,"briefTitle":241,"status":143,"phases":11014,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":11015,"interventions":11016},[89],[247],[249,232],{"trials":11018,"activeCount":101},[],{"trials":11020,"activeCount":101},[],{"trials":11022,"activeCount":101},[],{"trials":11024,"activeCount":101},[],{"intervention":11026,"totalTrials":228,"cells":11027},"Lavender",{"EARLY_PHASE1":11028,"PHASE1":11030,"PHASE2":11041,"PHASE3":11043,"PHASE4":11045,"NA":11047},{"trials":11029,"activeCount":101},[],{"trials":11031,"activeCount":101},[11032],{"nctId":11033,"briefTitle":11034,"status":158,"phases":11035,"primaryCompletion":11036,"completion":11036,"start":11037,"enrollment":834,"conditions":11038,"interventions":11040},"NCT03328143","Feasibility of Aromatherapy in an Awake Craniotomy Environment",[89],"2019-06-12","2018-04-03",[11039],"Intracranial Pathology",[11026],{"trials":11042,"activeCount":101},[],{"trials":11044,"activeCount":101},[],{"trials":11046,"activeCount":101},[],{"trials":11048,"activeCount":101},[],{"intervention":11050,"totalTrials":228,"cells":11051},"bitopertin",{"EARLY_PHASE1":11052,"PHASE1":11054,"PHASE2":11064,"PHASE3":11066,"PHASE4":11068,"NA":11070},{"trials":11053,"activeCount":101},[],{"trials":11055,"activeCount":101},[11056],{"nctId":11057,"briefTitle":11058,"status":177,"phases":11059,"primaryCompletion":11060,"completion":11060,"start":1570,"enrollment":101,"conditions":11061,"interventions":11063},"NCT07123363","Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria\u002FX-linked Protoporphyria and Increased Liver Stiffness and\u002For Liver Enzymes at Baseline",[89],"2035-12",[11062],"Protoporphyria",[11050],{"trials":11065,"activeCount":101},[],{"trials":11067,"activeCount":101},[],{"trials":11069,"activeCount":101},[],{"trials":11071,"activeCount":101},[],{"intervention":11073,"totalTrials":228,"cells":11074},"rosuvastatin",{"EARLY_PHASE1":11075,"PHASE1":11077,"PHASE2":11088,"PHASE3":11090,"PHASE4":11092,"NA":11094},{"trials":11076,"activeCount":101},[],{"trials":11078,"activeCount":101},[11079],{"nctId":11080,"briefTitle":11081,"status":143,"phases":11082,"primaryCompletion":11083,"completion":11083,"start":1732,"enrollment":1850,"conditions":11084,"interventions":11087},"NCT01051401","Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer",[89],"2014-01",[11085,1658,11086,8473,8474,8475,8476,1659],"Cardiovascular Complications","Stage I Breast Cancer",[11073],{"trials":11089,"activeCount":101},[],{"trials":11091,"activeCount":101},[],{"trials":11093,"activeCount":101},[],{"trials":11095,"activeCount":101},[],{"intervention":11097,"totalTrials":228,"cells":11098},"Dasatinib + Quercetin",{"EARLY_PHASE1":11099,"PHASE1":11101,"PHASE2":11112,"PHASE3":11114,"PHASE4":11116,"NA":11118},{"trials":11100,"activeCount":101},[],{"trials":11102,"activeCount":101},[11103],{"nctId":11104,"briefTitle":11105,"status":158,"phases":11106,"primaryCompletion":11107,"completion":11107,"start":11108,"enrollment":3354,"conditions":11109,"interventions":11111},"NCT02874989","Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial",[89],"2019-06-03","2016-12-16",[11110],"Idiopathic Pulmonary Fibrosis (IPF)",[11097],{"trials":11113,"activeCount":101},[],{"trials":11115,"activeCount":101},[],{"trials":11117,"activeCount":101},[],{"trials":11119,"activeCount":101},[],{"intervention":11121,"totalTrials":228,"cells":11122},"Lidocaine Hydrochloride 2% gel enema",{"EARLY_PHASE1":11123,"PHASE1":11125,"PHASE2":11136,"PHASE3":11138,"PHASE4":11140,"NA":11142},{"trials":11124,"activeCount":101},[],{"trials":11126,"activeCount":101},[11127],{"nctId":11128,"briefTitle":11129,"status":158,"phases":11130,"primaryCompletion":11131,"completion":11132,"start":7287,"enrollment":8231,"conditions":11133,"interventions":11135},"NCT03797703","Efficacy of Lidocaine Gel Enema After Endoscopic Hemorrhoid Band Ligation for Relief of Post Procedural Pain",[89],"2020-05-29","2020-06-05",[11134],"Hemorrhoids",[11121],{"trials":11137,"activeCount":101},[],{"trials":11139,"activeCount":101},[],{"trials":11141,"activeCount":101},[],{"trials":11143,"activeCount":101},[],{"intervention":11145,"totalTrials":228,"cells":11146},"Beta-blocker therapy",{"EARLY_PHASE1":11147,"PHASE1":11149,"PHASE2":11161,"PHASE3":11163,"PHASE4":11165,"NA":11167},{"trials":11148,"activeCount":101},[],{"trials":11150,"activeCount":101},[11151],{"nctId":11152,"briefTitle":11153,"status":143,"phases":11154,"primaryCompletion":4147,"completion":5051,"start":11155,"enrollment":23,"conditions":11156,"interventions":11160},"NCT00700947","Using Beta Blockers to Treat Mitral Regurgitation",[89],"2007-10",[6691,11157,11158,11159],"Mitral Regurgitation","Heart Valve Disease","Mitral Valve Insufficiency",[11145],{"trials":11162,"activeCount":101},[],{"trials":11164,"activeCount":101},[],{"trials":11166,"activeCount":101},[],{"trials":11168,"activeCount":101},[],{"intervention":11170,"totalTrials":228,"cells":11171},"Tenecteplase",{"EARLY_PHASE1":11172,"PHASE1":11174,"PHASE2":11184,"PHASE3":11186,"PHASE4":11188,"NA":11190},{"trials":11173,"activeCount":101},[],{"trials":11175,"activeCount":101},[11176],{"nctId":11177,"briefTitle":11178,"status":177,"phases":11179,"primaryCompletion":2510,"completion":3851,"start":11180,"enrollment":101,"conditions":11181,"interventions":11183},"NCT00431379","Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study",[89],"2007-02",[11182],"Acute Respiratory Distress Syndrome",[11170],{"trials":11185,"activeCount":101},[],{"trials":11187,"activeCount":101},[],{"trials":11189,"activeCount":101},[],{"trials":11191,"activeCount":101},[],{"intervention":11193,"totalTrials":228,"cells":11194},"PET-CT scans supplemented with 11C-Choline tracer",{"EARLY_PHASE1":11195,"PHASE1":11197,"PHASE2":11205,"PHASE3":11207,"PHASE4":11209,"NA":11211},{"trials":11196,"activeCount":101},[],{"trials":11198,"activeCount":101},[11199],{"nctId":11200,"briefTitle":11201,"status":158,"phases":11202,"primaryCompletion":10396,"completion":7288,"start":3859,"enrollment":3569,"conditions":11203,"interventions":11204},"NCT00804245","C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer",[89],[348],[11193],{"trials":11206,"activeCount":101},[],{"trials":11208,"activeCount":101},[],{"trials":11210,"activeCount":101},[],{"trials":11212,"activeCount":101},[],{"intervention":11214,"totalTrials":228,"cells":11215},"Insulin aspart",{"EARLY_PHASE1":11216,"PHASE1":11218,"PHASE2":11228,"PHASE3":11230,"PHASE4":11232,"NA":11234},{"trials":11217,"activeCount":101},[],{"trials":11219,"activeCount":101},[11220],{"nctId":11221,"briefTitle":11222,"status":158,"phases":11223,"primaryCompletion":11224,"completion":11224,"start":11225,"enrollment":1871,"conditions":11226,"interventions":11227},"NCT02462161","Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart",[89],"2019-04-16","2015-03-20",[1457,1458],[11214],{"trials":11229,"activeCount":101},[],{"trials":11231,"activeCount":101},[],{"trials":11233,"activeCount":101},[],{"trials":11235,"activeCount":101},[],{"intervention":11237,"totalTrials":228,"cells":11238},"Autologous Muscle Progenitor Cells",{"EARLY_PHASE1":11239,"PHASE1":11241,"PHASE2":11250,"PHASE3":11252,"PHASE4":11254,"NA":11256},{"trials":11240,"activeCount":101},[],{"trials":11242,"activeCount":101},[11243],{"nctId":11244,"briefTitle":11245,"status":158,"phases":11246,"primaryCompletion":4159,"completion":4159,"start":11083,"enrollment":1477,"conditions":11247,"interventions":11249},"NCT01953315","Muscle Progenitor Cell Therapy for Urinary Incontinence",[89],[11248],"Urinary Incontinence",[11237],{"trials":11251,"activeCount":101},[],{"trials":11253,"activeCount":101},[],{"trials":11255,"activeCount":101},[],{"trials":11257,"activeCount":101},[],{"intervention":4112,"totalTrials":228,"cells":11259},{"EARLY_PHASE1":11260,"PHASE1":11262,"PHASE2":11268,"PHASE3":11270,"PHASE4":11272,"NA":11274},{"trials":11261,"activeCount":101},[],{"trials":11263,"activeCount":101},[11264],{"nctId":4105,"briefTitle":4106,"status":158,"phases":11265,"primaryCompletion":3798,"completion":3798,"start":4108,"enrollment":1850,"conditions":11266,"interventions":11267},[89],[4110],[4112,4113,4098],{"trials":11269,"activeCount":101},[],{"trials":11271,"activeCount":101},[],{"trials":11273,"activeCount":101},[],{"trials":11275,"activeCount":101},[],{"intervention":11277,"totalTrials":228,"cells":11278},"C11-Choline",{"EARLY_PHASE1":11279,"PHASE1":11281,"PHASE2":11290,"PHASE3":11292,"PHASE4":11294,"NA":11296},{"trials":11280,"activeCount":101},[],{"trials":11282,"activeCount":101},[11283],{"nctId":11284,"briefTitle":11285,"status":158,"phases":11286,"primaryCompletion":7288,"completion":7288,"start":1656,"enrollment":31,"conditions":11287,"interventions":11289},"NCT01051479","A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer",[89],[11288],"Esophageal Cancer",[11277],{"trials":11291,"activeCount":101},[],{"trials":11293,"activeCount":101},[],{"trials":11295,"activeCount":101},[],{"trials":11297,"activeCount":101},[],{"intervention":11299,"totalTrials":228,"cells":11300},"Estradiol patch",{"EARLY_PHASE1":11301,"PHASE1":11303,"PHASE2":11315,"PHASE3":11317,"PHASE4":11319,"NA":11321},{"trials":11302,"activeCount":101},[],{"trials":11304,"activeCount":101},[11305],{"nctId":11306,"briefTitle":11307,"status":158,"phases":11308,"primaryCompletion":11309,"completion":11309,"start":11310,"enrollment":271,"conditions":11311,"interventions":11314},"NCT03681691","The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women",[89],"2021-07-19","2019-05-13",[11312,11313],"Diabetes Type 2","Dementia",[11299],{"trials":11316,"activeCount":101},[],{"trials":11318,"activeCount":101},[],{"trials":11320,"activeCount":101},[],{"trials":11322,"activeCount":101},[],{"intervention":11324,"totalTrials":228,"cells":11325},"Muscadine Grape Skin Extract",{"EARLY_PHASE1":11326,"PHASE1":11328,"PHASE2":11342,"PHASE3":11344,"PHASE4":11346,"NA":11348},{"trials":11327,"activeCount":101},[],{"trials":11329,"activeCount":101},[11330],{"nctId":11331,"briefTitle":11332,"status":158,"phases":11333,"primaryCompletion":11334,"completion":11335,"start":11336,"enrollment":1871,"conditions":11337,"interventions":11341},"NCT02583269","Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery",[89],"2017-12-19","2023-04-24","2016-03",[11338,11339,11340],"Advanced Malignant Neoplasm","Metastatic Malignant Neoplasm","Unresectable Malignant Neoplasm",[11324],{"trials":11343,"activeCount":101},[],{"trials":11345,"activeCount":101},[],{"trials":11347,"activeCount":101},[],{"trials":11349,"activeCount":101},[],{"intervention":8119,"totalTrials":228,"cells":11351},{"EARLY_PHASE1":11352,"PHASE1":11354,"PHASE2":11360,"PHASE3":11362,"PHASE4":11364,"NA":11366},{"trials":11353,"activeCount":101},[],{"trials":11355,"activeCount":101},[11356],{"nctId":8114,"briefTitle":8115,"status":158,"phases":11357,"primaryCompletion":7181,"completion":7181,"start":5454,"enrollment":1090,"conditions":11358,"interventions":11359},[89],[5116],[8119,167,6396],{"trials":11361,"activeCount":101},[],{"trials":11363,"activeCount":101},[],{"trials":11365,"activeCount":101},[],{"trials":11367,"activeCount":101},[],{"intervention":11369,"totalTrials":228,"cells":11370},"Lavender Oil",{"EARLY_PHASE1":11371,"PHASE1":11373,"PHASE2":11385,"PHASE3":11387,"PHASE4":11389,"NA":11391},{"trials":11372,"activeCount":101},[],{"trials":11374,"activeCount":101},[11375],{"nctId":11376,"briefTitle":11377,"status":158,"phases":11378,"primaryCompletion":11379,"completion":7629,"start":11380,"enrollment":245,"conditions":11381,"interventions":11383},"NCT03090750","Effects of Aromatherapy on Anxiety in Invasive Radiologic Procedure",[89],"2016-12-19","2015-07-16",[30,11382],"Anxiety Preoperative",[11369,11384],"Bergamot Oil",{"trials":11386,"activeCount":101},[],{"trials":11388,"activeCount":101},[],{"trials":11390,"activeCount":101},[],{"trials":11392,"activeCount":101},[],{"intervention":11384,"totalTrials":228,"cells":11394},{"EARLY_PHASE1":11395,"PHASE1":11397,"PHASE2":11403,"PHASE3":11405,"PHASE4":11407,"NA":11409},{"trials":11396,"activeCount":101},[],{"trials":11398,"activeCount":101},[11399],{"nctId":11376,"briefTitle":11377,"status":158,"phases":11400,"primaryCompletion":11379,"completion":7629,"start":11380,"enrollment":245,"conditions":11401,"interventions":11402},[89],[30,11382],[11369,11384],{"trials":11404,"activeCount":101},[],{"trials":11406,"activeCount":101},[],{"trials":11408,"activeCount":101},[],{"trials":11410,"activeCount":101},[],{"intervention":7349,"totalTrials":228,"cells":11412},{"EARLY_PHASE1":11413,"PHASE1":11415,"PHASE2":11421,"PHASE3":11423,"PHASE4":11425,"NA":11427},{"trials":11414,"activeCount":101},[],{"trials":11416,"activeCount":101},[11417],{"nctId":7344,"briefTitle":7345,"status":158,"phases":11418,"primaryCompletion":3616,"completion":1537,"start":1560,"enrollment":1733,"conditions":11419,"interventions":11420},[89],[33],[1565,7349],{"trials":11422,"activeCount":101},[],{"trials":11424,"activeCount":101},[],{"trials":11426,"activeCount":101},[],{"trials":11428,"activeCount":101},[],{"intervention":1874,"totalTrials":228,"cells":11430},{"EARLY_PHASE1":11431,"PHASE1":11433,"PHASE2":11439,"PHASE3":11441,"PHASE4":11443,"NA":11445},{"trials":11432,"activeCount":101},[],{"trials":11434,"activeCount":101},[11435],{"nctId":1866,"briefTitle":1867,"status":158,"phases":11436,"primaryCompletion":1454,"completion":1869,"start":1870,"enrollment":1871,"conditions":11437,"interventions":11438},[89],[19],[1565,1874,1662,1875,1876],{"trials":11440,"activeCount":101},[],{"trials":11442,"activeCount":101},[],{"trials":11444,"activeCount":101},[],{"trials":11446,"activeCount":101},[],{"intervention":1875,"totalTrials":228,"cells":11448},{"EARLY_PHASE1":11449,"PHASE1":11451,"PHASE2":11457,"PHASE3":11459,"PHASE4":11461,"NA":11463},{"trials":11450,"activeCount":101},[],{"trials":11452,"activeCount":101},[11453],{"nctId":1866,"briefTitle":1867,"status":158,"phases":11454,"primaryCompletion":1454,"completion":1869,"start":1870,"enrollment":1871,"conditions":11455,"interventions":11456},[89],[19],[1565,1874,1662,1875,1876],{"trials":11458,"activeCount":101},[],{"trials":11460,"activeCount":101},[],{"trials":11462,"activeCount":101},[],{"trials":11464,"activeCount":101},[],{"intervention":1574,"totalTrials":228,"cells":11466},{"EARLY_PHASE1":11467,"PHASE1":11469,"PHASE2":11475,"PHASE3":11477,"PHASE4":11479,"NA":11481},{"trials":11468,"activeCount":101},[],{"trials":11470,"activeCount":101},[11471],{"nctId":1567,"briefTitle":1568,"status":177,"phases":11472,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":101,"conditions":11473,"interventions":11474},[89],[19],[1574,1575,58,1576,1577,53],{"trials":11476,"activeCount":101},[],{"trials":11478,"activeCount":101},[],{"trials":11480,"activeCount":101},[],{"trials":11482,"activeCount":101},[],{"intervention":11484,"totalTrials":228,"cells":11485},"Amifampridine",{"EARLY_PHASE1":11486,"PHASE1":11488,"PHASE2":11500,"PHASE3":11502,"PHASE4":11504,"NA":11506},{"trials":11487,"activeCount":101},[],{"trials":11489,"activeCount":101},[11490],{"nctId":11491,"briefTitle":11492,"status":158,"phases":11493,"primaryCompletion":11494,"completion":11494,"start":11495,"enrollment":34,"conditions":11496,"interventions":11499},"NCT05769478","Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA",[89],"2024-10-29","2023-09-15",[11497,11498],"Botulism","Iatrogenic Botulism",[11484],{"trials":11501,"activeCount":101},[],{"trials":11503,"activeCount":101},[],{"trials":11505,"activeCount":101},[],{"trials":11507,"activeCount":101},[],{"intervention":11509,"totalTrials":228,"cells":11510},"nicotine replacement therapy",{"EARLY_PHASE1":11511,"PHASE1":11513,"PHASE2":11528,"PHASE3":11530,"PHASE4":11532,"NA":11534},{"trials":11512,"activeCount":101},[],{"trials":11514,"activeCount":101},[11515],{"nctId":11516,"briefTitle":11517,"status":158,"phases":11518,"primaryCompletion":11519,"completion":6841,"start":1375,"enrollment":1362,"conditions":11520,"interventions":11527},"NCT01457469","Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer",[89],"2012-01",[11521,7279,11522,11523,11524,11525,11526,3624,8788],"Limited Stage Small Cell Lung Cancer","Stage IA Non-small Cell Lung Cancer","Stage IB Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer",[11509],{"trials":11529,"activeCount":101},[],{"trials":11531,"activeCount":101},[],{"trials":11533,"activeCount":101},[],{"trials":11535,"activeCount":101},[],{"intervention":11537,"totalTrials":228,"cells":11538},"EUCRISA",{"EARLY_PHASE1":11539,"PHASE1":11541,"PHASE2":11552,"PHASE3":11554,"PHASE4":11556,"NA":11558},{"trials":11540,"activeCount":101},[],{"trials":11542,"activeCount":101},[11543],{"nctId":11544,"briefTitle":11545,"status":158,"phases":11546,"primaryCompletion":11547,"completion":11547,"start":11548,"enrollment":2080,"conditions":11549,"interventions":11551},"NCT03250663","Eucrisa for Atopic Dermatitis",[89],"2022-07-27","2017-10-01",[11550],"Mild to Moderate Atopic Dermatitis",[11537],{"trials":11553,"activeCount":101},[],{"trials":11555,"activeCount":101},[],{"trials":11557,"activeCount":101},[],{"trials":11559,"activeCount":101},[],{"intervention":11561,"totalTrials":228,"cells":11562},"sildenafil citrate",{"EARLY_PHASE1":11563,"PHASE1":11565,"PHASE2":11574,"PHASE3":11576,"PHASE4":11578,"NA":11580},{"trials":11564,"activeCount":101},[],{"trials":11566,"activeCount":101},[11567],{"nctId":11568,"briefTitle":11569,"status":158,"phases":11570,"primaryCompletion":11336,"completion":11336,"start":6243,"enrollment":1377,"conditions":11571,"interventions":11573},"NCT01950923","Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer",[89],[11572],"Kidney Tumor",[11561],{"trials":11575,"activeCount":101},[],{"trials":11577,"activeCount":101},[],{"trials":11579,"activeCount":101},[],{"trials":11581,"activeCount":101},[],{"intervention":11583,"totalTrials":228,"cells":11584},"siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401",{"EARLY_PHASE1":11585,"PHASE1":11587,"PHASE2":11609,"PHASE3":11611,"PHASE4":11613,"NA":11615},{"trials":11586,"activeCount":101},[],{"trials":11588,"activeCount":101},[11589],{"nctId":11590,"briefTitle":11591,"status":158,"phases":11592,"primaryCompletion":11593,"completion":11594,"start":11595,"enrollment":1608,"conditions":11596,"interventions":11608},"NCT03087591","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",[89],"2019-07-31","2020-12-08","2017-04-28",[11597,11598,11599,11600,11601,11602,7233,11603,11604,11605,11606,11607],"Metastatic Malignant Neoplasm in the Brain","Metastatic Solid Neoplasm","Recurrent Colorectal Carcinoma","Recurrent Pancreatic Carcinoma","Recurrent Solid Neoplasm","Stage IV Colorectal Cancer","Stage IVA Colorectal Cancer","Stage IVA Pancreatic Cancer","Stage IVB Colorectal Cancer","Stage IVB Pancreatic Cancer","Unresectable Solid Neoplasm",[11583],{"trials":11610,"activeCount":101},[],{"trials":11612,"activeCount":101},[],{"trials":11614,"activeCount":101},[],{"trials":11616,"activeCount":101},[],{"intervention":11618,"totalTrials":228,"cells":11619},"siRNA-transfected peripheral blood mononuclear cells APN401",{"EARLY_PHASE1":11620,"PHASE1":11622,"PHASE2":11638,"PHASE3":11640,"PHASE4":11642,"NA":11644},{"trials":11621,"activeCount":101},[],{"trials":11623,"activeCount":101},[11624],{"nctId":11625,"briefTitle":11626,"status":158,"phases":11627,"primaryCompletion":1423,"completion":1423,"start":1607,"enrollment":2055,"conditions":11628,"interventions":11637},"NCT02166255","APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",[89],[11629,7232,11630,7242,11631,11632,11633,11634,11635,7233,11636,1647],"Recurrent Melanoma","Recurrent Renal Cell Cancer","Stage III Renal Cell Cancer","Stage IIIA Melanoma","Stage IIIB Melanoma","Stage IIIC Melanoma","Stage IV Melanoma","Stage IV Renal Cell Cancer",[11618],{"trials":11639,"activeCount":101},[],{"trials":11641,"activeCount":101},[],{"trials":11643,"activeCount":101},[],{"trials":11645,"activeCount":101},[],{"intervention":8001,"totalTrials":228,"cells":11647},{"EARLY_PHASE1":11648,"PHASE1":11650,"PHASE2":11656,"PHASE3":11658,"PHASE4":11660,"NA":11662},{"trials":11649,"activeCount":101},[],{"trials":11651,"activeCount":101},[11652],{"nctId":7993,"briefTitle":7994,"status":177,"phases":11653,"primaryCompletion":2281,"completion":179,"start":1032,"enrollment":101,"conditions":11654,"interventions":11655},[89],[7997,7998,7999],[8001,8002],{"trials":11657,"activeCount":101},[],{"trials":11659,"activeCount":101},[],{"trials":11661,"activeCount":101},[],{"trials":11663,"activeCount":101},[],{"intervention":7621,"totalTrials":228,"cells":11665},{"EARLY_PHASE1":11666,"PHASE1":11668,"PHASE2":11674,"PHASE3":11676,"PHASE4":11678,"NA":11680},{"trials":11667,"activeCount":101},[],{"trials":11669,"activeCount":101},[11670],{"nctId":7606,"briefTitle":7607,"status":143,"phases":11671,"primaryCompletion":2488,"completion":1869,"start":7609,"enrollment":1850,"conditions":11672,"interventions":11673},[89],[7611,7612,7613,7614,7615,7616,7617,7618,7619],[3626,7621,7622],{"trials":11675,"activeCount":101},[],{"trials":11677,"activeCount":101},[],{"trials":11679,"activeCount":101},[],{"trials":11681,"activeCount":101},[],{"intervention":11683,"totalTrials":228,"cells":11684},"Corticosteroid",{"EARLY_PHASE1":11685,"PHASE1":11687,"PHASE2":11699,"PHASE3":11701,"PHASE4":11703,"NA":11705},{"trials":11686,"activeCount":101},[],{"trials":11688,"activeCount":101},[11689],{"nctId":11690,"briefTitle":11691,"status":158,"phases":11692,"primaryCompletion":11693,"completion":11693,"start":11694,"enrollment":17,"conditions":11695,"interventions":11697},"NCT05868577","Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis",[89],"2024-09-18","2023-10-18",[11696],"Chronic Plantar Fasciitis",[11683,11698],"Local anesthetic (LA) with Saline",{"trials":11700,"activeCount":101},[],{"trials":11702,"activeCount":101},[],{"trials":11704,"activeCount":101},[],{"trials":11706,"activeCount":101},[],{"intervention":11698,"totalTrials":228,"cells":11708},{"EARLY_PHASE1":11709,"PHASE1":11711,"PHASE2":11717,"PHASE3":11719,"PHASE4":11721,"NA":11723},{"trials":11710,"activeCount":101},[],{"trials":11712,"activeCount":101},[11713],{"nctId":11690,"briefTitle":11691,"status":158,"phases":11714,"primaryCompletion":11693,"completion":11693,"start":11694,"enrollment":17,"conditions":11715,"interventions":11716},[89],[11696],[11683,11698],{"trials":11718,"activeCount":101},[],{"trials":11720,"activeCount":101},[],{"trials":11722,"activeCount":101},[],{"trials":11724,"activeCount":101},[],{"intervention":11726,"totalTrials":228,"cells":11727},"Fingolimod",{"EARLY_PHASE1":11728,"PHASE1":11744,"PHASE2":11746,"PHASE3":11748,"PHASE4":11750,"NA":11752},{"trials":11729,"activeCount":101},[11730],{"nctId":11731,"briefTitle":11732,"status":158,"phases":11733,"primaryCompletion":6346,"completion":11734,"start":11735,"enrollment":2080,"conditions":11736,"interventions":11742},"NCT04088630","Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage",[88],"2024-06-05","2020-08-07",[11737,11738,11739,11740,11741],"Intracerebral Hemorrhage","Cerebral Edema","Stroke Hemorrhagic","Intracerebral Hemorrhage, Hypertensive","Intracerebral Hemorrhage Intraparenchymal",[11726,11743],"Open-label Fingolimod",{"trials":11745,"activeCount":101},[],{"trials":11747,"activeCount":101},[],{"trials":11749,"activeCount":101},[],{"trials":11751,"activeCount":101},[],{"trials":11753,"activeCount":101},[],{"intervention":11743,"totalTrials":228,"cells":11755},{"EARLY_PHASE1":11756,"PHASE1":11762,"PHASE2":11764,"PHASE3":11766,"PHASE4":11768,"NA":11770},{"trials":11757,"activeCount":101},[11758],{"nctId":11731,"briefTitle":11732,"status":158,"phases":11759,"primaryCompletion":6346,"completion":11734,"start":11735,"enrollment":2080,"conditions":11760,"interventions":11761},[88],[11737,11738,11739,11740,11741],[11726,11743],{"trials":11763,"activeCount":101},[],{"trials":11765,"activeCount":101},[],{"trials":11767,"activeCount":101},[],{"trials":11769,"activeCount":101},[],{"trials":11771,"activeCount":101},[],{"intervention":11773,"totalTrials":228,"cells":11774},"Nicotine Replacement Patch",{"EARLY_PHASE1":11775,"PHASE1":11787,"PHASE2":11789,"PHASE3":11791,"PHASE4":11793,"NA":11795},{"trials":11776,"activeCount":101},[11777],{"nctId":11778,"briefTitle":11779,"status":158,"phases":11780,"primaryCompletion":11781,"completion":11782,"start":11783,"enrollment":11784,"conditions":11785,"interventions":11786},"NCT01434342","Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients",[88],"2014-06-01","2015-01-01","2011-10-01",146,[33,8788,19,7508,348],[11773],{"trials":11788,"activeCount":101},[],{"trials":11790,"activeCount":101},[],{"trials":11792,"activeCount":101},[],{"trials":11794,"activeCount":101},[],{"trials":11796,"activeCount":101},[],{"intervention":11798,"totalTrials":228,"cells":11799},"Dobutamine",{"EARLY_PHASE1":11800,"PHASE1":11812,"PHASE2":11814,"PHASE3":11816,"PHASE4":11818,"NA":11820},{"trials":11801,"activeCount":101},[11802],{"nctId":11803,"briefTitle":11804,"status":143,"phases":11805,"primaryCompletion":3584,"completion":10787,"start":7885,"enrollment":1596,"conditions":11806,"interventions":11810},"NCT00763035","Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)",[88],[3907,11807,11808,11809],"Asthma","Chronic Obstructive Pulmonary Disease (COPD)","Angina",[11811,11798],"Regadenoson",{"trials":11813,"activeCount":101},[],{"trials":11815,"activeCount":101},[],{"trials":11817,"activeCount":101},[],{"trials":11819,"activeCount":101},[],{"trials":11821,"activeCount":101},[],{"intervention":11823,"totalTrials":228,"cells":11824},"Allogeneic Young Plasma",{"EARLY_PHASE1":11825,"PHASE1":11836,"PHASE2":11838,"PHASE3":11840,"PHASE4":11842,"NA":11844},{"trials":11826,"activeCount":101},[11827],{"nctId":11828,"briefTitle":11829,"status":177,"phases":11830,"primaryCompletion":11831,"completion":11831,"start":11832,"enrollment":101,"conditions":11833,"interventions":11835},"NCT04241159","Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults",[88],"2020-08","2020-05",[11834,5850],"Frailty Syndrome",[11823],{"trials":11837,"activeCount":101},[],{"trials":11839,"activeCount":101},[],{"trials":11841,"activeCount":101},[],{"trials":11843,"activeCount":101},[],{"trials":11845,"activeCount":101},[],{"intervention":11847,"totalTrials":228,"cells":11848},"Otezla - Standard Care",{"EARLY_PHASE1":11849,"PHASE1":11858,"PHASE2":11860,"PHASE3":11862,"PHASE4":11864,"NA":11866},{"trials":11850,"activeCount":101},[11851],{"nctId":11852,"briefTitle":11853,"status":177,"phases":11854,"primaryCompletion":2222,"completion":9671,"start":11855,"enrollment":101,"conditions":11856,"interventions":11857},"NCT05601492","Adherence to Otezla",[88],"2025-06",[3741],[11847],{"trials":11859,"activeCount":101},[],{"trials":11861,"activeCount":101},[],{"trials":11863,"activeCount":101},[],{"trials":11865,"activeCount":101},[],{"trials":11867,"activeCount":101},[],{"intervention":11869,"totalTrials":228,"cells":11870},"Amnion Membrane Powder",{"EARLY_PHASE1":11871,"PHASE1":11884,"PHASE2":11886,"PHASE3":11888,"PHASE4":11890,"NA":11892},{"trials":11872,"activeCount":101},[11873],{"nctId":11874,"briefTitle":11875,"status":158,"phases":11876,"primaryCompletion":11877,"completion":11877,"start":11878,"enrollment":136,"conditions":11879,"interventions":11883},"NCT03754218","Amnion Wound Covering for Enhanced Wound Healing",[88],"2023-11-22","2019-12-01",[11880,11881,11882],"Burns","Wound of Skin","Skin Wound",[11869],{"trials":11885,"activeCount":101},[],{"trials":11887,"activeCount":101},[],{"trials":11889,"activeCount":101},[],{"trials":11891,"activeCount":101},[],{"trials":11893,"activeCount":101},[],{"intervention":11895,"totalTrials":228,"cells":11896},"Ketoconazole",{"EARLY_PHASE1":11897,"PHASE1":11914,"PHASE2":11916,"PHASE3":11918,"PHASE4":11920,"NA":11922},{"trials":11898,"activeCount":101},[11899],{"nctId":11900,"briefTitle":11901,"status":143,"phases":11902,"primaryCompletion":11903,"completion":11903,"start":11904,"enrollment":1548,"conditions":11905,"interventions":11913},"NCT03796273","Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases",[88],"2022-10-23","2019-03-13",[11906,11907,11908,9715,11909,11910,11911,11912],"Anatomic Stage IV Breast Cancer AJCC v8","Astrocytoma","Breast Carcinoma Metastatic in the Brain","Invasive Breast Carcinoma","Oligodendroglioma","Prognostic Stage IV Breast Cancer AJCC v8","Recurrent Glioma",[11895],{"trials":11915,"activeCount":101},[],{"trials":11917,"activeCount":101},[],{"trials":11919,"activeCount":101},[],{"trials":11921,"activeCount":101},[],{"trials":11923,"activeCount":101},[],{"intervention":11925,"totalTrials":228,"cells":11926},"fluocinonide 0.05% ointment",{"EARLY_PHASE1":11927,"PHASE1":11935,"PHASE2":11937,"PHASE3":11939,"PHASE4":11941,"NA":11943},{"trials":11928,"activeCount":101},[11929],{"nctId":11930,"briefTitle":11931,"status":158,"phases":11932,"primaryCompletion":11336,"completion":6732,"start":4182,"enrollment":834,"conditions":11933,"interventions":11934},"NCT01802580","Using an Internet Study to Improve Adherence for Psoriasis Patients",[88],[3741],[11925],{"trials":11936,"activeCount":101},[],{"trials":11938,"activeCount":101},[],{"trials":11940,"activeCount":101},[],{"trials":11942,"activeCount":101},[],{"trials":11944,"activeCount":101},[],{"intervention":11946,"totalTrials":228,"cells":11947},"Bupropion Hydrochloride",{"EARLY_PHASE1":11948,"PHASE1":11965,"PHASE2":11967,"PHASE3":11969,"PHASE4":11971,"NA":11973},{"trials":11949,"activeCount":101},[11950],{"nctId":11951,"briefTitle":11952,"status":143,"phases":11953,"primaryCompletion":11954,"completion":11955,"start":2487,"enrollment":1946,"conditions":11956,"interventions":11962},"NCT02582008","Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy",[88],"2018-10-06","2019-09-06",[11957,2679,11958,11959,11960,1707,11961],"Current Smoker","Hypopharyngeal Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma","Nasopharyngeal Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[11946,11963,11964],"Nicotine Replacement","Varenicline",{"trials":11966,"activeCount":101},[],{"trials":11968,"activeCount":101},[],{"trials":11970,"activeCount":101},[],{"trials":11972,"activeCount":101},[],{"trials":11974,"activeCount":101},[],{"intervention":11963,"totalTrials":228,"cells":11976},{"EARLY_PHASE1":11977,"PHASE1":11983,"PHASE2":11985,"PHASE3":11987,"PHASE4":11989,"NA":11991},{"trials":11978,"activeCount":101},[11979],{"nctId":11951,"briefTitle":11952,"status":143,"phases":11980,"primaryCompletion":11954,"completion":11955,"start":2487,"enrollment":1946,"conditions":11981,"interventions":11982},[88],[11957,2679,11958,11959,11960,1707,11961],[11946,11963,11964],{"trials":11984,"activeCount":101},[],{"trials":11986,"activeCount":101},[],{"trials":11988,"activeCount":101},[],{"trials":11990,"activeCount":101},[],{"trials":11992,"activeCount":101},[],{"intervention":11964,"totalTrials":228,"cells":11994},{"EARLY_PHASE1":11995,"PHASE1":12001,"PHASE2":12003,"PHASE3":12005,"PHASE4":12007,"NA":12009},{"trials":11996,"activeCount":101},[11997],{"nctId":11951,"briefTitle":11952,"status":143,"phases":11998,"primaryCompletion":11954,"completion":11955,"start":2487,"enrollment":1946,"conditions":11999,"interventions":12000},[88],[11957,2679,11958,11959,11960,1707,11961],[11946,11963,11964],{"trials":12002,"activeCount":101},[],{"trials":12004,"activeCount":101},[],{"trials":12006,"activeCount":101},[],{"trials":12008,"activeCount":101},[],{"trials":12010,"activeCount":101},[],{"intervention":12012,"totalTrials":228,"cells":12013},"Simvastatin",{"EARLY_PHASE1":12014,"PHASE1":12025,"PHASE2":12027,"PHASE3":12029,"PHASE4":12031,"NA":12033},{"trials":12015,"activeCount":101},[12016],{"nctId":12017,"briefTitle":12018,"status":177,"phases":12019,"primaryCompletion":12020,"completion":12020,"start":4194,"enrollment":101,"conditions":12021,"interventions":12024},"NCT02971410","Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma",[88],"2021-11",[12022,12023],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[12012],{"trials":12026,"activeCount":101},[],{"trials":12028,"activeCount":101},[],{"trials":12030,"activeCount":101},[],{"trials":12032,"activeCount":101},[],{"trials":12034,"activeCount":101},[],{"intervention":7597,"totalTrials":228,"cells":12036},{"EARLY_PHASE1":12037,"PHASE1":12043,"PHASE2":12045,"PHASE3":12047,"PHASE4":12049,"NA":12051},{"trials":12038,"activeCount":101},[12039],{"nctId":7591,"briefTitle":7592,"status":158,"phases":12040,"primaryCompletion":7594,"completion":7594,"start":1870,"enrollment":1871,"conditions":12041,"interventions":12042},[88],[36],[3626,7597,7598],{"trials":12044,"activeCount":101},[],{"trials":12046,"activeCount":101},[],{"trials":12048,"activeCount":101},[],{"trials":12050,"activeCount":101},[],{"trials":12052,"activeCount":101},[],{"intervention":12054,"totalTrials":228,"cells":12055},"Calcipotriol",{"EARLY_PHASE1":12056,"PHASE1":12067,"PHASE2":12069,"PHASE3":12071,"PHASE4":12073,"NA":12075},{"trials":12057,"activeCount":101},[12058],{"nctId":12059,"briefTitle":12060,"status":177,"phases":12061,"primaryCompletion":12062,"completion":2339,"start":12063,"enrollment":101,"conditions":12064,"interventions":12065},"NCT05416320","Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)",[88],"2023-11","2023-08",[3571],[12054,12066],"Subject's already prescribed drug",{"trials":12068,"activeCount":101},[],{"trials":12070,"activeCount":101},[],{"trials":12072,"activeCount":101},[],{"trials":12074,"activeCount":101},[],{"trials":12076,"activeCount":101},[],{"intervention":12066,"totalTrials":228,"cells":12078},{"EARLY_PHASE1":12079,"PHASE1":12085,"PHASE2":12087,"PHASE3":12089,"PHASE4":12091,"NA":12093},{"trials":12080,"activeCount":101},[12081],{"nctId":12059,"briefTitle":12060,"status":177,"phases":12082,"primaryCompletion":12062,"completion":2339,"start":12063,"enrollment":101,"conditions":12083,"interventions":12084},[88],[3571],[12054,12066],{"trials":12086,"activeCount":101},[],{"trials":12088,"activeCount":101},[],{"trials":12090,"activeCount":101},[],{"trials":12092,"activeCount":101},[],{"trials":12094,"activeCount":101},[],{"intervention":12096,"totalTrials":228,"cells":12097},"Biotene OralBalance® gel",{"EARLY_PHASE1":12098,"PHASE1":12107,"PHASE2":12109,"PHASE3":12111,"PHASE4":12113,"NA":12115},{"trials":12099,"activeCount":101},[12100],{"nctId":12101,"briefTitle":12102,"status":158,"phases":12103,"primaryCompletion":11519,"completion":6426,"start":7609,"enrollment":17,"conditions":12104,"interventions":12106},"NCT01314742","Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates",[88],[12105],"Ventilator-associated Pneumonia",[12096],{"trials":12108,"activeCount":101},[],{"trials":12110,"activeCount":101},[],{"trials":12112,"activeCount":101},[],{"trials":12114,"activeCount":101},[],{"trials":12116,"activeCount":101},[],{"intervention":12118,"totalTrials":228,"cells":12119},"Fluoride varnish",{"EARLY_PHASE1":12120,"PHASE1":12130,"PHASE2":12132,"PHASE3":12134,"PHASE4":12136,"NA":12138},{"trials":12121,"activeCount":101},[12122],{"nctId":12123,"briefTitle":12124,"status":158,"phases":12125,"primaryCompletion":12126,"completion":12126,"start":591,"enrollment":4125,"conditions":12127,"interventions":12129},"NCT07218068","Intensive Preventative Dental Program Pilot Study",[88],"2024-07-10",[12128],"Dental Diseases",[12118],{"trials":12131,"activeCount":101},[],{"trials":12133,"activeCount":101},[],{"trials":12135,"activeCount":101},[],{"trials":12137,"activeCount":101},[],{"trials":12139,"activeCount":101},[],{"intervention":12141,"totalTrials":228,"cells":12142},"[F-18] fluorinated dihydrotestosterone",{"EARLY_PHASE1":12143,"PHASE1":12151,"PHASE2":12153,"PHASE3":12155,"PHASE4":12157,"NA":12159},{"trials":12144,"activeCount":101},[12145],{"nctId":12146,"briefTitle":12147,"status":143,"phases":12148,"primaryCompletion":1869,"completion":1869,"start":4315,"enrollment":136,"conditions":12149,"interventions":12150},"NCT01724619","Update and Biodistribution of [F-18]FMDHT pET\u002FCT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT",[88],[348],[12141],{"trials":12152,"activeCount":101},[],{"trials":12154,"activeCount":101},[],{"trials":12156,"activeCount":101},[],{"trials":12158,"activeCount":101},[],{"trials":12160,"activeCount":101},[],{"intervention":12162,"totalTrials":228,"cells":12163},"Ergocalciferol",{"EARLY_PHASE1":12164,"PHASE1":12174,"PHASE2":12176,"PHASE3":12178,"PHASE4":12180,"NA":12182},{"trials":12165,"activeCount":101},[12166],{"nctId":12167,"briefTitle":12168,"status":158,"phases":12169,"primaryCompletion":12170,"completion":12171,"start":223,"enrollment":10,"conditions":12172,"interventions":12173},"NCT03747523","Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels",[88],"2019-12-20","2020-01-27",[12162],[12162],{"trials":12175,"activeCount":101},[],{"trials":12177,"activeCount":101},[],{"trials":12179,"activeCount":101},[],{"trials":12181,"activeCount":101},[],{"trials":12183,"activeCount":101},[],{"intervention":12185,"totalTrials":228,"cells":12186},"Initial Bolus",{"EARLY_PHASE1":12187,"PHASE1":12200,"PHASE2":12202,"PHASE3":12204,"PHASE4":12206,"NA":12208},{"trials":12188,"activeCount":101},[12189],{"nctId":12190,"briefTitle":12191,"status":158,"phases":12192,"primaryCompletion":12193,"completion":12193,"start":12194,"enrollment":549,"conditions":12195,"interventions":12198},"NCT02991404","Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty",[88],"2017-11-15","2017-02-17",[12196,4523,12197],"Total Knee Arthroplasty","Adductor Canal Block",[12185,12199],"Continuous",{"trials":12201,"activeCount":101},[],{"trials":12203,"activeCount":101},[],{"trials":12205,"activeCount":101},[],{"trials":12207,"activeCount":101},[],{"trials":12209,"activeCount":101},[],{"intervention":12211,"totalTrials":228,"cells":12212},"Vitamin A Compound",{"EARLY_PHASE1":12213,"PHASE1":12227,"PHASE2":12229,"PHASE3":12231,"PHASE4":12233,"NA":12235},{"trials":12214,"activeCount":101},[12215],{"nctId":12216,"briefTitle":12217,"status":143,"phases":12218,"primaryCompletion":8275,"completion":8275,"start":12219,"enrollment":37,"conditions":12220,"interventions":12226},"NCT03870529","High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer",[88],"2019-08-19",[1669,12221,12222,12223,12224,12225],"Stage I Lung Cancer","Stage Ib Lung Carcinoma","Stage IA Lung Carcinoma AJCC V7","Stage IIA Lung Carcinoma","Stage IIIA Lung Carcinoma",[12211],{"trials":12228,"activeCount":101},[],{"trials":12230,"activeCount":101},[],{"trials":12232,"activeCount":101},[],{"trials":12234,"activeCount":101},[],{"trials":12236,"activeCount":101},[],{"intervention":12238,"totalTrials":228,"cells":12239},"Adipose Derived",{"EARLY_PHASE1":12240,"PHASE1":12249,"PHASE2":12251,"PHASE3":12253,"PHASE4":12255,"NA":12257},{"trials":12241,"activeCount":101},[12242],{"nctId":12243,"briefTitle":12244,"status":177,"phases":12245,"primaryCompletion":12246,"completion":12246,"start":9671,"enrollment":101,"conditions":12247,"interventions":12248},"NCT05515523","Stromal Vascular Fraction (SVF) for Knee Post-Trauma Osteoarthritis (PTOA)",[88],"2027-11",[3801],[12238],{"trials":12250,"activeCount":101},[],{"trials":12252,"activeCount":101},[],{"trials":12254,"activeCount":101},[],{"trials":12256,"activeCount":101},[],{"trials":12258,"activeCount":101},[],{"intervention":1443,"totalTrials":228,"cells":12260},{"EARLY_PHASE1":12261,"PHASE1":12267,"PHASE2":12269,"PHASE3":12271,"PHASE4":12273,"NA":12275},{"trials":12262,"activeCount":101},[12263],{"nctId":1435,"briefTitle":1436,"status":158,"phases":12264,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":37,"conditions":12265,"interventions":12266},[88],[1441],[351,1443,1444,1038],{"trials":12268,"activeCount":101},[],{"trials":12270,"activeCount":101},[],{"trials":12272,"activeCount":101},[],{"trials":12274,"activeCount":101},[],{"trials":12276,"activeCount":101},[],{"intervention":1444,"totalTrials":228,"cells":12278},{"EARLY_PHASE1":12279,"PHASE1":12285,"PHASE2":12287,"PHASE3":12289,"PHASE4":12291,"NA":12293},{"trials":12280,"activeCount":101},[12281],{"nctId":1435,"briefTitle":1436,"status":158,"phases":12282,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":37,"conditions":12283,"interventions":12284},[88],[1441],[351,1443,1444,1038],{"trials":12286,"activeCount":101},[],{"trials":12288,"activeCount":101},[],{"trials":12290,"activeCount":101},[],{"trials":12292,"activeCount":101},[],{"trials":12294,"activeCount":101},[],{"intervention":12296,"totalTrials":228,"cells":12297},"Local infiltration of bupivacaine",{"EARLY_PHASE1":12298,"PHASE1":12309,"PHASE2":12311,"PHASE3":12313,"PHASE4":12315,"NA":12317},{"trials":12299,"activeCount":101},[12300],{"nctId":12301,"briefTitle":12302,"status":177,"phases":12303,"primaryCompletion":12304,"completion":12304,"start":12305,"enrollment":101,"conditions":12306,"interventions":12307},"NCT03388814","Speeding Recovery From Pain and Opioid Use",[88],"2020-06","2018-11",[4523,19,347,5233],[12296,12308],"Pectoralis Nerve block",{"trials":12310,"activeCount":101},[],{"trials":12312,"activeCount":101},[],{"trials":12314,"activeCount":101},[],{"trials":12316,"activeCount":101},[],{"trials":12318,"activeCount":101},[],{"intervention":12308,"totalTrials":228,"cells":12320},{"EARLY_PHASE1":12321,"PHASE1":12327,"PHASE2":12329,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12322,"activeCount":101},[12323],{"nctId":12301,"briefTitle":12302,"status":177,"phases":12324,"primaryCompletion":12304,"completion":12304,"start":12305,"enrollment":101,"conditions":12325,"interventions":12326},[88],[4523,19,347,5233],[12296,12308],{"trials":12328,"activeCount":101},[],{"trials":12330,"activeCount":101},[],{"trials":12332,"activeCount":101},[],{"trials":12334,"activeCount":101},[],{"trials":12336,"activeCount":101},[],{"intervention":167,"totalTrials":258,"cells":12338},{"EARLY_PHASE1":12339,"PHASE1":12349,"PHASE2":12359,"PHASE3":12361,"PHASE4":12363,"NA":12381},{"trials":12340,"activeCount":101},[12341],{"nctId":12342,"briefTitle":12343,"status":158,"phases":12344,"primaryCompletion":12193,"completion":12193,"start":12345,"enrollment":37,"conditions":12346,"interventions":12348},"NCT03059498","PECS Block: Plasma Bupivacaine Level",[88],"2017-06-06",[12347],"Nerve Blocks",[167],{"trials":12350,"activeCount":101},[12351,12355],{"nctId":8114,"briefTitle":8115,"status":158,"phases":12352,"primaryCompletion":7181,"completion":7181,"start":5454,"enrollment":1090,"conditions":12353,"interventions":12354},[89],[5116],[8119,167,6396],{"nctId":156,"briefTitle":157,"status":158,"phases":12356,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":12357,"interventions":12358},[89],[164,165],[135,167],{"trials":12360,"activeCount":101},[],{"trials":12362,"activeCount":101},[],{"trials":12364,"activeCount":101},[12365,12369,12373,12377],{"nctId":1018,"briefTitle":1019,"status":158,"phases":12366,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":12367,"interventions":12368},[92],[1025],[1027,167,993],{"nctId":5111,"briefTitle":5112,"status":143,"phases":12370,"primaryCompletion":5114,"completion":5114,"start":1888,"enrollment":1586,"conditions":12371,"interventions":12372},[92],[5116],[5098,167],{"nctId":210,"briefTitle":211,"status":158,"phases":12374,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":12375,"interventions":12376},[92],[217],[167,152],{"nctId":1029,"briefTitle":1030,"status":158,"phases":12378,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":12379,"interventions":12380},[92],[1036],[1027,167,993,1038],{"trials":12382,"activeCount":101},[12383],{"nctId":12384,"briefTitle":12385,"status":177,"phases":12386,"primaryCompletion":12387,"completion":12387,"start":10266,"enrollment":101,"conditions":12388,"interventions":12391},"NCT02181205","Sphenopalatine Ganglion Block for Post-Dural Puncture Headache",[93],"2016-12-31",[12389,12390],"Postdural Puncture Headache","Sphenopalatine Ganglion Block",[12392],"bupivacaine",{"intervention":1738,"totalTrials":1850,"cells":12394},{"EARLY_PHASE1":12395,"PHASE1":12397,"PHASE2":12399,"PHASE3":12417,"PHASE4":12419,"NA":12421},{"trials":12396,"activeCount":101},[],{"trials":12398,"activeCount":101},[],{"trials":12400,"activeCount":101},[12401,12405,12409,12413],{"nctId":1884,"briefTitle":1885,"status":158,"phases":12402,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":1890,"conditions":12403,"interventions":12404},[90],[1892,1893],[1738,1895,1662],{"nctId":7495,"briefTitle":7496,"status":158,"phases":12406,"primaryCompletion":7498,"completion":5396,"start":7499,"enrollment":834,"conditions":12407,"interventions":12408},[89,90],[33],[1738,1895],{"nctId":3613,"briefTitle":3614,"status":158,"phases":12410,"primaryCompletion":3596,"completion":3596,"start":3616,"enrollment":1733,"conditions":12411,"interventions":12412},[90],[3618,3619,3620,3621,3622,1735,3623,3624,1736],[1738,3600,3626,3627,3628,1565],{"nctId":2682,"briefTitle":2683,"status":158,"phases":12414,"primaryCompletion":2434,"completion":2434,"start":2685,"enrollment":37,"conditions":12415,"interventions":12416},[90],[36],[2688,1738,1565,2689],{"trials":12418,"activeCount":101},[],{"trials":12420,"activeCount":101},[],{"trials":12422,"activeCount":101},[12423],{"nctId":1728,"briefTitle":1729,"status":158,"phases":12424,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":12425,"interventions":12426},[],[1735,1736],[1738,1564],{"intervention":12428,"totalTrials":215,"cells":12429},"trivalent influenza vaccine",{"EARLY_PHASE1":12430,"PHASE1":12432,"PHASE2":12441,"PHASE3":12443,"PHASE4":12445,"NA":12447},{"trials":12431,"activeCount":101},[],{"trials":12433,"activeCount":101},[12434],{"nctId":12435,"briefTitle":12436,"status":158,"phases":12437,"primaryCompletion":10266,"completion":10266,"start":7181,"enrollment":2080,"conditions":12438,"interventions":12440},"NCT01941758","High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors",[89],[12439],"Central Nervous System Neoplasm",[12428],{"trials":12442,"activeCount":101},[],{"trials":12444,"activeCount":101},[],{"trials":12446,"activeCount":101},[],{"trials":12448,"activeCount":101},[12449,12461],{"nctId":12450,"briefTitle":12451,"status":158,"phases":12452,"primaryCompletion":12453,"completion":12454,"start":1423,"enrollment":12455,"conditions":12456,"interventions":12457},"NCT02747407","Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors",[],"2020-01","2021-09-09",55,[11907,9715,11910],[12458,12459,12460],"Hepatitis A Vaccine","Tetanus Toxoid Vaccine","Trivalent Influenza Vaccine",{"nctId":12462,"briefTitle":12463,"status":158,"phases":12464,"primaryCompletion":6426,"completion":6426,"start":5846,"enrollment":20,"conditions":12465,"interventions":12466},"NCT01474174","Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors",[],[12439],[12428],{"intervention":7429,"totalTrials":215,"cells":12468},{"EARLY_PHASE1":12469,"PHASE1":12471,"PHASE2":12477,"PHASE3":12479,"PHASE4":12481,"NA":12483},{"trials":12470,"activeCount":101},[],{"trials":12472,"activeCount":101},[12473],{"nctId":7416,"briefTitle":7417,"status":158,"phases":12474,"primaryCompletion":4776,"completion":4776,"start":4089,"enrollment":1946,"conditions":12475,"interventions":12476},[89],[7420,7421,7422,7423,7424,7425,7426,7427],[3626,7235,2689,7429],{"trials":12478,"activeCount":101},[],{"trials":12480,"activeCount":101},[],{"trials":12482,"activeCount":101},[],{"trials":12484,"activeCount":101},[12485,12498],{"nctId":12486,"briefTitle":12487,"status":158,"phases":12488,"primaryCompletion":12489,"completion":12489,"start":12490,"enrollment":12491,"conditions":12492,"interventions":12496},"NCT01407770","Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial\u002FEthnic Groups of Patients With Breast Cancer",[],"2014-08-26","2011-09-20",1000,[19,12493,551,25,12494,3967,12495],"Cognitive Ability, General","Psychosocial Deprivation","Skin Abnormalities",[12497,7429],"DNA analysis",{"nctId":12499,"briefTitle":12500,"status":143,"phases":12501,"primaryCompletion":4776,"completion":10396,"start":5525,"enrollment":97,"conditions":12502,"interventions":12503},"NCT00899197","Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer",[],[19],[12504,7429,7622],"tamoxifen citrate",{"intervention":7622,"totalTrials":215,"cells":12506},{"EARLY_PHASE1":12507,"PHASE1":12509,"PHASE2":12515,"PHASE3":12517,"PHASE4":12519,"NA":12521},{"trials":12508,"activeCount":101},[],{"trials":12510,"activeCount":101},[12511],{"nctId":7606,"briefTitle":7607,"status":143,"phases":12512,"primaryCompletion":2488,"completion":1869,"start":7609,"enrollment":1850,"conditions":12513,"interventions":12514},[89],[7611,7612,7613,7614,7615,7616,7617,7618,7619],[3626,7621,7622],{"trials":12516,"activeCount":101},[],{"trials":12518,"activeCount":101},[],{"trials":12520,"activeCount":101},[],{"trials":12522,"activeCount":101},[12523,12527],{"nctId":12499,"briefTitle":12500,"status":143,"phases":12524,"primaryCompletion":4776,"completion":10396,"start":5525,"enrollment":97,"conditions":12525,"interventions":12526},[],[19],[12504,7429,7622],{"nctId":12528,"briefTitle":12529,"status":158,"phases":12530,"primaryCompletion":3820,"completion":3820,"start":12531,"enrollment":1377,"conditions":12532,"interventions":12533},"NCT00896857","Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer",[],"2004-04",[19],[12534,12535,7622,12536,7598],"RNA analysis","polymerase chain reaction","reverse transcriptase-polymerase chain reaction",{"intervention":12535,"totalTrials":97,"cells":12538},{"EARLY_PHASE1":12539,"PHASE1":12541,"PHASE2":12543,"PHASE3":12545,"PHASE4":12547,"NA":12549},{"trials":12540,"activeCount":101},[],{"trials":12542,"activeCount":101},[],{"trials":12544,"activeCount":101},[],{"trials":12546,"activeCount":101},[],{"trials":12548,"activeCount":101},[],{"trials":12550,"activeCount":101},[12551,12559],{"nctId":12552,"briefTitle":12553,"status":177,"phases":12554,"enrollment":101,"conditions":12555,"interventions":12557},"NCT00607802","Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer",[93],[1647,12556],"Unspecified Childhood Solid Tumor, Protocol Specific",[12558,12535],"leukocyte therapy",{"nctId":12528,"briefTitle":12529,"status":158,"phases":12560,"primaryCompletion":3820,"completion":3820,"start":12531,"enrollment":1377,"conditions":12561,"interventions":12562},[],[19],[12534,12535,7622,12536,7598],{"intervention":11811,"totalTrials":97,"cells":12564},{"EARLY_PHASE1":12565,"PHASE1":12571,"PHASE2":12573,"PHASE3":12575,"PHASE4":12577,"NA":12579},{"trials":12566,"activeCount":101},[12567],{"nctId":11803,"briefTitle":11804,"status":143,"phases":12568,"primaryCompletion":3584,"completion":10787,"start":7885,"enrollment":1596,"conditions":12569,"interventions":12570},[88],[3907,11807,11808,11809],[11811,11798],{"trials":12572,"activeCount":101},[],{"trials":12574,"activeCount":101},[],{"trials":12576,"activeCount":101},[],{"trials":12578,"activeCount":101},[],{"trials":12580,"activeCount":101},[12581],{"nctId":12582,"briefTitle":12583,"status":158,"phases":12584,"primaryCompletion":12585,"completion":12585,"start":422,"enrollment":204,"conditions":12586,"interventions":12608},"NCT03505736","Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer",[],"2020-03-05",[12587,12588,12589,12590,12591,12592,12593,12594,12595,12596,12597,12598,12599,12600,12601,12602,12603,12604,12605,12606,12607],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Premenopausal","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8",[12609,11811],"Adenosine",{"intervention":12611,"totalTrials":97,"cells":12612},"gemtuzumab ozogamicin",{"EARLY_PHASE1":12613,"PHASE1":12615,"PHASE2":12617,"PHASE3":12626,"PHASE4":12628,"NA":12630},{"trials":12614,"activeCount":101},[],{"trials":12616,"activeCount":101},[],{"trials":12618,"activeCount":101},[12619],{"nctId":12620,"briefTitle":12621,"status":177,"phases":12622,"primaryCompletion":6243,"completion":6243,"start":6841,"enrollment":101,"conditions":12623,"interventions":12625},"NCT01548911","Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia",[90],[2491,2492,2493,2494,2495,2496,12624,2467],"Adult Acute Promyelocytic Leukemia (M3)",[12611],{"trials":12627,"activeCount":101},[],{"trials":12629,"activeCount":101},[],{"trials":12631,"activeCount":101},[12632],{"nctId":12633,"briefTitle":12634,"status":12635,"phases":12636,"conditions":12637,"interventions":12640},"NCT01869803","Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia","APPROVED_FOR_MARKETING",[],[2491,2492,2493,2494,2495,2496,12624,12638,2467,12639],"Childhood Acute Promyelocytic Leukemia (M3)","Recurrent Childhood Acute Myeloid Leukemia",[12611],{"intervention":12609,"totalTrials":97,"cells":12642},{"EARLY_PHASE1":12643,"PHASE1":12645,"PHASE2":12647,"PHASE3":12653,"PHASE4":12655,"NA":12657},{"trials":12644,"activeCount":101},[],{"trials":12646,"activeCount":101},[],{"trials":12648,"activeCount":101},[12649],{"nctId":7951,"briefTitle":7952,"status":158,"phases":12650,"primaryCompletion":7954,"completion":7954,"start":2628,"enrollment":1871,"conditions":12651,"interventions":12652},[90],[25],[7935,7957],{"trials":12654,"activeCount":101},[],{"trials":12656,"activeCount":101},[],{"trials":12658,"activeCount":101},[12659],{"nctId":12582,"briefTitle":12583,"status":158,"phases":12660,"primaryCompletion":12585,"completion":12585,"start":422,"enrollment":204,"conditions":12661,"interventions":12662},[],[12587,12588,12589,12590,12591,12592,12593,12594,12595,12596,12597,12598,12599,12600,12601,12602,12603,12604,12605,12606,12607],[12609,11811],{"intervention":12664,"totalTrials":97,"cells":12665},"amantadine",{"EARLY_PHASE1":12666,"PHASE1":12668,"PHASE2":12670,"PHASE3":12672,"PHASE4":12674,"NA":12676},{"trials":12667,"activeCount":101},[],{"trials":12669,"activeCount":101},[],{"trials":12671,"activeCount":101},[],{"trials":12673,"activeCount":101},[],{"trials":12675,"activeCount":101},[],{"trials":12677,"activeCount":101},[12678,12685],{"nctId":12679,"briefTitle":12680,"status":177,"phases":12681,"primaryCompletion":12682,"completion":12682,"start":7885,"enrollment":101,"conditions":12683,"interventions":12684},"NCT00800514","Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)",[93],"2010-11",[882],[12664,12664],{"nctId":12686,"briefTitle":12687,"status":158,"phases":12688,"primaryCompletion":7708,"completion":7708,"start":12689,"enrollment":12690,"conditions":12691,"interventions":12694},"NCT00627250","Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability",[93],"2003-03",76,[12692,12693,882],"Irritable Mood","Aggression",[12695],"Amantadine",{"intervention":12497,"totalTrials":97,"cells":12697},{"EARLY_PHASE1":12698,"PHASE1":12700,"PHASE2":12702,"PHASE3":12704,"PHASE4":12706,"NA":12708},{"trials":12699,"activeCount":101},[],{"trials":12701,"activeCount":101},[],{"trials":12703,"activeCount":101},[],{"trials":12705,"activeCount":101},[],{"trials":12707,"activeCount":101},[],{"trials":12709,"activeCount":101},[12710,12714],{"nctId":12486,"briefTitle":12487,"status":158,"phases":12711,"primaryCompletion":12489,"completion":12489,"start":12490,"enrollment":12491,"conditions":12712,"interventions":12713},[],[19,12493,551,25,12494,3967,12495],[12497,7429],{"nctId":12715,"briefTitle":12716,"status":158,"phases":12717,"primaryCompletion":1732,"completion":1732,"start":12718,"enrollment":12719,"conditions":12720,"interventions":12721},"NCT00766454","Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer",[],"1998-11",1104,[19],[12497,12722,3627],"mutation analysis",{"intervention":4113,"totalTrials":97,"cells":12724},{"EARLY_PHASE1":12725,"PHASE1":12727,"PHASE2":12733,"PHASE3":12735,"PHASE4":12737,"NA":12739},{"trials":12726,"activeCount":101},[],{"trials":12728,"activeCount":101},[12729],{"nctId":4105,"briefTitle":4106,"status":158,"phases":12730,"primaryCompletion":3798,"completion":3798,"start":4108,"enrollment":1850,"conditions":12731,"interventions":12732},[89],[4110],[4112,4113,4098],{"trials":12734,"activeCount":101},[],{"trials":12736,"activeCount":101},[],{"trials":12738,"activeCount":101},[],{"trials":12740,"activeCount":101},[12741],{"nctId":12742,"briefTitle":12743,"status":177,"phases":12744,"primaryCompletion":12387,"completion":12387,"start":12745,"enrollment":101,"conditions":12746,"interventions":12749},"NCT02101047","Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension",[93],"2015-08",[12747,12748],"Complications; Cesarean Section","Spinal Anesthetics Causing Adverse Effects in Therapeutic Use",[4113],{"intervention":7598,"totalTrials":97,"cells":12751},{"EARLY_PHASE1":12752,"PHASE1":12758,"PHASE2":12760,"PHASE3":12762,"PHASE4":12764,"NA":12766},{"trials":12753,"activeCount":101},[12754],{"nctId":7591,"briefTitle":7592,"status":158,"phases":12755,"primaryCompletion":7594,"completion":7594,"start":1870,"enrollment":1871,"conditions":12756,"interventions":12757},[88],[36],[3626,7597,7598],{"trials":12759,"activeCount":101},[],{"trials":12761,"activeCount":101},[],{"trials":12763,"activeCount":101},[],{"trials":12765,"activeCount":101},[],{"trials":12767,"activeCount":101},[12768],{"nctId":12528,"briefTitle":12529,"status":158,"phases":12769,"primaryCompletion":3820,"completion":3820,"start":12531,"enrollment":1377,"conditions":12770,"interventions":12771},[],[19],[12534,12535,7622,12536,7598],{"intervention":3627,"totalTrials":97,"cells":12773},{"EARLY_PHASE1":12774,"PHASE1":12776,"PHASE2":12778,"PHASE3":12784,"PHASE4":12786,"NA":12788},{"trials":12775,"activeCount":101},[],{"trials":12777,"activeCount":101},[],{"trials":12779,"activeCount":101},[12780],{"nctId":3613,"briefTitle":3614,"status":158,"phases":12781,"primaryCompletion":3596,"completion":3596,"start":3616,"enrollment":1733,"conditions":12782,"interventions":12783},[90],[3618,3619,3620,3621,3622,1735,3623,3624,1736],[1738,3600,3626,3627,3628,1565],{"trials":12785,"activeCount":101},[],{"trials":12787,"activeCount":101},[],{"trials":12789,"activeCount":101},[12790],{"nctId":12715,"briefTitle":12716,"status":158,"phases":12791,"primaryCompletion":1732,"completion":1732,"start":12718,"enrollment":12719,"conditions":12792,"interventions":12793},[],[19],[12497,12722,3627],{"intervention":1428,"totalTrials":97,"cells":12795},{"EARLY_PHASE1":12796,"PHASE1":12802,"PHASE2":12804,"PHASE3":12806,"PHASE4":12808,"NA":12810},{"trials":12797,"activeCount":101},[12798],{"nctId":12190,"briefTitle":12191,"status":158,"phases":12799,"primaryCompletion":12193,"completion":12193,"start":12194,"enrollment":549,"conditions":12800,"interventions":12801},[88],[12196,4523,12197],[12185,12199],{"trials":12803,"activeCount":101},[],{"trials":12805,"activeCount":101},[],{"trials":12807,"activeCount":101},[],{"trials":12809,"activeCount":101},[],{"trials":12811,"activeCount":101},[12812],{"nctId":1420,"briefTitle":1421,"status":158,"phases":12813,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":321,"conditions":12814,"interventions":12815},[93],[1426],[1428,1429,350,1361],{"intervention":12817,"totalTrials":228,"cells":12818},"valsartan",{"EARLY_PHASE1":12819,"PHASE1":12821,"PHASE2":12823,"PHASE3":12825,"PHASE4":12827,"NA":12829},{"trials":12820,"activeCount":101},[],{"trials":12822,"activeCount":101},[],{"trials":12824,"activeCount":101},[],{"trials":12826,"activeCount":101},[],{"trials":12828,"activeCount":101},[],{"trials":12830,"activeCount":101},[12831],{"nctId":12832,"briefTitle":12833,"status":143,"phases":12834,"primaryCompletion":12835,"completion":12835,"start":3799,"enrollment":228,"conditions":12836,"interventions":12840},"NCT02606279","Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients",[93],"2016-08-04",[12837,7025,12838,12839],"HIV","Sarcopenia","Angiotensin Receptor Antagonists",[12817],{"intervention":12842,"totalTrials":228,"cells":12843},"levocetirizine or placebo",{"EARLY_PHASE1":12844,"PHASE1":12846,"PHASE2":12848,"PHASE3":12850,"PHASE4":12852,"NA":12854},{"trials":12845,"activeCount":101},[],{"trials":12847,"activeCount":101},[],{"trials":12849,"activeCount":101},[],{"trials":12851,"activeCount":101},[],{"trials":12853,"activeCount":101},[],{"trials":12855,"activeCount":101},[12856],{"nctId":12857,"briefTitle":12858,"status":143,"phases":12859,"primaryCompletion":1537,"completion":244,"start":12860,"enrollment":1608,"conditions":12861,"interventions":12864},"NCT01008592","The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism",[],"2009-04",[12862,12863],"Rhinitis","Urticaria",[12842],{"intervention":12866,"totalTrials":228,"cells":12867},"Methotrexate intravenous 25mg\u002Fml",{"EARLY_PHASE1":12868,"PHASE1":12870,"PHASE2":12872,"PHASE3":12874,"PHASE4":12876,"NA":12878},{"trials":12869,"activeCount":101},[],{"trials":12871,"activeCount":101},[],{"trials":12873,"activeCount":101},[],{"trials":12875,"activeCount":101},[],{"trials":12877,"activeCount":101},[],{"trials":12879,"activeCount":101},[12880],{"nctId":12881,"briefTitle":12882,"status":143,"phases":12883,"primaryCompletion":7458,"completion":7458,"start":5846,"enrollment":97,"conditions":12884,"interventions":12886},"NCT00779142","Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies",[93],[12885],"Diabetic Macular Edema",[12866],{"intervention":12888,"totalTrials":228,"cells":12889},"Carbamazepine",{"EARLY_PHASE1":12890,"PHASE1":12892,"PHASE2":12894,"PHASE3":12896,"PHASE4":12898,"NA":12900},{"trials":12891,"activeCount":101},[],{"trials":12893,"activeCount":101},[],{"trials":12895,"activeCount":101},[],{"trials":12897,"activeCount":101},[],{"trials":12899,"activeCount":101},[],{"trials":12901,"activeCount":101},[12902],{"nctId":12903,"briefTitle":12904,"status":158,"phases":12905,"primaryCompletion":6243,"completion":7277,"start":3820,"enrollment":2833,"conditions":12906,"interventions":12907},"NCT00621751","Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression",[93],[882],[12888],{"intervention":12558,"totalTrials":228,"cells":12909},{"EARLY_PHASE1":12910,"PHASE1":12912,"PHASE2":12914,"PHASE3":12916,"PHASE4":12918,"NA":12920},{"trials":12911,"activeCount":101},[],{"trials":12913,"activeCount":101},[],{"trials":12915,"activeCount":101},[],{"trials":12917,"activeCount":101},[],{"trials":12919,"activeCount":101},[],{"trials":12921,"activeCount":101},[12922],{"nctId":12552,"briefTitle":12553,"status":177,"phases":12923,"enrollment":101,"conditions":12924,"interventions":12925},[93],[1647,12556],[12558,12535],{"intervention":12927,"totalTrials":228,"cells":12928},"Topical Triamcinolone",{"EARLY_PHASE1":12929,"PHASE1":12931,"PHASE2":12933,"PHASE3":12935,"PHASE4":12937,"NA":12939},{"trials":12930,"activeCount":101},[],{"trials":12932,"activeCount":101},[],{"trials":12934,"activeCount":101},[],{"trials":12936,"activeCount":101},[],{"trials":12938,"activeCount":101},[],{"trials":12940,"activeCount":101},[12941],{"nctId":12942,"briefTitle":12943,"status":177,"phases":12944,"primaryCompletion":12945,"completion":12945,"start":12946,"enrollment":101,"conditions":12947,"interventions":12948},"NCT01385527","Pediatric Atopic Dermatitis (AD) Internet Survey",[93],"2014-10-27","2011-06",[4547],[12927],{"intervention":12950,"totalTrials":228,"cells":12951},"fluocinonide 0.05% cream",{"EARLY_PHASE1":12952,"PHASE1":12954,"PHASE2":12956,"PHASE3":12958,"PHASE4":12960,"NA":12962},{"trials":12953,"activeCount":101},[],{"trials":12955,"activeCount":101},[],{"trials":12957,"activeCount":101},[],{"trials":12959,"activeCount":101},[],{"trials":12961,"activeCount":101},[],{"trials":12963,"activeCount":101},[12964],{"nctId":12965,"briefTitle":12966,"status":158,"phases":12967,"primaryCompletion":12968,"completion":12968,"start":1607,"enrollment":1608,"conditions":12969,"interventions":12971},"NCT02176148","Cutaneous Lupus Medication Experience Study",[],"2020-12-04",[12970],"Cutaneous Lupus",[12950],{"intervention":12973,"totalTrials":228,"cells":12974},"Inhaled Nitric Oxide",{"EARLY_PHASE1":12975,"PHASE1":12977,"PHASE2":12979,"PHASE3":12981,"PHASE4":12983,"NA":12985},{"trials":12976,"activeCount":101},[],{"trials":12978,"activeCount":101},[],{"trials":12980,"activeCount":101},[],{"trials":12982,"activeCount":101},[],{"trials":12984,"activeCount":101},[],{"trials":12986,"activeCount":101},[12987],{"nctId":12988,"briefTitle":12989,"status":158,"phases":12990,"primaryCompletion":12991,"completion":12991,"start":3799,"enrollment":1871,"conditions":12992,"interventions":12995},"NCT02151877","Efficacy of Nitric Oxide Administration in Attenuating Ischemia\u002FReperfusion Injury During Neonatal Cardiopulmonary Bypass",[93],"2018-08-15",[12993,12994],"Ischemia\u002FReperfusion Injury After Neonatal Cardiac Surgery","Inflammatory Reaction After Neonatal Cardiac Surgery",[12973],{"intervention":12458,"totalTrials":228,"cells":12997},{"EARLY_PHASE1":12998,"PHASE1":13000,"PHASE2":13002,"PHASE3":13004,"PHASE4":13006,"NA":13008},{"trials":12999,"activeCount":101},[],{"trials":13001,"activeCount":101},[],{"trials":13003,"activeCount":101},[],{"trials":13005,"activeCount":101},[],{"trials":13007,"activeCount":101},[],{"trials":13009,"activeCount":101},[13010],{"nctId":12450,"briefTitle":12451,"status":158,"phases":13011,"primaryCompletion":12453,"completion":12454,"start":1423,"enrollment":12455,"conditions":13012,"interventions":13013},[],[11907,9715,11910],[12458,12459,12460],{"intervention":12459,"totalTrials":228,"cells":13015},{"EARLY_PHASE1":13016,"PHASE1":13018,"PHASE2":13020,"PHASE3":13022,"PHASE4":13024,"NA":13026},{"trials":13017,"activeCount":101},[],{"trials":13019,"activeCount":101},[],{"trials":13021,"activeCount":101},[],{"trials":13023,"activeCount":101},[],{"trials":13025,"activeCount":101},[],{"trials":13027,"activeCount":101},[13028],{"nctId":12450,"briefTitle":12451,"status":158,"phases":13029,"primaryCompletion":12453,"completion":12454,"start":1423,"enrollment":12455,"conditions":13030,"interventions":13031},[],[11907,9715,11910],[12458,12459,12460],{"intervention":13033,"totalTrials":228,"cells":13034},"Loratadine",{"EARLY_PHASE1":13035,"PHASE1":13037,"PHASE2":13039,"PHASE3":13041,"PHASE4":13043,"NA":13045},{"trials":13036,"activeCount":101},[],{"trials":13038,"activeCount":101},[],{"trials":13040,"activeCount":101},[],{"trials":13042,"activeCount":101},[],{"trials":13044,"activeCount":101},[],{"trials":13046,"activeCount":101},[13047],{"nctId":13048,"briefTitle":13049,"status":158,"phases":13050,"primaryCompletion":13051,"completion":13051,"start":1607,"enrollment":434,"conditions":13052,"interventions":13053},"NCT02305979","Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies",[],"2017-09",[2208,8280],[13033],{"intervention":13055,"totalTrials":228,"cells":13056},"Domperidone Oral Product",{"EARLY_PHASE1":13057,"PHASE1":13059,"PHASE2":13061,"PHASE3":13063,"PHASE4":13065,"NA":13067},{"trials":13058,"activeCount":101},[],{"trials":13060,"activeCount":101},[],{"trials":13062,"activeCount":101},[],{"trials":13064,"activeCount":101},[],{"trials":13066,"activeCount":101},[],{"trials":13068,"activeCount":101},[13069],{"nctId":13070,"briefTitle":13071,"status":13072,"phases":13073,"conditions":13074,"interventions":13076},"NCT04996134","Domperidone Expanded Access Treatment Program","NO_LONGER_AVAILABLE",[],[13075],"Gastroparesis",[13055],{"intervention":13078,"totalTrials":228,"cells":13079},"Trimethoprim\u002FSulfamethoxazole",{"EARLY_PHASE1":13080,"PHASE1":13082,"PHASE2":13084,"PHASE3":13086,"PHASE4":13088,"NA":13090},{"trials":13081,"activeCount":101},[],{"trials":13083,"activeCount":101},[],{"trials":13085,"activeCount":101},[],{"trials":13087,"activeCount":101},[],{"trials":13089,"activeCount":101},[],{"trials":13091,"activeCount":101},[13092],{"nctId":13093,"briefTitle":13094,"status":177,"phases":13095,"primaryCompletion":8087,"completion":8087,"start":7718,"enrollment":101,"conditions":13096,"interventions":13098},"NCT00900510","Antibiotic Therapy After Incision and Drainage for Abscess",[93],[13097],"Abscess",[13078],{"intervention":13100,"totalTrials":228,"cells":13101},"Amantadine Hydrochloride",{"EARLY_PHASE1":13102,"PHASE1":13104,"PHASE2":13106,"PHASE3":13108,"PHASE4":13110,"NA":13112},{"trials":13103,"activeCount":101},[],{"trials":13105,"activeCount":101},[],{"trials":13107,"activeCount":101},[],{"trials":13109,"activeCount":101},[],{"trials":13111,"activeCount":101},[],{"trials":13113,"activeCount":101},[13114],{"nctId":13115,"briefTitle":13116,"status":158,"phases":13117,"primaryCompletion":5871,"completion":3819,"start":1888,"enrollment":13118,"conditions":13119,"interventions":13121},"NCT00779324","Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study",[93],168,[13120,12693],"Brain Injury",[13100],{"intervention":13123,"totalTrials":228,"cells":13124},"Conservative medical management",{"EARLY_PHASE1":13125,"PHASE1":13127,"PHASE2":13129,"PHASE3":13131,"PHASE4":13133,"NA":13135},{"trials":13126,"activeCount":101},[],{"trials":13128,"activeCount":101},[],{"trials":13130,"activeCount":101},[],{"trials":13132,"activeCount":101},[],{"trials":13134,"activeCount":101},[],{"trials":13136,"activeCount":101},[13137],{"nctId":13138,"briefTitle":13139,"status":158,"phases":13140,"primaryCompletion":13141,"completion":13141,"start":13142,"enrollment":1377,"conditions":13143,"interventions":13146},"NCT05674240","Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain",[],"2026-03-20","2022-12-06",[13144,1479,13145,260],"Cancer Pain","Cancer Associated Pain",[13123],{"intervention":13148,"totalTrials":228,"cells":13149},"SCS in combination with CMM",{"EARLY_PHASE1":13150,"PHASE1":13152,"PHASE2":13154,"PHASE3":13156,"PHASE4":13158,"NA":13160},{"trials":13151,"activeCount":101},[],{"trials":13153,"activeCount":101},[],{"trials":13155,"activeCount":101},[],{"trials":13157,"activeCount":101},[],{"trials":13159,"activeCount":101},[],{"trials":13161,"activeCount":101},[13162],{"nctId":13163,"briefTitle":13164,"status":143,"phases":13165,"primaryCompletion":13166,"completion":13166,"start":13167,"enrollment":1362,"conditions":13168,"interventions":13170},"NCT05985291","BurstDR Stimulation for Painful Diabetic Neuropathy",[],"2025-10-06","2023-07-03",[13169],"Painful Diabetic Neuropathy",[13148],{"intervention":13172,"totalTrials":228,"cells":13173},"Policosanol supplement (oral capsule) vs. placebo",{"EARLY_PHASE1":13174,"PHASE1":13176,"PHASE2":13178,"PHASE3":13180,"PHASE4":13182,"NA":13184},{"trials":13175,"activeCount":101},[],{"trials":13177,"activeCount":101},[],{"trials":13179,"activeCount":101},[],{"trials":13181,"activeCount":101},[],{"trials":13183,"activeCount":101},[],{"trials":13185,"activeCount":101},[13186],{"nctId":13187,"briefTitle":13188,"status":158,"phases":13189,"completion":13190,"start":10371,"enrollment":834,"conditions":13191,"interventions":13193},"NCT00255216","Policosanol for the Treatment of Hypercholesterolemia",[93],"2005-08",[13192],"Hyperlipidemia",[13172],{"intervention":13195,"totalTrials":228,"cells":13196},"Phentermine",{"EARLY_PHASE1":13197,"PHASE1":13199,"PHASE2":13201,"PHASE3":13203,"PHASE4":13205,"NA":13207},{"trials":13198,"activeCount":101},[],{"trials":13200,"activeCount":101},[],{"trials":13202,"activeCount":101},[],{"trials":13204,"activeCount":101},[],{"trials":13206,"activeCount":101},[],{"trials":13208,"activeCount":101},[13209],{"nctId":13210,"briefTitle":13211,"status":177,"phases":13212,"primaryCompletion":244,"completion":244,"start":8088,"enrollment":101,"conditions":13213,"interventions":13214},"NCT00771654","Phentermine\u002FGastric Band Weight Loss Study",[93],[16],[13195],{"intervention":12722,"totalTrials":228,"cells":13216},{"EARLY_PHASE1":13217,"PHASE1":13219,"PHASE2":13221,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13218,"activeCount":101},[],{"trials":13220,"activeCount":101},[],{"trials":13222,"activeCount":101},[],{"trials":13224,"activeCount":101},[],{"trials":13226,"activeCount":101},[],{"trials":13228,"activeCount":101},[13229],{"nctId":12715,"briefTitle":12716,"status":158,"phases":13230,"primaryCompletion":1732,"completion":1732,"start":12718,"enrollment":12719,"conditions":13231,"interventions":13232},[],[19],[12497,12722,3627],{"intervention":1541,"totalTrials":228,"cells":13234},{"EARLY_PHASE1":13235,"PHASE1":13237,"PHASE2":13239,"PHASE3":13241,"PHASE4":13243,"NA":13245},{"trials":13236,"activeCount":101},[],{"trials":13238,"activeCount":101},[],{"trials":13240,"activeCount":101},[],{"trials":13242,"activeCount":101},[],{"trials":13244,"activeCount":101},[],{"trials":13246,"activeCount":101},[13247],{"nctId":1533,"briefTitle":1534,"status":158,"phases":13248,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":461,"conditions":13249,"interventions":13250},[93],[1539],[1541,350,1542],{"intervention":1542,"totalTrials":228,"cells":13252},{"EARLY_PHASE1":13253,"PHASE1":13255,"PHASE2":13257,"PHASE3":13259,"PHASE4":13261,"NA":13263},{"trials":13254,"activeCount":101},[],{"trials":13256,"activeCount":101},[],{"trials":13258,"activeCount":101},[],{"trials":13260,"activeCount":101},[],{"trials":13262,"activeCount":101},[],{"trials":13264,"activeCount":101},[13265],{"nctId":1533,"briefTitle":1534,"status":158,"phases":13266,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":461,"conditions":13267,"interventions":13268},[93],[1539],[1541,350,1542],{"intervention":13270,"totalTrials":228,"cells":13271},"Omegaven IV lipid emulsion",{"EARLY_PHASE1":13272,"PHASE1":13274,"PHASE2":13276,"PHASE3":13278,"PHASE4":13280,"NA":13282},{"trials":13273,"activeCount":101},[],{"trials":13275,"activeCount":101},[],{"trials":13277,"activeCount":101},[],{"trials":13279,"activeCount":101},[],{"trials":13281,"activeCount":101},[],{"trials":13283,"activeCount":101},[13284],{"nctId":13285,"briefTitle":13286,"status":12635,"phases":13287,"conditions":13288,"interventions":13289},"NCT02929303","Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD",[],[8853],[13270],{"intervention":1429,"totalTrials":228,"cells":13291},{"EARLY_PHASE1":13292,"PHASE1":13294,"PHASE2":13296,"PHASE3":13298,"PHASE4":13300,"NA":13302},{"trials":13293,"activeCount":101},[],{"trials":13295,"activeCount":101},[],{"trials":13297,"activeCount":101},[],{"trials":13299,"activeCount":101},[],{"trials":13301,"activeCount":101},[],{"trials":13303,"activeCount":101},[13304],{"nctId":1420,"briefTitle":1421,"status":158,"phases":13305,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":321,"conditions":13306,"interventions":13307},[93],[1426],[1428,1429,350,1361],{"intervention":13309,"totalTrials":228,"cells":13310},"Benzoyl peroxide 5% gel",{"EARLY_PHASE1":13311,"PHASE1":13313,"PHASE2":13315,"PHASE3":13317,"PHASE4":13319,"NA":13321},{"trials":13312,"activeCount":101},[],{"trials":13314,"activeCount":101},[],{"trials":13316,"activeCount":101},[],{"trials":13318,"activeCount":101},[],{"trials":13320,"activeCount":101},[],{"trials":13322,"activeCount":101},[13323],{"nctId":13324,"briefTitle":13325,"status":158,"phases":13326,"primaryCompletion":1537,"completion":1537,"start":7718,"enrollment":37,"conditions":13327,"interventions":13328},"NCT01176955","A Novel Method to Improve Acne Outcomes",[93],[4318],[13309],{"intervention":13330,"totalTrials":228,"cells":13331},"proteomic profiling",{"EARLY_PHASE1":13332,"PHASE1":13334,"PHASE2":13336,"PHASE3":13338,"PHASE4":13340,"NA":13342},{"trials":13333,"activeCount":101},[],{"trials":13335,"activeCount":101},[],{"trials":13337,"activeCount":101},[],{"trials":13339,"activeCount":101},[],{"trials":13341,"activeCount":101},[],{"trials":13343,"activeCount":101},[13344],{"nctId":13345,"briefTitle":13346,"status":158,"phases":13347,"primaryCompletion":5396,"start":7386,"enrollment":549,"conditions":13348,"interventions":13349},"NCT00373035","Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy",[],[348],[13330],{"intervention":13351,"totalTrials":228,"cells":13352},"Furosemide",{"EARLY_PHASE1":13353,"PHASE1":13355,"PHASE2":13357,"PHASE3":13359,"PHASE4":13361,"NA":13363},{"trials":13354,"activeCount":101},[],{"trials":13356,"activeCount":101},[],{"trials":13358,"activeCount":101},[],{"trials":13360,"activeCount":101},[],{"trials":13362,"activeCount":101},[],{"trials":13364,"activeCount":101},[13365],{"nctId":13366,"briefTitle":13367,"status":158,"phases":13368,"primaryCompletion":10396,"completion":5373,"start":1374,"enrollment":1477,"conditions":13369,"interventions":13371},"NCT01318967","Measurement of Kidney Blood Flow and Oxygen Levels by MRI",[93],[13370],"Chronic Kidney Disease",[13351],{"intervention":13373,"totalTrials":228,"cells":13374},"4 degree chilled saline",{"EARLY_PHASE1":13375,"PHASE1":13377,"PHASE2":13379,"PHASE3":13381,"PHASE4":13383,"NA":13385},{"trials":13376,"activeCount":101},[],{"trials":13378,"activeCount":101},[],{"trials":13380,"activeCount":101},[],{"trials":13382,"activeCount":101},[],{"trials":13384,"activeCount":101},[],{"trials":13386,"activeCount":101},[13387],{"nctId":13388,"briefTitle":13389,"status":158,"phases":13390,"primaryCompletion":10396,"completion":10396,"start":13391,"enrollment":13392,"conditions":13393,"interventions":13395},"NCT01413399","A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest",[93],"2011-08",542,[13394],"Out-of-Hospital Cardiac Arrest",[13373],{"intervention":13397,"totalTrials":228,"cells":13398},"Pegaptanib",{"EARLY_PHASE1":13399,"PHASE1":13401,"PHASE2":13403,"PHASE3":13405,"PHASE4":13407,"NA":13409},{"trials":13400,"activeCount":101},[],{"trials":13402,"activeCount":101},[],{"trials":13404,"activeCount":101},[],{"trials":13406,"activeCount":101},[],{"trials":13408,"activeCount":101},[],{"trials":13410,"activeCount":101},[13411],{"nctId":13412,"briefTitle":13413,"status":158,"phases":13414,"primaryCompletion":1454,"completion":9070,"start":4776,"enrollment":1850,"conditions":13415,"interventions":13418},"NCT00790803","Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema",[93],[13416,13417],"Uveitis","Cystoid Macular Edema",[13397],{"intervention":12504,"totalTrials":228,"cells":13420},{"EARLY_PHASE1":13421,"PHASE1":13423,"PHASE2":13425,"PHASE3":13427,"PHASE4":13429,"NA":13431},{"trials":13422,"activeCount":101},[],{"trials":13424,"activeCount":101},[],{"trials":13426,"activeCount":101},[],{"trials":13428,"activeCount":101},[],{"trials":13430,"activeCount":101},[],{"trials":13432,"activeCount":101},[13433],{"nctId":12499,"briefTitle":12500,"status":143,"phases":13434,"primaryCompletion":4776,"completion":10396,"start":5525,"enrollment":97,"conditions":13435,"interventions":13436},[],[19],[12504,7429,7622],{"intervention":13438,"totalTrials":228,"cells":13439},"influenza vaccination",{"EARLY_PHASE1":13440,"PHASE1":13442,"PHASE2":13444,"PHASE3":13446,"PHASE4":13448,"NA":13450},{"trials":13441,"activeCount":101},[],{"trials":13443,"activeCount":101},[],{"trials":13445,"activeCount":101},[],{"trials":13447,"activeCount":101},[],{"trials":13449,"activeCount":101},[],{"trials":13451,"activeCount":101},[13452],{"nctId":13453,"briefTitle":13454,"status":158,"phases":13455,"primaryCompletion":13456,"completion":13457,"start":13458,"enrollment":2080,"conditions":13459,"interventions":13463},"NCT03061955","Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)",[],"2017-03-31","2019-04-26","2016-10-01",[13460,13461,13462],"Influenza Virus Vaccine Adverse Reaction (Disorder)","Influenza","Malignancy",[13438],{"intervention":13465,"totalTrials":228,"cells":13466},"Acthar",{"EARLY_PHASE1":13467,"PHASE1":13469,"PHASE2":13471,"PHASE3":13473,"PHASE4":13475,"NA":13477},{"trials":13468,"activeCount":101},[],{"trials":13470,"activeCount":101},[],{"trials":13472,"activeCount":101},[],{"trials":13474,"activeCount":101},[],{"trials":13476,"activeCount":101},[],{"trials":13478,"activeCount":101},[13479],{"nctId":13480,"briefTitle":13481,"status":177,"phases":13482,"primaryCompletion":13483,"completion":13483,"start":11083,"enrollment":101,"conditions":13484,"interventions":13486},"NCT02006849","ACTH Treatment of APOL1- Associated Nephropathy",[93],"2019-01",[13485],"Kidney Disease",[13465],{"intervention":13488,"totalTrials":228,"cells":13489},"Botulinum toxin type A",{"EARLY_PHASE1":13490,"PHASE1":13492,"PHASE2":13494,"PHASE3":13496,"PHASE4":13498,"NA":13500},{"trials":13491,"activeCount":101},[],{"trials":13493,"activeCount":101},[],{"trials":13495,"activeCount":101},[],{"trials":13497,"activeCount":101},[],{"trials":13499,"activeCount":101},[],{"trials":13501,"activeCount":101},[13502],{"nctId":13503,"briefTitle":13504,"status":143,"phases":13505,"primaryCompletion":11336,"completion":1423,"start":2488,"enrollment":1477,"conditions":13506,"interventions":13508},"NCT02051933","The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures",[93],[13507],"Equinus Contracture",[13488,13509],"sodium chloride",{"intervention":13509,"totalTrials":228,"cells":13511},{"EARLY_PHASE1":13512,"PHASE1":13514,"PHASE2":13516,"PHASE3":13518,"PHASE4":13520,"NA":13522},{"trials":13513,"activeCount":101},[],{"trials":13515,"activeCount":101},[],{"trials":13517,"activeCount":101},[],{"trials":13519,"activeCount":101},[],{"trials":13521,"activeCount":101},[],{"trials":13523,"activeCount":101},[13524],{"nctId":13503,"briefTitle":13504,"status":143,"phases":13525,"primaryCompletion":11336,"completion":1423,"start":2488,"enrollment":1477,"conditions":13526,"interventions":13527},[93],[13507],[13488,13509],{"intervention":13529,"totalTrials":228,"cells":13530},"Adasuve",{"EARLY_PHASE1":13531,"PHASE1":13533,"PHASE2":13535,"PHASE3":13537,"PHASE4":13539,"NA":13541},{"trials":13532,"activeCount":101},[],{"trials":13534,"activeCount":101},[],{"trials":13536,"activeCount":101},[],{"trials":13538,"activeCount":101},[],{"trials":13540,"activeCount":101},[],{"trials":13542,"activeCount":101},[13543],{"nctId":13544,"briefTitle":13545,"status":158,"phases":13546,"primaryCompletion":11336,"completion":11336,"start":13547,"enrollment":13548,"conditions":13549,"interventions":13551},"NCT02504450","Outcomes of Antipsychotic Medication Used in the Emergency Department",[],"2015-04",93,[13550],"Agitation,Psychomotor",[13529,13552],"Alternative medications",{"intervention":13552,"totalTrials":228,"cells":13554},{"EARLY_PHASE1":13555,"PHASE1":13557,"PHASE2":13559,"PHASE3":13561,"PHASE4":13563,"NA":13565},{"trials":13556,"activeCount":101},[],{"trials":13558,"activeCount":101},[],{"trials":13560,"activeCount":101},[],{"trials":13562,"activeCount":101},[],{"trials":13564,"activeCount":101},[],{"trials":13566,"activeCount":101},[13567],{"nctId":13544,"briefTitle":13545,"status":158,"phases":13568,"primaryCompletion":11336,"completion":11336,"start":13547,"enrollment":13548,"conditions":13569,"interventions":13570},[],[13550],[13529,13552],{"intervention":12534,"totalTrials":228,"cells":13572},{"EARLY_PHASE1":13573,"PHASE1":13575,"PHASE2":13577,"PHASE3":13579,"PHASE4":13581,"NA":13583},{"trials":13574,"activeCount":101},[],{"trials":13576,"activeCount":101},[],{"trials":13578,"activeCount":101},[],{"trials":13580,"activeCount":101},[],{"trials":13582,"activeCount":101},[],{"trials":13584,"activeCount":101},[13585],{"nctId":12528,"briefTitle":12529,"status":158,"phases":13586,"primaryCompletion":3820,"completion":3820,"start":12531,"enrollment":1377,"conditions":13587,"interventions":13588},[],[19],[12534,12535,7622,12536,7598],{"intervention":12536,"totalTrials":228,"cells":13590},{"EARLY_PHASE1":13591,"PHASE1":13593,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13601},{"trials":13592,"activeCount":101},[],{"trials":13594,"activeCount":101},[],{"trials":13596,"activeCount":101},[],{"trials":13598,"activeCount":101},[],{"trials":13600,"activeCount":101},[],{"trials":13602,"activeCount":101},[13603],{"nctId":12528,"briefTitle":12529,"status":158,"phases":13604,"primaryCompletion":3820,"completion":3820,"start":12531,"enrollment":1377,"conditions":13605,"interventions":13606},[],[19],[12534,12535,7622,12536,7598],{"intervention":13608,"totalTrials":228,"cells":13609},"Pre-Radiation Dental Evaluation\u002FSample Collection",{"EARLY_PHASE1":13610,"PHASE1":13612,"PHASE2":13614,"PHASE3":13616,"PHASE4":13618,"NA":13620},{"trials":13611,"activeCount":101},[],{"trials":13613,"activeCount":101},[],{"trials":13615,"activeCount":101},[],{"trials":13617,"activeCount":101},[],{"trials":13619,"activeCount":101},[],{"trials":13621,"activeCount":101},[13622],{"nctId":13623,"briefTitle":13624,"status":177,"phases":13625,"primaryCompletion":192,"completion":192,"start":8874,"enrollment":101,"conditions":13626,"interventions":13627},"NCT06362421","Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer",[],[11961,2057],[13608,13628],"Oral Medicine Consultation Visit\u002FSample Collection",{"intervention":13628,"totalTrials":228,"cells":13630},{"EARLY_PHASE1":13631,"PHASE1":13633,"PHASE2":13635,"PHASE3":13637,"PHASE4":13639,"NA":13641},{"trials":13632,"activeCount":101},[],{"trials":13634,"activeCount":101},[],{"trials":13636,"activeCount":101},[],{"trials":13638,"activeCount":101},[],{"trials":13640,"activeCount":101},[],{"trials":13642,"activeCount":101},[13643],{"nctId":13623,"briefTitle":13624,"status":177,"phases":13644,"primaryCompletion":192,"completion":192,"start":8874,"enrollment":101,"conditions":13645,"interventions":13646},[],[11961,2057],[13608,13628],{"intervention":13648,"totalTrials":228,"cells":13649},"Nicotine patch",{"EARLY_PHASE1":13650,"PHASE1":13652,"PHASE2":13654,"PHASE3":13656,"PHASE4":13658,"NA":13660},{"trials":13651,"activeCount":101},[],{"trials":13653,"activeCount":101},[],{"trials":13655,"activeCount":101},[],{"trials":13657,"activeCount":101},[],{"trials":13659,"activeCount":101},[],{"trials":13661,"activeCount":101},[13662],{"nctId":13663,"briefTitle":13664,"status":158,"phases":13665,"primaryCompletion":13666,"completion":13666,"start":13667,"enrollment":13668,"conditions":13669,"interventions":13676},"NCT05030272","Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings",[93],"2025-12-30","2021-09-21",343,[8788,13670,13671,13672,13673,13674,13675],"Mental Illness","Recurring Major Depressive Disorder","Bipolar Disorder","Schizophrenia","Schizoaffective Disorder","Persistent Depressive Disorder",[13648,13677,13678],"Nicotine gum","Nicotine Lozenges",{"intervention":13677,"totalTrials":228,"cells":13680},{"EARLY_PHASE1":13681,"PHASE1":13683,"PHASE2":13685,"PHASE3":13687,"PHASE4":13689,"NA":13691},{"trials":13682,"activeCount":101},[],{"trials":13684,"activeCount":101},[],{"trials":13686,"activeCount":101},[],{"trials":13688,"activeCount":101},[],{"trials":13690,"activeCount":101},[],{"trials":13692,"activeCount":101},[13693],{"nctId":13663,"briefTitle":13664,"status":158,"phases":13694,"primaryCompletion":13666,"completion":13666,"start":13667,"enrollment":13668,"conditions":13695,"interventions":13696},[93],[8788,13670,13671,13672,13673,13674,13675],[13648,13677,13678],{"intervention":13678,"totalTrials":228,"cells":13698},{"EARLY_PHASE1":13699,"PHASE1":13701,"PHASE2":13703,"PHASE3":13705,"PHASE4":13707,"NA":13709},{"trials":13700,"activeCount":101},[],{"trials":13702,"activeCount":101},[],{"trials":13704,"activeCount":101},[],{"trials":13706,"activeCount":101},[],{"trials":13708,"activeCount":101},[],{"trials":13710,"activeCount":101},[13711],{"nctId":13663,"briefTitle":13664,"status":158,"phases":13712,"primaryCompletion":13666,"completion":13666,"start":13667,"enrollment":13668,"conditions":13713,"interventions":13714},[93],[8788,13670,13671,13672,13673,13674,13675],[13648,13677,13678],{"intervention":13716,"totalTrials":228,"cells":13717},"Lidocaine Cream",{"EARLY_PHASE1":13718,"PHASE1":13720,"PHASE2":13722,"PHASE3":13724,"PHASE4":13726,"NA":13728},{"trials":13719,"activeCount":101},[],{"trials":13721,"activeCount":101},[],{"trials":13723,"activeCount":101},[],{"trials":13725,"activeCount":101},[],{"trials":13727,"activeCount":101},[],{"trials":13729,"activeCount":101},[13730],{"nctId":13731,"briefTitle":13732,"status":158,"phases":13733,"primaryCompletion":13734,"completion":13734,"start":13735,"enrollment":1946,"conditions":13736,"interventions":13739},"NCT04176705","Fractional Ablative Laser Treatment for Skin Grafts",[93],"2023-09-29","2020-12-14",[13737,13738],"Burn Scar","Skin Graft Scar",[13716,13740],"Triamcinolone Acetonide Cream",{"intervention":13740,"totalTrials":228,"cells":13742},{"EARLY_PHASE1":13743,"PHASE1":13745,"PHASE2":13747,"PHASE3":13749,"PHASE4":13751,"NA":13753},{"trials":13744,"activeCount":101},[],{"trials":13746,"activeCount":101},[],{"trials":13748,"activeCount":101},[],{"trials":13750,"activeCount":101},[],{"trials":13752,"activeCount":101},[],{"trials":13754,"activeCount":101},[13755],{"nctId":13731,"briefTitle":13732,"status":158,"phases":13756,"primaryCompletion":13734,"completion":13734,"start":13735,"enrollment":1946,"conditions":13757,"interventions":13758},[93],[13737,13738],[13716,13740],{"intervention":13760,"totalTrials":228,"cells":13761},"home intravenous ertapenem",{"EARLY_PHASE1":13762,"PHASE1":13764,"PHASE2":13766,"PHASE3":13768,"PHASE4":13770,"NA":13772},{"trials":13763,"activeCount":101},[],{"trials":13765,"activeCount":101},[],{"trials":13767,"activeCount":101},[],{"trials":13769,"activeCount":101},[],{"trials":13771,"activeCount":101},[],{"trials":13773,"activeCount":101},[13774],{"nctId":13775,"briefTitle":13776,"status":158,"phases":13777,"primaryCompletion":7181,"completion":7181,"start":1375,"enrollment":13778,"conditions":13779,"interventions":13781},"NCT02724410","Role of Intravenous Versus Home Oral Antibiotics in Perforated Appendicitis",[93],82,[13780],"Perforated Appendicitis",[13760,13782],"home oral amoxicillin-clavulanate",{"intervention":13782,"totalTrials":228,"cells":13784},{"EARLY_PHASE1":13785,"PHASE1":13787,"PHASE2":13789,"PHASE3":13791,"PHASE4":13793,"NA":13795},{"trials":13786,"activeCount":101},[],{"trials":13788,"activeCount":101},[],{"trials":13790,"activeCount":101},[],{"trials":13792,"activeCount":101},[],{"trials":13794,"activeCount":101},[],{"trials":13796,"activeCount":101},[13797],{"nctId":13775,"briefTitle":13776,"status":158,"phases":13798,"primaryCompletion":7181,"completion":7181,"start":1375,"enrollment":13778,"conditions":13799,"interventions":13800},[93],[13780],[13760,13782],{"intervention":13802,"totalTrials":228,"cells":13803},"daptomycin",{"EARLY_PHASE1":13804,"PHASE1":13806,"PHASE2":13808,"PHASE3":13810,"PHASE4":13812,"NA":13814},{"trials":13805,"activeCount":101},[],{"trials":13807,"activeCount":101},[],{"trials":13809,"activeCount":101},[],{"trials":13811,"activeCount":101},[],{"trials":13813,"activeCount":101},[],{"trials":13815,"activeCount":101},[13816],{"nctId":13817,"briefTitle":13818,"status":177,"phases":13819,"primaryCompletion":13820,"completion":13820,"start":9540,"enrollment":101,"conditions":13821,"interventions":13822},"NCT00296049","Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy",[93],"2006-03",[4882,10991,1647,12556],[13802,13823],"vancomycin",{"intervention":13823,"totalTrials":228,"cells":13825},{"EARLY_PHASE1":13826,"PHASE1":13828,"PHASE2":13830,"PHASE3":13832,"PHASE4":13834,"NA":13836},{"trials":13827,"activeCount":101},[],{"trials":13829,"activeCount":101},[],{"trials":13831,"activeCount":101},[],{"trials":13833,"activeCount":101},[],{"trials":13835,"activeCount":101},[],{"trials":13837,"activeCount":101},[13838],{"nctId":13817,"briefTitle":13818,"status":177,"phases":13839,"primaryCompletion":13820,"completion":13820,"start":9540,"enrollment":101,"conditions":13840,"interventions":13841},[93],[4882,10991,1647,12556],[13802,13823],{"intervention":13843,"totalTrials":228,"cells":13844},"IV interferon",{"EARLY_PHASE1":13845,"PHASE1":13847,"PHASE2":13849,"PHASE3":13851,"PHASE4":13853,"NA":13855},{"trials":13846,"activeCount":101},[],{"trials":13848,"activeCount":101},[],{"trials":13850,"activeCount":101},[],{"trials":13852,"activeCount":101},[],{"trials":13854,"activeCount":101},[],{"trials":13856,"activeCount":101},[13857],{"nctId":13858,"briefTitle":13859,"status":158,"phases":13860,"primaryCompletion":2435,"completion":2435,"start":3860,"enrollment":1548,"conditions":13861,"interventions":13863},"NCT01192698","Intravenous Interferon During Liver Transplant",[93],[8352,13862],"Cirrhosis",[13843],{"intervention":13865,"totalTrials":228,"cells":13866},"Irinotecan",{"EARLY_PHASE1":13867,"PHASE1":13869,"PHASE2":13871,"PHASE3":13873,"PHASE4":13875,"NA":13877},{"trials":13868,"activeCount":101},[],{"trials":13870,"activeCount":101},[],{"trials":13872,"activeCount":101},[],{"trials":13874,"activeCount":101},[],{"trials":13876,"activeCount":101},[],{"trials":13878,"activeCount":101},[13879],{"nctId":13880,"briefTitle":13881,"status":177,"phases":13882,"primaryCompletion":8302,"completion":8302,"start":7277,"enrollment":101,"conditions":13883,"interventions":13884},"NCT01847495","Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis",[93],[7508],[13865]]